ID,Title (News Shots) ,Title 2 (Press Release),"Content 1
 (News Shot)","Content 2
(Newswire.pharmashots.com)
PressRelease",Image URL,Categories,Company Name,Product ,Tags (Inidication|Category|Tags),Status,Date,userID
31064,Top COVID-19 Deals (Part I): Biopharma Drug Development,,"<!-- wp:list -->
<ul><li>The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at an unprecedented speed to develop vaccines, treatments, and tests</li><li>This article covers last four months of deal data provided by Chris Dokomajilar of DealForma.</li><li>This first part is on 20 deals by biopharma companies for the development of drug therapies for COVID-19. Our team at PharmaShots is compiling a series of articles for deals among biopharma and healthcare companies</li></ul>
<!-- /wp:list -->

<!-- wp:paragraph -->
<p>During the last four months (upto 15 Apr 2020) around 131 deals were made, the breakup of deals are as follows: </p>
<!-- /wp:paragraph -->

<!-- wp:list -->
<ul><li>41 were done between biopharma companies, </li><li>41 between biopharma and govt. organizations/foundations/consortium</li><li>29 between biopharma and universities</li><li>11 between biopharma/medical devices/diagnostics/digital health companies</li><li>9 among  universities and academic institutions </li></ul>
<!-- /wp:list -->

<!-- wp:paragraph -->
<p>Please contact <a href=""mailto:shiwani@pharmashots.com"" class=""aioseop-link""><strong>shiwani@pharmashots.com</strong></a> to get this full detailed report including all 131 deals. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>The following 20 deals are in alphabetical order</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>1.</strong>&nbsp;&nbsp;&nbsp;&nbsp; <strong>AbCellera Partnered with Eli Lilly to Co-develop Antibody Therapies Targeting COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31133} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture5-1024x166.jpg"" alt="""" class=""wp-image-31133"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 12, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Value: Undisclosed&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The agreement will leverage AbCellera’s rapid pandemic response
platform, developed under the DARPA P3 program along with Eli Lilly’s
development and manufacturing capabilities. The companies will equally share
the initial development cost. Lilly will be solely responsible for the further
unique antibody isolated from US patients who have recovered from COVID-19, which
they will later screen to find the most effective in neutralizing SARS-CoV-2. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>2.&nbsp;</strong> <strong>Amgen Signed an Agreement with Adaptive Biotechnologies to Develop Therapies for COVID-19 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31134} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture1-1-1024x158.jpg"" alt="""" class=""wp-image-31134"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: April 2, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The partnership leverages Adaptive’s immune medicine platform for the
identification of virus-neutralizing antibodies in conjunction with Amgen’s expertise
in immunology and novel antibody development. Adaptive extended its platform to
discover antibodies from recovered COVID-19 patients, which will enable the
company to identify antibodies from survivors of COVID-19. Amgen will leverage
its expertise to select, develop, and manufacture antibodies designed to bind
and neutralize SARS-CoV-2. Additionally, both companies have signed an MoU
enabling the partners to commence work immediately.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>3.</strong>&nbsp; <strong>Biogen Partnered with Vir Biotechnology to Develop Antibodies Against COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31135} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture2-1024x157.jpg"" alt="""" class=""wp-image-31135"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 12, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Biogen has partnered with Vir to develop and manufacture a mAb targeting
SARS-CoV-2. Biogen will be responsible for cell line development, process
development, and clinical manufacturing activities to advance the development
of several mAbs targeting SARS-CoV-2, which were isolated from patients who
survived SARS infection. Vir is also evaluating its antibodies as an effective
treatment or prophylaxis against SARS-CoV-2. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>4. CNS Pharmaceuticals Signed an Agreement with WPD Pharmaceuticals to Develop Therapies for COVID-19 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31136} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture17-1024x154.jpg"" alt="""" class=""wp-image-31136"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 23, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1M</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>CNS Pharmaceuticals to get exclusive rights for the development and
commercialization of WP1122 to treat infection from multiple viruses, including
coronavirus SARS-CoV-2. WPD will receive $0.225M up front, R&amp;D funding, and
is eligible for $0.775M in milestones on the completion of its Phase II study,
plus 50% of the net sales in WPD's licensed territories excluding Poland. Those
territories include 29 countries in Europe and Asia. WPD in-licensed WP1122 and
a portfolio from Moleculin Biotech in certain territories, and those licensing
costs are reimbursable from the royalties in this deal. WP1122 is a prodrug of
2-DG (2-deoxy-D-glucose) and is targeted to treat COVID-19.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>5.</strong>&nbsp; <strong>Cytocom Signed a Development and Commercialization Agreement with Immune Therapeutics to Develop Therapies for COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31137} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture9-1024x157.jpg"" alt="""" class=""wp-image-31137"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 20, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Cytocom and Immune Therapeutics partnered to develop Lodonal and IRT-101
for targeting COVID-19. Additionally, the companies plan to gain Fast Track
Approval for Lodonal to prevent and treat COVID-19. Immune’s ITX401 is a Phase III
candidate targeted to treat pancreatic cancer and the company plans to initiate
evaluation of safety and efficacy of Lodonal with Keytruda and Opvido in
partnership with Cytocom.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>6.&nbsp;</strong> <strong>CytoDyn Signed a License Agreement with Longen China Group to Co-Develop Leronlimab (PRO 140)</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31138} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture3-1024x157.jpg"" alt="""" class=""wp-image-31138"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Feb 12, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>CytoDyn granted Longen rights to co-develop and co-commercialize
leronlimab (PRO 140) for the treatment of COVID-19 and oncology indications in
China. Leronlimab is an IgG4 mAb that blocks CCR5, which has completed 9
clinical trials in 800+ patients and received the US FDA’s Fast Track
Designation.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>7.</strong>  <strong>Cytovia Signed an Agreement with Macromoltek to Develop NK Immunotherapies Against COVID-19 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31139} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture4-1024x158.jpg"" alt="""" class=""wp-image-31139"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 7, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Cytovia signed an agreement with Macromoltek to develop NK immunotherapies
for the treatment of COVID-19. The partners will accelerate the development of
new therapies by applying Macromoltek’s machine learning and AI-driven
platform.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>8.&nbsp;</strong> <strong>Generation Bio Partnered with Vir Biotechnology to Develop mAbs Against COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31140} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture7-1024x165.jpg"" alt="""" class=""wp-image-31140"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p> <strong>Deal Date: Apr 7, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Generation Bio and Vir partnered to utilize Generation Bio’s non-viral gene therapy platform for Vir’s current and future human mAbs against SARS-CoV-2. Additionally, the companies will combine Generation Bio’s platform with Vir’s neutralizing antibodies targeting SARS-CoV-2. Generation Bio’s close-ended DNA (ceDNA) is a novel, cell-targeted lipid nanoparticle delivery system that allows the development of targeted therapies for rare diseases.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>9.</strong>&nbsp; <strong>GSK Partnered with Vir to Develop Antibodies Against COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31141} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture8-1024x158.jpg"" alt="""" class=""wp-image-31141"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 6, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $250M</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>GlaxoSmithKline and Vir partnered to combine Vir’s mAb platform
technology with GSK’s expertise in functional genomics and CRISPR screening to
identify anti-coronavirus compounds. GSK made an equity investment of $250M in
Vir at $37.73, a 10% premium to the closing share price on Friday, March 27,
2020. The identification of novel antiviral antibodies can further be utilized
as a preventive measure for COVID-19 outbreak.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>10.&nbsp; Neurimmune Signed an Exclusive Agreement with Ethris to Develop an Inhaled mRNA-based Antibody Therapy for COVID-19 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31142} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture6-1024x165.jpg"" alt="""" class=""wp-image-31142"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 1, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Neurimmune partnered with Ethris to combine Neurimmune’s expertise in
developing human antibodies based on high-throughput immunoglobulin sequence
analyses from recovered COVID-19 patients with Ethris’ pulmonary SNIM RNA
therapeutics platform. The first drug candidate is expected to be evaluated in
Q4’20 pending regulatory approval. Ethris’ ETH42 is a preclinical candidate
targeted to treat the rare pulmonary disease, primary ciliary dyskinesia. The
companies will co-conduct research and development activities with cost and
profit sharing.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>11.</strong> <strong>Novartis Signed a Clinical Trial Agreement with Incyte to Evaluate Jakavi (ruxolitinib) to Treat COVID-19</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31143} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture10-1024x157.jpg"" alt="""" class=""wp-image-31143"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 2, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The Phase III RUXCOVID study will assess Jakavi + SOC vs. SOC as monotherapy
in patients with severe COVID-19. Incyte intends to commence an open-label
emergency Expanded Access Program (EAP) in the US to allow eligible patients
with COVID-19 associated cytokine storm to receive ruxolitinib. Jakavi is a JAK
1 and 2 tyrosine kinases inhibitor and an approved therapy in 101 countries for
patients with MF and 75+ countries for PV. The study will be sponsored by
Incyte in the US and ex-US by Novartis.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>12.</strong> <strong>Novellus Signed a License Option Agreement with Citius for its Stem-Cell Therapy to Treat COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31144} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture12-1024x156.jpg"" alt="""" class=""wp-image-31144"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 1, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novellus granted Citius an exclusive option to license for the development and commercialization of stem
cell therapies utilizing Novellus' mRNA-based cell-reprogramming technology to
treat acute respiratory distress syndrome (ARDS) associated with COVID-19 for 6
months. The focus of the agreement is to evaluate Novellus's iPSC derived mesenchymal
stem cells (MSCs) to enhance the immunomodulatory response in patients. MSCs have
the capability to suppress and prevent cytokine storm and have been evaluated
in 900+ trials targeted to treat lung cancer. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>13. Oncology Pharma to Expand its 2019 Agreement with Kalos to Treat COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31145} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture11-1024x156.jpg"" alt="""" class=""wp-image-31145"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 6, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Ocology Pharma and Kalos amended their 2019 agreement to evaluate
Kalos's anti-cancer drug KTH-222 for treating COVID-19. The focus of the partnership
is to evaluate KTH-222 as a monotherapy and/or in combination with FDA-approved
antiviral therapies to treat COVID-19. In 2019, Oncology Pharma signed an
exclusive, worldwide license and co-development agreement with Kalos for its
KTH-222. KTH-222 is an anti-drug cancer candidate involved in regulating cell
growth while inhibiting the mitogen-activated protein kinase (MAPK) pathway.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>14. Samsung Biologics Partnered with Vir Biotechnology to Develop Antibodies for COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31146} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture13-1024x153.jpg"" alt="""" class=""wp-image-31146"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 9, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $362M&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Samsung Biologics signed an agreement with Vir for large scale
manufacturing for its SARS-CoV-2 mAb program. Samsung will initiate
manufacturing in October 2020 with expected commercialization in early 2021.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>15.</strong> <strong>Sihuan Pharmaceutical Partnered with Hetero Labs</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31147} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture15-1024x153.jpg"" alt="""" class=""wp-image-31147"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Feb 12, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sihuan Pharmaceutical partnered with Hetero Labs to commence R&amp;D, regulatory affairs, manufacturing, and commercialization in China focused on CVS, CNS, and anti-infectives, including coronavirus SARS-CoV-2.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>16.</strong> <strong>Sorrento Initiated the Next Phase of its Partnership with Celularity</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31163} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture14-1024x153.jpg"" alt="""" class=""wp-image-31163"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Jan 29, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>&nbsp; Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sorrento will provide manufacturing support to Celularity as it intends
to commence its Phase I/II clinical study of CYNK-001 in 89 adults with
COVID-19. Sorrento’s manufacturing capacity will scale up CYNK-001 production,
which will be used in this study along with its clinical trials in AML, MM, and
GBM. Celularity is also planning to manufacture CYNK-001 at its newly built
manufacturing facility in Florham Park, New Jersey.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>17. Sorrento Signed an Exclusive License Agreement with Mabpharm to Treat COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31151} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture16-1024x153.jpg"" alt="""" class=""wp-image-31151"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 24, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Mabpharm granted Sorrento exclusive rights to develop and commercialize Mabpharm’s ACE-MAB fusion protein to treat COVID-19 in the North American and European markets. Mabpharm will retain its rights in the rest of the world, including the China and Japanese markets. ACE-MAB is a bi-specific fusion protein platform that binds to the spike protein of coronavirus, including SARS-CoV-2 and SARS-CoV, which further inhibits its binding to respiratory epithelial cells. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>18.</strong> <strong>Vir Biotechnology Signed a License Agreement with Xencor to Utilize Xtend Fc Technology in Antibodies Targeting COVID-19 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31152} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture20-1024x154.jpg"" alt="""" class=""wp-image-31152"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 25, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Xencor granted Vir non-exclusive access to Xencor’s Xtend Fc technology
for extending the half-life of novel antibodies being evaluated for COVID-19.
Vir will be responsible for research, development, regulatory, and commercial
activities across influenza and hepatitis B infection. Xencor will continue to
assess the impact of COVID-19 to ongoing and planned clinical studies. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>19. Vir and Alnylam Expanded Their Existing Partnership to Develop RNAi Therapeutics Targeting Host Factors for COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31153} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture19-1024x154.jpg"" alt="""" class=""wp-image-31153"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: March 4, 2020 and April 2, 2020 Expansions of October 17,
2017 Deal</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Vir and Alnylam expanded their 2017 partnership twice to evaluate both
RNAi therapies and host factors required for SARS-CoV-2 infection, including
ACE2 and TMPRSS2. The third host factor target is expected to emerge from Vir’s
ongoing genomics efforts in identifying novel host factors relevant to COVID-19.
Vir will be responsible for the development of selected candidates and the
commercialization of any therapy developed under the collaboration. Alnylam
will have an option to either share equal profits and losses associated with
each COVID-19 program or may receive milestones and royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>20. WuXi Signed an Agreement with Vir Biotechnology for the Global Development of Antibodies Against COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31154} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/Picture18-1024x154.jpg"" alt="""" class=""wp-image-31154"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Feb 25, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>WuXi and Vir will jointly develop, manufacture, and commercialize Vir’s antibody. WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development. Wuxi Biologics was granted rights to commercialize therapies in Greater China while Vir retains worldwide commercial rights for the therapies. The collaboration accelerates the advancement of mAbs against the global threat of COVID-19.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Source:</strong> <a class=""aioseop-link"" href=""https://dealforma.com/"">Dealforma</a> database, official press releases and SEC filling </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post: </strong><a href=""https://www.pharmashots.com/32271/biopharma-vaccine-development-deals-for-covid-19/"">Insights+ COVID-19 Deals (Part II): Biopharma Vaccine Development</a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post: </strong><a href=""https://www.pharmashots.com/35625/insights-covid-19-deals-part-iii-biopharma-and-govt-institutions/"">Insights+ COVID-19 Deals (Part III): Biopharma and Govt. Institutions</a></p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2020/04/BIOPHARMA-DRUG-DEVELOPMENT-DEALS-FOR-COVID-19-_752x440-1.png|https://pharmashots.com/wp-content/uploads/2020/04/BIOPHARMA-DRUG-DEVELOPMENT-DEALS-FOR-COVID-19-_752x440.png,Top 20,Top COVID-19 Deals,,AbCellera|Adaptive Biotechnologies|Alnylam|Amgen|Biogen|BioPharma|Celularity|Citius|CNS Pharmaceuticals|Cytocom|CytoDyn|Cytovia|Deals|Eli Lilly|Ethris|Generation Bio|GSK|Hetero Labs|Immune Therapeutics|Incyte|Kalos|Longen China Group|Mabpharm|Macromoltek|Neurimmune|Novartis|Novellus|Oncology Pharma|Samsung Biologics|Sihuan Pharmaceutical|Sorrento|Top 20|Vir Biotechnology|WPD Pharmaceuticals|WuXi|Xencor,publish,4/17/2020,17
32271,Top COVID-19 Deals (Part II): Biopharma Vaccine Development,,"<!-- wp:list -->
<ul><li>The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at unprecedented speed to develop vaccines, treatments, and tests</li><li>This article covers the last four months of deal data provided by Chris Dokomajilar of DealForma</li><li>Our team at PharmaShots is compiling a series of articles for deals among biopharma and healthcare companies</li></ul>
<!-- /wp:list -->

<!-- wp:paragraph -->
<p> During the last four months (up to 15 Apr 2020) around 131 deals were made, the breakup of deals are as follows: </p>
<!-- /wp:paragraph -->

<!-- wp:list -->
<ul><li>41 were done between biopharma companies, </li><li>41 between biopharma and govt. organizations/foundations/consortium</li><li>29 between biopharma and universities</li><li>11 between biopharma/medical devices/diagnostics/digital health companies</li><li>9 among  universities and academic institutions</li></ul>
<!-- /wp:list -->

<!-- wp:paragraph -->
<p> <a class=""aioseop-link"" href=""https://www.pharmashots.com/31064/biopharma-drug-development-deals-for-covid-19/"">Click here</a> to read our first part of the article with biopharma drug development deals for COVID-19</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Please contact <a href=""mailto:shiwani@pharmashots.com""><strong>shiwani@pharmashots.com</strong></a> to get this full detailed report including all 131 deals. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>The following 20 deals are in alphabetical order</strong> <strong>as follow:</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>&nbsp;<strong>1. Altimmune Signs a  Development and Commercialization Deal with Janssen </strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32345],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/1-1024x147.png"" alt="""" data-id=""32345"" data-link=""https://www.pharmashots.com/?attachment_id=32345"" class=""wp-image-32345"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 8, 2020 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.2M &nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Altimmune granted Janssen rights to develop and commercialize vaccines for the prevention of COVID-19. Altimmune is eligible for up to $1.2M in development milestones, plus royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>2. Bharat Biotech Research Partnership with Flugen to Develop Coroflu</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32346],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/2-1024x147.png"" alt="""" data-id=""32346"" data-link=""https://www.pharmashots.com/?attachment_id=32346"" class=""wp-image-32346"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 3, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Bharat Biotech signed a research partnership with Flugen to develop a vaccine, CoroFlu based on FluGen's influenza vaccine candidate, M2SR for COVID-19. FluGen's will inject gene sequences from SARS-CoV-2 into M2SR to develop CoroFlu. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>3.</strong> <strong>BioNTech Development and Distribution Deal with Pfizer for BNT162</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32347],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/3-1024x147.png"" alt="""" data-id=""32347"" data-link=""https://www.pharmashots.com/?attachment_id=32347"" class=""wp-image-32347"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>&nbsp;Deal Date: Mar 17, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $748M</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>BioNTech granted Pfizer worldwide (excluding China) rights to co-develop and distribute BioNTech’s mRNA vaccine program, BNT162, for the prevention of COVID-19 infection. On Apr. 9, 2020, the partners disclosed the financial terms where BioNTech will receive $185M, including $72M in cash and $113M in equity and is eligible for up to $563M in milestones. Additionally, both companies will share development costs equally. Initially, Pfizer will be responsible for 100 percent of the development costs and BioNTech will repay Pfizer its 50 percent share of these costs during the commercialization of the vaccine.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>4. BioNTech Development and Commercialization Deal with Fosun Pharma</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32348],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/4-1024x147.png"" alt="""" data-id=""32348"" data-link=""https://www.pharmashots.com/?attachment_id=32348"" class=""wp-image-32348"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 16, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $135M</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>BioNTech granted Fosun Pharma rights to develop and commercialize BioNTech’s mRNA vaccine candidate, BNT162, by leveraging Fosun Pharma’s clinical development, regulatory, and commercial capabilities for the prevention of COVID-19 infections in China. BioNTech is eligible to receive up to $135M, including an undisclosed upfront, a purchase of 1,580,777 ordinary shares of BioNTech for $50M, and undisclosed milestones. Additionally, both companies will share profits from sales in China.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>5.</strong> <strong>Dynavax Research Partnership with Clover to Develop a Vaccine</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32365],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/5-1-1024x147.png"" alt="""" data-id=""32365"" data-link=""https://www.pharmashots.com/?attachment_id=32365"" class=""wp-image-32365"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 24, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Dynavax signed a research partnership with Clover to develop a protein-based vaccine with CpG 1018 adjuvant by using patented Trimer-Tag technology for COVID-19.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>6.</strong> <strong>Emergent BioSolutions Contract Service Deal with Vaxart</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32350],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/6-1024x147.png"" alt="""" data-id=""32350"" data-link=""https://www.pharmashots.com/?attachment_id=32350"" class=""wp-image-32350"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 18, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Emergent BioSolutions signed a contract service deal with Vaxart to provide services to develop and manufacture Vaxart’ s experimental oral vaccine based on VAAST platform for coronavirus.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>7. Generex Development and Commercialization Deal with Beijing Zhonghua and Sinotek-Advocates for COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32351],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/7-1024x147.png"" alt="""" data-id=""32351"" data-link=""https://www.pharmashots.com/?attachment_id=32351"" class=""wp-image-32351"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 2, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $6M</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Generex granted Beijing Zhonghua and Sinotek-Advocates exclusive rights to develop and commercialize a vaccine using Generex's Ii-Key peptide vaccine platform for coronavirus in China. Generex will receive $1M up front and is eligible for up to $5M in development and regulatory milestones, plus undisclosed royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>8. Geovax Research Partnership with Bravovax to Co-Develop a Coronavirus Vaccine </strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32352],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/8-1024x147.png"" alt="""" data-id=""32352"" data-link=""https://www.pharmashots.com/?attachment_id=32352"" class=""wp-image-32352"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Jan 27, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>GeoVax signed a research partnership with BravoVax to co-develop a coronavirus vaccine by using the MVA-VLP vaccine platform for coronavirus.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>9.</strong> <strong>Ginkgo Contract Service Deal with Moderna</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32353],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/9-1024x147.png"" alt="""" data-id=""32353"" data-link=""https://www.pharmashots.com/?attachment_id=32353"" class=""wp-image-32353"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 15, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> Ginkgo signed a contract service deal with Moderna to provide bioengineering know-how, platform infrastructure, and expertise to improve the efficacy of raw materials for the manufacturing of mRNA vaccine, mRNA-1273, for coronavirus.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>10. GSK Research Partnership with Clover to Evaluate A Protein-Based Vaccine For COVID-19 (COVID-19 S-Trimer)</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32354],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/10-1024x147.png"" alt="""" data-id=""32354"" data-link=""https://www.pharmashots.com/?attachment_id=32354"" class=""wp-image-32354"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 24, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>GSK signed a research partnership with Clover to evaluate a protein-based vaccine, COVID-19 S-Trimer, using GSK's pandemic adjuvant system, a Trimer-Tag technology, for coronavirus.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>11.</strong> <strong>GSK Research Partnership with Xiamen Innovax To Develop COVID-19 XWG-03</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32355],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/11-1024x147.png"" alt="""" data-id=""32355"" data-link=""https://www.pharmashots.com/?attachment_id=32355"" class=""wp-image-32355"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 5, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>GSK signed a research partnership with Xiamen Innovax to develop a recombinant protein-based vaccine, COVID-19 XWG-03, using GSK's adjuvant system for the prevention of COVID-19.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>12</strong>. <strong>Hoth Therapeutics and Voltron Therapeutics Research Partnership with Massachusetts General Hospital to Develop a Vaccine</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32356],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/12-1024x147.png"" alt="""" data-id=""32356"" data-link=""https://www.pharmashots.com/?attachment_id=32356"" class=""wp-image-32356"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 2, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Hoth Therapeutics and Voltron Therapeutics signed a research partnership with Vaccine and Immunotherapy Center (VIC) at the Massachusetts General Hospital to co-develop a vaccine using VIC's Self-Assembling Vaccine (SAV) platform for coronavirus.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>13. Immunoprecise Research Partnership with Evqlv To Develop a Vaccine And Antibody for SARS-CoV-2 virus</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32357],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/13-1024x147.png"" alt="""" data-id=""32357"" data-link=""https://www.pharmashots.com/?attachment_id=32357"" class=""wp-image-32357"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>&nbsp;Deal Date: Mar 2, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>ImmunoPrecise signed a research partnership with EVQLV to develop a vaccine and antibodies using EVQLV's in silico antibody design and discovery platform and IPA's discovery technologies for SARS-CoV-2 coronavirus.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>14. Novavax Development and Commercialization Deal with Emergent Biosolutions For Covid-19 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32358],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/14-1024x147.png"" alt="""" data-id=""32358"" data-link=""https://www.pharmashots.com/?attachment_id=32358"" class=""wp-image-32358"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 10, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novavax granted Emergent BioSolutions exclusive rights to its recombinant protein nanoparticle technology and Matrix-M adjuvant to develop vaccine candidate for coronavirus.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>15. Sanofi Research Partnership with GSK to Develop Vaccines </strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32359],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/15-1024x147.png"" alt="""" data-id=""32359"" data-link=""https://www.pharmashots.com/?attachment_id=32359"" class=""wp-image-32359"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 14, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sanofi signed a research partnership with GSK to develop vaccines using Sanofi's S-protein based antigen with GSK's adjuvant technology for coronavirus.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>16. Sanofi Research Partnership with Translate Bio to Develop an mRNA Vaccine </strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32360],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/16-1024x147.png"" alt="""" data-id=""32360"" data-link=""https://www.pharmashots.com/?attachment_id=32360"" class=""wp-image-32360"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 27, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sanofi signed a research partnership with Translate Bio to develop the mRNA vaccine for SARS-CoV-2.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>17.</strong> <strong>Sartorius Contract Service Deal with Cansino Biologics and Institute Of Bioengineering</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32361],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/17-1024x147.png"" alt="""" data-id=""32361"" data-link=""https://www.pharmashots.com/?attachment_id=32361"" class=""wp-image-32361"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 25, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> Sartorius signed a contract service deal with CanSino Biologics and Institute of Bioengineering to access its BIOSTAT STR single-use bioreactor system to develop a vaccine for coronavirus SARS-CoV-2 in China </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>18.</strong> <strong>Sorrento Research Partnership with Smartpharm to Develop Gene-Encoded Antibody Vaccine</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32362],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/18-1024x147.png"" alt="""" data-id=""32362"" data-link=""https://www.pharmashots.com/?attachment_id=32362"" class=""wp-image-32362"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 23, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sorrento signed a research partnership with SmartPharm to develop gene-encoded antibody vaccine for COVID-19 by using monoclonal antibodies against SARS-CoV-2 virus discovered or generated by Sorrento which will be encoded into a gene for delivery using SmartPharm’s non-viral nanoparticle platform. In addition, Sorrento and SmartPharm will develop gene-encoded antibodies that can be administered as prophylaxis against SARS-CoV-2 infection </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>19. Takis Research Partnership with Evvivax to Develop Vaccine for Coronavirus 2019-nCoV</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32363],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/19-1024x147.png"" alt="""" data-id=""32363"" data-link=""https://www.pharmashots.com/?attachment_id=32363"" class=""wp-image-32363"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Jan 27, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: Undisclosed</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Takis signed a research partnership with Evvivax to develop vaccine for coronavirus 2019-nCoV by combining genetic technologies and expertise.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>20. Vir Research Partnership with GSK to Develop Vir-7831 and Vir-7832</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[32364],""linkTo"":""none"",""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/20-1024x147.png"" alt="""" data-id=""32364"" data-link=""https://www.pharmashots.com/?attachment_id=32364"" class=""wp-image-32364"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 6, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $250M</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Vir signed a research partnership with GSK to develop VIR-7831 and VIR-7832 and to identify new anti-viral antibodies using GSK’s expertise in functional genomics with Vir’s CRISPR screening and machine learning approach for the prevention of SARS-CoV-2. Additionally, the partners will develop new vaccine candidates for SARS-CoV-2 by combining GSK’s vaccines technologies and VIR’s expertise to identify neutralising epitopes. Vir will receive $250M in up front equity at $37.73 per share and a 10% premium.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post : </strong><a href=""https://www.pharmashots.com/31064/biopharma-drug-development-deals-for-covid-19/"">Insights+ COVID-19 Deals (Part I): Biopharma Drug Development</a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post :</strong> <a href=""https://www.pharmashots.com/35625/insights-covid-19-deals-part-iii-biopharma-and-govt-institutions/"">Insights+ COVID-19 Deals (Part III): Biopharma and Govt. Institutions</a></p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2020/05/Image20200501194609.png,Top 20,Top COVID-19 Deals,,Altimmune|Beijing Zhonghua|Bharat Biotech|BioNTech|BioPharma|Bravovax|Cansino Biologics|Clover|COVID-19|Deals|Development|Dynavax|Emergent BioSolutions|Evqlv|Evvivax|Flugen|Fosun Pharma|Generex|GeoVax|Ginkgo|GSK|Hoth Therapeutics|Immunoprecise|Janssen|Moderna|Novavax|Pfizer|Sanofi|Sartorius|Sinotek-Advocates|SmartPharm|Sorrento|Takis|Translate|vaccine|Vaxart|Vir|Voltron Therapeutics|Xiamen Innovax|Top 20,publish,5/1/2020,17
35625,Top COVID-19 Deals (Part III): Biopharma and Govt. Institutions,,"<!-- wp:list -->
<ul><li>The emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at unprecedented speed to develop vaccines, treatments, and kits</li><li>This article covers the last six months of deal data provided by Chris Dokomajilar of DealForma</li><li>&nbsp;During the last six months (up to Jun 25, 2020) around 403 deals were made, the breakup of deals are as follows:</li></ul>
<!-- /wp:list -->

<!-- wp:list -->
<ul><li>&nbsp;&nbsp; &nbsp;107 were done between biopharma companies,</li><li>&nbsp;&nbsp; &nbsp;88 between biopharma and govt. organizations/foundations/consortium</li><li>&nbsp;&nbsp;&nbsp; 61 between biopharma and universities</li><li>&nbsp;&nbsp; &nbsp;60 between biopharma/medical devices/diagnostics/digital health companies</li><li>&nbsp;&nbsp;&nbsp; 33 among universities and academic institutions</li></ul>
<!-- /wp:list -->

<!-- wp:paragraph -->
<p>We have compiled a list of 20 deals among biopharma companies and government organizations based on transaction values.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>1. <strong>Barda Contract Service Deal with AstraZeneca to Develop Azd1222 Recombinant Adenovirus Vaccine</strong></strong> <strong>(formerly ChAdOx1 nCoV-19)</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35635],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/1-1-1024x147.png"" alt="""" data-id=""35635"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/1-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35635"" class=""wp-image-35635"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: May 21, 2020</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.2B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>BARDA signed a contract service deal with AstraZeneca to develop and manufacture the AZD1222 recombinant adenovirus vaccine (formerly ChAdOx1 nCoV-19) for COVID-19. AZD1222 was developed by Oxford University's Jenner Institute, working with the Oxford Vaccine Group. AstraZeneca to manufacture 400 million doses and secure total manufacturing capacity for 1 billion doses by September 2020. AstraZeneca to receive $1B from BARDA to support P-III development.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>2.</strong> <strong>Johnson &amp; Johnson Research Partnership with BARDA</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35636],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/2-1-1024x147.png"" alt="""" data-id=""35636"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/2-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35636"" class=""wp-image-35636"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Feb 11, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Johnson &amp; Johnson (J&amp;J) signed a research partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop a vaccine using Janssen's AdVac and PER.C6 technologies for the treatment of coronavirus disease (COVID-19). Additionally, J&amp;J to upscale the vaccine manufacturing facility. Financials were not disclosed but BARDA to fund the P-I study to accelerate the development of a vaccine candidate.&nbsp;&nbsp; On Mar 30, 2020, J&amp;J selected the lead vaccine candidate for coronavirus disease and expected to initiate the human study by Sep 2020. Johnson &amp; Johnson intends to launch the Vaccine in early 2021 with a global supply of over one billion. BARDA and J&amp;J to co-fund the vaccine development program more than $1B, plus an additional undisclosed commitment from BARDA.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>3.</strong> <strong>BARDA Contract Service Deal with Phlow</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35637],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/3-2-1024x147.png"" alt="""" data-id=""35637"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/3-2.png"" data-link=""https://www.pharmashots.com/?attachment_id=35637"" class=""wp-image-35637"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: May 19, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.81B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>BARDA signed a contract service deal with Phlow to manufacture up to 1.6M doses of five essential generic medicines used in the prevention of COVID-19, including medicines for sedation, pain management, and certain antibiotics. Phlow to receive $354M upfront with an option payment of $458M from BARDA.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>4. Emergent BioSolutions Contract Service Deal with Health &amp; Human Services</strong> <strong>(HHS)</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35638],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/4-1-1024x147.png"" alt="""" data-id=""35638"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/4-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35638"" class=""wp-image-35638"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Jun 01, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.68M</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Emergent BioSolutions signed a contract service deal with Health &amp; Human Services to manufacture COVID-19 vaccines. Emergent BioSolutions to receive $542.7M. Additionally, HHS to provide $85.5M for the expansion of product fill/finish capacity.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>5. BARDA Grant to Moderna for its mRNA-1273 SARS-CoV-2 Vaccine</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35639],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/5-1-1024x147.png"" alt="""" data-id=""35639"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/5-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35639"" class=""wp-image-35639"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Apr 16, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.48B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Moderna received $483M as a grant from the Biomedical Advanced Research and Development Authority (BARDA) to develop Moderna's mRNA vaccine candidate, mRNA-1273 for SARS-CoV-2.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>6. Government of Canada Grant to AbCellera to Discover Antibodies for the Treatment of COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35640],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/6-1-1024x147.png"" alt="""" data-id=""35640"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/6-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35640"" class=""wp-image-35640"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: May 03, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.175B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>AbCellera received $175.6M as a grant from the Government of Canada to discover antibodies for the prevention of COVID-19 and to build technology and manufacturing infrastructure for antibody therapies.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>7.</strong> <strong>SiO2 Materials Science Contract Service Deal with BARDA</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35642],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/7-1-1024x147.png"" alt="""" data-id=""35642"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/7-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35642"" class=""wp-image-35642"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Jun 08, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.143B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>SiO2 Materials Science signed a contract service deal with the Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) in partnership with the Biomedical Advanced Research and Development Authority (BARDA) to accelerates the production of SiO2 Materials' primary packaging platform for storing vaccines and therapeutics of SARS-CoV-2. SiO2 to receive $143M for the contract.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>8.</strong> <strong>HHS-DOD Defense Production Act (DPA) Contract Service Deal with ApiJect for Population-scale Emergency Drug Injection Solution</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35643],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/8-1-1024x147.png"" alt="""" data-id=""35643"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/8-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35643"" class=""wp-image-35643"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: May 12, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.138B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The U.S. Department of Health and Human Services and Department of Defense signed a contract service deal with ApiJect under the Defense Production Act (DPA) to accelerate the development of high-speed population-scale emergency drug injection solutions with prefilled syringes through its subsidiary RAPID USA under its emergency program Project Jumpstart. ApiJect to receive $138M for the contract.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>9.</strong> <strong>Novavax Contract Service Deal with the US Department of Defense</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35644],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/9-1-1024x147.png"" alt="""" data-id=""35644"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/9-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35644"" class=""wp-image-35644"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Jun 04, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.06B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novavax signed a contract service deal with the US Department of Defense to manufacture the antigen component and Matrix-M adjuvant component of the vaccine, NVX-CoV2373 for 10 million doses of vaccine for the prevention of COVID-19. Novavax to receive $60M from DoD.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>10. BARDA Contract Service Deal with Emergent Biosolutions to Develop Plasma-Based Therapeutics for COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35645],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/10-1-1024x147.png"" alt="""" data-id=""35645"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/10-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35645"" class=""wp-image-35645"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Apr 09, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.036B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>BARDA signed a contract service deal with Emergent Biosolutions to develop plasma-based therapeutics for COVID-19. Emergent's Center for Innovation in Advanced Development and Manufacturing to conduct the research and to receive $14.5M from BARDA and is eligible to receive up to $22M for additional development.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>11.</strong> <strong>BARDA Contract Service Deal with Genentech to Develop Actemra for COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35647],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/11-1-1024x147.png"" alt="""" data-id=""35647"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/11-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35647"" class=""wp-image-35647"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Apr 06, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.025B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>BARDA signed a contract service deal with Genentech to develop Actemra for the treatment of COVID-19. Genentech to receive $25M from BARDA to support the development.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>12. BARDA Grant to SAB Biotherapeutics</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35648],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/12-1-1024x147.png"" alt="""" data-id=""35648"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/12-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35648"" class=""wp-image-35648"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Apr 02, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.016B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>SAB Biotherapeutics along with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) to receive $7.2M as a grant from BARDA to complete manufacturing and preclinical studies, with an option to conduct a P-I study of SAB-185 for the treatment of COVID-19. &nbsp;On Apr 16, 2020, BARDA expanded the contract, and SAB Biotherapeutics to receive up to $9.4M.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>13.</strong> <strong>BARDA Grant to Emergent to Develop COVID-HIG</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35654],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/13-1-1024x147.png"" alt="""" data-id=""35654"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/13-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35654"" class=""wp-image-35654"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Apr 02, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.014B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Emergent BioSolutions to receive $14.5M as a grant from BARDA to develop COVID-HIG, a human plasma-derived therapy candidate for the prevention of SARS-CoV-2.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>14.</strong> <strong>DOD Contract Service Deal with Ology Bioservices for COVID-19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35655],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/14-2-1024x147.png"" alt="""" data-id=""35655"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/14-2.png"" data-link=""https://www.pharmashots.com/?attachment_id=35655"" class=""wp-image-35655"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Mar 23, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.014M</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The Department of Defense (DOD) signed a contract service deal with Ology Bioservices for the development and manufacturing of monoclonal antibodies for the prevention of Coronavirus disease, COVID-19. Ology to receive $14M.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>15. Ology Bioservices and Inovio Contract Service Deal with Department of Defense</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35656],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/15-1-1024x147.png"" alt="""" data-id=""35656"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/15-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35656"" class=""wp-image-35656"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Mar 24, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.011B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Ology Bioservices and Inovio signed a contract service deal with the Department of Defense to manufacture Inovio's DNA vaccine (INO-4800) for prevention of COVID-19 virus infection to deliver the vaccine rapidly and efficiently to the Department of Defense. Ology Bioservices to receive $11.9M from the Department of Defense.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>16.</strong> <strong>Government of Quebec Grant to Medicago</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35657],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/16-2-1024x147.png"" alt="""" data-id=""35657"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/16-2.png"" data-link=""https://www.pharmashots.com/?attachment_id=35657"" class=""wp-image-35657"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Mar 21, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.007B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Medicago to receive $7M as a grant from the Government of Quebec to develop a vaccine for the prevention of COVID-19.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>17.</strong> <strong>Horizon 2020 Grant to Cobra Biologics</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35658],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/17-1-1024x147.png"" alt="""" data-id=""35658"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/17-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35658"" class=""wp-image-35658"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Mar 30, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.003B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Cobra Biologics and Karolinska Institutet to receive $3.3M as a grant from Horizon 2020 to develop phase I clinical trial testing of a DNA vaccine for the prevention of COVID-19.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>18. NIH Grant to CytoAgents</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35659],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/18-1-1024x147.png"" alt="""" data-id=""35659"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/18-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35659"" class=""wp-image-35659"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date:May 13 , 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.001B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>CytoAgents to receive a $1.6M Phase-2 SBIR grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) to develop GP1681 for the prevention of Influenza and COVID-19.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>19. Israel Innovation Authority (IIA) Grant to Enlivex</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35660],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/19-1-1024x147.png"" alt="""" data-id=""35660"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/19-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35660"" class=""wp-image-35660"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: Apr 13 , 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.001B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Enlivex to receive $1.5M as a grant from Israel Innovation Authority (IIA) to develop Allocetra for the prevention of COVID-19 and organ dysfunction associated with sepsis.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>20. NIH Grant to Adjuvance</strong></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[35661],""linkTo"":""none""} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/20-1-1024x147.png"" alt="""" data-id=""35661"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/20-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=35661"" class=""wp-image-35661"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Date: May 19, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.001B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Adjuvance to receive $1.47M as a grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to evaluate TQL1055 for the prevention of COVID-19.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><strong>Related Post :&nbsp;</strong></strong><a href=""https://www.pharmashots.com/31064/biopharma-drug-development-deals-for-covid-19/"">Insights+ COVID-19 Deals (Part I): Biopharma Drug Development</a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post:&nbsp;</strong><a href=""https://www.pharmashots.com/32271/biopharma-vaccine-development-deals-for-covid-19/"">Insights+ COVID-19 Deals (Part II): Biopharma Vaccine Development</a></p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2020/06/Top-20.png,Top 20,Top COVID-19 Deals,,AbCellera|Actemra|Adjuvance|ApiJect|AstraZeneca|BARDA|Cobra Biologics|CytoAgents|DOD|Emergent|Enlivex|Government of Canada|Government of Quebec|Health &amp; Human Services|HHS-DOD Defense Production Act|Horizon 2020|Inovio|Israel Innovation Authority|Johnson &amp; Johnson|Medicago|Moderna|NIH|Novavax|Ology Bioservices|Phlow|SAB Biotherapeutics|SiO2 Materials Science|US Department of Defense,publish,6/26/2020,17
15083,Top 10 Oncology Companies By 2018 Revenue,,"<!-- wp:paragraph -->
<p><strong>The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top oncology companies are now developing more advanced, effective, and tolerable drugs to improve treatment outcomes and the patient experience. Roche proved to be on top 10 list of Oncology companies. Our team at PharmaShots has compiled a list of top 10 oncology companies based on their 2018 total revenue.</strong></p>
<!-- /wp:paragraph -->

<!-- wp:html -->
<a href=""#""><img alt="" "" src=""https://public.tableau.com/static/images/To/Top20OncologyCompaniesby2018Revenue/Top20BioPharmaCompanies/1_rss.png"" style=""border: none""></a>   
<p></p>
<!-- /wp:html -->

<!-- wp:paragraph -->
<p><strong>10. ABBVIE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $32.73B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Total Employees: ~30,000 &nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $3.93B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Pharma Segment Revenue:</strong> <strong>$32.73B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1900&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong> <strong>Headquarter: Illinois, United States&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$114.73B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>AbbVie is a global, research-based biopharmaceutical company that develops therapies majorly for Chronic Autoimmune Diseases, Oncology, Virology with additional targets like cystic fibrosis and women's health. In Apr’18, AbbVie initiated P-III trial for the combination therapy of Imbruvica + Venclexta vs chlorambucil plus Gazyva (obinutuzumab) to treat 1L chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). AbbVie’s key product Humira (adalimumab) is a biologic therapy and is approved in the US, Canada, Mexico, and EU. In Dec’18, AbbVie pact a deal with Lupin to develop novel therapies for cancer.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>9. ELI LILLY</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $24.55B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~38,680 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $4.26B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharma Segment Revenue: $22.93B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1901&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: Indiana, United States&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$112.52B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Eli Lilly and Company is a global pharmaceutical firm focused on delivering therapies in two divisions Human Pharmaceutical products and Animal Health products. The pharmaceutical portfolio offers products for Cardiovascular, Endocrinology, Immunology, Neuroscience, and Oncology. In Q4’18, Lilly’s Verzenio was approved in Japan and EU for metastatic breast cancer. In 2018 Lilly expanded its oncology portfolio by acquisition of Loxo Oncology.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>8. ASTRAZENECA</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $22.09B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~50,000 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $6.02B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharma Segment Revenue: $21.04B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1999&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: Cambridge, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$51.5B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>AstraZeneca is a global, biopharmaceutical company focusing on Oncology, Respiratory, Neurology, Autoimmune and other therapy areas. In Dec’18 AstraZeneca and Merck’s Lynparza (olaparib) received FDA’s approval as 1L treatment for BRCA-Mutated Advanced Ovarian Cancer. In early 2018 AstraZeneca granted Innate Pharma the commercialization rights for Lumoxiti in the US and EU. The company also has the PD molecule Imfinzi, an approved product for bladder and lung cancer.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>7. PFIZER</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $53.64B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~92,400</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $7.20B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharma Segment Revenue: $53.64B &nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1849&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: New York, United States </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$232.96B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Pfizer is a research-based, global biopharmaceutical company having a vast portfolio including Oncology, Medicines, Vaccine and other health care products for the prevention &amp; treatment of untreated diseases. In 2018, Pfizer’s leading Oncology drugs Vizimpro (dacomitinib), Talzenna (talazoparib) and Lorbrena (lorlatinib) received FDA’s approvals for NSCLC, Breast Cancer and ALK+ NSCLC respectively.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>6. MERCK &amp; CO.</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $42.29B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~69,000 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $8.24B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharma Segment Revenue: $42.29B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1891&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$205.15B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Merck &amp; Co. is a global health care company delivering innovative health care products with its Prescription medicines, Oncology drugs, Vaccines, Biologic therapies and Animal Health care products. In Mar’18, Merck and Eisai signed worldwide collaboration for the co-development and co-commercialization of Eisai’s Lenvima. Merck has numerous successful therapies in its portfolio including Keytruda with net sales of $7.17B in 2018 and has 900+ trials for Keytruda including 600+ in oncology</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>5. JOHNSON &amp; JOHNSON </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $81.58B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~135,100</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $9.84B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharma Segment Revenue: $40.73B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1887&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$350.76B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Johnson &amp; Johnson (J&amp;J) is an American multinational medical device, pharmaceutical, and consumer packaged goods manufacturing company. The pharmaceutical department of the company focuses on Immunology, Oncology, Infectious Diseases and Vaccines, Neuroscience, Cardiovascular and Metabolism and the medical device sector is focused on Orthopedics and Cardiovascular Disease solutions. Johnson’s Oncology portfolio generated total revenue of $9.8B in 2018 exceeding 35.6% to 2017.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>4. BRISTOL-MYERS SQUIBB </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $22.56B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~23,300</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $10.31B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharma Segment Revenue: $22.56B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1989&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$75.05B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Bristol-Myers Squibb is an American pharmaceutical company focused on Oncology, Cardiovascular, Immuno-Science, and Fibrosis. Its blockbusters drug Opdivo (nivolumab) used for cancer has generated sales of $6.7B in 2018. In Dec’18 the company collaborated with Vedanta Biosciences for the development of combination therapies for Advanced or Metastatic Cancers. BMS acquired Celgene in 2019 to strengthen its portfolio of Oncology, Immunology, Inflammation, and Cardiology.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>3. NOVARTIS</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $51.9B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~125,161 Employees&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $13.42B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharma Segment Revenue: $42.3B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1996&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: Basel, Switzerland </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$216.96B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: SIX Swiss Exchange, NYSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novartis is a multinational group of companies specializing in the research, development, manufacture and marketing drugs which is divided into two categories: Novartis Oncology and Novartis Pharmaceuticals. The Oncology portfolio offers drugs in areas of Cancer and Hematologic disorders. While the pharma portfolio offers in Ophthalmology, Neuroscience, Immunology, Hepatology including Dermatology and Respiratory. In Dec’18 the company acquired Endocyte to strengthen its portfolio of nuclear medicine and radioligand therapy used for treating cancer.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>2. CELGENE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $15.42B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~16,962</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $13.65B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharma Segment Revenue: $15.26B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:</strong> <strong>1986&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$66.70B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NASDAQ </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Celgene is an integrated global biopharmaceutical company focused on developing therapies in Oncology, Immunology, Hematology, and Inflammatory Diseases. Celgene’s one of the leading Cancer drug Revlimid is in P-III trials including Otezla, is evaluated in patients with r/r follicular or marginal zone lymphoma &amp; Behcet's disease respectively. Additionally, in 2018 Celgene expanded its collaboration with Dragonfly for Solid and Hematological Cancers. In 2019, Celgene is acquired by BMS for $74B.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>1. ROCHE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $56.91B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Total Employees: ~92,400</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $26.06B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharma Segment Revenue: $44.10B&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1849&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: New York, United States&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$226.50B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Roche Holding AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche’s Oncology portfolio is currently focusing on Breast, Bladder, Cervical, Ovarian, Liver, etc. In 2018, Roche achieved good growth in both the divisions and delivered therapies like Xofluza (baloxavir marboxil) for influenza and targets serious diseases like cancer, multiple sclerosis, &amp; hemophilia.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>*Companies listed above are based on oncology segment revenue. Celgene and BMS <br>oncology segment revenue has been taken prior to acquisition.</p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2019/05/Top-10-Oncology1.png,Top 20,Top 20 Oncology Companies,,AbbVie|AstraZeneca|Bristol-Myers Squibb|Celgene|Companies|Eli Lilly|JandJ|Merck|Novartis|Oncology|Pfizer|Revenue|Roche|Top 20,publish,5/31/2019,17
52031,Top 20 Animal Health Companies Based on 2019 Revenue,,"<!-- wp:paragraph -->
<p>Healthy animals contribute to the elimination of hunger and sustainable food production. The diseases that affect animal health also affect humans. Tackling them while they are present in animals not only safeguards our health, but it is also easier, more effective, and less expensive to address. Monitoring animal health and preventing animal disease outbreaks is vital to the economy and safety of the food supply. Production of healthy livestock helps to ensure a safe food supply and keep consumer prices stable. In the top 20 ledgers, Zoetis ensured the top position with total revenue of $6.26B. Our team at PharmaShots has compiled the report of the top 20 Animal Health companies based on the 2019 animal health revenue.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52057,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/20-1024x165.png"" alt="""" class=""wp-image-52057""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $0.07B&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1954</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $3.2B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~11,696</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Novo mesto, Slovenia, Europe</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: WSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>KRKA is an international generic pharmaceutical company. The Company produces prescription and over-the-counter drugs for the treatment of cardiovascular, gastrointestinal, infectious, central nervous system, blood, respiratory tract, musculoskeletal, urogenital, and dermatological diseases. Krka’s modern animal health products provide effective and simple management of the most important bacterial infections, parasitic diseases, and pain control.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52058,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/19-1024x163.png"" alt="""" class=""wp-image-52058""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $0.09B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1988</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $0.11B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~220</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: North Yorkshire, England</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: LON</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Animalcare Group is an international veterinary sales and marketing organization operating in seven countries and exports to approximately 32 countries in Europe and a further 16 worldwide. The Group develops and supplies veterinary pharmaceutical products and services to support the veterinary profession.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52059,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/18-1024x163.png"" alt="""" class=""wp-image-52059""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $0.096B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1917</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $0.11B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~3,265</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Espoo, Finland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Orion is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The newest addition to Orion's proprietary products is the prescription medicine Sileo (dexmedetomidine) oromucosal gel for dogs suffering from acute noise anxiety.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52060,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/17-1024x192.png"" alt="""" class=""wp-image-52060""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $0.097B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>&nbsp;Founded Year: 1972</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $0.20B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~217</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: New Malden, England</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: LON</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Eco Animal Health Group PLC is a United Kingdom-based engaged in the manufacture and marketing of animal health products. The company's product portfolio includes Aivlosin - macrolide antibiotic for the treatment of respiratory and enteric diseases in pigs and poultry; Ecomectin, Ecoheart, Ecotraz, and Ecomintic for treatment and prevention of parasites in cattle, sheep, pigs, horses, and dogs and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52061,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/16-1024x160.png"" alt="""" class=""wp-image-52061""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $0.12B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1988</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $1.19B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~386</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Loveland, Colorado, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Heska was created by veterinary professionals for veterinary professionals dedicated to perfecting and supporting the core technology and services that truly impact the quality of pet care and help to ensure positive outcomes for veterinarians and their patients. Heska provides state-of-the-art chemistry, hematology, and blood gas &amp; electrolyte systems, single-step heartworm, early renal health screens, allergy testing, and allergy treatment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52062,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/15-1024x159.png"" alt="""" class=""wp-image-52062""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue:&nbsp; $0.15B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1987</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $0.30B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~1200</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: São Paulo, Brazil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: BVMF</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Ouro Fino Saude Animal is engaged in the production and sale of veterinary drugs, vaccines, and other products for cattle, pigs, poultry, sheep, horses, goats, and pets. The company’s reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidians, Antimicrobials, Biological, Ectoparasiticides, Endectocides, Fortifiers / Supplements, and others.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52063,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/14-1024x157.png"" alt="""" class=""wp-image-52063""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue:&nbsp;&nbsp; $0.15B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2002</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $O.49B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~1,700</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Bangalore, India</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sequent Scientific Ltd is an India-based integrated pharmaceutical company operating an animal and a human health division. The Company operates in three segments which include active pharmaceutical ingredients (API), Analytical Services, and Animal Health. The Company’s APIs in animal health include Albendazole, Buparavaquone, Butaphosphan and Nitroscanate, and others.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52064,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/13-1024x156.png"" alt="""" class=""wp-image-52064""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $0.41B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1981</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $3.84B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~1,764</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Lansing, Michigan, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Neogen develops and markets products and services dedicated to food and animal safety. The company's diagnostic products are used by food and animal producers to test for foodborne bacteria, food allergen, natural toxins, drug, and chemical residues, plant diseases, and quality assurance.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52065,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/12-1024x155.png"" alt="""" class=""wp-image-52065""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $0.44B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1933</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $1.24B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~2,372</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Lure, France</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: EPA</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Vetoquinol is a veterinary pharmaceutical laboratory that develops, manufactures, and markets veterinary drugs and non-medicinal products and services in Europe, North America, and Asia-Pacific. With a presence in 24 countries through its subsidiaries, its strong network of 100 distributor partners provides visibility for its products in more than 80 countries.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52066,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/11-1024x156.png"" alt="""" class=""wp-image-52066""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $0.52B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1955</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: -&nbsp;N/A</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~1,375</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Chiyoda-ku, Tokyo</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: -</strong> <strong>N/A</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Kyoritsu Seiyaku Corporation manufactures drugs for animals. It develops, manufactures, and distributes various drugs for animals, pet care products, veterinary diet, and pet food, as well as provides veterinary services. Kyoritsu Seiyaku also offers human pharmaceuticals such as infertility and osteoporosis treatment drugs.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52067,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/10-1024x152.png"" alt="""" class=""wp-image-52067""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $0.60B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1997</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $4.87B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~1,753</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Lostock Gralam, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: LON</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Dechra Pharmaceuticals is an international pharmaceutical business focused on the veterinary market, with its key area of specialization being the development and marketing of companion animal products. The Company is engaged in the development, manufacturing, and marketing of products for veterinarians.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52068,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/9-1024x151.png"" alt="""" class=""wp-image-52068""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $0.80B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1946</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $0.77B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~1,700</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Teaneck, New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Phibro Animal Health is an animal health and mineral nutrition company. The Company offers antibacterials, anticoccidials, anthelmintics, vaccines, and nutritional products for the treatment of animals and serves personal care, industrial chemical, and chemical catalyst industries worldwide.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52069,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/8-1024x150.png"" alt="""" class=""wp-image-52069""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $1.05B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1968</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $2.08B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~4,900</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Carros, France</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: EPA</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Virbac is a France-based veterinarian pharmaceutical company specialized in the development and production of vaccines and medicines for domestic animals and livestock. Its development is focused mainly on formulating drugs designed to prevent or cure certain animal diseases.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52070,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/7-1024x149.png"" alt="""" class=""wp-image-52070""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $1.76B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1863</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $55.67B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~1,03,824</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Leverkusen, Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: ETR</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Bayer is a life science company, and its segments include Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. Bayer’s Animal Health segment is engaged in the development, production, and marketing of prescription and nonprescription veterinary products. Bayer has completed the sale of its Animal Health business unit to Elanco in Aug 2020.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52071,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/6-1024x190.png"" alt="""" class=""wp-image-52071""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue:&nbsp; $2.25B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1983</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $38.82B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~9,200</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Westbrook, Maine, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Idexx Laboratories provides diagnostic, detection, and information systems for veterinary, food, and water testing applications. The Company also operates an international network of veterinary reference laboratories and offers its products to customers worldwide.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52072,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/5-1024x146.png"" alt="""" class=""wp-image-52072""/><figcaption> </figcaption></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $3.07B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1954</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $14.14B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~5,760</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Greenfield, Indiana, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Elanco is a global animal health company that develops, manufactures, and markets products for companion and food animals and serves clients worldwide. Elanco acquired Bayer AG's animal health unit in a deal valued at $7.6B, creating one of the biggest stand-alone veterinary medicine companies in the world.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52073,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/4-1024x146.png"" alt="""" class=""wp-image-52073""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $3.97B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2018</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $3.37B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~5,500</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Portland, Maine</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Covetrus is a global animal-health company that provides animal-health technology and services. The Company combines practice management software, prescription management, multi-channel client engagement services, and supply chain infrastructure to promote connectivity between veterinarians and their clients worldwide.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52077,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/3-1-1024x150.png"" alt="""" class=""wp-image-52077""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $4.39</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>&nbsp;<strong>Founded Year: 1891</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $205.08B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~71,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Kenilworth, New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>MSD Animal Health, a division of Merck provides services and technologies, to prevent, treat, and control diseases across all major farm and companion animal species. It consists of commercial offices in more than 50 countries and business operations in more than 150 markets and runs a global network of manufacturing and R&amp;D facilities</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52075,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/02-1024x144.png"" alt="""" class=""wp-image-52075""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $4.53B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1885</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;-</strong> <strong>N/A</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~51,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Ingelheim Am Rhein, Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: -</strong> <strong>N/A</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Boehringer Ingelheim serves clients worldwide, researches, develops, and manufactures pharmaceutical products, as well as offers prescription medicines and consumer health care products for human and animal health. The Boehringer Ingelheim Animal Health business is a global leader in the animal health industry and a part of Boehringer Ingelheim.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":52076,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/11/01-1024x176.png"" alt="""" class=""wp-image-52076""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Revenue: $6.26B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2012</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;$78.40B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~10,600</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Madison, New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Zoetis is a global leader in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products with a focus on both livestock and companion animals. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post: </strong><a href=""https://pharmashots.com/50844/top-20-immunology-companies-based-2019-immunology-segment-revenue/""><strong>Top 20 Immunology Companies Based 2019 Immunology Segment Revenue</strong></a></p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2020/11/TOP-20-1.jpg|https://pharmashots.com/wp-content/uploads/2020/11/20.png|https://pharmashots.com/wp-content/uploads/2020/11/19.png|https://pharmashots.com/wp-content/uploads/2020/11/18.png|https://pharmashots.com/wp-content/uploads/2020/11/17.png|https://pharmashots.com/wp-content/uploads/2020/11/16.png|https://pharmashots.com/wp-content/uploads/2020/11/15.png|https://pharmashots.com/wp-content/uploads/2020/11/14.png|https://pharmashots.com/wp-content/uploads/2020/11/13.png|https://pharmashots.com/wp-content/uploads/2020/11/12.png|https://pharmashots.com/wp-content/uploads/2020/11/11.png|https://pharmashots.com/wp-content/uploads/2020/11/10.png|https://pharmashots.com/wp-content/uploads/2020/11/9.png|https://pharmashots.com/wp-content/uploads/2020/11/8.png|https://pharmashots.com/wp-content/uploads/2020/11/7.png|https://pharmashots.com/wp-content/uploads/2020/11/6.png|https://pharmashots.com/wp-content/uploads/2020/11/5.png|https://pharmashots.com/wp-content/uploads/2020/11/4.png|https://pharmashots.com/wp-content/uploads/2020/11/02.png|https://pharmashots.com/wp-content/uploads/2020/11/01.png|https://pharmashots.com/wp-content/uploads/2020/11/3-1.png|https://pharmashots.com/wp-content/uploads/2020/11/Top-20.jpg,Top 20,Top 20 Animal Health Companies,,AnimalCare|Bayer|Boehringer Ingelheim|Covertus|Dechra Pharmaceutical|Eco Animal Health|Elanco|Heska|Idexx|KRKA|Kyoritsu Seiyaku|Merck|Neogen|Orion|Ouro Fino Sade Animal|Phibro Animal Health|SeQuent Scientific Limited|Vetoquinol|Virbac|Zoetis,publish,11/12/2020,17
20970,Top 20 Biopharma Acquisitions of 2018 Based on the Total Deal Value,,"<!-- wp:paragraph -->
<p>Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology, neuroscience, oncology, rare diseases, and plasma-derived therapies. This article is based on the 2018 deals data as provided by Chris Dokomajilar of <a href=""https://dealforma.com/"">DealForma</a>. Our team at PharmaShots compiled a list of top 20 acquisitions of 2018 based on their total deal value.   </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21198} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/20.png"" alt="""" class=""wp-image-21198"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Takeda Acquired TiGenix </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Jan 5, 2018&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $600M&nbsp; &nbsp;&nbsp; &nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Takeda acquired TiGEnix for EUR 1.78 per share for a total of approximately EUR 520M ($600M) in cash. The acquisition strengthened Takeda’s late-stage gastroenterology pipeline and presence in the US specialty care market. In 2016, Takeda and TiGenix signed an exclusive WW ex-US license deal to develop and commercialize Cx601 (darvadstrocel). The acquisition was completed in July 2018.   </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21199} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/19.png"" alt="""" class=""wp-image-21199"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Emergent Acquired Adapt</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Aug 28, 2018&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $735M&nbsp;  &nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Emergent acquired Adapt for $635M up front and up to $100M in sales based contingent payments. The acquisition strengthened Emergent's opioid-based drug abuse portfolio. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21200} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/18.png"" alt="""" class=""wp-image-21200"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Roche Acquired Tusk with its Pre-clinical Immuno-Oncology Programs </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Sept 28, 2018 &nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $760M&nbsp; &nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Roche acquired Tusk Therapeutics, a pre-clinical immuno-oncology company developing antibodies to deplete regulatory T-cells in tumors. Roche continued to develop the antibody. Turk's portfolio of other immune-oncology targets spun off into Black Belt Therapeutics. Tusk shareholders received $81.2M up front and were eligible for up to $678.9M in contingent payments.&nbsp; </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21201} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/17.png"" alt="""" class=""wp-image-21201"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Novo Nordisk Acquired Ziylo for its Glucose Binding Molecule Platform</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Aug 17, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $800M+&nbsp; &nbsp; &nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novo Nordisk acquired Ziylo for $800M up front plus undisclosed contingent payments. The acquisition strengthened Novo's metabolic portfolio to develop glucose responsive insulins. Separate from the acquisition, certain pipeline compounds spun off into a new company, Carbometrics. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21202} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/16.png"" alt="""" class=""wp-image-21202"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>PTC Acquired Agilis</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Jul 19, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $945M&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>PTC Therapeutics acquired Agilis Biotherapeutics for $50M up front, $150M in its common stock, and up to $745M in contingent payments, plus a 2% to 6% royalty to Agilis shareholders. The acquisition strengthened PTC's rare monogenic disease portfolio. The acquisition completed on August 23, 2018. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21203} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/15.png"" alt="""" class=""wp-image-21203"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Janssen Biotech Acquired Benevir Biopharm with its Preclinical Oncolytic
Virus Therapies </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: May 3, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.04B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Janssen Biotech acquired BeneVir Biopharm for $1.04B in up front and  potential milestone payments. The acquisition strengthened Janssen's oncology portfolio. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21204} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/14.png"" alt="""" class=""wp-image-21204"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Lundbeck Acquired Prexton Therapeutics</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 16, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.1B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Lundbeck acquired Prexton for $1.11B. The acquisition strengthened Lundbeck's neurology portfolio. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21205} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/13.png"" alt="""" class=""wp-image-21205"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Alexion Acquired Syntimmune </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Sept 26, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.2B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Alexion acquired Syntimmune. The acquisition strengthened Alexion's portfolio of antibody therapeutics targeting the Fc receptor (FcRn). Syntimmune shareholders received $400M up front and are eligible for up to $800M in contingent payments. On November 2, 2018, Alexion Pharmaceuticals completed the acquisition of Syntimmune.&nbsp; </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21206} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/12.png"" alt="""" class=""wp-image-21206"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Eli Lilly Acquired Armo BioSciences</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: May 9, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.37B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Eli Lilly acquired ARMO BioSciences for $1.6B at a 66% premium, for each $50.00 per share. The acquisition strengthened Lilly's immuno-oncology portfolio.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21208} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/11.png"" alt="""" class=""wp-image-21208"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Novartis Acquired Endocyte </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Nov 18, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.1B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novartis acquired Endocyte. The acquisition strengthened Novartis' radiopharmaceuticals portfolio. Endocyte shareholders received is $24 per share, valued at approximately $2.1B. On December 21, 2018, Novartis completed the acquisition of Endocyte.&nbsp; </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21210} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/10.png"" alt="""" class=""wp-image-21210"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>JNJ Acquired Ci:z</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Nov 23, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.1B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Johnson &amp; Johnson acquired Ci:z Holdings. The acquisition strengthened JNJ's science-based dermo-cosmetic beauty products portfolio and market presence in Japan. Ci:z shareholders received &nbsp;$52.3 per share at a 55% premium, or approximately $2B. The acquisition completed on January 17, 2019.&nbsp;&nbsp; </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21255} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Image-10.png"" alt="""" class=""wp-image-21255"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Advent International Purchased Zentiva Generic Unit</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 19, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.4B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Advent International purchased Zentiva, a generic business unit of Sanofi. Sanofi received $2.4B. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21254} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Image20190927152248.png"" alt="""" class=""wp-image-21254"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Boston Scientific Acquired BTG </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> Deal Date: Nov 20, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $4.3B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Boston Scientific acquired BTG. The acquisition strengthened Boston's peripheral interventions portfolio. BTG shareholders received $1.07 per share, or approximately $4.2B, which represents a 36.6% premium. The acquisition closed on August 19, 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21214} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/07.png"" alt="""" class=""wp-image-21214"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Sanofi Acquired Ablynx</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Jan 29, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $4.66B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sanofi acquired Ablynx for $4.8B (€3.9B) at $49.64 (€45) per share in cash and a premium of 21%. Ablynx had a previous offer from Novo Nordisk, which it rejected. That offer was for  €2.6B. Sanofi and Ablynx have partnered since July 2017 to find new treatments for inflammatory diseases. Ablynx's lead product is caplacizumab for thrombotic thrombocytopenic purpura. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21221} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/06-1.png"" alt="""" class=""wp-image-21221"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>GSK Acquired TESARO </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Dec 3, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $5.1B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>GlaxoSmithKline acquired TESARO for $75 per share in cash. The acquisition strengthened GSK's oncology pipeline and commercial capabilities in oncology. TESARO shareholders received an aggregate cash consideration of roughly $5.1B (£4.0B). The acquisition price of $75/share represents a 110% premium to TESARO’s 30 day Volume Weighted Average Price of $35.67. On January 22, 2019, GSK completed the acquisition of TESARO. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21222} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/05.png"" alt="""" class=""wp-image-21222"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><a><strong> </strong></a> <strong>Celgene Acquired Impact Biomedicines </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Jan 7, 2018 </strong>  </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $7B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Celgene acquired Impact Biomedicines for approximately $1.1B in cash up front and up to $1.4B in contingent payments based on the approval of fedratinib for myelofibrosis and other indications. Fedratinib is in P-III tested for myelofibrosis. Impact is also eligible for additional sales-based milestone payments. Starting from global annual net sales of $1B, aggregate tiered sales-based milestone payments could total a maximum of $4.5B if the global annual net sales exceeded $5B. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21223} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/04-1.png"" alt="""" class=""wp-image-21223"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Novartis Acquired Avexis </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 9, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $8.7B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novartis acquired gene therapy company AveXis for $218 per share, or approximately $8.7B. AveXis' compounds were based on its AAV9 gene therapy technology with its lead compound AVXS-101, being developed for SMA along with others in development for Rett Syndrome. Novartis completed the acquisition on May 15, 2018. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21224} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/03-1.png"" alt="""" class=""wp-image-21224"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Celgene Acquired Juno</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Jan 22, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $10.4B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Celgene acquired Juno Therapeutics for $9B. Previously, Celgene owned 9.7% of shares in Juno. The acquisition strengthened Celgene's cellular immunotherapy portfolio.<strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21226} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/02-1.png"" alt="""" class=""wp-image-21226"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Sanofi Acquired Bioverativ for $11.6B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Jan 22, 2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $11.6B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sanofi acquired Bioverativ for $11.6B at a premium of 64% to the January 19, 2018 closing price. The acquisition strengthened Sanofi's rare blood disorders pipeline. <strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":21227} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/01.png"" alt="""" class=""wp-image-21227"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Takeda Acquired Shire </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: May 8, 2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $57.17B</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Takeda acquired Shire. Shire shareholders received $30.33 in
cash and either 0.839 new Takeda shares or 1.678 Takeda ADSs at a premium of
64.4%.</p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2019/09/main.png,Top 20,Top 20 Life Sciences Deals,,Ablynx|Acquisitions|Adapt|Advent International|Agilis|Alexion|ARMO BioSciences|AveXis|Based|BeneVir Biopharm|Bioverativ|Boston Scientifi|BTG|Celgen|Celgene|Ci:z|Deal|Eli Lilly|Emergent|Endocyte|GlaxoSmithKline|Impact Biomedicine|Janssen|Johnson and Johnson|Juno Therapeutics|Lundbeck|Novartis|Novo Nordisk|Prexton|PTC Therapeutics|Roche|Sanofi|Shire|Syntimmune|Takeda|Tesaro|TiGEnix|Top 20|Total|Tusk Therapeutics|Value|Zentiva|Ziylo,publish,9/27/2019,17
13911,Top 20 BioPharma Companies based on 2018 Total Revenue,,"<h1 style=""color: #404040;font-style: normal"">Top 20 BioPharma Companies based on 2018 Total Revenue</h1>

<!-- wp:paragraph -->
<p><strong>The global pharma companies have been advancing their pipelines with emerging needs of patients. Pharma companies are also focusing on diagnostics &amp; devices, which were emerged as one of major revenue generator in 2018, with the development of new products and devices. The year 2018 also proved to be a record with approval of 55 novel drugs. The top 20&nbsp;companies&nbsp;on the ledger changed from their 2017 ranking, leading to major ups &amp; downs in the positions. Johnson and Johnson again proved to be the among the highest rank in 2018 generating revenue of $81.5B. Our team at PharmaShots has compiled a list of top 20 pharma companies based on their 2018 total revenue.</strong></p>
<!-- /wp:paragraph -->

<!-- wp:html -->
<div class=""tableauPlaceholder"" id=""viz1556714099464""><a href=""#""><img alt="" "" src=""https://public.tableau.com/static/images/To/Top20BioPharmaCompaniesby2018Revenue/Top20BioPharmaCompanies/1_rss.png"" style=""border: none""></a>   </div>                                    var divElement = document.getElementById('viz1556714099464');                    var vizElement = divElement.getElementsByTagName('object')[0];                    vizElement.style.width='100%';vizElement.style.height=(divElement.offsetWidth*0.75)+'px';                    var scriptElement = document.createElement('script');                    scriptElement.src = 'https://public.tableau.com/javascripts/api/viz_v1.js';                    vizElement.parentNode.insertBefore(scriptElement, vizElement);
<!-- /wp:html -->

<!-- wp:image {""id"":13599} -->
<figure><img src=""http://pharmashots.com/wp-content/uploads/2019/04/Biogen.png"" alt="""" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $13.45B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~7,800 &nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $10.86B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: $2.56B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp;</strong>&nbsp;<strong>1978 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: Massachusetts, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$46B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Biogen is a global biopharmaceutical company focusing on neurology with a broad portfolio including Tecfidera, Avonex, Plegridy, Tysabri and Fampyra. Biogen has expanded its business in 2018, with the acquisition of BIIB100 &amp; BIIB110 candidates from Karyopharm and AliveGen respectively and further collaborated with Pfizer for BIIB100. The company has expanded its partnership with Ionis Pharmaceuticals with ten year agreement for the development of&nbsp;antisense&nbsp;oligonucleotide&nbsp;(ASO) drug candidates in neurological diseases. Biogen has also entered into a research collaboration with C4 Therapeutics (C4T) for its novel protein degradation platform.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":13600} -->
<figure><img src=""http://pharmashots.com/wp-content/uploads/2019/04/Celgene.png"" alt="""" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $15.42B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~16,962</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $15.26B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: $0.01B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:</strong>&nbsp;<strong>1986&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$66B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Celgene is an integrated global biopharmaceutical company focused on developing therapies for cancer &amp; inflammatory diseases. Celgene’s numerous key products are in P-III trials including Revlimid, Otezla, evaluated in patients with r/r follicular or marginal zone lymphoma &amp; Behcet’s disease respectively. In 2019, Celgene has been acquired by BMS for $74B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":13601} -->
<figure><img src=""http://pharmashots.com/wp-content/uploads/2019/04/allergan.png"" alt="""" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $15.78B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~17,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $15.42B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: $0.36B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1950 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: Dublin, Ireland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$48B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Allergan is an Irish pharmaceutical company focused on developing &amp; commercializing pharmaceuticals, devices, biologic, surgical and regenerative medicine for the people around the globe. Allergan didn’t has much difference in revenue in comparison to its 2017 revenue. Allergan’s blockbuster products, Botox cosmetic, Botox therapeutic, Vraylar, and Juvederm added nearly $1B to its 2018 revenue.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":13602} -->
<figure><img src=""http://pharmashots.com/wp-content/uploads/2019/04/Novonordisk.png"" alt="""" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $16.90B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~43,202</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $16.67B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: $0.23B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1989&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: Bagsværd, Denmark</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$97B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: Copenhagen </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novo Nordisk is a global healthcare company focusing on therapies for Diabetes, Obesity, Hemophilia and growth disorders. 2018 was a progressive year for Novo Nordisk as it reached its target with the launch of Ozempic for the treatment of Type-2 Diabetes. Novo Nordisk is expected to increase its sales by 2-5% in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":13603} -->
<figure><img src=""http://pharmashots.com/wp-content/uploads/2019/04/teva-1.png"" alt="""" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $18.854B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~45,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $17.48B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: $1.36B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:</strong>&nbsp;<strong>1944 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: Petah Tikva, Israel</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$16B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Teva Pharmaceutical is an Israeli multinational pharmaceutical company focused on generics, specialty medicines and biopharmaceuticals. Company’s specialty portfolio includes Capaxone for multiple sclerosis, Ajovy for the treatment of migraine &amp; Austedo for movement disorder. Teva’s biosimilars (developed by Celltrion) were approved by the FDA in 2018, including Truxima &amp; Herzuma biosimilar to rituximab &amp; trastuzumab respectively.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":13605} -->
<figure><img src=""http://pharmashots.com/wp-content/uploads/2019/04/astrazeneca.png"" alt="""" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $22.09B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~50,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $21.04B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: $1.04B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp; 1999&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: Cambridge, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$105.8B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Exchange: LSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>AstraZeneca is a global, biopharmaceutical company focusing on Oncology, Respiratory, Neurology, Autoimmune and other therapy areas. In Dec’18 AstraZeneca and Merck’s Lynparza (olaparib) received FDA’s approval as 1L treatment for BRCA-Mutated Advanced Ovarian Cancer and signed an immune-oncology clinical collaboration with AVEO oncology. In May’18 AstraZeneca has also received FDA’s approval for its&nbsp;Lokelma&nbsp;(sodium zirconium&nbsp;cyclosilicate) for the treatment of hyperkalemia in adults.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":13608} -->
<figure><img src=""http://pharmashots.com/wp-content/uploads/2019/04/Gilead.png"" alt="""" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $22.12B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~11,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $21.67B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: $0.45B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1987&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$84B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Gilead Sciences is a research-based biopharmaceutical company with a broad portfolio of drugs. Biktarvy, Descovy, Odefsey, Genvoya, Stribild are approved in the US &amp; EU for HIV infection in adults. Biktarvy received FDA’s approval in Feb’18 for the treatment-naive HIV-1 infected in adults.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":13609} -->
<figure><img src=""http://pharmashots.com/wp-content/uploads/2019/04/BMS.png"" alt="""" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $22.56B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~23,300</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $22.56B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1989&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$75B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Bristol-Myers Squibb (BMS) is an American pharmaceutical company focused on Oncology, Cardiovascular, Immunology and Fibrosis. Its blockbuster drugs, Opdivo (nivolumab) for cancer &amp; Eliquis as anticoagulant positioned BMS in the top 20 global pharma companies. BMS remained to be in the highlights, with its acquisition of Celgene in early 2019. The acquisition will boost up BMS’ pipeline in Oncology, Immunology, Inflammation &amp; Cardiology.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":13610} -->
<figure><img src=""http://pharmashots.com/wp-content/uploads/2019/04/Amgen.png"" alt="""" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $23.74B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~21,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $22.53B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: $1.2B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1980 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$120B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Amgen is one of the leading biotechnology company developing novel therapies focused on Cardiology, Oncology, Neurology, Nephrology, and Inflammatory diseases. The company’s total revenue increased by 7%, leading to a total increment of $6.2B. The company recently launched products Repatha (evolocumab), Prolia (denosumab), Kyprolis (carfilzomib) and Xgeva (denosumab) which presented a double- digit growth.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":13611} -->
<figure><img src=""http://pharmashots.com/wp-content/uploads/2019/04/Lilly.png"" alt="""" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $24.55B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees:&nbsp; ~38,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $22.93B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: $1.62B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1901&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: Indiana, United States&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$139B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Eli Lilly and Company is a global pharmaceutical firm focused on developing therapies in the areas of diabetes, lung cancer, osteoporosis &amp; men’s health. In Sep’18, Lilly’s animal health business Elanco completed its IPO on NYSE. In 2018, it had collaborated with Hydra Biosciences, AC immune to develop immune &amp;&nbsp;neurodegenerativetherapies respectively. The&nbsp;FDA&nbsp;granted fast track designation to Lilly’s Olumiant for SLE in Dec’18.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":13612} -->
<figure><img src=""http://pharmashots.com/wp-content/uploads/2019/04/Abbott.png"" alt="""" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $30.57B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~103,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $9.43B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: $21.14B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1900&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: Illinois, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$130B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Abbott Laboratories is an American healthcare company with a broad pipeline of generics, diagnostic, natural products, Cardiovascular and Neuromodulation products. In 2018, Abbott received FDA’s approval for the Advisor HD grid mapping catheter, sensor enabled MitraClip, a heart valve repair device, HeartMate 3 left ventricular assist device (LVAD), XIENCE Sierra drug eluting stent system</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":13613} -->
<figure><img src=""http://pharmashots.com/wp-content/uploads/2019/04/abbvie.png"" alt="""" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $32.73B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~30,000 &nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $32.73B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1900&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: Illinois, United States&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$122B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>AbbVie&nbsp;is a global, research-based biopharmaceutical company that develops therapies majorly for Chronic autoimmune diseases, Oncology, Virology with additional targets like cystic fibrosis and Women’s health. In Oct’18 Health Canada approved AbbVie’s Orilissa (elagolix) for pain associated with endometriosis.&nbsp;Its blockbuster&nbsp;product Humira (adalimumab) is a biologic therapy and is approved in multiple countries globally. In Dec’18, AbbVie pact a deal with Lupin to develop novel therapies for cancer.</p>
<!--",,https://pharmashots.com/wp-content/uploads/2019/07/Top-20-BioPharma-Companies-based-on-2018-Total-Revenue-e1562326777257.png,Top 20,Top 20 BioPharma Companies,,Abbott|AbbVie|Allergan|Amgen|AstraZeneca|Bayer|Biogen|BioPharma|Bristol-Myers Squibb|Celgene|Companies|Eli Lilly|Gilead|GSK|Johnson n Johnson|Merck|Novartis|Novo Nordisk|Pfizer|Roche|Sanofi|Teva|Top 20|Total,publish,5/1/2019,17
31711,Top 20 BioPharma Companies based on 2019 Total Revenue,,"<!-- wp:list -->
<ul><li>The global biopharma companies are developing novel therapies &amp; devices which is, in turn, enhancing their portfolio and encouraging them in this undergoing competition to stay in the topmost position</li><li>The top 20 companies’ chartbusters changed their 2019 ranking, but the history of Johnson and Johnson did not change and it continued being at the top again in 2019 as well with a generated revenue of $82.05B</li><li>PharmaShots has compiled a list of top 20 biopharma companies based on their 2019 total revenue</li></ul>
<!-- /wp:list -->

<!-- wp:paragraph -->
<p><strong>You can also get a PDF version of this report by contacting me through email at <a href=""mailto:shiwani@pharmashots.com"">c</a></strong><strong><a href=""mailto:shiwani@pharmashots.com"">o</a></strong><strong><a href=""mailto:shiwani@pharmashots.com"">n</a></strong><strong><a href=""mailto:shiwani@pharmashots.com"">n</a></strong><strong><a href=""mailto:shiwani@pharmashots.com"">e</a></strong><strong><a href=""mailto:shiwani@pharmashots.com"">c</a></strong><a href=""mailto:shiwani@pharmashots.com""><strong>t</strong></a><a href=""mailto:shiwani@pharmashots.com""><strong>@pharmashots.com</strong></a><strong>. </strong></p>
<!-- /wp:paragraph -->

<!-- wp:html -->
<div class=""tableauPlaceholder"" id=""viz1588069356680""><a href=""#""><img alt="" "" src=""https://public.tableau.com/static/images/To/Top20BioPharmaCompaniesby2019Revenue/Top20BioPharmaCompanies/1_rss.png"" style=""border: none""></a>   </div>  
<!-- /wp:html -->

<!-- wp:image {""id"":31757} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/image.png"" alt="""" class=""wp-image-31757""/></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total
Revenue:
$14.37B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;Total Employees: ~7,400&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $14.37B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp; 1978&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarter: Massachusetts, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market
Cap:
~$55.03B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Biogen is a global biopharma company focused on neurology with a broad portfolio including Tecfidera, Avonex, Plegridy, Tysabri, and Fampyra. In 2019, Eisai and Biogen terminated their two P-III clinical trial studies of Elenbecestat (E2609) for Early Alzheimer’s Disease. Additionally, in Mar 2019, Fujifilm acquired Biogen’s Danish biologics manufacturing facility for $890M for the expansion of their bio CDMO business further providing Biogen tax relaxation?. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31758} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/image-1.png"" alt="""" class=""wp-image-31758""/></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue:
$16.08B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Employees: ~17,400</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $16.08B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:
1950&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: Dublin, Ireland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:
~$58.01B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Exchange: NYSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Allergan is an Irish pharma company focused on developing and commercializing pharmaceutical products, biologics, and regenerative medicine around the globe. In Jul 2019, Allergan voluntarily recalled BIOCELL Textured Breast Implants and Tissue Expanders? as a precaution following the US FDA’s notification on global safety of breast implant-associated with anaplastic large cell lymphoma (BIA-ALCL). In Dec 2019, Allergan with its partner Amgen filed a BLA to the US FDA for its ABP 798 (biosimilar, rituximab) which is approved for RA, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) in the US and EU. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31759} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/image-2.png"" alt="""" class=""wp-image-31759""/></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue:
$16.88B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Employees: ~40,039</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $16.88B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1944&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Headquarter: Petah Tikva, Israel</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$9.30B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Stock Exchange: NYSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Teva Pharmaceutical is an Israeli multinational pharma company focused on generics, specialty medicines, and biopharmaceuticals. Teva completed its two-year major restructuring plan in 2019, reducing its cost base by over $3B and net debt by more than $9B. Teva's worldwide restructuring was started in Dec 2017 leading to the closure or sale of 13 manufacturing sites and shutting down almost 40 offices and labs. In Jul 2019, Teva reported the results of Fremanezumab in P-IIIb FOCUS study to treat migraine in adults. Additionally,&nbsp;in Nov 2019, Teva with its partner Celltrion launched Truxima (biosimilar, Rituxan) in the US.&nbsp;&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31760} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/image-3.png"" alt="""" class=""wp-image-31760"" /><figcaption></figcaption></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $18.13B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~57,071</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $7.53B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Pharma Segment Revenue: $10.59</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:
1800&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter:
Darmstadt, Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$12.83
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Exchange: ETR &nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Merck KGaA is a German pharma company that develops therapies in the areas of oncology, neurodegenerative, autoimmune &amp; inflammatory diseases, cardiovascular, fertility, endocrinology, and over-the-counter products. In Mar 2019, Merck KGaA terminated its P-III JAVELIN Ovarian PARP 100 Study with Pfizer targeted for Advanced Ovarian Cancer due to its unmet needs of benefit observed in combination with avelumab. The company also showed some interest in AI by signing an agreement with Iktos for its Artificial Intelligence (AI) Technology in Mar 2019. In Q1’20 the company divested its Allergopharma, its allergen immunotherapy subsidiary to Dermapharm while focusing on the development of therapies for patients with difficult-to-treat diseases. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31761} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/image-4.png"" alt="""" class=""wp-image-31761"" /><figcaption></figcaption></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Total Revenue:
$18.33B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
Employees: ~43,258</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $18.33B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1989&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Headquarter: Bagsværd, Denmark</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:
~$105.16B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: Copenhagen </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novo Nordisk is a global healthcare company focusing on therapies for diabetes, obesity, hemophilia, and growth disorders. In Sep 2019, Novo Nordisk’s Rybelsus (semaglutide) received the US FDA’s approval as the first oral GLP-1 analog for T2D patients. In Nov 2019, the company signed an exclusive license agreement with UBE Industries for its UD-014, which is currently in evaluation for its anti-inflammatory MOA and antioxidative effect on endothelial cells, targeted for NASH. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31762} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/image-5.png"" alt="""" class=""wp-image-31762""/></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $22.31B&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
Employees:&nbsp; ~33,625</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $22.31B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1901&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Headquarter: Indiana, United States </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:
~$132.49B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Eli Lilly and Company is a global pharmaceutical firm
focused on developing therapies in the areas of diabetes, lung cancer,
osteoporosis &amp; men’s health. In Aug 2019, ? Eli Lilly signed a license
agreement with Innovent to develop and commercialize OXM3 in China. In Q2’19
Eli Lilly launched its Emgality in the US to treat Cluster headache and is
currently evaluated in P-III in Japan. In Q4’19 Eli Lilly’s Baqsimi received
the EU’s approval to treat severe hypoglycemia and was launched in the US in
late Q3’19.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31763} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/image-6.png"" alt="""" class=""wp-image-31763""/></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $22.44B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Total Employees: ~11,800</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $22.44B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1987&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Headquarter: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:
~$95.60B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Gilead Sciences is a research-based
biopharmaceutical company with a broad portfolio of drugs. In Jul 2019, Gilead
signed an exclusive worldwide license agreement with Durect for its HIV and
Hepatitis B products. In Oct 2019, Gilead received the US FDA’s approval for
Descovy (emtricitabine) to treat HIV Pre-Exposure Prophylaxis. Additionally, in
Q1’20 Gilead acquired Forty-Seven for $4.9B to strengthen its immune-oncology
portfolio with the addition of Forty Seven’s magrolimab, FSI-174 &amp; FSI-189.
</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31764} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/image-7.png"" alt="""" class=""wp-image-31764""/></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $23.36B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~23,400</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $23.26B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1980&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Headquarter: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:
~$122.96B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NASDAQ </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Amgen is one of the leading biotechnology company developing novel therapies focused on cardiology, oncology, neurology, nephrology, and inflammatory diseases.&nbsp;In Oct 2019, the company received Health Canada approval for EVENITY (romosozumab) to treat osteoporosis in postmenopausal women at high risk for fracture. In Nov 2019, Amgen acquired stakes in BeiGene for the expansion of its Oncology Portfolio in China.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31765} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/image-8.png"" alt="""" class=""wp-image-31765""/></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue:
$24.38B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;Total Employees: ~50,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $24.38B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp;
1999&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter:
Cambridge, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:
~$102.72B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>AstraZeneca is a global, biopharmaceutical company focused on oncology, respiratory, neurology, autoimmune, and other therapy areas. The AstraZeneca’s Oncology product Tagrisso alone generated revenue of $3.189B in 2019. In Aug 2019, AstraZeneca with its Partner Fibrogen received the NMPA’s approval for Roxadustat to treat anemia in non-dialysis-dependent patients with chronic kidney disease in China. In early Q1’20 AstraZeneca divested its hypertension therapies portfolio to Atnahs Pharma for $390M. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31766} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/image-9.png"" alt="""" class=""wp-image-31766""/></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue:
$26.14B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;Total Employees: ~30,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $26.14B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:
1887&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:
~$123.06B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Bristol-Myers Squibb (BMS) is an American pharmaceutical company focused on oncology, cardiovascular, immunology, and fibrosis. BMS completed acquisition of Celgene in Nov 2019 after the announcement of it in early 2019. In Jun 2019, BMS signed an agreement to sell its manufacturing facility to Catalent to maintain its footprints in Italy. Additionally, in Dec 2019 the company divested its UPSA Consumer Health Business to Taisho for $1.6B with the focus to develop treatments in serious diseases further strengthening Taisho’s OTC platform. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31767} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/image-10.png"" alt="""" class=""wp-image-31767""/></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue: $31.90B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Total Employees: ~107,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $4.48B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Non-Pharma Segment Revenue: $27.39B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1900&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Headquarter: Illinois, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:
~$139.91B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Abbott Laboratories is an American healthcare company with a broad pipeline of generics, diagnostic, natural products, cardiovascular and neuromodulation products along with medical devices and diagnostics. In early Q2’19, Abbott signed an agreement with Banyan Biomarkers to develop Traumatic Brain Injury (TBI) assessment blood test for patients with traumatic brain injury in the US. In Apr 2020, Abbott launched its third a lab-based serology blood test to detect AB, IgG that identifies a person with COVID-19.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":31768} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/04/image-11.png"" alt="""" class=""wp-image-31768"" /><figcaption></figcaption></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:p",,https://pharmashots.com/wp-content/uploads/2020/04/top-20a.png,Top 20,Top 20 BioPharma Companies,,Abbott|AbbVie|Allergan|Amgen|AstraZeneca|Bayer|Biogen|BioPharma Companies|BMS|Eli Lilly|Gilead|GSK|J&amp;J|Merck &amp; Co|Merck KGaA|Novartis|Novo Nordisk|Pfizer|Revenue|Roche|Sanofi|Teva|Top 20,publish,4/24/2020,17
58267,Top 20 BioPharma Companies based on 2020 Total Revenue,,"<!-- wp:list -->
<ul><li>Despite having the global Covid-19 pandemic, the biopharma companies were involved in multiple M&A and licensing deals. The major focus of the year remains the production and distribution of vaccines to combat the COVID-19 globally</li><li>All of the Biopharma companies on our list are on the front line to combat this global crisis. The top 20 companies on the list changed from their 2019 ranking, leading to major ups &amp; downs in the positions</li><li>J&amp;J remains at the top with a revenue of $82.5B, followed by Roche &amp; Bayer with $65.95B &amp; $50.62B respectively. PharmaShots has compiled a list of the top 20 biopharma companies based on their 2020 total revenue</li></ul>
<!-- /wp:list -->

<!-- wp:image {""align"":""center"",""id"":58270,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/20-1024x175.jpg"" alt="""" class=""wp-image-58270""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue: &nbsp;$13.44B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $13.44B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp; 1978</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;&nbsp;&nbsp;&nbsp;$268.02B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~</strong> <strong>9,100</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Massachusetts,United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. In Mar 2020, Biogen acquired BIIB118 (CK1 inhibitor) from Pfizer, while in Oct 2020 collaborated with Denali to co-develop &amp; co-commercialize Denali’s LRRK2 inhibitors for PD.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58271,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/19-1024x174.jpg"" alt="""" class=""wp-image-58271""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;$16.65B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp;&nbsp; $16.65B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1944</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp; $11.34B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~40,216</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Petah Tikva, Israel</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Teva is a global pharmaceutical company that deals with generics, specialty, and over-the-counter products. In Jan 2020 and Mar 2020, the company launched Herzuma (trastuzumab-pkrb) a trastuzumab biosimilar, in Canada and the US, respectively.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58272,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/18-1024x173.jpg"" alt="""" class=""wp-image-58272""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;&nbsp; $20.86B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $20.86B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1989</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp; $69.25B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~45,323</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Bagsværd, Denmark</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: Copenhagen</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Novo Nordisk is a global healthcare company, and a leader in diabetes and obesity care. It has a strong presence in other chronic diseases such as NASH, CV, and AD. In 2020, Novo Nordisk’s Rybelsus got approved in the EU, the UK, and Japan.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58273,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/17-1024x171.jpg"" alt="""" class=""wp-image-58273""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;$21.44B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp;&nbsp;$8.11B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1800</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: &nbsp;&nbsp;$173.48B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~$58,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: $13.33B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Darmstadt, Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: ETR</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>The Merck Group, commonly known as Merck KGaA, is a German multinational science and technology company and its focus includes oncology, immuno-oncology, and neurology &amp; immunology. In Jun’2019, the US FDA has approved IND for M5049 to treat Covid-19 pneumonia.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58274,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/16-1024x169.jpg"" alt="""" class=""wp-image-58274""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;&nbsp;$23.92&nbsp;B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp;&nbsp;$17.62B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1885</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: &nbsp;&nbsp;&nbsp;Nil</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~</strong> <strong>52,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: $6.3B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Ingelheim am Rhein, Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: Nil</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Boehringer Ingelheim is a research-driven biopharmaceutical company and has three core business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Boehringer Ingelheim reinforced its position in immune-oncology therapies by acquiring shares in the Northern Biologics, which was subsequently renamed BI IO Canada.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58275,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/15-1024x168.jpg"" alt="""" class=""wp-image-58275""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;&nbsp; $24.53B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp; $24.53B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1901</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;&nbsp; $182.32B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~34,960</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Indiana, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Eli Lilly is an American pharmaceutical company headquartered in Indianapolis, Indiana. The company develops, manufactures, and markets products in one business segment i.e human pharmaceutical products. In 2020, Baricitinib was granted EUA for suspected or laboratory confirmed COVID-19, in combination with remdesivir, in hospitalized adults and pediatric patients.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58276,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/14-1024x166.jpg"" alt="""" class=""wp-image-58276""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;&nbsp;&nbsp; $24.69B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp;&nbsp;&nbsp; $24.69B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1987</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;&nbsp;&nbsp; $65.60B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~ 13,600</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. In 2020, Gilead entered 18 partnerships and acquisitions to enhance its commercial portfolio and clinical pipeline across multiple therapeutic areas which include the acquisition of Immunomedics that added Trodelvy and other pipeline programs to our oncology portfolio.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58277,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/13-1024x165.jpg"" alt="""" class=""wp-image-58277""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp; $25.40B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp;&nbsp; $25.40B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1980</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: &nbsp;&nbsp;&nbsp;$248.12B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~ 22,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Amgen is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In Dec 2020, the US FDA has approved d Riabni, a biosimilar to Rituxan (rituximab), for adult patients with NHL, CLL, granulomatosis with polyangiitis, and microscopic polyangiitis and was launched in the US in Jan 2021.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58278,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/12-1024x163.jpg"" alt="""" class=""wp-image-58278""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;&nbsp; $26.60B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $26.60B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp; 1999</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $131.78B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~76,100</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Cambridge, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>AstraZeneca is a global pharmaceutical focusing on Oncology; Cardiovascular, Renal &amp; Metabolism and Respiratory &amp; Immunology. In May’2020, AZ collaborated with RedX and got an exclusive global license to develop &amp; commercialize RXC006 targeting fibrotic diseases including IPF.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58279,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/11-1024x162.jpg"" alt="""" class=""wp-image-58279""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $34.60B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue: $4.30B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1900</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $120.11B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~109,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: $30.3B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Illinois, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Illinois. It has four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The products in the pharmaceutical segment include Creon, Duphaston, Lipanthyl, TriCor, Serc, etc.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58317,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/10-1-1024x161.jpg"" alt="""" class=""wp-image-58317""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;&nbsp;&nbsp; $41.90B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp; $41.90B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1849</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $35.91B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~ 1,01,200</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Pfizer Inc. is a research-based, global biopharmaceutical company. In Apr 2020, it collaborated with BioNTech to develop, manufacture, and commercialize an mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19.  While in Nov 2020, it spun off Upjohn Business with Mylan, which created a new global generic pharmaceutical company, Viatris.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58281,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/09-1024x161.jpg"" alt="""" class=""wp-image-58281""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp; $42.51B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$42.51B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1887</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;&nbsp;&nbsp; $62.06B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~30,250</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Bristol-Myers Squibb (BMS) is an American pharmaceutical company focused on oncology, cardiovascular, and immunology. In Oct 2020, BMS obtained a global exclusive license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life cytokine DF6002. Later it has completed the acquisition of MyoKardia &amp; Forbius in Nov &amp; Sep 2020 respectively.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58282,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/08-1024x160.jpg"" alt="""" class=""wp-image-58282""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;&nbsp; $44.07B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Revenue:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $30.19B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1973</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $100.34B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~ 99,412</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: $13.88B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Paris, France</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: EPA</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sanofi is a global healthcare leader in vaccines providing healthcare solutions in 170+ countries around the world. In 2020, Sanofi entered into multiple agreements which include its collaboration with Kiadis Pharma, Kymera Therapeutics, Principia Biopharma and has completed the acquisition of Synthorx for $68/ share in cash, representing an aggregate equity value of ~$2.5B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58283,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/07-1024x158.jpg"" alt="""" class=""wp-image-58283""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;&nbsp;&nbsp; $45.80B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $45.80B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2012</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;&nbsp;&nbsp;&nbsp;$105.21B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~47,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Illinois, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>AbbVie is a global, research-based biopharmaceutical company that develops therapies majorly for chronic autoimmune diseases, oncology, virology with additional targets like cystic fibrosis and women’s health and has an enriched pipeline in immunology and neuroscience. The company completed Allergan’s acquisition which enhances its growth platform.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58284,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/06-1024x157.jpg"" alt="""" class=""wp-image-58284""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp; $46.59B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp; $30.84B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2000&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;&nbsp;&nbsp;&nbsp; $90.76B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~ 94,066</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: $15.75B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Brentford, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: LON</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>GSK is a global healthcare company serving the world with drugs, vaccines &amp; consumer healthcare products and is a leader in the areas of respiratory and HIV. In 2020, GSK collaborated with Sanofi to develop an adjuvanted COVID-19 vaccine and allied with VIR and Innovax to combat COVID-19.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58285,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/05-1024x156.jpg"" alt="""" class=""wp-image-58285""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;&nbsp;&nbsp; $47.99B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp; $43.02B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1891</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;&nbsp;&nbsp; $76.12B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 74,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: $4.97B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: NewJersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Merck &amp; Co. is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products<strong>. </strong>In Feb’2020, Merck announced its intention to spin-off products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through distribution of Organon’s publicly traded stock to the company shareholders. The spin-off is expected to be completed late in the Q2’21.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58286,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/04-1024x155.jpg"" alt="""" class=""wp-image-58286""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $48.66B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp;&nbsp;$48.66B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1996</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: &nbsp;&nbsp;&nbsp;$86.62B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~105,794</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Basel, Switzerland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: SIX Swiss Exchange, NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Novartis is a multinational group of companies specializing in research, development, manufacturing, and marketing with a broad range of healthcare solutions including generic and ophthalmic therapies. In Nov’2020, Novartis has secured a global license to Mesoblast’s cell therapy remestemcel-L in the treatment of COVID-19 while its Tabrecta got FDA’s approval for NSCLC with METex14 in May’2020.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58287,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/04/03-1024x153.jpg"" alt="""" class=""wp-image-58287""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Revenue:&nbsp;&nbsp; $50.62B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Pharma Segment Revenue:&nbsp;&nbsp; $21.08B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1863</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $63.33B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~99,538</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Non-Pharma Segment Revenue: $29.54B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Leverkusen, Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: ETR</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Bayer is a leading life science firm with three divisions pharmaceuticals, consumer health, and crop science. In Sept’2020, Bayer completed the acquisition of 100% of the shares in biotech company KaNDy, further expanding its development portfolio in women’s health while in Dec’2020, it acquired Asklepios BioPharmaceutical.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":58288,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploa",,https://pharmashots.com/wp-content/uploads/2021/04/Website-Size-1.png|https://pharmashots.com/wp-content/uploads/2021/04/20.jpg|https://pharmashots.com/wp-content/uploads/2021/04/19.jpg|https://pharmashots.com/wp-content/uploads/2021/04/18.jpg|https://pharmashots.com/wp-content/uploads/2021/04/17.jpg|https://pharmashots.com/wp-content/uploads/2021/04/16.jpg|https://pharmashots.com/wp-content/uploads/2021/04/15.jpg|https://pharmashots.com/wp-content/uploads/2021/04/14.jpg|https://pharmashots.com/wp-content/uploads/2021/04/13.jpg|https://pharmashots.com/wp-content/uploads/2021/04/12.jpg|https://pharmashots.com/wp-content/uploads/2021/04/11.jpg|https://pharmashots.com/wp-content/uploads/2021/04/10.jpg|https://pharmashots.com/wp-content/uploads/2021/04/09.jpg|https://pharmashots.com/wp-content/uploads/2021/04/08.jpg|https://pharmashots.com/wp-content/uploads/2021/04/07.jpg|https://pharmashots.com/wp-content/uploads/2021/04/06.jpg|https://pharmashots.com/wp-content/uploads/2021/04/05.jpg|https://pharmashots.com/wp-content/uploads/2021/04/04.jpg|https://pharmashots.com/wp-content/uploads/2021/04/03.jpg|https://pharmashots.com/wp-content/uploads/2021/04/02.jpg|https://pharmashots.com/wp-content/uploads/2021/04/01.jpg|https://pharmashots.com/wp-content/uploads/2021/04/Top-20.jpg|https://pharmashots.com/wp-content/uploads/2021/04/Website-Size.png|https://pharmashots.com/wp-content/uploads/2021/04/10-1.jpg,Top 20,Top 20 BioPharma Companies,,Abbott Laboratories|AbbVie|Amgen|AstraZeneca|Bayers|BioPharma Companies|Boehringer Ingelheim|Bristol Myers Squibb|Eli Lilly And Co.|Gilead Sciences|GlaxoSmithKline|Johnson and Johnson|Merck &amp; Co.|Merck KGA|Novartis|Novo Nordisk|Pfizer|Revenue|Roche|Sanofi|Teva|Top 20,publish,4/8/2021,17
56030,Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value,,"<!-- wp:list -->
<ul><li>The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination.</li><li>Sanofi and Hanmi’s agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology, lapscovery. The second position goes to the Merck KGaA termination of its development and commercialization deal with Pfizer &nbsp;</li><li>This article is based on the 2020 biopharma deals data provided by Chris Dokomajilar of DealForma. PharmaShots has compiled a list of the top 20 terminations of 2020 based on total deal value</li></ul>
<!-- /wp:list -->

<!-- wp:image {""align"":""center"",""id"":56043,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/20-1024x153.jpg"" alt="""" class=""wp-image-56043"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Sanofi Terminated its 2015 Agreement with Hanmi</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Nov. 2015, Hanmi granted Sanofi exclusive, worldwide rights to its protein/peptide discovery technology, lapscovery to develop and commercialize a late-stage GLP1-RA agonist, efpeglenatide weekly insulin, and a fixed-dose weekly GLP-1-RA/insulin drug combination for the treatment of diabetes. Additionally, Hanmi had an exclusive option to co-commercialize the products in Korea and China. Hanmi received $434.7M up front and was eligible for up to $3.8B in development, regulatory, and sales-based milestones, plus double-digit royalties. In May 2020, Sanofi terminated the agreement and Hanmi regained worldwide rights.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56044,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/19-1024x153.jpg"" alt="""" class=""wp-image-56044"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Merck KGaA Terminated its Development and Commercialization Deal with Pfizer</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Merck KGaA partnered with Pfizer to jointly develop &amp; commercialize MSB0010718C for multiple types of cancer. The companies would develop the Ab as a single agent and in combination with Pfizer's and Merck KGaA's portfolio of approved and investigational oncology therapies. Both companies would collaborate on up to 20 immuno-oncology clinical development programs expected to commence in 2015, including up to 6 trials in P-II or P-III. Pfizer and Merck KGaA also partnered separately to co-promote Pfizer's Xalkori in the US and other markets. Merck KGaA received $850M up front and was eligible to receive up to $2B in regulatory and sales milestones. Both companies would jointly fund all development and commercialization costs and split profits. On Mar. 19, 2019, Merck &amp; Pfizer discontinued the P-III trial (JAVELIN Ovarian PARP 100) due to clinical trial results to develop avelumab in combination with CT followed by maintenance therapy of avelumab in combination with PARP inhibitor (talazoparib) for LA or metastatic ovarian cancer (Stage III or Stage IV). On Mar. 13, 2020, the companies terminated their P-III JAVELIN Head and Neck 100 trial of Bavencio (avelumab) with CRT for LA SCCHN as it failed to hit its 1Eps.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56045,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/18-1024x153.jpg"" alt="""" class=""wp-image-56045"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong><strong>AbbVie (Allergan) Terminated its Development and Commercialization Deal with Assembly Biosciences</strong></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Jan. 2017, Assembly Biosciences granted Allergan exclusive, worldwide rights to co-develop and commercialize ABI-M201 and ABI-M301 for the treatment of ulcerative colitis and Crohn's disease, plus an additional two drugs for the treatment of Irritable Bowel Syndrome with Diarrhoea, with Constipation (IBS-C), or Mixed (IBS-M). Allergan and Assembly shared development costs until proof-of-concept studies. Assembly received $50M up front and was eligible for up to $2.77B in milestones, plus royalties. In May 2020, AbbVie acquired Allergan and on Jun. 18, 2020, AbbVie, terminated the agreement with Assembly Biosciences.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56046,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/17-1024x153.jpg"" alt="""" class=""wp-image-56046"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong><strong>Eli Lilly Terminated its 2017 Agreement with CureVac</strong></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Oct. 2017, CureVac granted Eli Lilly rights to develop and commercialize its 5 mRNA cancer vaccines using CureVac's RNActive technology for up to 5 cancer vaccines that target neoantigens across multiple tumor types. Lilly was responsible for target identification, clinical development, and commercialization. CureVac was responsible for mRNA design, formulation, and manufacturing of clinical supplies. CureVac had the option to co-promote vaccines in Germany. CureVac received $50M up front, an equity investment of $51M (€45M), and CureVac would be eligible to receive more than $1.7B in development and sales milestones if all 5 vaccines are successfully developed, plus tiered royalties. In Jun. 2020, Eli Lilly terminated the agreement.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56047,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/16-1024x153.jpg"" alt="""" class=""wp-image-56047"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Voyager Terminated its Option and License Deal with AbbVie</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Feb. 2019, Voyager granted AbbVie options to license exclusive, worldwide rights to vectorized antibody-based gene therapies for Parkinson's and other neurodegenerative diseases. Voyager would perform preclinical development to vectorize antibodies directed against alpha-synuclein designated by AbbVie. AbbVie would select one or more vectorized antibodies to advance into IND-enabling studies and clinical development. Voyager would be responsible for research, IND-enabling, and P-I clinical activities and costs. After completing P-I, AbbVie had an option to license the vectorized alpha-synuclein antibody program for further clinical development and global commercialization for Parkinson's disease and other synucleinopathies. Voyager received $65M up front and was eligible for up to $245M in preclinical and P-I option payments, up to an additional $728M in development and regulatory milestones for each alpha-synuclein vectorized antibody compound, and up to $500M in total sales milestones, plus tiered royalties. On Aug. 3, 2020, Voyager Therapeutics terminated the agreement with AbbVie.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56049,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/15-1024x153.jpg"" alt="""" class=""wp-image-56049"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>AstraZeneca Terminated its Development and Commercialization Deal with Allergan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Oct. 2016, AstraZeneca's global biologics research and development arm, MedImmune, granted Allergan exclusive, worldwide rights to develop and commercialize MEDI2070. The IL-23 monoclonal antibody was being developed for the treatment of Crohn's disease and ulcerative colitis and was developed in partnership with Amgen Inc. under a 2012 deal. AstraZeneca received $250M up front and was eligible for up to $1.27B in milestones, plus royalties. AstraZeneca would share one-third of all payments and royalties with Amgen Inc. Amgen would also receive a single-digit inventory royalty on MEDI2070. On Jan. 27, 2020, AstraZeneca and Allergan mutually terminated the agreement, Allergan funded the ongoing study of brazikumab in CD and UC including CDx.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56050,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/14-1024x153.jpg"" alt="""" class=""wp-image-56050"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Eli Lilly Terminated its Research Partnership and Option to License Agreement with NextCure</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Nov. 2018, Lilly signed a research partnership with NextCure with an option to license immuno-oncology therapies using NextCure's FIND-IO platform. Lilly had the exclusive option to license the antibodies resulting from the study. NextCure received $25M up front and Lilly invested $15M in NextCure. If Lilly exercised its option to license the drug, NextCure would be eligible to receive up to $1.4B in milestones, plus royalties. On Jan. 10, 2020, Eli Lilly terminated the agreement with NextCure effective Mar. 3, 2020.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56051,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/13-1024x153.jpg"" alt="""" class=""wp-image-56051"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Bridge Biotherapeutics and Boehringer Ingelheim Mutually Terminated their Development and Commercialization Deal</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Jul. 2019, Bridge granted Boehringer exclusive, worldwide rights to develop and commercialize BBT-877 for the treatment of fibrosing interstitial lung diseases such as idiopathic pulmonary fibrosis (IPF). The Bridge received $50.48M up front and was eligible for up to $1.23B in milestones, plus royalties. On Nov. 9, 2020, Bridge Biotherapeutics and Boehringer mutually terminated the agreement.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56052,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/12-1024x153.jpg"" alt="""" class=""wp-image-56052"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Voyager Terminated its License Option Deal with AbbVie</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Nov. 2018, Voyager granted AbbVie an option to license the development and commercialization of its vectorized antibodies targeting tau by combining AbbVie's monoclonal antibody expertise and Voyager's gene therapy platform and expertise to generate AAV vectors for the treatment of neurodegenerative diseases, including Alzheimer's disease. Both companies planned to identify 5 antibodies based on Voyager's gene therapy platform and select 3 antibodies for development. AbbVie had an option to license up to 2 antibodies following the completion of P-I and would be fully responsible for development costs. Voyager received $69M up front, and was eligible for up to $155M in preclinical and P-I option payments, and was eligible for up to $895M in development and regulatory milestones, plus royalties. On Aug. 3, 2020, Voyager terminated the agreement with AbbVie.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56053,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/11-1024x153.jpg"" alt="""" class=""wp-image-56053"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Amgen Terminated its 2006 Research Partnership with Cytokinetics</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Dec. 2006, Cytokinetics signed a research partnership with Amgen to develop CK-1827452 for the treatment of heart failure. Amgen had an exclusive option to license the drug candidate worldwide excluding Japan before the completion of a P-IIa study. Cytokinetics was responsible for initial development. Upon exercising its option, Amgen was responsible for all further development costs. Also, the partners developed cardiac myosin as a backup compound. Cytokinetics received $75M up front, including $33M in its common stock at a premium of $6.9M. Upon option exercise, Cytokinetics received a $50M option exercise fee and was eligible for up to $600M in development, regulatory, and sales milestones, plus escalating royalties. Cytokinetics had the option to co-fund the P-III study in exchange for additional royalties. If Cytokinetics decided to co-fund the study, it could co-promote the drug in North America. In 2013, Amgen licensed Japan rights, and in 2016 Amgen sublicensed the rights for Europe and the Commonwealth of Independent States to Servier. On Nov. 23, 2020, Amgen terminated the agreement and Cytokinetics regained worldwide rights for omecamtiv mecarbil and backup compound AMG 594. The termination was effective May 20, 2021. The sublicense agreement between Amgen and Servier would remain effective post-termination.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56054,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/10-1024x153.jpg"" alt="""" class=""wp-image-56054"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Roivant Terminated its Development and Commercialization Deal with Poxel</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Feb. 2018, Poxel granted Roivant Sciences and its subsidiary Metavant rights to develop and commercialize its oral therapy, Imeglimin, for T2 Diabetes. Poxel received $35M up front and was eligible for up to $600M in milestones, plus royalties. Roivant invested $15M in Poxel's common stock by purchasing 1,431,399 ordinary shares at €8.5 per share. Roivant was responsible for worldwide development and commercialization. Poxel planned to contribute $25M to the development and had an option to co-promote the product. In Nov. 2020, Metavant terminated the agreement with Poxel for the development of Imeglimin following a strategic analysis.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56055,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/9-1024x153.jpg"" alt="""" class=""wp-image-56055"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Alexion Terminated its Development and Commercialization Deal with Affibody</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Mar. 2019, Affibody granted Alexion rights to develop and commercialize ABY-039 for IgG-mediated autoimmune diseases. Affibody received $25M up front and was eligible for up to $625M in development and sales-based milestones, plus tiered low double-digit royalties. Additionally, Affibody had an option to co-promote the bivalent antibody-mimetic targeting the neonatal Fc receptor (FcRn) in the US. In Feb. 2020, Alexion terminated the agreement following unfavourable early-stage data.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56056,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/8-1024x153.jpg"" alt="""" class=""wp-image-56056"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Boehringer Ingelheim Terminated its Development and Commercialization Deal with Zealand</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Jun. 2011, Zealand granted Boehringer Ingelheim exclusive, worldwide rights to develop and commercialize glucagon/GLP-1 dual agonists, including ZP2929, for the treatment of type-2 diabetes and obesity. Zealand received $52.4M up front, including reimbursements cost and $5.6M in research funding, and was eligible for up to $532.2M in development and commercial milestones, plus double-digit royalties. In Mar. 2020, Boehringer Ingelheim terminated the agreement and Zealand regained worldwide rights.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56057,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/7-1024x153.jpg"" alt="""" class=""wp-image-56057"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>BMS (Celgene) Terminated its Development and Commercialization Deal with Jounce</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Jul. 2019, Jounce granted Celgene exclusive, worldwide rights to develop and commercialize JTX-8064 targeting the LILRB2 receptor on macrophages. Jounce received $50M up front and was eligible for up to $480M in milestones, plus royalties. In Jun. 2020, Bristol Myers Squibb terminated the agreement.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56058,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/6-1024x153.jpg"" alt="""" class=""wp-image-56058"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Cytokinetics Terminated its Development and Commercialization Deal with Astellas </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Jun. 2013, Cytokinetics granted Astellas exclusive, worldwide rights to co-develop and commercialize CK-2127107 for skeletal muscle weakness. Cytokinetics had the option to co-promote products in the US and Canada. Cytokinetics received $16M up front, $24M in R&amp;D reimbursement, and was eligible for over $250M in development and sales milestones for collaboration products, including up to $112M for CK-2127107 and up to $200M in sales milestones, plus undisclosed royalties. On Dec. 22, 2014, Cytokinetics restated the agreement and granted Astellas exclusive, worldwide rights to co-develop &amp; commercialize CK-2127107 and other products for SMA and other neuromuscular indications. Cytokinetics was responsible for P-II in patients with SMA and other neuromuscular diseases. Both companies would co-develop and co-commercialize CK-2127107 and other skeletal troponin activators in neuromuscular indications. Cytokinetics had the option to co-fund certain development costs, co-promote &amp; conduct commercial activities for CK-2127107 in non-neuromuscular and neuromuscular indications in the US, Canada, and EU. On Jul. 27, 2016, Cytokinetics extended the agreement and granted Astellas additional rights to develop and commercialize tirasemtiv and CK-2127107 for ALS. Cytokinetics received a $100M option exercise fees and was eligible for additional milestones, plus royalties based on sales of tirasemtiv in Astellas' countries. Also, Astellas was eligible for royalties based on Cytokinetics' sales of tirasemtiv in its territory. On Apr. 23, 2020, the companies mutually terminated the agreement, Astellas contributed one-third of the development cost, or ~$12M, in an exchange of royalties in the US, Canada, and the EU for 10 years or reduced royalties until 2034. Also, Astellas returned all inventory and IP related to FRSA compounds and agreed not to engage in any research and development activities on FSRA compounds for 4 years.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56059,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/5-1024x153.jpg"" alt="""" class=""wp-image-56059"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Calithera Terminated its Development and Commercialization Deal with Incyte</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Jan. 2017, Calithera granted Incyte worldwide rights to develop and commercialize its arginase inhibitor, CB-1158, for the treatment of hematology and oncology indications. Incyte would fund 70% of the development cost while Calithera would fund 30%. Incyte and Calithera would share profits and losses, with Incyte at 60% and Calithera at 40%, based on U.S. sales. Incyte and Calithera planned to co-detail the drug in the U.S. and Calithera was eligible for up to $483M, including upfront and milestones, plus royalties ex-U.S. In Sep. 2020, Calithera terminated the agreement and regained worldwide rights.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56060,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/4-1024x153.jpg"" alt="""" class=""wp-image-56060"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Idorsia Terminated its Option and License Deal with Santhera for Vamorolon</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Nov. 2018, Idorsia granted Santhera an option to sublicense the development and commercialization of vamorolone for the treatment of DMD worldwide, excluding Japan and South Korea. Idorsia received 1M new registered shares of Santhera and an upfront cash payment of $20M. Idorsia became the largest shareholder in Santhera with a 13.3% equity position. The option was exercisable upon receipt of data from the P-IIb VISION-DMD study (VBP15-004). If exercised, Idorsia would receive a one-time payment of $30M and was eligible for regulatory &amp; commercial milestones of up to $80M for the DMD indication and four one-time sales milestone payments of up to $130M in total. Idorsia was also eligible for regulatory milestone payments of up to $205M for three additional indications. On Sep. 2, 2020, Santhera exercised its option to license vamorolone for all indications including DMD, and revised the terms of the agreement. Vamorolone was originally developed by ReveraGen, and Actelion had the option rights. In Jun. 2017, Actelion spun off Idorsia as a separate entity along with vamorolone rights before its merger with Johnson &amp; Johnson. According to the revised terms of the agreement, Idorsia received 366,667 shares in Santhera's common stock and CHF10M in the form of convertible notes, up to 65% was converted in the form of Santhera common stock and transfer the control rights to its original developer ReveraGen BioPharma. Santhera had replaced Idorsia as party to the ReveraGen agreement.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56061,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/3-1024x153.jpg"" alt="""" class=""wp-image-56061"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>AMAG Terminated its Development and Commercialization Deal with Palatin Technologies</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Jan. 2017, Palatin Technologies granted AMAG Pharmaceuticals rights to develop and commercialize Rekynda (bremelanotide) for the treatment of female sexual disorders in North America. Palatin received $60M up front, up to $380M in milestones, and $25M in reimbursement payments, plus royalties. In Jul. 2020, AMAG terminated the agreement and Palatin Technologies regained the rights plus $16.3M in termination fees.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56063,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/2-1024x153.jpg"" alt="""" class=""wp-image-56063"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Gilead Terminated its Development and Commercialization Deal with Precision BioSciences</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Sep. 2018, Precision granted Gilead rights to develop and commercialize therapies for Hepatitis B Virus targeting HBV cccDNA and integrated HBV DNA present in human hepatocytes using Precision's ARCUS platform. Precision would focus on the development, formulation, and preclinical studies. Gilead was responsible for clinical studies and commercialization. Precision received research funding and was eligible for up to $445M in milestone payments and royalties. In Sep. 2020, Gilead terminated its agreement with Precision BioSciences.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":56062,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/02/1-1024x153.jpg"" alt="""" class=""wp-image-56062"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>ReveraGen&nbsp;Terminated its Option and License Deal with Actelion (Idorsia after the spin-off from Actelion)</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Nov. 2016, Actelion signed a research partnership with ReveraGen BioPharma with an option to license vamorolone for the treatment of DMD and other indications. Actelion would co-develop the compound for the next 28 months and would contribute $1M annually. ReveraGen received $10M up front, up to $165M in dev. and reg. milestones for DMD, and up to $190M for an additional three indications, plus tiered double-digit royalties. On Jun. 16, 2017, Actelion was acquired by Johnson &amp; Johnson. Actelion spun off Idorsia as a new company. In 2018, Idorsia maintained the option rights for vamorolone and restructured the agreement. It agreed to contribute the research for an additional year (until mid-2020). ReveraGen initially received $15M to maintain the agreement, a $20M option fee, and would be eligible for up to $75M in milestones for the DMD indication, and three additional sales milestones of up to $120M. Royalties and milestone payments for other indications remain unchanged. In Nov. 2018, Idorsia granted Santhera an option to sublicense the development and commercialization of vamorolone for DMD worldwide, excluding Japan and South Korea. On Sep. 2, 2020, Santhera exercised its option to license vamorolone for all indications including DMD with the control rights transferred to ReveraGen BioPharma.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post: <a href=""https://pharmashots.com/25104/top-biopharma-deal-terminatio-of-2018-2019-total-value-received/"">Top Biopharma Deal Terminations of 2018-2019 by Total Value Received</a></strong></p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2021/02/News-Video-23.png|https://pharmashots.com/wp-content/uploads/2021/02/20.jpg|https://pharmashots.com/wp-content/uploads/2021/02/19.jpg|https://pharmashots.com/wp-content/uploads/2021/02/18.jpg|https://pharmashots.com/wp-content/uploads/2021/02/17.jpg|https://pharmashots.com/wp-content/uploads/2021/02/16.jpg|https://pharmashots.com/wp-content/uploads/2021/02/16-1.jpg|https://pharmashots.com/wp-content/uploads/2021/02/15.jpg|https://pharmashots.com/wp-content/uploads/2021/02/14.jpg|https://pharmashots.com/wp-content/uploads/2021/02/13.jpg|https://pharmashots.com/wp-content/uploads/2021/02/12.jpg|https://pharmashots.com/wp-content/uploads/2021/02/11.jpg|https://pharmashots.com/wp-content/uploads/2021/02/10.jpg|https://pharmashots.com/wp-content/uploads/2021/02/9.jpg|https://pharmashots.com/wp-content/uploads/2021/02/8.jpg|https://pharmashots.com/wp-content/uploads/2021/02/7.jpg|https://pharmashots.com/wp-content/uploads/2021/02/6.jpg|https://pharmashots.com/wp-content/uploads/2021/02/5.jpg|https://pharmashots.com/wp-content/uploads/2021/02/4.jpg|https://pharmashots.com/wp-content/uploads/2021/02/3.jpg|https://pharmashots.com/wp-content/uploads/2021/02/1.jpg|https://pharmashots.com/wp-content/uploads/2021/02/2.jpg|https://pharmashots.com/wp-content/uploads/2021/02/Top-20.png,Top 20,Top 20 Biopharma Deal Terminations,,Celgene|AbbVie|Affibody|Alexion|Allergan|AMAG|Amgen|Assembly Biosciences|Astellas|AstraZeneca|BMS|Boehringer Ingelheim|Bridge Biotherapeutics|Calithera|CureVac|Cytokinetics|Deal|DealForma|Eli Lilly|Galapagos|Gilead|Hanmi|Idorsia|Incyte|Jounce|Merck KGaA|NextCure|Palatin Technologies|Pfizer|PharmaShots|Poxel|Precision Biosciences|ReveraGen|Roivant|Sanofi|Santhera|Servier|Terminations|Top 20|Total Deal Value|Voyager|Zealand,publish,2/11/2021,17
54453,Top 20 Biopharma M&A of 2020 by Total Deal Value,,"<!-- wp:list -->
<ul><li>Biopharma merger and acquisition activity in 2020 was mainly filled with late-stage, bolt-on acquisitions, which were orders of magnitude smaller than the mega M&A deals of prior years.</li><li>AstraZeneca holds the top rank by acquiring Alexion Pharmaceuticals among the top 20 acquisitions with a total deal value of $39B at a 1-day premium of 45% strengthening its capabilities in immunology, neurology, metabolic cardiovascular, nephrology, and rare disease.</li><li>This article is based on the 2020 deals data as provided by the <a href=""https://dealforma.com"">DealForma database</a>. Our team at <a href=""https://pharmashots.com/"">PharmaShots</a> compiled a list of the top 20 acquisitions of 2020 based on total deal value.</li></ul>
<!-- /wp:list -->

<!-- wp:image {""align"":""center"",""id"":54478,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/20-1024x260.jpg"" alt="""" class=""wp-image-54478""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Dec 17, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.77B&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>Novartis acquired Cadent Therapeutics</a>. The acquisition strengthens Novartis' neuroscience portfolio with the addition of Cadent’s NMDAr program, including CAD-9303, an NMDAr positive allosteric modulator in Phase I for schizophrenia, and MIJ-821, an NMDAr negative allosteric modulator in Phase I for treatment-resistant depression. CAD-9303 and MIJ-821 were licensed to Novartis in 2015. Additionally, Novartis will gain full rights to CAD-1883, a clinical-stage SK channel positive allosteric modulator for movement disorders. Cadent Therapeutics received $210M up front and is eligible for up to $560M in milestones.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54477,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/19-1024x261.jpg"" alt="""" class=""wp-image-54477""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Aug 11, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.87B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Bayer acquired KaNDy Therapeutics with its Phase IIb compound, NT-814, a small molecule for menopause and vasomotor symptoms. The acquisition strengthens Bayer's drug development portfolio in women’s healthcare. KaNDy Therapeutics received $425M up front and is eligible for up to $450M in R&amp;D milestones and additional undisclosed sales-based milestones.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54476,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/18-1024x256.jpg"" alt="""" class=""wp-image-54476""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Aug 25, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $0.93B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>ACADIA Pharmaceuticals acquired CerSci Therapeutics</a> with its lead candidate, ACP-044, a Phase I small molecule for acute &amp; chronic pain. The acquisition strengthens ACADIA's non-opioid pain therapies portfolio. CerSci shareholders received $52.5M up front and are eligible for up to $887M in development and sales-based milestones.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54475,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/17-1024x255.jpg"" alt="""" class=""wp-image-54475""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Dec 15, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.04B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>Eli Lilly acquired Prevail Therapeutics</a>. The acquisition strengthens Eli Lilly's gene therapies portfolio with Prevail's clinical and preclinical disease-modifying AAV9 gene therapy assets in neuroscience. Prevail's pipeline includes PR001 in Phase I/II for Parkinson's disease and in preclinical studies for neuronopathic Gaucher disease, and PR006 in Phase I/II for frontotemporal dementia with GRN mutations. Prevail shareholders received $880M up front at a purchase price of $22.50 per share which represents a premium of approximately 117% plus 1 non-tradable CVR worth up to $4.00 per share in cash (or an aggregate of approximately $160M), for a deal total of up to $26.50 per share in cash, approximately $1.04B. The CVR is payable upon the first regulatory approval for the commercial sale of a Prevail product in one of the countries, including the US, Japan, UK, Germany, France, Italy, or Spain.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54474,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/16-1024x252.jpg"" alt="""" class=""wp-image-54474""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Jan 10, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.1B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>Eli Lilly acquired Dermira</a> with its IL-13 inhibitor antibody lebrikizumab, which is in Phase III for moderate-to-severe atopic dermatitis, and its marketed QBREXZA (glycopyrronium) medicated cloth for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). Dermira licensed lebrikizumab from Genentech/Roche, which acquired the compound when it acquired Tanox, the originator. Dermira shareholders received $18.75 per share in cash at a 1-day premium of 2.2% for approximately $1.1B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54473,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/15-1024x255.jpg"" alt="""" class=""wp-image-54473""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Oct 15, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.3B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>Lilly acquired Disarm Therapeutics</a>. The acquisition strengthens Lilly's neurology portfolio with the addition of preclinical SARM1 inhibitors, a small molecule for peripheral neuropathy and other neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis. Disarm shareholders received $135M up front and are eligible for up to $1.225B in development, regulatory, and commercial milestones if Lilly develops and commercializes new medicines based on Disarm's approach.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54472,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/14-1024x248.jpg"" alt="""" class=""wp-image-54472""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: May 5, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.3B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>Alexion Pharmaceuticals acquired Portola Pharmaceuticals</a> including its balance sheet and debt of approximately $215M. The acquisition expands Alexion's hematology, neurology, and critical care portfolio. Portola shareholders received $18 per share in cash at a premium of 130% for a total of $1.38B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54471,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/13-1024x241.jpg"" alt="""" class=""wp-image-54471""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Dec 10, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.4B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>Boehringer Ingelheim acquired NBE-Therapeutics</a>. The acquisition strengthens Boehringer Ingelheim's oncology pipeline with NBE-002, Phase I immunoconjugates for TNBC, lung, and ovarian cancers. NBE-Therapeutics is eligible to receive up to EUR 1.18B ($1.428B).</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54470,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/12-1024x248.jpg"" alt="""" class=""wp-image-54470""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Dec 10, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.7B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>Gilead Sciences acquired MYR</a>. The acquisition strengthens Gilead's infectious disease and liver disease portfolio with the addition of hepcludex, a lipoprotein approved for Hepatitis D in Europe and in Phase III for Hepatitis D, in Phase II for Hepatitis B, in Phase I for dyslipidemia, and in preclinical studies for NASH and primary biliary cholangitis. MYR shareholders received EUR 1.15B ($1.39B) up front and are eligible for up to EUR 300M ($363.7M) in milestones.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54492,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/11-1024x249.jpg"" alt="""" class=""wp-image-54492""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Nov 6, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $1.8B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>Novo Nordisk acquired Emisphere Technologies</a> for $1.8B. The acquisition strengthens Novo Nordisk's biologics segment with the addition of Eligen SNAC drug delivery technology. Additionally, Novo Nordisk will buy out its Eligen SNAC royalty stream obligations with MHR Fund Management, Emisphere's largest shareholder. Novo Nordisk partnered with Emisphere in 2007 to develop oral biologics by applying Eligen SNAC. Emisphere shareholders received $7.82 per share in cash representing a 15% 1-day premium at approximately $1.35B. Additionally, Novo Nordisk will pay $450M to MHR Fund in connection with its royalty stream obligations.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54490,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/10-1024x246.jpg"" alt="""" class=""wp-image-54490""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: June 11, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.1B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novo Nordisk acquired Corvidia Therapeutics. The acquisition strengthens Novo Nordisk's cardiovascular disease portfolio with Phase II ziltivekimab, an antibody for inflammatory cardiovascular risk in CKD patients. Corvidia received $725M up front and is eligible for up to $1.375B in regulatory and sales-based milestones.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54489,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/9-1024x245.jpg"" alt="""" class=""wp-image-54489""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Aug 31, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.6B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>Nestle acquired Aimmune Therapeutics</a>. The acquisition strengthens Nestle's food allergy portfolio with Palforzia, an approved protein for peanut allergy. Aimmune Therapeutics received $2.6B at $34.50 per share at a 1-day premium of 174%. Nestle previously acquired 25% of the company starting with their 2016 partnership.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54488,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/8-1024x246.jpg"" alt="""" class=""wp-image-54488""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Nov 5, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.7B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>Merck acquired VelosBio</a>. The acquisition strengthens Merck's oncology pipeline with the addition of Phase II VLS-101 antibody-drug conjugate targeting ROR1 for hematologic malignancies and solid tumors plus preclinical ADCs and bispecific antibodies. VelosBio shareholders will receive $2.75B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54487,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/7-1024x256.jpg"" alt="""" class=""wp-image-54487""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Aug 17, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $3.6B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sanofi acquired Principia Biopharma. The acquisition strengthens Sanofi's autoimmune and allergic diseases portfolio with tolebrutinib (SAR442168), a small molecule in Phase III for multiple sclerosis and in Phase II for CNS disorders. Principia Biopharma received $3.6B at a purchase price of $100 per share at a premium of 10%. In 2017, Sanofi and Principia partnered on the development and commercialization of SAR442168, which was in Phase IIb for multiple sclerosis. Principia's lead compound was rilzabrutinib, which was in Phase III for pemphigus.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54486,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/6-1024x251.jpg"" alt="""" class=""wp-image-54486""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Oct 26, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $4B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Bayer acquired Asklepios BioPharmaceutical for $4B. The acquisition strengthens Bayer's cell and gene therapy portfolio with the addition of AskBio's AAV technology platform, CDMO facilities, and preclinical and clinical compounds for neuromuscular, CNS, cardiovascular, and metabolic diseases. Its leading gene therapy is in Phase I/II for Pompe disease. This also complements Bayer's 2019 acquisition of BlueRock Therapeutics. Asklepios is eligible to receive 75% of the milestone payments in the next five years.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54485,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/5-1024x244.jpg"" alt="""" class=""wp-image-54485""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 2, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $4.9B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Gilead acquired Forty-Seven with its lead product magrolimab, a monoclonal antibody targeting CD47 in Phase Ib for acute myeloid leukemia (AML). The company is also studying myelodysplastic syndrome (MDS) and diffuse large B-cell lymphoma (DLBCL). The acquisition strengthens Gilead's oncology portfolio. Forty-Seven received $4.9B at $95.50 per share at a premium of 65%.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54482,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/4-1024x237.jpg"" alt="""" class=""wp-image-54482""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Aug 19, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $6.5B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>Johnson &amp; Johnson acquired Momenta Pharmaceuticals</a> for $6.5B at $52.50 per share at a premium of 79%. The acquisition strengthens Johnson &amp; Johnson's portfolio of autoimmune disease therapies with Phase III nipocalimab (M281), an anti-FcRn antibody for warm autoimmune hemolytic anemia, which is also in Phase II for myasthenia gravis among other indications. Momenta's potential pipeline may have indications in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology, and autoimmune hematology. Nipocalimab recently received a rare pediatric disease designation.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54481,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/3-1024x237.jpg"" alt="""" class=""wp-image-54481""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Oct 05, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $13.1B&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Bristol Myers Squibb acquired MyoKardia for $13.1B at $225 per share at a 1-day premium of 61%. MyoKardia's mavacamten, a small molecule in Phase III for obstructive hypertrophic cardiomyopathy (HCM), has an NDA submission expected in Q1 2021 and is in Phase II for Non-obstructive Hypertrophic Cardiomyopathy. MyoKardia also has 2 clinical compounds, danicamtiv (MYK-491) in Phase II for genetic dilated cardiomyopathy, systolic dysfunction, and atrial fibrillation, and MYK-224, a Phase I small molecule for hypertrophic cardiomyopathy.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54480,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/2-1024x232.jpg"" alt="""" class=""wp-image-54480""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Sep 13, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $21B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Gilead acquired Immunomedics for $21B at $88.00 per share at a premium of 108%. The acquisition gives Gilead trodelvy, an antibody-drug conjugate approved for mTNBC. Trodelvy (sacituzumab govitecan-hziy) is a Trop-2 directed ADC, which received accelerated approval for mTNBC in the US. Trodelvy is also being studied in Phase III for 3L HR+/HER2- breast cancer and Phase II for bladder cancer, NSCLC, and other solid tumors.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":54479,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/1-1024x232.jpg"" alt="""" class=""wp-image-54479""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Dec 12, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $39B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><a>AstraZeneca acquired Alexion</a> for $39B including its drugs Soliris, Ultomiris, and 11 pipeline molecules in 20 different clinical programs. Soliris is an anti-complement component 5 mAb approved for paroxysmal nocturnal haemoglobinuria, atypical haemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder and is in Phase III for Guillain-Barre syndrome. Ultomiris is an approved antibody for Paroxysmal nocturnal hemoglobinuria and Hemolytic uremic syndrome and is in Phase III for generalized Myasthenia gravis, neuromyelitis optica spectrum disorder (NOSMD), hematopoietic stem cell transplant-associated thrombotic microangiopathy, Amyotrophic lateral sclerosis, complement-mediated thrombotic microangiopathy, severe pneumonia or acute respiratory distress syndrome in COVID-19. Alexion's expertise in the complement cascade beyond C5 and additional modalities, including the pathway of the complement system, will strengthen AstraZeneca's portfolio including immunology, neurology, metabolic cardiovascular, nephrology, and rare disease. Alexion shareholders received $60 per share in cash and 2.1243 ADS shares of AstraZeneca valued at $175 per share at a premium of 45%, or approximately $39B. Upon completion, Alexion will own 15% of the combined company.</p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2021/01/Untitled-design-6.jpg,Top 20,Top 20 Life Sciences Deals,,Acadia Pharmaceuticals|Aimmune Therapeutics|Alexion Pharmaceuticals|Asklepios BioPharmaceutical|Bayer|Boehringer Ingelheim|Cadent Therapeutics|CerSci Therapeutics|Corvidia Therapeutics|Dermira|Disarm Therapeutics|Eli Lilly|Emisphere Technologies|Forty Seven|Gilead|Gilead Sciences|Johnson &amp; Johnson|KaNDy Therapeutics|Lilly|Merck|MYR|NBE-Therapeutics|Nestle|Novartis|Novo Nordisk|Portola Pharmaceuticals|Prevail Therapeutics|Principia Biopharma|Sanofi|VelosBio,publish,1/7/2021,17
16995,Top 20 Diagnostics Companies Based On 2018 Revenue,,"<p></p>

<!-- wp:paragraph -->
</p>
<p>With the era of growing diseases, Diagnostics have played a vital role in diagnosing multiple diseases and disorders. The healthcare system is changing, with a greater focus on value, reducing errors and giving more cost-effective care and treatments. The Diagnostic ledger has not changed much in comparison to 2017. Roche Diagnostics holds to be at the first position with generated revenue of $13B in top 20 Diagnostic firms. Our team at <a href=""https://www.pharmashots.com/"">PharmaShots</a> has compiled a list of top 20 diagnostics companies based on their 2018 diagnostics revenue.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17017} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Exact.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $0.45B </strong> <strong>                                                      Total Employees: ~1,977 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1995                                                                      Stock Exchange: NASDAQ   </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$15B                                                                        Headquarters: Wisconsin, </strong><strong style=""font-family: Roboto, sans-serif;font-size: 16px;font-style: normal"">United States</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has an accurate, non-invasive, screening test called Cologuard, used for the detection of colorectal cancer and precancer. Additionally, in 2018, Exact and Pfizer collaborated to co-promote Cologuard, a novel FDA approved non-invasive stool DNA screening test for colorectal cancer.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17018} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Varex.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $0.60B</strong> <strong>                                                     Total Employees: ~2,000 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 2017                                                                     Stock Exchange: NASDAQ</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$1.1B                                                                     Headquarters: Utah, </strong><strong style=""font-family: Roboto, sans-serif;font-size: 16px;font-style: normal"">United States</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Varex Imaging is a designer and manufacturer of X-ray imaging components including X-ray tubes, digital detectors and other image processing solutions. In Feb 2018, the company launched a new Power Chain solution line supporting computed tomography (CT) systems improving total cost of ownership, shorten development times, simplify the supply chain, and provide a higher level of system integration and support from the early stages of gantry design through product release and production.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17020} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/DiaSorin.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $0.76B </strong> <strong>                                                     Total Employees: ~1,971 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1968                                                                     Stock Exchange: BIT   </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$6.5B                                                                     Headquarters: Saluggia, Italy </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>DiaSorin is an Italian in-vitro diagnostics firm and is involved in developing, producing and commercializing diagnostic tests for a wide range of clinical areas. The tests are designed for hospital and private testing laboratories, in the markets of immunodiagnostics and molecular diagnostics which are used to identify biological components aimed at determining the presence of specific elements in patient’s blood sample. In 2018, the company also launched LIAISON QuantiFERON TB Gold PLUS test for the detection of Tuberculosis.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17021} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Grifols-1.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $0.78B </strong> <strong>                                                     Total Employees: ~21,243</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1940                                                                     Stock Exchange: NASDAQ </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$19B                                                                       Headquarters: Barcelona, Spain </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Grifols is a global healthcare company dedicated to improving the health and well-being of people around the globe and is divided in four divisions- Bioscience, Diagnostic, Hospital and Bio Supplies. The company focusses on developing therapies for rare, chronic and life-threatening conditions. In Oct 2018, the company received FDA’s approval for ID CORE XT Test for IVD use in the US for molecular red blood cell typing. </p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17022} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Konica.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $0.84B</strong> <strong>                                                       Total Employees: ~44,360 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 2003                                                                       Stock Exchange: TYO </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$5.04B                                                                     Headquarters: Tokyo, Japan </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Konica Minolta is the global developer, manufacturer of multi-functional peripherals (MFPs), printers, equipment for production print systems and graphic arts, equipment for healthcare systems, measuring instruments for industrial and healthcare applications, inkjet print heads and textile printers for industrial use, and related consumables and solution services.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17023} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Hologic.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $1.12B</strong> <strong>                                                       Total Employees: ~5,500 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1986                                                                       Stock Exchange: NASDAQ </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$13B                                                                        Headquarters: Massachusetts, United                                                                                                                   States </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Hologic is a medical technology company primarily focused on women’s health, beauty products development and marketing medical devices for surgery and medical imaging. Hologic is acquiring SuperSonic Imagine, a French based company for its Ultrasound products, which will further strengthen its breast health portfolio with best-in-class technology used for diagnosing cancer in women with dense breasts. The US FDA also granted PMA approval for Aptima HBV Quant Assay for quantitation of hepatitis B viral load on the fully automated Panther system.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17024} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/BioRad.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $1.41B</strong> <strong>                                                      Total Employees: ~8,260 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1952                                                                      Stock Exchange: NYSE </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$9.29B                                                                    Headquarters: California, United States </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Bio-Rad is a leading healthcare industry involved in blood typing products, offering a wide variety of platforms, reagents, data management, and connectivity solutions. In 2018, the company launched two process chromatography media, CHT Ceramic Hydroxyapatite XT media and Nuvia HP-Q Anion Exchange resin for protein purification of biotherapeutics.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17025} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/BD.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $1.50B </strong> <strong>                                                      Total Employees: ~76,032</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1895                                                                      Stock Exchange: NYSE </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$69B                                                                       Headquarters: New Jersey, United States </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>BD is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products for physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Diagnostic segment has generated global sales of $1.50B in 2018 with total increment of 11.5% to 2017. Additionally, in 2018 BD acquired TVA Medical, a company that develops minimally invasive vascular access solutions for patients with chronic kidney disease requiring hemodialysis.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17026} -->
</p>
<p><a href=""http://www.pharmashots.com/wp-content/uploads/2019/07/ortho-band-2.png""><img src=""http://www.pharmashots.com/wp-content/uploads/2019/07/ortho-band-2-1024x166.png"" alt="""" width=""747"" height=""121"" /></a></p>
<p> </p>
<figure></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $1.80B</strong> <strong>                                                      Total Employees: ~4, 400 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1939                                                                      Stock Exchange: N/A</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: NA                                                                             Headquarters: New Jersey, United States </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Ortho Clinical Diagnostics develops in-vitro products and diagnostic equipment for blood testing. In 2014, The Carlyle Group acquired the company from J&amp;J for $4.15B. The company, now operates as an independent entity. In 2018, company received FDA’s approval for its VITROS HIV Combo Test, a fourth-generation test used for detecting HIV-1 and HIV-2 antibodies (Ab) and the p24 antigen (Ag) for use on Ortho's VITROS 3600 Immunodiagnostic System.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17027} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Sysmex.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $2.70B </strong> <strong>                                                      Total Employees: ~11,252 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1968                                                                      Stock Exchange: TYO</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$14.5B                                                                    Headquarters: Hyogo, Japan </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Sysmex is a Japanese firm involved in development, manufacturing, sales and export/import of diagnostic instruments, reagents and related softwares. In Dec 2018 its OncoGuide NCC Oncopanel System received manufacturing and marketing approval in Japan. Additionally, in 2018 Sysmex launched Automated Blood Coagulation Analyzers CN-6000 and CN-3000. The company diagnostic department generated sales of $2.7B in 2018.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17028} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Biomerieux.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $2.74B</strong> <strong>                                                        Total Employees: ~11,200 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1963                                                                        Stock Exchange: Euronext Paris</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$9.8B                                                                        Headquarters: Marcy-l'Étoile, France  </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>BioMerieux develops and produces in-vitro diagnostic solutions like systems, reagents, software and services for private and hospital laboratories, mainly for the diagnosis of infectious diseases. BioMerieux provides diagnostic solutions (systems, reagents, software) which determine the source of diseases and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases and for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. </p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17029} -->
</p>
<figure><a href=""http://www.pharmashots.com/wp-content/uploads/2019/07/9-1.png""><img src=""http://www.pharmashots.com/wp-content/uploads/2019/07/9-1-1024x151.png"" alt="""" width=""747"" height=""110"" /></a></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $3.50B</strong> <strong>                                                         Total Employees: ~31,844 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1934                                                                         Stock Exchange: TYO  </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$26B                                                                          Headquarters: Tokyo, Japan </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Fujifilm Medical is a leader in diagnostic imaging products and medical informatics solutions and is divided into three business categories: Imaging Solutions, Healthcare &amp; Material Solutions and Document Solutions. In Apr, 2018 Fujifilm collaborated with LPixel to use AI technology designed to support diagnosing medical images.  </p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17042} -->
</p>
<figure><a href=""http://www.pharmashots.com/wp-content/uploads/2019/07/8.png""><img src=""http://www.pharmashots.com/wp-content/uploads/2019/07/8-1024x150.png"" alt="""" width=""747"" height=""109"" /></a></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $3.72B</strong>                                                         <strong>Total Employees: ~70,000 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1902                                                                        Stock Exchange: NYSE   </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$118B                                                                       Headquarters: Massachusetts,                                                                                                                               United States</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Thermo Fisher is serving globally with its primary brands: Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services. The Specialty Diagnostic of Thermo Fischer generated sales of $3.72B which grew 7% more than the 2017 revenue. Additionally, in 2018 Thermo Fischer launched its Complementary Diagnostic Immunoassay used for measuring the concentration of a novel therapeutic antibiotic, plazomicin, using the automated clinical chemistry analyzer, Beckman Coulter AU 680.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17031} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Canon-1.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $4.04B</strong> <strong>                                                     Total Employees: ~25,891 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1937                                                                     Stock Exchange: TYO   </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$39.61B                                                                  Headquarters: Tokyo, Japan </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Canon Inc. is a Japanese multinational corporation specialized in the manufacturing of imaging and optical products, including cameras, camcorders, photocopiers, steppers, computer printers and medical equipment’s. Canon Medical’s next-generation 3-Tesla MRI scanner, the Vantage Galan 3T, maximizes high-resolution imaging performance while minimizing space requirements and energy consumption. The device also employs noise-reduction technology to provide greater comfort to patients.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17032} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Siemens.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $4.49B</strong> <strong>                                                      Total Employees: ~50,000 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1971                                                                      Stock Exchange: ETR </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$35.59B                                                                  Headquarters: Erlangen, Germany</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Siemens Healthineers is a subsidiary of Siemens AG, a diagnostic company focused on the development of diagnostic, therapeutic imaging, laboratory diagnostics, molecular medicine, digital health services, and enterprise services. In Aug, 2018, Siemens Healthineers collaborated with NuVasive to develop and advance technology designed for minimally invasive spinal surgery.Its diagnostic segment generated sales of $4.49B in 2018.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17033} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/GE-healthcare.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $4.90B </strong> <strong>                                                         Total Employees: ~53,800 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1994                                                                        Stock Exchange: NYSE </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: NA                                                                               Headquarters: Illinois, United States </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>GE Healthcare is a leading global wholly owned subsidiary of General Electric Company focused on the development, manufacturing, and commercialization of healthcare technologies. The portfolio provides solutions and products in diagnosis, treatment, and monitoring of patients. The company has more than 4M imaging, mobile diagnostics and monitoring units installed globally in 43 global centers. GE Healthcare also have an AIR Technology, AI-based technology for intelligent MR slice presentation using artificial neural networks delivering consistent and accurate scans.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17034} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Danaher.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $6.35B </strong> <strong>                                                      Total Employees: ~71,000 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1969                                                                      Stock Exchange: NYSE </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$102B                                                                    Headquarter: Washington, D.C                                                                                                                                </strong><strong style=""font-size: 16px"">United States</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Danaher Corporation designs, manufactures and markets professional, medical, industrial and commercial products and services. The company has focus on Life Sciences, Diagnostics, Dental, and Environmental &amp; Applied Solutions. The Danaher’s Diagnostic segment generated sales of $6.3B in 2018. Additionally, Danaher acquired Integrated DNA Technologies (IDT) to expand its footprint in genomic market and to develop diagnostic tests and lifesaving therapies.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17035} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Abbott.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $7.49B                                                           Total Employees: ~103,000</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1900                                                                          Stock Exchange: NYSE</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$149B                                                                         Headquarter: Illinois, United States                                                                </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Abbott Laboratories is an American healthcare company with a broad pipeline of generics, diagnostic, natural products, cardiovascular and neuromodulation products. Its Diagnostic segment is divided in four divisions Rapid Diagnostics, Molecular Diagnostics, Core Laboratory Diagnostics, Diabetes Care. Abbott has also introduced a Diagnostic system Alinity, in EU and other markets which is usually involved in clinical chemistry, immunoassays, molecular diagnostics, hematology, POC testing, and blood and plasma screening.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17037} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Philips.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $8.10B                                                         Total Employees: ~77,400 </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1891                                                                        Stock Exchange: NYSE </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$39.92B                                                                   Headquarter: Amsterdam, The                                                                                                                                Netherlands </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Philips Healthcare has focused their research and development efforts to develop new approaches in the areas of radiology, cardiology, oncology, decision support, home health, respiratory and other critical areas. Its parent company, Royal Philips is a diversified company focusing on improving public health with meaningful innovation offering treatments at a lower cost. Philips Healthcare@home providing a wide range of healthcare services at the patient’s home with the help of experienced and certified in Basic Life Support (BLS) professionals.</p>
<p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":17038} -->
</p>
<figure><img src=""https://www.pharmashots.com/wp-content/uploads/2019/07/Roche.png"" alt="""" /></figure>
<p>
<!-- /wp:image -->

<!-- wp:paragraph -->
</p>
<p><strong>Diagnostic Revenue: $13.08B                                              Total Employees: ~92,400</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Founded Year: 1896                                                               Stock Exchange: SWX</strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p><strong>Market Cap: ~$230B                                                              Headquarter: Basel, Switzerland </strong></p>
<p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
</p>
<p>Roche is a Swiss multinational healthcare company operating worldwide under pharmaceuticals and diagnostics divisions. Roche has a focus on multiple therapy areas including ophthalmology, oncology and immunology. The Diagnostics segment of Roche is divided into four segments: Molecular Diagnostics, Diabetes Care, Tissue Diagnostics, Centralized and Point of Care Solutions. The total revenue generated by Diagnostic segment is $13.08B</p>
<p>
<!-- /wp:paragraph -->

<p></p>",,https://pharmashots.com/wp-content/uploads/2019/07/Top20-biopharm-Companies3.png,Top 20,Top 20 Diagnostics Companies,,Abbott|Based|Becton Dickinson|Bio-Rad|BioMerieux|Canon|Companies|Danaher|Diagnostics|DiaSorin|Fujifilm|GE Healthcare|Grifols|Hologic|Konica Minolta|Ortho Clinical Diagnostics|Philips|Revenue|Roche|Siemens Healthineers|Sysmex|Thermo Fischer|Top 20|Varex Imaging,publish,7/19/2019,17
34661,Top 20 Diagnostics Companies Based on 2019 Revenue,,"<!-- wp:paragraph {""align"":""left""} -->
<p class=""has-text-align-left"">Diagnostics has emerged as one of the largest and fastest-growing segments with evolving diseases. The segment has played a vital role in diagnosing growing and ageing global population with increasing health expenditure and more prevalent lifestyle ailments including obesity, cancer, and cardiovascular diseases. Our team at <a href=""https://www.pharmashots.com/"">PharmaShots</a> has compiled a list of top 20 diagnostics companies based on their 2019 diagnostics revenue.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph {""align"":""left""} -->
<p class=""has-text-align-left""> According to the 2018 list, the top three companies were Roche along with Philips and Abbott with which generated revenue of $13.08B, $8.10B, and $7.49B, respectively. The list of 2019 has affected a lot of companies in their position. This year Siemens is at 1st rank in 2019, following GE Healthcare and Roche has generated revenue of $15.83B, $14.64B, and $13.38B, respectively. GE Healthcare struggled to reach the second position which stood fifth in 2018. Unfortunately, Roche showed a decline in its diagnostic revenue along with position from the first position to third in 2019 reflected a difference of $2.45B to Siemens. LabCorp generated diagnostic revenue of $7B and stood on the fifth position. Danaher generated revenue of $6.56B and reached on the sixth position showing an increment of $0.21B. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph {""align"":""left""} -->
<p class=""has-text-align-left""><strong>You can also get a PDF version of this report by contacting through email at&nbsp;</strong><a href=""mailto:shiwani@pharmashots.com""><strong>shiwani@pharmashots.com</strong></a><strong>.</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[34693]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/20-1024x166.png"" alt="""" data-id=""34693"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/20.png"" data-link=""https://www.pharmashots.com/?attachment_id=34693"" class=""wp-image-34693"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $0.59B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Total Employees: ~2,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;     Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$0.67B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;     Headquarters: Utah, US</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Varex Imaging is a designer and manufacturer of X-ray imaging components including X-ray tubes, digital detectors, and other image processing solutions. In Mar 2019, Varex acquired Direct Conversion AB for $83.7M to strengthen Varex's diagnostics imaging services with the addition of linear array digital detector products.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[34694]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/19-1024x164.png"" alt="""" data-id=""34694"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/19.png"" data-link=""https://www.pharmashots.com/?attachment_id=34694"" class=""wp-image-34694"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $0.79B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~1,939</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1968&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    Stock Exchange: BIT&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$10.45B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarters: Saluggia, Italy</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>DiaSorin is an Italian in-vitro diagnostics firm and is involved in developing, producing, and commercializing diagnostic tests for a wide range of clinical areas. The tests are designed for hospital and private testing laboratories, in the markets of immunodiagnostics and molecular diagnostics which are used to identify biological components aimed at determining the presence of specific elements in the patient’s blood sample. In Jan 2019, DiaSorin launched LIAISON Calprotectin test post it was approved by the US FDA.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[34695]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/18-1024x163.png"" alt="""" data-id=""34695"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/18.png"" data-link=""https://www.pharmashots.com/?attachment_id=34695"" class=""wp-image-34695"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $0.82B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~24,016</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1940&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; Stock Exchange: BME&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$18.96B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Headquarters: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Grifols is a global healthcare company dedicated to improving the health and well-being of people around the globe and is divided into four divisions- Bioscience, Diagnostic, Hospital, and Bio Supplies. The company focusses on developing therapies for rare, chronic, and life-threatening conditions. In Jan 2019, Grifols signed a license agreement with Rigel Pharmaceuticals to commercialize fostamatinib disodium hexahydrate in all potential future indications in the EU and Turkey. In Sep 2019, Grifols signed an agreement with Mondragon to jointly develop healthcare sector-related automation, robotics, and instrumentation as well as other technologies and infrastructure. </p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[34696]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/17-1024x161.png"" alt="""" data-id=""34696"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/17.png"" data-link=""https://www.pharmashots.com/?attachment_id=34696"" class=""wp-image-34696"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $0.87B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~4,110</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1995&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Stock Exchange: NASDAQ&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$13.89B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Headquarters: Madison, Wisconsin</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has an accurate, non-invasive, screening test called Cologuard, used for the detection of colorectal cancer and precancer. In Jun 2019, the company built its new clinical laboratory focusing to fight against Colorectal Cancer. In Aug 2019, Exact presented data from its blood-based test for the detection of hepatocellular carcinoma and received the US FDA’s Breakthrough Device Designation. </p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[34697]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/16-1024x160.png"" alt="""" data-id=""34697"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/16.png"" data-link=""https://www.pharmashots.com/?attachment_id=34697"" class=""wp-image-34697"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $0.95B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~72,332</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1934&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$23.81B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Headquarters: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Fujifilm Medical is a leader in diagnostic imaging products and medical informatics solutions and is divided into three business categories: Imaging Solutions, Healthcare &amp; Material Solutions, and Document Solutions. In Jul 2019, Fujifilm Sonosite signed an agreement with Partners HealthCare with the focus to apply AI to improve the utility and functionality of portable ultrasound. Additionally, in Jul 2019, the company collaborated with Axcelead Drug Discovery to develop novel drug efficacy evaluation methods and toxicity testing using iPSCs based platform for drug discovery solutions.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[34699]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/15-1024x159.png"" alt="""" data-id=""34699"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/15.png"" data-link=""https://www.pharmashots.com/?attachment_id=34699"" class=""wp-image-34699"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $1.10B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~49,567</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1873&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$1.95B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Headquarters: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Konica Minolta is the global developer, manufacturer of multi-functional peripherals (MFPs), equipment for production print systems and graphic arts, equipment for healthcare systems, measuring instruments for healthcare applications,  and related consumables and solution services. The company also makes medical and graphic imaging products, such as X-ray image processing systems, colour proofing systems, and X-ray film; photometers, 3-D digitizers, and other sensing products</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[34700]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/14-1024x157.png"" alt="""" data-id=""34700"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/14.png"" data-link=""https://www.pharmashots.com/?attachment_id=34700"" class=""wp-image-34700"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $2.31B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~8,120</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1952&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$13.43B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Headquarters: California, US</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Bio-Rad is a leading healthcare industry involved in blood typing products, offering a wide variety of platforms, reagents, data management, and connectivity solutions. In Apr 2019, Bio-Rad’s BioPlex 2200 Lyme Total Assay received the US FDA’s approval for aiding in the diagnosis of Lyme disease. Additionally, in Feb 2019, Bio-Rad receives the US FDA’s clearance for the Ih-500, expanding its offering for the blood testing market.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[34702]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/13-1024x156.png"" alt="""" data-id=""34702"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/13.png"" data-link=""https://www.pharmashots.com/?attachment_id=34702"" class=""wp-image-34702"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $2.61B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~6,478</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1986&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$13.43B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarters: Massachusetts, US&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Hologic is a medical technology company primarily focused on women’s health, beauty products development, and marketing medical devices for surgery and medical imaging. Hologic is acquiring SuperSonic Imagine, a French-based company for its Ultrasound products, which will further strengthen its breast health portfolio with best-in-class technology used for diagnosing cancer in women with dense breasts. In Jun 2019, Hologic acquired SuperSonic Imagine for $85M, with the focus to strengthen its diagnostics and surgical solutions in breast health. In Nov 2019, Hologic’s LOCalizer radiofrequency identification (RFID) received CE Mark for the expansion of its use in long-term placement in breast lesions which are implanted 30 days prior for greater flexibility and convenience to patients and providers.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[34703]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/12-1024x155.png"" alt="""" data-id=""34703"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/12.png"" data-link=""https://www.pharmashots.com/?attachment_id=34703"" class=""wp-image-34703"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $2.80B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Employees: ~9,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1968&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$15.87B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Headquarters: Kobe, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sysmex is a Japanese firm involved in the development, manufacturing, sales, and export/import of diagnostic instruments, reagents, and related software. In Mar 2019, Sysmex reported the launch of Caresphere LWS a laboratory information system for enhancing the efficiency of clinical testing. In Nov 2019, Sysmex and OPTiM signed an agreement to establish a joint venture for accelerating and commercializing digital medicine to support next-generation healthcare and diagnostics.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[34704]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/11-1024x153.png"" alt="""" data-id=""34704"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/11.png"" data-link=""https://www.pharmashots.com/?attachment_id=34704"" class=""wp-image-34704"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $3.00B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~12,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1963&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Stock Exchange: EPA</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$15.11B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarters: Marcy-l’Étoile, France</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>BioMerieux develops and produces in-vitro diagnostic solutions like systems, reagents, software, and services for private and hospital laboratories, mainly for the diagnosis of infectious diseases. BioMerieux provides diagnostic solutions (systems, reagents, software) which determine the source of diseases and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases and for detecting microorganisms in agri-food, pharmaceutical, and cosmetic products. In Feb 2019, BioMerieux acquired Invisible Sentinel for $75M, which will further strengthen its position in food pathogen testing and spoilage organism detection. In late 2019, BioMerieux submitted the BIOFIRE Blood Culture Identification 2 (BCID2) Panel to the US FDA for 510(k) clearance aimed for bloodstream infections. </p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[34705]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/10-1024x152.png"" alt="""" data-id=""34705"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/10.png"" data-link=""https://www.pharmashots.com/?attachment_id=34705"" class=""wp-image-34705"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $3.71B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Employees: ~75,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1902&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Stock Exchange: NYSE&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$139.34B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarters: Massachusetts, US</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Thermo Fisher is globally serving its primary brands: Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services. The company has four main segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. Thermo Fisher’s Specialty Diagnostics Segment has five primary business– Clinical Diagnostics, ImmunoDiagnostics, Microbiology, Transplant Diagnostics, and Healthcare Market Channel, offering a variety of diagnostic test kits, reagents, culture media, and instruments. In Apr 2019, the company acquired Brammer Bio for $1.67B in cash for the expansion of its contract manufacturing capabilities. In Jun 2019, Thermo Fischer sold its Anatomical Pathology business to PHC Holdings Corporation for $1.14B.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[34706]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/06/9-1024x151.png"" alt="""" data-id=""34706"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/06/9.png"" data-link=""https://www.pharmashots.com/?attachment_id=34706"" class=""wp-image-34706"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $4.03B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~1,87,041</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1937&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Stock Exchange: TYO&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$28.29B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",,https://pharmashots.com/wp-content/uploads/2020/06/I.png,Top 20,Top 20 Diagnostics Companies,,Abbott Laboratories|Becton Dickinson|Bio-Rad|BioMerieux|Canon|Danaher|DiaSorin|Exact Sciences|Fujifilm Medical|GE Healthcare|Grifols|Hologic|Konica Minolta|LabCorp|Philips Healthcare|Roche|Siemens Healthineers|Sysmex|Thermo Fisher|Varex Imaging,publish,6/12/2020,17
61128,Top 20 Diagnostics Companies Based on 2020 Revenue,,"<!-- wp:list -->
<ul><li>The extraordinary demand for COVID-19 testing kits that were seen in 2020 and is yet to subside in 2021 resulted in many of the world’s biggest diagnostics companies being thrust into the limelight</li><li>Siemens Healthineers, GE Healthcare, Roche, and Abbott are the top players in the race of the global diagnostic companies. The companies are in the race to develop fast, accurate methods for detecting patients infected with the SARS-CoV-2 virus &nbsp;</li><li>Our team at PharmaShots has compiled a list of the top 20 diagnostics companies based on their 2020 diagnostics revenue</li></ul>
<!-- /wp:list -->

<!-- wp:image {""align"":""center"",""id"":61108,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/20-1024x185.png"" alt="""" class=""wp-image-61108"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $0.58B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~2,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:  <strong>~$1.05B</strong>                                                                    Headquarters: Utah, US</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Varex Imaging is a leading innovator, designer and manufacturer of X-ray tubes, digital detectors, linear accelerators, and other image software processing solutions. The company is one the largest global manufacturers of X-ray components and each year, it produces over 27,000 X-ray tubes and 20,000 X-ray detectors.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61109,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/19-1024x185.png"" alt="""" class=""wp-image-61109"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $0.94B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~22,200</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1940                                                                     Stock Exchange: BME</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: &nbsp;~<strong>$16.0</strong>3B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarters: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Grifols is a global healthcare company dedicated to improving the health and well-being of people around the globe and is divided into four divisions- Bioscience, Diagnostic, Hospital, and Bio Supplies. In 2020, the EC approved Tavlesse (fostamatinib) to treat immune thrombocytopenia (ITP) in adult patients who are refractory to other treatment whereas, in Aug’2020, the FDA granted EUA for convalescent plasma to treat patients with COVID-19. In Sept’2021, the company acquired the remaining stake in Alkahest to boost its R&amp;D efforts.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61110,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/18-1024x168.png"" alt="""" class=""wp-image-61110"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $0.97B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~44,961</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1873&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:<strong>~$2.94</strong>B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarters: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Konica Minolta is the global developer, manufacturer of multi-functional peripherals (MFPs), equipment for production print systems and graphic arts, equipment for healthcare systems, measuring instruments for healthcare applications, and related consumables and solution services. The company is dealing with ultrasounds, digital radiography and has a healthcare T segment as well. SONIMAGE MX1 is a POC ultrasound system that delivers advanced technology to ensure excellent image quality and efficient workflow with exceptional value.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61111,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/17-1024x182.png"" alt="""" class=""wp-image-61111"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $1.07B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~2,045</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1968&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Exchange: BIT&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:   <strong>~$9.</strong>76B                                                                     Headquarters: Saluggia, Italy</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>DiaSorin is an Italian in-vitro diagnostics firm and is involved in developing, producing, and commercializing diagnostic tests for a wide range of clinical areas. In Oct’2020, DiaSorin launches its new LIAISON SARS-CoV-2 Ag for quantitative detection of SARS-CoV-2 in symptomatic patients through nasal and nasopharyngeal swabs. In Apr’2021, DiaSorin to acquire Luminex for $1.8B to broaden its positioning in the molecular diagnostics space.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61112,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/16-1024x175.png"" alt="""" class=""wp-image-61112"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $1.30B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~8,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1952&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:  ~<strong>$17.31B</strong>                                                                  Headquarters: California, US</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Bio-Rad is a leading healthcare industry involved in blood typing products, offering a wide variety of platforms, reagents, data management, and connectivity solutions. Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics and generated 49% and 51%, respectively. Bio-Rad offers SARS-CoV-2 / COVID-19 assay and research solutions to address the COVID-19 pandemic.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61113,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/15-1024x166.png"" alt="""" class=""wp-image-61113"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $1.49B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~5,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1995&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Exchange: NASDAQ&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: <strong>~$</strong>20.39B                                                                       Headquarters: Madison, Wisconsin</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. In Dec’2020, the company reported the data from the RxPONDER trial that demonstrated the benefit of CT in early-stage, node-positive breast cancer.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61114,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/14-1024x170.png"" alt="""" class=""wp-image-61114"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $1.76B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~4, 500</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1939&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: <strong>$4.90B </strong>                                                                     Headquarters: New Jersey, US</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Ortho Clinical Diagnostics develops in-vitro products and diagnostic equipment for blood testing. The company operates in two lines of business, Clinical Laboratories and Transfusion Medicine. In Jan’2021, Ortho’s Vitros SARS-CoV-2 antigen test received the US FDA’s EUA for accurate, mass-scale COVID-19 testing.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61115,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/13-1024x179.png"" alt="""" class=""wp-image-61115"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $2.07B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~6,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1986                                                                         Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:   ~$15.84B                                                                   Headquarters: Massachusetts, US </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Hologic is a medical technology company primarily focused on women’s health, beauty products development, and marketing medical devices for surgery and medical imaging. The diagnostic segments include our molecular diagnostic assays, which run on advanced instrumentation systems (Panther, Panther Fusion, and Tigris), ThinPrep cytology system, and the Rapid Fetal Fibronectin Test. In 2020, in response to the COVID-19 global pandemic, it developed and launched Aptima SARS-CoV-2 assays for the detection of SARS-CoV-2. &nbsp;The company also developed and launched the Panther Fusion SARS-CoV-2 assay for the detection of SARS-CoV-2, which has received the FDA’s EUA in Mar’2020.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61116,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/12-1024x166.png"" alt="""" class=""wp-image-61116"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $2.73B                                                        Total Employees: ~9,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1968                                                                       Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$21.53B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarters: Kobe, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sysmex is a Japanese firm involved in the development, manufacturing, sales, and export/import of diagnostic instruments, reagents, and related software. To reduce the burden of Dementia, Sysmex collaborated with Eisai to develop a blood test that will enable diagnosis while placing less of a burden on the patient. The joint research aimed at enabling early-stage diagnoses, the selection of treatment methods and the monitoring of treatment results.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61117,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/11-1024x173.png"" alt="""" class=""wp-image-61117"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $3.09B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~73,906</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1934&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$<strong>36.03</strong>B                                                                    Headquarters: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Fujifilm Medical is a leader in diagnostic imaging products and medical informatics solutions and is divided into three business categories: Imaging Solutions, Healthcare &amp; Material Solutions, and Document Solutions. In 2020, The company commenced the development of an antigen test kit for diagnosis of SARS-CoV-2 infection and later, collaborated with Carelink in deploying Avigan in China. Additionally, Fujifilm concludes a manufacturing contract agreement with VLP Therapeutics, for a COVID-19 vaccine formulation.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61118,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/10-1024x160.png"" alt="""" class=""wp-image-61118"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $4.22B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~</strong> <strong>181897</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1937                                                                        Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:   ~$<strong>32.2</strong> B                                                                   Headquarters: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Canon is a Japanese multinational corporation specialized in the manufacturing of imaging and optical products, including cameras, camcorders, photocopiers, steppers, computer printers, and medical equipment. In 2020, Canon developed and offered a suite of total solutions for diagnosing COVID-19 infections, for example, CT equipment, X-rays system, ultrasounds system, rapid COVID-19 genetic and antigen testing. In Japan, the company partnered with Nagasaki University to develop set of reagents for COVID-19 RNA testing.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61119,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/9-1024x163.png"" alt="""" class=""wp-image-61119"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $4.70B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~70,093</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1895&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$71.11B                                                                  Headquarters: New Jersey, US</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>BD is a global medical technology company engaged in the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products for physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. In 2020, BD received CE Mark for its portable, rapid POC antigen test to detect SARS-CoV-2 in 15 minutes and got CE Mark for combination COVID-19, Influenza, RSV Test on BD MAX Molecular diagnostic system.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61120,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/8-1024x168.png"" alt="""" class=""wp-image-61120"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $5.34B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~75,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1902&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$178.23B                                                                  Headquarters: Massachusetts, US</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Thermo Fisher is globally serving its primary brands: Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services. The company has four main segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The company develops Applied Biosystems TaqPath COVID-19 Combo Kit, which received EUA n in the US in Mar’2020, followed by similar authorizations around the world. The company significantly expanded the portfolio of COVID-19 related products, launching the Thermo Fisher Scientific Amplitude Solution for high-throughput PCR-based testing and our Applied Biosystems TaqCheck PCR test for asymptomatic health surveillance. These innovations allow the company to establish worldwide leadership in COVID-19 diagnostic testing, supporting millions of COVID-19 PCR tests across the world.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61121,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/7-1024x159.png"" alt="""" class=""wp-image-61121"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $7.40B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~69,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1969&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$173.83B                                                               Headquarter: Washington, D.C, US     </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Danaher Corporation designs manufacture and markets professional, medical, industrial, and commercial products and services. The company has a focus on Life Sciences, Diagnostics, Dental, and Environmental &amp; Applied Solutions. The Company’s diagnostics segment offers analytical instruments, reagents, consumables, software, and services. In Mar’ 2020, the company completed the acquisition of GE LifeScience’s biopharma business knows as Cytiva.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61122,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/6-1024x163.png"" alt="""" class=""wp-image-61122"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $9.25B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~80,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1971&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: &nbsp;&nbsp;~$25.49B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: North Carolina, US</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>LabCorp is a leading global life sciences company targeting in guiding patient care. In 2020, Labcorp received FDA’s authorization to make at-home COVID-19 collection kits available through retail and collaborated with GENFIT to commercialize novel diagnostic test for liver diseases. Moreover, the company collaborated with public health authorities on no-charge antibody test program to accelerate COVID-19 blood plasma donation.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":61123,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/06/5-1024x157.png"" alt="""" class=""wp-image-61123"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Diagnostic Revenue: $10.00B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~81,592</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1891&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbs",,https://pharmashots.com/wp-content/uploads/2021/06/Top-20.jpg,Top 20,Top 20 Diagnostics Companies,,Abbott|BD|Bio-Rad|Canon|Danaher|Diagnostic Companies|DiaSorin|Exact Sciences|Fujifilm Medical|GE Healthcare|Grifols|Hologic|Konica Minolta|LabCorp|Ortho Clinical Diagnostics|Roche|Royal Philips|Seimens Healthineers|Sysmex|ThermoFisher|Varex Imaging,publish,6/10/2021,17
20409,Top 20 Generics Pharma Companies Based On 2018 Revenue,,"<!-- wp:paragraph -->
<p>The global generics pharmaceutical market is continuously growing and increasing with its accessibility &amp; benefits offered as efficient and economical drugs, are always needed in the market. Generics are approved copies of small molecule drugs which contain the same amount of active ingredients, dosage form, safety, strength, route of administration, quality, performance characteristics, as of originally marketed products. In the list of top 20 companies, Mylan retained the top position with a revenue of $11.43B while there was a 4% dip in its revenue as compared to 2017. Our team at PharmaShots has compiled a list of top 20 generics developing companies based on their 2018 generics revenue. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20483} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Piramal.png"" alt="""" class=""wp-image-20483"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $0.69B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Total Employees: ~7820 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1980&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarter: Mumbai, India </strong><strong></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$5.18B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Exchange: NSE</strong><strong></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Piramal Healthcare is a global pharmaceutical company offering therapies focussed on CNS, cardiovascular, anti-infective and anti-diabetic. In 2018, Primal launched its generic Desflurane as an inhalation vapour anaesthesia. Additionally, Piramal was granted 781 ANDAs approval in 2018 from the US FDA. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20484} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Mallinckrodt.png"" alt="""" class=""wp-image-20484"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $0.90B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~3700 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1867&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarter: </strong><strong>Surrey, United Kingdom </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$2.88B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE</strong><strong></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Mallinckrodt is a global pharmaceutical company that develops and manufactures therapies for multiple therapy areas including autoimmune and rare diseases in speciality areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy and neonatal respiratory critical care therapies, and analgesics. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20486} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/endo.png"" alt="""" class=""wp-image-20486"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $1.01B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~2,910 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1997&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarter: </strong><strong>Dublin, Ireland </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$1.00B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange:</strong> <strong>NASDAQ </strong><strong></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Endo International is an Ireland-based, global pharmaceutical company focusing on generic and branded pharmaceuticals for therapeutic areas that include Endocrinology, Medical Aesthetics, Orthopedics, Urology &amp; Men's Health. Endo’s Percocet (Oxycodone/acetaminophen) is an opioid analgesic approved for the treatment of moderate-to-moderately-severe pain and has generated global sales of $0.12B. <strong>  </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20489} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Torrent.png"" alt="""" class=""wp-image-20489"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $1.11B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~13,598 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1959&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarter: </strong><strong>Ahmedabad, India </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$4.05B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Torrent Pharma is a pharmaceutical company focused on developing therapies for Cardiovascular, Central Nervous System, GI, Vitamins Minerals Nutritionals (VMN) and Women Healthcare. The Company also has a focus in diabetology, pain management, gynaecology, oncology and anti-infective segments. In Jan 2018, the company acquired Bio-Pharm for the expansion of its capabilities in the US including manufacturing and R&amp;D presence. <br> </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20490} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Glenmark.png"" alt="""" class=""wp-image-20490"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p> <strong>Generic Segment </strong> <strong>Revenue: $1.43B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;       Total Employees: ~12,000 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1977&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarter: </strong><strong>Mumbai, India </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$1.47B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Glenmark is a global pharmaceutical company focusing on Generics, Specialty and OTC business in therapy areas like Dermatology, Respiratory and Oncology including Cardiology, Diabetes, and Oral Contraceptives. In 2018, the company received 25 ANDA approvals with 20 final approvals and 5 tentative approvals. Glenmark’s Colesevelam Hydrochloride Tablets is first generic available as an oral suspension. Glenmark’s generic portfolio consists of 152 generic products approved for marketing in the US. <strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20491} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Amneal.png"" alt="""" class=""wp-image-20491"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p> <strong>Generic Segment </strong> <strong>Revenue: $1.66B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Total Employees: ~6,000 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2002&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarter: </strong><strong>New Jersey, United States </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>&nbsp;Market Cap: ~$1.04B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Exchange: NYSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Amneal Pharmaceuticals is a global company developing and marketing generic and specialty drugs in multiple dosage forms for various diseases. The generic drug has generated a global sale of $0.13B with 8% increment to 2018. In Aug 2018 Amneal signed a 10-year license and supply agreement with Jerome Stevens for its Levothyroxine sodium tablets and will be effective in H1’19.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20492} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Stada.png"" alt="""" class=""wp-image-20492"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Generic Segment  Revenue: $1.55B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    Total Employees: ~10,416 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1895&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; Headquarter: Bad Vilbel, Germany</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $5.74B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: Xetra </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>STADA is an international pharmaceutical company which focuses on Generics and Branded Products. Its branded portfolio includes non-prescription (OTC), prescription (RX) and discretionary prescription (OTX) products. Naxolone (Tilidin Naloxone) is a generic drug targeted for pain and has generated worldwide sales of $0.42B with an increment of 4% to 2018. In 2018, their generic segment contributed 59% of the sales. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20493} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Sanofi.png"" alt="""" class=""wp-image-20493"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $1.69B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~100,000 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp; 1973&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarter: Paris, France </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$111.10B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: Euronext </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sanofi is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacturing and marketing of therapeutic solutions. The company is focused on Rare Diseases, Multiple Sclerosis, Immunology, Rare Blood Disorder, Oncology, Diabetes, Cardiovascular, Established Prescription Products, Generics, Consumer Healthcare, and Vaccines. In Sept 2018, Sanofi completed the divestment of their European generics business Zentiva to Advent International. Additionally, Sanofi launched authorized generics of Renvela (sevelamer carbonate) in the US market as tablet and powder formulation in 2017 and 2018 respectively </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20494} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Sawai.png"" alt="""" class=""wp-image-20494"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $1.70B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    Total Employees: ~3,131 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp; 1929&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter:
Osaka, Japan </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$2.32B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: TOKYO&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sawai Pharmaceutical is a generic pharmaceutical focus on drugs for multiple therapy areas i.e. cardiovascular, antihyperlipidemic agents, diabetes drugs, anticancer drugs, and OTC drugs. In Dec 2018 Sawai launched six generic products with 14 strengths namely Mirtazapine OD Tablets 15/30 mg, Atomoxetine Capsules 5/10/25/40 mg, Toaraset, Ropinirole ER Tablets 2/8 mg, Frewell, Capecitabine 300 mg. Additionally, the company retains 310 products with 756 strengths.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20495} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Cipla.png"" alt="""" class=""wp-image-20495"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong> Generic Segment Revenue: $1.73B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Total Employees: ~26000 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1935&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;      Headquarter: Mumbai, India </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$5.29B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;      Stock Exchange: NSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Cipla is a global leading pharmaceutical company ranked at 10<sup>th</sup> position among the US firms. Cipla is a leading firm in generics that majorly focusses on Cardiology, Oncology and Diabetology. Cipla’s Isuprel (isoproterenol hydrochloride) is a generic drug administered as IV, IM, SC and intracardiac routes used for the treatment of bradycardia, heart block, and rarely for asthma.  In 2018, the company has launched 15 generic products and filed 15 generic in-house filings with two in-licensing products.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20496} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Reddys-1.png"" alt="""" class=""wp-image-20496"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $1.77B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    Total Employees: ~21,966&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1984&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; Headquarter: Telangana, India </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$6.32B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Dr Reddy's Laborataries is a global pharmaceutical company with three divided segments Pharmaceutical Services &amp; Active Ingredients, Global Generics and Proprietary Products. The company focusses on GI, cardiovascular, diabetology, oncology, pain management and anti-infective. In 2018, the company filed 20 ANDAs with the US FDA along with 110 generic filings pending approval, comprising 107 ANDAs and 3 NDA filed under the Section 505(b)(2) route.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20497} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Hikma.png"" alt="""" class=""wp-image-20497"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $2.01B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;Total Employees: ~8,400&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp; 1978&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;     Headquarter: London, United Kingdom </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$5.80B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: LSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Hikma is a global pharmaceutical firm focusing on the development and marketing of generics, branded products and injectables anti-infectives, cardiovascular, CNS, diabetes including oncology, pain management and respiratory. The company's generic segmnet has demonstrated 13% increment to 2017. The company launched 90+ products in 2018.&nbsp; Additionally, in 2018 the company received the US FDA’s approval for Ritonavir Tablets USP, 100 mg used in combination with antiretroviral agents for treatment of human immunodeficiency virus (HIV-1) infection. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20498} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Lupin.png"" alt="""" class=""wp-image-20498"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $2.25B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~20,000 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1968&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;     Headquarter: Mumbai, India </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$4.82B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Exchange: NSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Lupin is a pharmaceutical firm involved in developing and delivering a wide range of generic formulations, biosimilar products and APIs globally. The company holds 3<sup>rd</sup> largest position as pharmaceutical-based on global revenue in India and 6<sup>th</sup> as a generic leader in Japan. The company is focused on multiple therapy area including Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds a global leadership position for the Anti-TB segment. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20499} -->
<figure class=""wp-block-image""></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $2.83B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Total Employees: ~22000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1986&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarter: Telangana, India </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$5.14B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Aurobindo Pharma Limited is a world-leading manufacturer of generic pharmaceuticals and active pharmaceutical ingredients. The company is focused on therapeutic/product areas encompassing Antibiotics, Antiretrovirals, CVS, CNS, Systemic Gastroenterologicals, Anti-Allergies, Anti-Diabetics and other therapeutic areas. In 2018, Aurobindo acquires Apotex’ Business in Poland, Czech Republic, the Netherlands, Spain and Belgium to strengthen its approach and capabilities of generic products in European markets. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":20500} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/09/Fresenius-1024x160.png"" alt="""" class=""wp-image-20500"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $3.04B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~112,658 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp; 1996&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Headquarter: Bad Homburg, Germany
</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~25.03B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: Xetra&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Fresenius Kabi is a global healthcare company that develops and provide products as well as services for Dialysis, Generic &amp; IV drugs, Biosimilars, Medical Devices in addition to Infusion and Nutrition therapies. Fresenius portfolio has around ",,https://pharmashots.com/wp-content/uploads/2019/09/Chart.png,Top 20,Top 20 Generics Pharma Companies,,Amneal Pharmaceuticals|Aurobindo Pharma|Cipla|Dr Reddy’s|Hikma|Endo International|Fresenius|Glenmark|Lupin|Mallinckrodt|Mylan|Pfizer|Piramal Healthcare|Sandoz|Sanofi|Sawai Pharmaceutical|STADA|Sun Pharma|Teva|Torrent,publish,9/13/2019,17
53422,Top 20 Generics Pharma Companies Based On 2019 Revenue,,"<!-- wp:paragraph -->
<p>The global generics pharmaceutical market has become an intimidating segment of the pharmaceutical drug market which continuously growing and increasing with its accessibility &amp; benefits offered as efficient and economical drugs. Generics are approved copies of small molecule drugs that contain the same amount of active ingredients, dosage form, safety, strength, route of administration, quality, performance characteristics, as of originally marketed products. A report by Global Data says that Indian generic manufacturers are doing particularly well in the generic marketplace, and more and more companies are moving their manufacturing facilities overseas to cut costs. In the list of top 20 companies, Mylan reserved the top position with a revenue of $11.5B in 2019. Our team at PharmaShots has compiled a list of the top 20 generics developing companies based on their 2019 generics revenue.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53437,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture21-1024x162.png"" alt="""" class=""wp-image-53437"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $0.24B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1980</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$4.41B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~6,579</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Mumbai, India</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Piramal Healthcare is a global pharmaceutical company offering therapies focussed on CNS, cardiovascular, anti-infective, and anti-diabetic. Piramal Healthcare has generated a revenue of $0.24B in 2019 from its generic segment<strong>.</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53438,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture20-1024x164.png"" alt="""" class=""wp-image-53438"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $0.73B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1867</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$0.02B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~3,400</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Surrey, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: OTCMKTS</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Mallinckrodt is a global pharmaceutical company that develops and manufactures therapies for multiple therapy areas including autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy, and neonatal respiratory critical care therapies, and analgesics. Mallinckrodt has generated a revenue of $0.73B in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53439,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture19-1024x163.png"" alt="""" class=""wp-image-53439"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $0.87B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1997</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;~</strong> <strong>$1.21B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~3,172</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Dublin, Ireland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Endo International is an Ireland-based, global pharmaceutical company focusing on generic and branded pharmaceuticals for therapeutic areas that include Endocrinology, Medical Aesthetics, Orthopedics, Urology &amp; Men’s Health. Endo’s Percocet (Oxycodone/acetaminophen) is an opioid analgesic approved for the treatment of moderate-to-moderately-severe pain. Endo has generated global sales of $0.87B in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53440,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture18-1024x161.png"" alt="""" class=""wp-image-53440"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $1.05B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1959</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$6.13B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~12,881</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Ahmedabad, India</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Torrent Pharma is a pharmaceutical company focused on developing therapies for Cardiovascular, Central Nervous System, GI, Vitamins Minerals Nutritionals (VMN), and Women's Healthcare. The Company also has a focus on diabetology, pain management, gynecology, oncology, and anti-infective segments. Torrent has generated a sale of $1.05B from the generic portfolio in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53441,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture17-1024x160.png"" alt="""" class=""wp-image-53441"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $1.20B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1973</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$124.6=06B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~1,00,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Paris, France</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: EPA</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sanofi is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacturing, and marketing of therapeutic solutions. The company is focused on Rare Diseases, Multiple Sclerosis, Immunology, Rare Blood Disorder, Oncology, Diabetes, Cardiovascular, Established Prescription Products, Generics, Consumer Healthcare, and Vaccines. Sanofi has generated $1.20B sale from its generic portfolio.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53442,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture16-1024x159.png"" alt="""" class=""wp-image-53442"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $1.30B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2002&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$1.26B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~5,500</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Amneal Pharmaceuticals is a global company developing and marketing generic and specialty drugs in multiple dosage forms for various diseases. The generic drug has generated a global sale of $1.30B in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53443,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture15-1024x157.png"" alt="""" class=""wp-image-53443"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $1.41B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1977</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$2.02B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~13,014</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Mumbai, India</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Glenmark is a global pharmaceutical company focusing on Generics, Specialty, and OTC business in therapy areas like Dermatology, Respiratory, and Oncology including Cardiology, Diabetes, and Oral Contraceptives. In 2019, Glenmark reported sales of $1.41B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53444,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture14-1024x167.png"" alt="""" class=""wp-image-53444"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $1.69B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1929</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$2.04B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~2,568</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:&nbsp;Osaka, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sawai Pharmaceutical is a generic pharmaceutical focus on drugs for multiple therapy areas i.e. cardiovascular, antihyperlipidemic agents, diabetes drugs, anticancer drugs, and OTC drugs. Sawai Pharmaceutical has generated a revenue of $1.69B in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53445,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture13-1024x155.png"" alt="""" class=""wp-image-53445"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $1.72B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1895</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;NA</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~11,100</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Bad Vilbel, Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NA</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>STADA is an international pharmaceutical company that focuses on Generics and Branded Products. Its branded portfolio includes non-prescription (OTC), prescription (RX), and discretionary prescription (OTX) products. Naxolone (Tilidin Naloxone) is a generic drug targeted for pain. STADA has generated worldwide sales of $1.72B from its generic segment in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53446,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture12-1024x153.png"" alt="""" class=""wp-image-53446"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $1.83B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1984</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$11.32B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~21,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Telangana, India</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Dr. Reddy’s Laborataries is a global pharmaceutical company with three divided segments Pharmaceutical Services &amp; Active Ingredients, Global Generics, and Proprietary Products. The company focuses on GI, cardiovascular, diabetology, oncology, pain management, and anti-infective. In 2019, Dr. Reddy’s has recorded the sale of $1.83B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53447,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture11-1024x163.png"" alt="""" class=""wp-image-53447"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $2B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1968</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$5.80B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~24,301</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Mumbai, India</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Lupin is a pharmaceutical firm involved in developing and delivering a wide range of generic formulations, biosimilar products, and APIs globally. The company holds the 3rd largest position as pharmaceutical-based on global revenue in India and 6th as a generic leader in Japan. The company is focused on multiple therapy areas including Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective, and NSAID space and holds a global leadership position for the Anti-TB segment. Lupin has generated total revenue of $2B from its generic segment in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53448,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture10-1024x171.png"" alt="""" class=""wp-image-53448"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $2.20B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1978</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$7.63B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~8,600</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: London, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: LON</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Hikma is a global pharmaceutical firm focusing on the development and marketing of generics, branded products, and injectables anti-infectives, cardiovascular, CNS, diabetes including oncology, pain management, and respiratory. The company’s generic segment has demonstrated the sale of $2.20B in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53449,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture9-1024x150.png"" alt="""" class=""wp-image-53449"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $2.27B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1935</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$8.31B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~26,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Mumbai, India</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Cipla is a global leading pharmaceutical company ranked at 10th position among the US firms. Cipla is a leading firm in generics that majorly focuses on Cardiology, Oncology, and Diabetology. In Apr’20 Cipla received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation from the FDA. In 2019, Cipla has generated a revenue of $1.79B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53450,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture8-1024x149.png"" alt="""" class=""wp-image-53450"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $3.06B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1986</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$7.09B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~18,469</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Telangana, India</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Aurobindo Pharma Limited is a world-leading manufacturer of generic pharmaceuticals and active pharmaceutical ingredients. The company is focused on therapeutic/product areas encompassing Antibiotics, Antiretrovirals, CVS, CNS, Systemic Gastroenterologicals, Anti-Allergies, Anti-Diabetics, and other therapeutic areas. Aurobindo has generated a total sale of $3.06B in 2019 from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53451,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture7-1024x147.png"" alt="""" class=""wp-image-53451"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $3.29B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1996</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$25.63B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~2,94,134</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Bad Homburg, Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: ETR</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Fresenius Kabi is a global healthcare company that develops and provides products as well as services for Dialysis, Generic &amp; IV drugs, Biosimilars, Medical Devices in addition to Infusion and Nutrition therapies. Fresenius portfolio has around 90+ intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs that treat multiple disorders. In 2019, the company has generated a total revenue of $3.29B from its generic sales.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53452,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture6-1024x146.png"" alt="""" class=""wp-image-53452"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $4.28B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1983</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$18.33B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~36,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Mumbai, India</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sun Pharma is the world’s fourth-largest and India’s top generic pharmaceutical company. Sun Pharma’s manufacturing operations are focused on producing generics, branded generics, specialty products, over-the-counter products, anti-retroviral, and active pharmaceutical ingredients (APIs). Apart from this, the firm offers products for several therapy areas such as dermatology, psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics, and ophthalmology. Sun Pharma has a pipeline of 98 ANDAs and 5 NDAs awaiting approval from the US FDA. Sun Pharma has reported a global sale of $4.28B in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53453,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture5-1024x159.png"" alt="""" class=""wp-image-53453"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $9.32B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1944</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;~$11.67B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~40,039</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Petah Tikva, Israel</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Teva is a global pharmaceutical firm leading in generic products with a portfolio consisting of over 35,000 products in every therapy area. The products manufactured include a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. Teva has generated a revenue of $9.32B in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53454,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture4-1024x145.png"" alt="""" class=""wp-image-53454"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $9.73B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1886</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: NA</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~26,500</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Holzkirchen, Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NA</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sandoz, a Novartis division is a global leader in developing, manufacturing, and marketing finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The company is organized globally into three divisions Retail Generics, Anti-Infectives, and Biopharmaceuticals. Sandoz is focused on therapies for Cardiovascular, CNS, Dermatology, Gastrointestinal &amp; Hormonal disorders, Metabolism, Oncology, Ophthalmic pain, and Respiratory disorders. In 2019, Sandoz has generated revenue of $9.73B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53455,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture3-1024x144.png"" alt="""" class=""wp-image-53455"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $10.23B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1849</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$232.68B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~83,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Pfizer is a research-based global biopharmaceutical company with a portfolio of Internal Medicine, Vaccines, Oncology, Inflammation &amp; Immunology, Rare Disease, and Consumer Healthcare. Upjohn-Pfizer’s generic business unit has an off-patent branded and generic products business, headquartered in China includes approximately 20 off-patent solid oral dose brands as well as certain generic products. In 2019, Pfizer’s generic segment has generated a global sales revenue of $10.23B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":53456,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/12/Picture2-1024x143.png"" alt="""" class=""wp-image-53456"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Generic Segment Revenue: $11.5B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1961</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~21.57B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~35000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Pennsylvania, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Mylan is a global pharmaceutical company focused on manufacturing of prescription generic, branded generic, brand-name including biosimilar drugs and OTC drugs for multiple diseases. Mylan focuses on drugs that are challenging to formulate and manufacture and usually have longer product life cycles than usual generic pharmaceuticals. Mylan has generated a revenue of $11.5B in 2019 from its generic segment. In Sep’19 Mylan launched its Fulvestrant Injection (50 mg/mL)/single-dose prefilled syringe which is a generic version of AstraZeneca’s Faslodex Injection and has received FDA’s ANDA as monothx. for advanced BC in women with menopause and combination therapy for advance &amp; m-BC.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post: </strong> <a href=""https://pharmashots.com/20409/top-20-generic-pharma-companies-based-on-2018-revenue/""><strong>Top 20 Generics Pharma Companies Based On 2018 Revenue</strong></a></p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2020/12/Website-Size-11.png,Top 20,Top 20 Generics Pharma Companies,,2019|Amneal Pharmaceuticals|Aurobindo Pharma|Based|Cipla|Companies|Dr Reddy’s|Endo International|Fresenius|Generics Pharma|Glenmark|Hikma|Lupin|Mallinckrodt|Mylan|Pfizer|Piramal Healthcare|Revenue|Sandoz|Sanofi|STADA|Sun Pharma|Teva|Top 20|Torrent,publish,12/10/2020,17
65918,Top 20 Generics Pharma Companies Based On 2020 Revenue,,"<!-- wp:paragraph -->
<p> </p>
<!-- /wp:paragraph -->

<!-- wp:list -->
<ul><li>Generic medicines are the backbone of the healthcare system and are identical to the innovator medicine in strength, effect, dosage form, and route of administration. These are allowed for sale after the patent expiry of the original drugs</li><li>Our team at PharmaShots has compiled a list of the top 20 generic companies based on their 2020 generic revenue</li><li>In the top 20 ledgers, Sandoz secured the top position with total revenue of $9.46B in the generic segment in 2020</li></ul>
<!-- /wp:list -->

<!-- wp:image {""align"":""center"",""id"":65927,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/20-1024x165.png"" alt="""" class=""wp-image-65927"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong> Generic Segment Revenue: $0.22B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> Founded Year: 1984&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> Market Cap:&nbsp;$8.20B </strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 6,579 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Mumbai, India</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NSE </strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Piramal Healthcare is one of the leading pharmaceutical companies that deals with producing medicines in therapeutic areas such as diabetes, cardiovascular, inflammation and infectious diseases. In June 2020, Piramal sells 20% in pharmaceutical business to Carlyle for $490 million. Piramal Healthcare has generated revenue of $0.22B in 2020 from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65928,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/19-1024x164.png"" alt="""" class=""wp-image-65928"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $0.31B </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> Founded Year: 1978</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> Market Cap:&nbsp;$5.40B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 12,609</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Bengaluru, India </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NSE</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Biocon is an Indian Biopharmaceutical company that pivots its attention towards producing innovative drugs in areas such as oncology, immunotherapy and nephrology products. Biocon manufactures generic active pharmaceutical ingredients. In November 2020, Biocon planned a capex of $280 million for generic business over the next three years. In 2020, Biocon has generated revenue of $0.31B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65931,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/18-1024x163.png"" alt="""" class=""wp-image-65931"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $0.68B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> <strong>Founded Year: 1867</strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap: $0.01B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 3,086</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Surrey, United Kingdom</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> Stock Exchange: OTCMKTS</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Mallinckrodt is an American-Irish pharmaceutical company. It targets on producing novel drugs in areas such as neurology, pulmonology, nephrology and rare diseases. In August 2020, Mallinckrodt announced US FDA filing acceptance of Biologics License Application for StrataGraft for the treatment of adults with thermal burns. In 2020, Mallinckrodt generated revenue of $0.68B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65932,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/17-1024x161.png"" alt="""" class=""wp-image-65932"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $0.78B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1997</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$1.02B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 3,397</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Dublin, Ireland</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NASDAQ</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Endo International is a global pharmaceutical company that runs its business across a wide range of therapeutic areas including Endocrinology, Medical Aesthetics, Orthopaedics, and Urology &amp; Men's Health. In December 2020, Endo completed acquisition of BioSpecifics. Endo has generated revenue of $0.78B from its generic segment in 2020.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65933,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/16-1024x160.png"" alt="""" class=""wp-image-65933"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $1.09B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1959</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$6.29B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 13,801</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Ahmedabad, India</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NSE</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Torrent is a leading pharmaceutical company and is ranked 8th in the Indian pharmaceutical market. It spotlights on developing novel therapies of Cardiovascular, central nervous system, gastro-intestinal, oncology, nephrology, anti-infective and pain management segments. Torrent Pharma is ranked 11th among Indian companies operating in the US generic market. Torrent has generated business of $1.09B from its generic segment.<strong> &nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65934,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/15-1024x159.png"" alt="""" class=""wp-image-65934"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $1.13B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1973</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$125.95B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 99,412</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Paris, France</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: EPA</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sanofi is a French multinational pharmaceutical company that covers 7 major therapeutic areas:&nbsp;cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines. In September 2020, Sanofi completed Principia Biopharma Inc. Acquisition. In 2020, Sanofi has generated a sale of $1.13B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65935,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/14-1024x157.png"" alt="""" class=""wp-image-65935"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $1.34B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 2002</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$1.67B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 6000</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: New Jersey, United States</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NYSE</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Amneal is an emerging pharmaceutical company that focuses across a broad range of therapeutic areas including&nbsp;cardiovascular, central nervous system, oncology, inflammation, anti-infective, dermatology, endocrinology, diabetes, and urology. In 2020, Amneal launched generic drugs Fluphenazine and Butrans. Amneal has generated a sale of $1.34B in 2020 from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65936,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/13-1024x156.png"" alt="""" class=""wp-image-65936"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $1.49B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1977</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$1.84B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 14,000</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Mumbai, India</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NSE</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Glenmark is an Indian pharmaceutical company that develops novel therapies for areas such as dermatology, respiratory, cardiology, diabetes, oncology and anti-infective. In June 2020, Glenmark became the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19. In December 2020, Glenmark became the first company to launch Remogliflozin and Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India. In 2020, Glenmark has generated a sale of $1.49B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65937,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/12-1024x155.png"" alt="""" class=""wp-image-65937"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $1.69B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1929</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$1.96B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 3003</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Osaka, Japan</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: TYO</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sawai is a Japan based pharmaceutical company &nbsp;associated with novel drug development in areas such as cardiovascular, diabetes drugs, anticancer drugs, and OTC drugs. In December 2020, Sawai launched two generic drugs with 10 strengths including Pregabalin and Rivastigmine. In 2020, Sawai has reported total sale of $1.69B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65938,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/11-1024x153.png"" alt="""" class=""wp-image-65938"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $2.01B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1895</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;NA</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 12,301</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Bad Vilbel, Germany</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NA</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Stada is German based pharmaceutical company that mainly focuses on production of generic and over-the-counter drugs. In 2020, Stada acquired Lobsor Pharmaceuticals AB. Stada also acquired the product portfolio of Opti Pharm AG, a Swiss company specializing in the trade and distribution of pharmaceutical products. Stada has generated sales of $2.01B from its generic segment in 2020.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65939,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/10-1024x152.png"" alt="""" class=""wp-image-65939"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $2.11B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1984</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$10.1B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 21,650</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Hyderabad, India</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NSE</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Dr.Reddy is an Indian pharmaceutical company that targets on developing novel therapies in areas such as oncology, cardiovascular, diabetes, dermatology, nephrology and urology. In June 2020, Dr. Reddy’s Laboratories completed the acquisition of select business divisions of Wockhardt. In 2020, Dr.Reddy has recorded sales of $2.11B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65940,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/09-1024x151.png"" alt="""" class=""wp-image-65940"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $2.16B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1968</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$5.63B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 18,302</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Mumbai, India</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NSE</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Lupin is an Indian pharmaceutical company that specifically focuses on developing novel drugs in therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.&nbsp;In August 2020, Lupin received approval for generic Albuterol Sulphate MDI. In 2020, Lupin has generated sales of $2.16B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65941,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/08-1024x150.png"" alt="""" class=""wp-image-65941"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $2.34B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1978</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$7.71B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 8,600</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: London, United Kingdom</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: LON</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Hikma is a British multinational pharmaceutical company that targets its business in key areas such as anti-infectives, cardiovascular, central nervous system, diabetes, oncology, respiratory. In March 2020, Hikma launched Everolimus tablets to expand its generics portfolio. In December 2020, Hikma also launched generic Advair Diskus. In 2020, Hikma has generated revenue of $2.34B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65942,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/07-1024x149.png"" alt="""" class=""wp-image-65942"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $2.61B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1935</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$9.60B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 25,845</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Mumbai, India</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NSE</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Cipla is an Indian pharmaceutical company that develops novel drugs for areas such as respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression. In 2020, Cipla received final approval for generic version of Migranal and Proventil. In 2020, Cipla has generated revenue of $2.61B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65943,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/06-1024x147.png"" alt="""" class=""wp-image-65943"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $3.38B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1986</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$5.31B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 18,469</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Hyderabad, India</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NSE</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Aurobindo Pharma is an Indian pharmaceutical company that is specialised in manufacturing generic pharmaceuticals. Aurobindo focuses on key therapeutic areas including neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, and gastroenterology. Aurobindo is among the top 10 pharmaceutical companies in India. In April 2020, Aurobindo received the final approval from l from the US Food and Drug Administration (USFDA) to manufacture and market Fluoxetine tablets in the strengths of 10 mg and 20 mg. In 2020, Aurobindo has generated sales of $3.38B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65944,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/05-1024x146.png"" alt="""" class=""wp-image-65944"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $3.58B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1999</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$26.12B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 311,269</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Bad Homburg, Germany</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: ETR</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Fresenius Kabi is a global healthcare company that focuses on multiple therapeutic areas including oncology, Generic &amp; IV drugs, and Biosimilars, Infusion and Nutrition therapies.&nbsp;In October 2020, Fresenius Kabi launched Diprivan, the company first smart labelled product with Radio Frequency Identification (RFI). In 2020, Fresenius Kabi has generated sales of $3.58B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65945,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/04-1024x146.png"" alt="""" class=""wp-image-65945"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $4.52B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1983</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$25.89B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 36,000</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Mumbai, India</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NSE</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sun Pharma is an Indian pharmaceutical company that manufactures drugs in multiple therapeutic areas including cardiology, psychiatry, neurology, gastroenterology and diabetology. In August 2020, Sun Pharma launched FluGuard, which is used for the treatment of mild to moderate cases of Covid-19 in India. In 2020, Sun Pharma has generated revenue of $4.52B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65946,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/03-1024x145.png"" alt="""" class=""wp-image-65946"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $5.28B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 2020</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$15.84B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 45,000</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Pennsylvania, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Viatris is a global healthcare company that specifically targets its business in therapeutic areas such as cardiovascular, oncology, immunology, CNS, infectious disease, gastroenterology, dermatology and respiratory for developing new drug therapies. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris.&nbsp;In 2020, Viatris has recorded sales of $5.28B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65947,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/02-1024x144.png"" alt="""" class=""wp-image-65947"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $9.31B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 1935</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$10.77B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 37,736</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Petah Tikva, Israel</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NYSE</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Teva is a global pharmaceutical company which is specialized in generic medicines. Teva is the world’s leading generic drug producer. In October 2020, Teva launched first generic versions of HIV-1 treatment Truvada and Atripla. In 2020, Teva has generated revenue of $9.31B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":65948,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/10/01-1024x143.png"" alt="""" class=""wp-image-65948"" /></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Generic Segment Revenue: $9.46B</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Founded Year: 2003</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Market Cap:&nbsp;$208.86B</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p> <strong>Total Employees: 26,500</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Headquarter: Holzkirchen, Germany</strong> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> <strong>Stock Exchange: NA</strong> </p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sandoz is a leading pharmaceutical company that mainly focuses on generics and Biosimilars.  The company is organized globally into three divisions Retail Generics, Anti-Infectives, and Biopharmaceuticals. In August 2020, Sandoz launched Ciprofloxacin and Dexamethasone otic suspension for the treatment of middle and outer ear canal bacterial infections. In 2020, Sandoz generated revenue of $9.46B from its generic segment.</p>
<!-- /wp:paragraph -->

<!-- wp:list -->
<ul><li><strong>For Viatris, only the biosimilar revenue was considered. Complex biosimilar and generics are not considered</strong></li><li><strong>In the annual report of Fresenius Kabi, the revenue was mentioned in percentage, so we calculated it as per the requirement</strong></li><li><strong>Source: Company annual reports, SEC filings, press releases, and company websites</strong></li><li><strong>Market Cap source: Google finance (as of 28<sup>th</sup> Oct 2021)</strong></li><li><strong>All revenues are reported in USD</strong></li></ul>
<!-- /wp:list -->

<!-- wp:paragraph -->
<p><strong>Related Post:</strong> <a href=""https://pharmashots.com/53422/top-20-generics-pharma-companies-based-on-2019-revenue/"">Top 20 Generics Pharma Companies Based On 2019 Revenue </a><",,https://pharmashots.com/wp-content/uploads/2021/10/Top-20.png|https://pharmashots.com/wp-content/uploads/2021/10/20.png|https://pharmashots.com/wp-content/uploads/2021/10/19.png|https://pharmashots.com/wp-content/uploads/2021/10/18.png|https://pharmashots.com/wp-content/uploads/2021/10/17.png|https://pharmashots.com/wp-content/uploads/2021/10/16.png|https://pharmashots.com/wp-content/uploads/2021/10/15.png|https://pharmashots.com/wp-content/uploads/2021/10/14.png|https://pharmashots.com/wp-content/uploads/2021/10/13.png|https://pharmashots.com/wp-content/uploads/2021/10/12.png|https://pharmashots.com/wp-content/uploads/2021/10/11.png|https://pharmashots.com/wp-content/uploads/2021/10/10.png|https://pharmashots.com/wp-content/uploads/2021/10/09.png|https://pharmashots.com/wp-content/uploads/2021/10/08.png|https://pharmashots.com/wp-content/uploads/2021/10/07.png|https://pharmashots.com/wp-content/uploads/2021/10/06.png|https://pharmashots.com/wp-content/uploads/2021/10/05.png|https://pharmashots.com/wp-content/uploads/2021/10/04.png|https://pharmashots.com/wp-content/uploads/2021/10/03.png|https://pharmashots.com/wp-content/uploads/2021/10/02.png|https://pharmashots.com/wp-content/uploads/2021/10/01.png,Top 20,Top 20 Generics Pharma Companies,,Amneal|Aurobindo|Biocon|Cipla|Dr. Reddy's|Endo|Fresnius Kabi|Generic companies|Glenmark|Hikma|Lupin|Mallinckrodt|PharmaShots|Piramal|Revenue|Sandoz|Sanofi|Sawai|STADA|Sun Pharma|Teva|Top 20|Torrent|Viatris,publish,10/28/2021,17
50844,Top 20 Immunology Companies Based 2019 Immunology Segment Revenue,,"<!-- wp:paragraph -->
<p>Immunology is an important branch of science which deals with the study of the immune system. The immune system is a highly regulated and balanced system and when the balance is disturbed, the disease can result. A lot of this work has importance in the development of new therapies and treatments that can handle or heal the condition by modifying the way the immune system is working or, in the case of vaccines, instructing the immune system and enhancing the immune reaction to specific pathogens. In the top 20 ledgers, AbbVie again ensured the top position with total revenue of $19.57B with its blockbuster drug, Humira (adalimumab) from its immunological segment. Our team at PharmaShots has compiled a list of the top 20 immunology companies based on their 2019 immunology revenue</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50867,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/20-3-1024x181.png"" alt="""" class=""wp-image-50867""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.01B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1979</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;~</strong> <strong>$0.49B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~178</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Antares<a> </a>Pharma is an American pharmaceutical company focus on developing and commercializing therapies for rheumatology, urology, endocrinology, and neurology. Antares has reported a total sale of $0.01B from its immunology segment in 2019</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50868,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/19-1-1024x164.png"" alt="""" class=""wp-image-50868""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.24B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2008</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;~$15.70B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~1,200</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Dublin, Ireland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Horizon Therapeutics is an Ireland based biopharmaceutical company focused on developing and commercializing therapies for the treatment of gout, rheumatoid arthritis, and rare diseases. Horizon has generated the sale of $0.24B from its four approved immunology products including Tepezza, Rayos, Duexis and Vimovo. Horizon’s Tepezza was selected for&nbsp;“2020 R&amp;D World R&amp;D 100 Award”</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50871,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/18-1-1024x163.png"" alt="""" class=""wp-image-50871""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.49B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1993</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$2.57B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~5,047</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Shenyang, China</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: HKD</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>3SBio is a fully integrated Chinese biotechnology company with market-leading biopharmaceutical franchises in oncology, auto-immune diseases, nephrology, metabolic diseases, and dermatology. There are three approved drugs in its immunology portfolio including Yisaipu, Tpiao and Xenopax. 3SBio’s Tpiao used to treat chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia has generated global sales of $0.33B in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50872,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/17-2-1024x161.png"" alt="""" class=""wp-image-50872""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.73B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1978</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$42.57B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~7,400</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Massachusetts, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Biogen is a global biopharma company focused on neurology, hematologic, and autoimmune diseases. Biogen has a total of six products in its immunology segment with four approved drugs including Tysabri, IMRALDI, FLIXABI, BENEPALI. Biogen’s lead drug Tysabri recorded a revenue of $1.89B. Biogen revealed the positive result of BIIB059 in the Phase 2 LILAC study for cutaneous lupus erythematosus and systemic lupus erythematosus.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50873,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/16-1-1024x160.png"" alt="""" class=""wp-image-50873""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.81B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;~$88.14</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~99,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Brentford, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: LON</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>GlaxoSmithKline (GSK) is a global healthcare company serving the world with drugs, vaccines &amp; consumer healthcare products. With only approved products, Benlysta, GSK has generated a revenue of $0.81B in 2019. In Jul 2019, GSK initiated the phase 3 study of otilimab for rheumatoid arthritis. In Sep’19, EMA granted a positive CHMP opinion for intravenous Benlysta in children with lupus and was approved in Oct 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50875,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/15-1-1024x168.png"" alt="""" class=""wp-image-50875""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.11B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2007</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$34.6B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~7,228</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Osaka, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Mitsubishi Tanabe is a Japanese pharma company focused on autoimmune diseases, diabetes and kidney diseases, neurological disorders, and vaccines. Mitsubishi has reported a total sale of $1.11B from its immunology segment in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50876,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/14-1-1024x157.png"" alt="""" class=""wp-image-50876""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.24B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1891</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$197.46B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~71,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Merck &amp; Co. is a global health care company delivering innovative health care products with its Prescription medicines, Oncology drugs, Vaccines, Biologic therapies, and Animal Health care products. Merck has recorded the sale of $1.24B in 2019 from its five approved drugs in its immunology portfolio including Simponi, Remicade, Renflexis, Brenzys, Hadlima. Simponi and Remicade was co-commercialized by Merck and Johnson &amp; Johnson and Simponi recorded the revenue of $0.83B in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50877,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/13-1-1024x156.png"" alt="""" class=""wp-image-50877""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.68B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1991</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$19.38B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~1,300</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Delaware, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Incyte Corp is a global biopharmaceutical firm focused on developing therapies in two categories Oncology and Inflammation &amp; Autoimmune. Incyte has generated a revenue of $1.68B from its immunological segment. In Jan’19, Incyte reports results of Itacitinib in GRAVITAS-301 P-III study for patients with treatment-naive acute graft-versus-host disease.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50878,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/12-1-1024x155.png"" alt="""" class=""wp-image-50878""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.79B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2005</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~&nbsp;$26.49B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~15,883</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Astellas Pharma is a Japanese multinational pharmaceutical company focused on the therapeutic fields of urology, immunology including transplantation and infectious diseases, oncology, neuroscience and DM complications, and metabolic diseases. Astellas has four drugs in its immunology portfolio including two approved drugs Smyraf And Prograf and has recorded the sale of $1.79B in 2019. In Jul’19, Astellas Pharma launched Smyraf 50 mg and 100 mg tablets for rheumatoid arthritis.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50879,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/11-1-1024x153.png"" alt="""" class=""wp-image-50879""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.79B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1901</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$135.16B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~33,625</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Indiana, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Eli Lilly and Company is a global pharmaceutical firm focused on delivering therapies in two divisions Human Pharmaceutical Products and Animal Health products. The pharmaceutical portfolio offers products for Cardiovascular, Endocrinology, Immunology, Neuroscience, and Oncology. Eli Lilly has two approved drugs including Taltz and Olumiant. Lilly’s Taltz, an approved drug for plaque psoriasis or psoriatic arthritis has generated a revenue of $1.6B in 2019. In Apr’19, Eli Lilly signs research and licensing agreement with avidity biosciences to develop therapies in immunology.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50880,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/10-1-1024x152.png"" alt="""" class=""wp-image-50880""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.92B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1928</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$20.49</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~7,600</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Brussels, Belgium</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: EBR</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>UCB is a global biopharmaceutical company focused on neurology, inflammatory, gastrointestinal and autoimmune disorders. UCB has recorded the sale of $1.92B in 2019 from its immunology segment with its only approved drug, Cimzia indicated for psoriatic arthritis (PsA). In Jul’19, Cimzia was approved by China’s NMPA.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50881,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/09-1-1024x151.png"" alt="""" class=""wp-image-50881""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $2.53B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1973</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;~$122.35B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~100,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Paris, France</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: EPA</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sanofi is a global healthcare leader in vaccines providing healthcare solutions in 170+ countries around the world. Sanofi is ranked third in the global market and first in EU and Latin America. Sanofi has four drugs in its immunology portfolio including one approved drug Kevzara, developed in partnership with Regeneron. In Dec’19, Sanofi presented the positive result from its pivoted phase 3 study of sutimlimab for cold agglutinin disease. Additionally, Sanofi restructured its agreement with Regeneron to obtain worldwide rights for Kevzara.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50882,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/08-1-1024x177.png"" alt="""" class=""wp-image-50882""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $2.97B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1887</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$135.30B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~30,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:&nbsp;New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Bristol-Myers Squibb is an American pharmaceutical company focused on Oncology, Cardiovascular, Immuno-Science, and Fibrosis. BMS has two approved drugs Orencia and Nulojix. BMS’ Orencia is a genetically-engineered fusion protein of human CTLA4 and the IgG1 Fc region, indicated to treat adult rheumatoid arthritis, juvenile idiopathic arthritis, and adult psoriatic arthritis has generated the highest revenue of $2.97B in 2019. The acquisition of Celgene in 2019, has boosted up BMS’ Immunology pipeline.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50883,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/07-1-1024x149.png"" alt="""" class=""wp-image-50883""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $3.66B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1925</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$52.60B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~49,578</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Osaka, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Takeda is a global biopharma company focused on Oncology, Gastroenterology (GI), Neuroscience, Immunology, and Rare Diseases. With three approved drugs including Immunoglobulin, Albumin, and Entyvio, Takeda has generated a $3.66B sale in 2019. In Apr’19, EMA accepted the application for a subcutaneous formulation of Entyvio in Crohn’s disease, and in Oct 2019, Takeda acquired CNP-101 from COUR Pharmaceuticals. In Feb’20, Takeda acquired PvP Biologics to strengthen its immunology pipeline. Additionally, Takeda got approval for Entyvio from China’s NMPA for Crohn’s disease in Mar 2020. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50884,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/06-1-1024x219.png"" alt="""" class=""wp-image-50884""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $4.22B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1996</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$205.93B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~109,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Basel, Switzerland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: SIX Swiss Exchange, NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Novartis is a group of companies specializing in research, development, manufacturing, and marketing with a broad range of healthcare solutions including generic and ophthalmic therapies. The company is focused on Immunology, Hepatology, Dermatology, Oncology, Neurology, and Ophthalmology. Novartis has the uppermost number of immunology drugs with eight approved products including ACZ885/Ilaris, AIN457/Cosentyx, Myfortic (Renal transplant), Neoral, Simulect, and Zortress. Novartis’ Cosentyx (secukinumab) used to treat Psoriasis, ankylosing spondylitis and psoriatic arthritis have generated global sales of $3.55B in 2019. In Apr’19 Novartis acquired IFM Tre to enhance its immunologic portfolio with its NLRP3 inhibitors for $1.5B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50885,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/05-1-1024x146.png"" alt="""" class=""wp-image-50885""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $4.73B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1849</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$206.05B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~83,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Pfizer is a research-based, global biopharmaceutical company having a vast portfolio including Oncology, Medicines, vaccines, and other health care products for the prevention &amp; treatment of untreated diseases. With 3 approved drugs including Xeljanz, Enbrel (outside the US and Canada), and Inflectra (Biosimilar), Pfizer has generated $4.73B sale from its immunology portfolio indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, Behcet's disease, and ulcerative colitis. Pfizer’s Xeljanz has generated revenue of $2.24B in 2019. In Jan’2019, CytoReason signed a research partnership with Pfizer to develop drugs using CytoReason's cell-centered models of the immune system.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50886,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/04-1-1024x146.png"" alt="""" class=""wp-image-50886""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $5.39B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1980</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$134.11B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~23,400</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Amgen is one of the leading biotechnology company developing novel therapies focused on cardiology, oncology, neurology, nephrology, and inflammatory diseases. Amgen has generated a total sale of $5.39B in 2019 with its drugs Otezla, Avsola, Enbrel, Nplate, and Prolia. Amgen’s Otezla used to treat certain types of psoriasis and psoriatic arthritis has generated sales of $1.6B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50887,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/03-1-1024x166.png"" alt="""" class=""wp-image-50887""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $8.79B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1896</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;~</strong> <strong>$281.59B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~98,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Basel, Switzerland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: SWX</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Roche Holding AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The immunology department focus on rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis including severe persistent allergic asthma (AA), chronic idiopathic urticaria (CIU), and idiopathic pulmonary fibrosis (IPF) with 3 approved drugs including Actemra, CellCept and Mabthera and has generated the sale of $8.97B in 2019. In Dec’2019, Roche signed an exclusive global option and license agreement with Rheos Medicines to develop and commercialize therapies for immune metabolism.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50888,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/02-1-1024x142.png"" alt="""" class=""wp-image-50888""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $13.95B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1887</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$378.94B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~132,100</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Johnson &amp; Johnson (J&amp;J) is an American multinational healthcare company focused on the development and commercialization of pharmaceutical, medical device, and consumer packaged products. The pharmaceutical portfolio offers products for Cardiovascular, Endocrinology, Immunology, Neuroscience, and Oncology. J&amp;J has generated $13.95B from its Immunology portfolio with 5 approved products including Remicade, Simponi, Stelara, Tremfya, Simponi Aria. Remicade was jointly marketed by J&amp;J and Merck and has generated a revenue of $4.38B in 2019. In Nov 2019, J&amp;J’s Tremfya meets the primary endpoint in the phase 3 study for Psoriatic Arthritis. Additionally, J&amp;J submit two applications with the USFDA for Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis. FDA approved Tremfya for Psoriatic Arthritis and Simponi Aria for polyarticular juvenile idiopathic arthritis and active psoriatic arthritis for patients 2 years of age and older in Jul 2020.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":50889,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/10/01-1-1024x143.png"" alt="""" class=""wp-image-50889""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $19.57B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2012</str",,https://pharmashots.com/wp-content/uploads/2020/10/Untitled-design-3.jpg|https://pharmashots.com/wp-content/uploads/2020/10/20-3.png|https://pharmashots.com/wp-content/uploads/2020/10/19-1.png|https://pharmashots.com/wp-content/uploads/2020/10/18-1.png|https://pharmashots.com/wp-content/uploads/2020/10/17-2.png|https://pharmashots.com/wp-content/uploads/2020/10/16-1.png|https://pharmashots.com/wp-content/uploads/2020/10/15-1.png|https://pharmashots.com/wp-content/uploads/2020/10/14-1.png|https://pharmashots.com/wp-content/uploads/2020/10/13-1.png|https://pharmashots.com/wp-content/uploads/2020/10/12-1.png|https://pharmashots.com/wp-content/uploads/2020/10/11-1.png|https://pharmashots.com/wp-content/uploads/2020/10/10-1.png|https://pharmashots.com/wp-content/uploads/2020/10/09-1.png|https://pharmashots.com/wp-content/uploads/2020/10/08-1.png|https://pharmashots.com/wp-content/uploads/2020/10/07-1.png|https://pharmashots.com/wp-content/uploads/2020/10/06-1.png|https://pharmashots.com/wp-content/uploads/2020/10/05-1.png|https://pharmashots.com/wp-content/uploads/2020/10/04-1.png|https://pharmashots.com/wp-content/uploads/2020/10/03-1.png|https://pharmashots.com/wp-content/uploads/2020/10/02-1.png|https://pharmashots.com/wp-content/uploads/2020/10/01-1.png,Top 20,Top 20 Immunology Companies,,3SBio|AbbVie|Amgen|Antares Pharma|Astellas|Biogen|BMS|Eli Lilly|GSK|Horizon|Immunology Companies|Incyte|J&amp;J|Merck|Mitsubishi Tanabe Pharma|Novartis|Pfizer|PharmaShots|Revenue|Roche|Sanofi|Takeda|Top 20|UCB,publish,10/22/2020,17
18454,Top 20 Immunology Companies Based on 2018 Immunology Segment Revenue,,"<!-- wp:paragraph -->
<p>The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology, Hematology and multiple diseases but due to a drastic increase in the immune disorders, Immunology segment has been widely spared across the globe. In the top 20 list, AbbVie secured the top position which generated revenue of $19.93B with its blockbuster drug, Humira (adalimumab). Our team at PharmaShots has compiled a list of top 20 immunology companies based on their 2018 immunology revenue.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18462} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/Kyowa.png"" alt="""" class=""wp-image-18462"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.10B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~7,242</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1949&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Headquarter: Tokyo, Japan </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$9.31B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Kyowa Kirin is a research and development firm focused on developing therapies for Nephrology, Immunology including allergy, Oncology and CNS products. Additionally, Kyowa kirin in-licensed KHK4827 (Brodalumab) injection from Amgen which is currently being evaluated in P-III for Axial Spondyloarthritis (axSpA).&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18463} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/Mitsubishi.png"" alt="""" class=""wp-image-18463"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.36B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~11,160</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2001&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarter: Osaka, Japan </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$6.28B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Mitsubishi Tanabe is a Japanese pharma company focused on autoimmune diseases, diabetes and kidney diseases, neurological disorders, and vaccines. Its leading product Simponi (golimumab) is an anti-TNF mAb inhibitor targeted for rheumatoid arthritis including prevention of articular structural damage. The product has generated worldwide revenue of $0.39B.&nbsp; </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18464} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/Horizon.png"" alt="""" class=""wp-image-18464"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.43B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~11,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2008&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: Dublin,
Ireland &nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$5.10B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Exchange:
NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Horizon is an Irish pharma company focused on the development and commercialization of therapies for rare diseases and rheumatic disorders. The company has two pre-clinical candidates HZN-003, PASylated Uricase and one P-IIb/ 4 candidate Krystexxa (pegloticase). Rayos (prednisone, delayed-release), one of its auto-immune product targeted for Rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus and multiple other indications, generated sales of $61.1M in 2018. Additionally, Duexis (ibuprofen and famotidine) is indicated in symptomatic relief of osteoarthritis and rheumatoid arthritis and it has generated a revenue of $114.7M in 2018.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18465} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/Biogen.png"" alt="""" class=""wp-image-18465"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.56B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~7,800&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp;
1978&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarter: Massachusetts, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$43.94B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Exchange:
NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Biogen is a US-based biotech company focused on the development of therapies in neuroscience particularly in multiple sclerosis and neuroimmunology, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain. The immunology segment is focused on autoimmune, inflammatory and fibrotic diseases. Biogen and Samsung Bioepis have developed three anti-tumor necrosis factor (TNF) biosimilars in immunology i.e Benepali (biosimilar, etanercept), Flixabi (biosimilar, infliximab) and Imraldi (biosimilar, adalimumab). </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18466} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/GSK.png"" alt="""" class=""wp-image-18466"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.57B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~100,000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Headquarter: Brentford, United
Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$101.10B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: LSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>GSK is a global leader in immuno-oncology, cell therapy, cancer epigenetics and genetic medicine. Its immune-inflammation segment is focused on chronic and debilitating conditions. Benlysta(belimumab) is a mAb inhibiting B-cell activating factor targeted to treat lupus symptoms. Benlysta generated sales of $0.59B in 2018. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18467} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/Takeda.png"" alt="""" class=""wp-image-18467"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.86B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~27,230 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1925&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarter: Tokyo, Japan </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$55.17B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Takeda is a global biopharma company focused on Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases and Immunology. Takeda’s Immunoglobulin generated sales of $0.67B and targeted for primary immunodeficiency and multifocal motor neuropathy. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18469} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/Sanofi.png"" alt="""" class=""wp-image-18469"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.98B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~</strong> <strong>100,000 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1973&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: Paris, France</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$103.94B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: Euronext</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sanofi is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture, and marketing of therapeutic solutions. The company focusses on multiple therapy areas including Oncology, Cardiology, Rare Diseases and Blood Disorder, Generics and Consumer Healthcare. Dupixent (dupilumab, SAR231893) is an interleukin-4 receptor alpha antagonist, targeted for atopic dermatitis, asthma including nasal polyposis. Additionally, Kevzara– sarilumab (SAR153191) is a mAb inhibiting Interleukin-6 Receptor, currently evaluated in P-IIb pediatric populations for two indications: polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. Also, two P-III studies have been initiated in 2018 for the treatment of polymyalgia rheumatic and giant cell arteritis.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18470} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/Lilly.png"" alt="""" class=""wp-image-18470"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.14B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Total Employees: ~38,000 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1901&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;      Headquarter: Indiana, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$110.03B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    Stock Exchange: NYSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Eli Lilly is a global pharmaceutical company focused on developing therapies for metabolic diseases Oncology, Bone / Osteoporosis &amp; Men’s health. In 2018, it collaborated with Hydra Biosciences, AC immune to develop immune &amp; neurodegenerative therapies respectively. The FDA granted fast track designation to Lilly’s Olumiant for SLE in Dec’18. Its immune product Taltz generated sales of 937.5M with a total rise of 68% compared to 2017. Additionally, Taltz (<em>ixekizumab</em>) was approved in the EU for active psoriatic arthritis in 2018. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18471} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/Merck.png"" alt="""" class=""wp-image-18471"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.47B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Total Employees: ~69,000 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1891&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$216.94B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Merck is a global pharmaceutical company developing products for prescription medicines, vaccines, biologics and animal health products. Its immunology product Simponi is a once-monthly subcutaneous treatment for inflammatory diseases approved in the EU, Turkey, and Russia and generated 9% growth in sales as compared to 2017. Remicade (infliximab) is a treatment for inflammatory diseases including Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, and Plaque Psoriasis. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18472} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/Celgene.png"" alt="""" class=""wp-image-18472"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.60B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;Total
Employees: ~16,962 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1986&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$67.54B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Celgene is a global biopharmaceutical company focused on the development and commercialization of therapies for cancer and inflammatory diseases with next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology, and neuro-inflammation. The company completed its two P-III trials (RADIANCE and SUNBEAM) for ozanimod in relapsing multiple sclerosis (RMS). It’s one of the leading immunology product Otezla (apremilast) generated sales of $1.6B in 2018 with an increment of 25.7% in net sales as of 2017. Celgene has been acquired by BMS in early 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18473} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/UCB.png"" alt="""" class=""wp-image-18473"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.63B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees:  7,432 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1928&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: Nivelle, France </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$15.08B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: Euronext </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>UCB is a biopharmaceutical company focused on research, development, manufacturing, and distribution of biopharmaceutical products in neurology and immunology disorders. One of its immunology product bimekizumab, currently evaluated in P-III program for psoriasis. In April 2018, UCB’s Cimzia (certolizumab pegol) received CHMP’s positive opinion to include a new indication in adult patients with moderate to severe plaque psoriasis. Cimzia generated global revenue of $1.6B with an increment of 5% as compared to 2017.&nbsp;&nbsp; </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18474} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/Chugai.png"" alt="""" class=""wp-image-18474"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.70B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~5,037</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1925&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: Tokyo,
Japan &nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$39.66B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: TYO </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Chugai Pharmaceuticals is a subsidiary of Roche, focused on developing therapies for Oncology, <br>Autoimmune Diseases, Bone and Joint Diseases and Renal Diseases including some other diseases. Actemra (tocilizumab) is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). RG7845 is an oral small molecule Bruton’s tyrosine kinase (BTK) inhibitor targeted to improve RA symptoms and is currently evaluated in P-I study for Rheumatoid arthritis patients. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18475} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/Astellas.png"" alt="""" class=""wp-image-18475"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.83B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~16,243</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2005&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: Tokyo,
Japan &nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$26.44B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: TYO </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Astellas is a Japanese biopharma company focusing on developing therapies related to Oncology, Immunology, Ophthalmology and muscle disease. In 2018, Astellas acquired Universal Cells, for its Universal Donor Cell Technology for the production of pluripotent stem cells involved in the reduction of immunological rejection in cell therapy. Additionally, in 2018 Astellas signed a WW exclusive licensing agreement with Tottori University for the development and commercialization of immunostimulatory gene-loading oncolytic virus.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18476} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/BMS.png"" alt="""" class=""wp-image-18476"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $2.71B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~23,300&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1989&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;Headquarter: New York, United
States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$77.36B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Bristol-Myers Squibb (BMS) is an American pharmaceutical company focused on Oncology, Cardiovascular, Immunology and Fibrosis. BMS remained to be in the highlights, with its acquisition of Celgene in early 2019. The acquisition will boost up BMS’ pipeline in Oncology, Immunology, Inflammation &amp; Cardiology. Its immune product Orencia (abatacept) is a protein indicated for adults to treat moderate to severe active RA and PsA. Additionally, the product generated sales of $2.7B in 2018 with 9% increment to 2017 revenue.<strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":18477} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/Novartis.png"" alt="""" class=""wp-image-18477"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $3.39B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;Total Employees: ~125,161</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1996&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;       Headquarter: Basel, Switzerland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$230B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;      Stock Exchange: SIX Swiss Exchange, NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novartis is a multinational group of companies specializing in the research, development, manufacturing, and marketin",,https://pharmashots.com/wp-content/uploads/2019/08/Picture1.png,Top 20,Top 20 Immunology Companies,,AbbVie|Amgen|Astellas Pharma|Biogen|BMS|Celgene|Chugai Pharmaceutical|Eli Lilly and Co|GlaxoSmithKline|Horizon Therapeutics|Immunology|Johnson and Johnson|Merck|Mitsubishi Tanabe Pharma|Novartis|Pfizer|Revenue|Roche|Sanofi|Takeda|Top 20|UCB,publish,8/9/2019,17
63340,Top 20 Immunology Companies Based on 2020 Immunology Segment Revenue,,"<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:list -->
<ul><li>Immunology deals with physiological functioning of the immune system in states of both health and disease as well as malfunctions of the immune system in immunological disorders</li><li>With the new advancement in immune sector, global pharmaceuticals continue to grow in the field despite the disruption during the COVID-19. As in 2019, Abbvie again secured the top position with total revenue of $22.15B, followed by J&amp;J, Roche, and Amgen</li><li>Our team at PharmaShots has compiled a list of top 20 immunology companies based on their 2020 immunology revenue</li></ul>
<!-- /wp:list -->

<!-- wp:image {""align"":""center"",""id"":63365,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/20-1024x181.jpg"" alt="""" class=""wp-image-63365""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.015B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1978</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$0.067B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 185</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Antares Pharma is a specialty pharmaceutical company focused primarily on the development &amp; commercialization of pharmaceutical products and technologies addressing the unmet needs in the targeted therapeutic areas. The company has reported a total sale of $0.015B from its immunology segment in 2020 from the sales of Otrexup in RA, pJIA, Psoriasis.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63366,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/19-1024x164.jpg"" alt="""" class=""wp-image-63366""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.09B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1993</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $2.326B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 5,525</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong> <strong>Shenyang, China</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: HKG</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>3S Bio is a Chinese Biotechnology company that focuses on oncology, nephrology, dermatology, and auto-immune diseases. The company unveiled the total sales of $0.09B in its immunology segment during the year 2020 from the sales of Yisaipu, which is a TNF a inhibitor indicated to treat RA, AS and psoriasis.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63390,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/18-1024x163.jpg"" alt="""" class=""wp-image-63390""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $0.99B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$100.73B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~99,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Brentford, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: LON</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>GSK is a global healthcare multinational company involves in the development, manufacture, and marketing of pharmaceutical products, vaccines, OTC medicines, and health-related consumer products. With only approved products, Benlysta, GSK has generated a revenue of $0.99B in 2020. In Dec 2020, the US FDA has approved Benlysta as the first medicine for adult patients with active LN.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63388,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/17-1024x161.jpg"" alt="""" class=""wp-image-63388""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.05B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2008&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $23.61B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 1,600</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Dublin, Ireland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Horizon is a biopharmaceutical company that focuses on rare and rheumatic diseases. Horizon has generated the sale of $1.05B from its four approved immunology products including Tepezza, Rayos, Duexis, and Vimovo. During the fiscal year 2020, Tepezza alone has generated $820M revenue, followed by Duexis ($125.3M), Rayos ($71.8M), and Vimovo ($37.6M).</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63387,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/16-1024x171.jpg"" alt="""" class=""wp-image-63387""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.08B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2007</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$42.9B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 6,805</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Osaka, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Mitsubishi Tanabe Pharma Corporation (MTPC) is a Japanese pharmaceutical company that focuses on diabetes, kidney diseases, autoimmune diseases, and vaccines. The company has reported a total sale of $1.08B from its immunology segment in 2020. In Dec’ 2020 MTPC initiates a long-term OLE trial to the phase III MT-1186-A03 trial of edaravone for Amyotrophic lateral sclerosis</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63386,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/15-1024x159.jpg"" alt="""" class=""wp-image-63386""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.16B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1891</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$190.33B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 58,096</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: &nbsp;New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Merck &amp; Co. is an American multinational pharmaceutical company. The company develops medicines (oncology, OTC, and generic drugs), vaccines, biologic therapies, and animal health products. In 2020, Merck-approved drugs including Simponi and Remicade generated revenue of $1.16B<strong>.</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63385,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/14-1024x157.jpg"" alt="""" class=""wp-image-63385""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.65B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2005</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$30.32B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 15,883</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Astellas is a Japanese multinational pharmaceutical company. It focuses on serving patients’ medical needs across multiple therapeutic areas, including cardiology, hematology, immunology, infectious diseases, oncology, and urology. Astellas immune drug, Prograf generated revenue of $1.65B in 2020. In Jan’2020, Astellas announced the construction of a new manufacturing facility for Prograf’s API in the Toyama technology center.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63384,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/13-1024x156.jpg"" alt="""" class=""wp-image-63384""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.93B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1991</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$16.26B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 1,773</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Delaware, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Incyte is a global biopharmaceutical company that focuses on oncology, inflammation, and autoimmune diseases. In 2020, Incyte has generated revenue of $1.93B in its immunology segment. In Jul’2020, Incyte and MorphoSys announced that the FDA approved Monjuvi (tafasitamab-cxix), which is indicated in combination with lenalidomide for R/R DLBCL</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63404,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/12-1-1024x155.jpg"" alt="""" class=""wp-image-63404""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $1.94B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1978</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $50.50B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 9,100</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Massachusetts, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Biogen is a US-based biotechnology company that focuses on developing and delivering innovative therapies globally for neurological, neurodegenerative, and autoimmune diseases. Major areas of it include MS, neuroimmunology, neuromuscular disorders including Spinal Muscular Atrophy (SMA), movement disorders including Parkinson’ disease, Ophthalmology, and neuropsychiatry. Biogen generated a revenue of $1.94 with Tysabri in the immunology segment. In Jun’2020, the company submitted the regulatory filing of Tysabri in the US and the EU.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63382,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/11-1024x153.jpg"" alt="""" class=""wp-image-63382""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Immunology Segment: $2.19B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1928</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $21.81B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 7,600</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Brussels, Belgium</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: EBR</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>UCB is a multinational biopharmaceutical company that specializes in two therapeutic areas, the central nervous system (CNS) and immunology. Cimzia has generated total revenue of $2.1B in 2020. In Jan’2020, UCB’s biologic Cimzia (certolizumab pegol) was approved by MHRA for the treatment of PsO, PsA, pustular psoriasis, and psoriatic erythroderma for which existing treatment methods are not sufficiently effective. The approval makes Cimzia the first Fc-free, PEGylated anti-TNF treatment option in Japan.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63381,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/10-1024x152.jpg"" alt="""" class=""wp-image-63381""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $2.46B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1876</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:  $257.75B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 35,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Indiana, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Eli Lilly is an American pharmaceutical company focused on immunology, neurodegenerative diseases, and endocrinology. Eli Lilly has two approved immunology products including Olumiant and Taltz. Its immune product, Taltz has generated revenue of $1.78B while the remaining is from Olumiant’s sales in 2020. Taltz and Olumiant drove the 37% increase in revenue in Immunology.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63380,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/09-1024x180.jpg"" alt="""" class=""wp-image-63380""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $3.16B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1887</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$149.73B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 30,250</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>BMS is a global biopharmaceutical company that focuses on multiple therapeutic areas including oncology, hematology, cardiovascular, and immunology. Its immune drug, Orencia generated revenue of $3.16 in 2020. The revenue of Orencia increased by 6% and 7% in the US and international market due to higher demand respectively. In Jun’2020, the company reported results of an open-label P-IV Early AMPLE biomarker study assessing the differences by which Orencia and adalimumab interfere with disease progression in the mod. to sev. RA patients.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63379,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/08-1024x152.jpg"" alt="""" class=""wp-image-63379""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $3.56B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1781</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$51.87B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 47,495</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Takeda is a Japanese multinational biopharmaceutical company. It is one of the top 20 largest pharmaceutical companies in the world by revenue. The company is focused on&nbsp;metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary. With Takeda’s immunology-approved drugs including Immunoglobulin and Albumin, Takeda has generated a $3.56B sale in 2020.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63378,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/07-1024x149.jpg"" alt="""" class=""wp-image-63378""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $4.56B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1849</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$269.75</strong>B</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 78,500</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Pfizer is an American multinational pharmaceutical company. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. Pfizer’s immune drug, Xeljanz generated revenue of $2.43B, followed by Enbrel ($1.35B) and inflectra ($0.65B) in 2020. In Sept’2020, the US FDA approved Xeljanz (tofacitinib) for the treatment of children and adolescents aged=2yrs. with active pcJIA.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63377,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/06-1024x147.jpg"" alt="""" class=""wp-image-63377""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $4.60B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1973</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$128.43B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 100,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Paris, France</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: EPA</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sanofi is a French multinational pharmaceutical company. The company covers seven major therapeutic areas; cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. Dupixent and Kevzara together contributed to the $4.60B revenue of the company in the immunology segment.&nbsp; In November 2020, Dupixent&nbsp;(dupilumab) was approved by European Commission as the first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63376,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/05-1024x146.jpg"" alt="""" class=""wp-image-63376""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $4.86</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1996</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:   $227.36B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 110,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Basel, Switzerland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: SWX</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world. The company is focused on immunology, Hepatology, Dermatology, oncology, Neurology, and Ophthalmology. Novartis’ immune drug, Cosentyx generated revenue of $3.9B and Ilaris generated 0.87B in 2020. Cosentyx received approval and launched in the EU and US for nr-axSpA, its fourth major indication, and in August became the first treatment approved in Japan for this indication. In April, Cosentyx also became the first IL17A inhibitor approved in China for the treatment of AS. In June, Ilaris was granted a new indication in the US for active Still’s disease including Adult-Onset Still’s Disease (AOSD).</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63375,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/04-1024x146.jpg"" alt="""" class=""wp-image-63375""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $7.19B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1980&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$129.45B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 24,300</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Amgen is an American multinational biopharmaceutical company that focuses on CV disease, oncology, bone health, neuroscience, immunology, nephrology, and inflammation. In 2020, Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis generated total sales of $4.9B whereas Otezla which is a PDE4 inhibitor generated a revenue of $2.1B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63374,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/03-1024x166.jpg"" alt="""" class=""wp-image-63374""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $9.30B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1896</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $347.83B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 101,465</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Basel, Switzerland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: SWX</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Roche is a Swiss multinational healthcare company. The immunology department of the company focuses on rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis. Roche’s immunotherapies include Actemra, Xolair, Esbriet, MabThera, Pulmozyme, CellCept, and others. &nbsp;Actemra produces the highest revenue among all with $3.23B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63373,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/02-1024x142.jpg"" alt="""" class=""wp-image-63373""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $15.05B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1886</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$457.45B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Employees: 134,500</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Johnson and Johnson is an American multinational company that focuses on multiple therapeutic areas including Cardiovascular &amp; Metabolism, Immunology, Infectious Diseases &amp; Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. In its immunology segment, J&amp;J focuses on core diseases like rheumatoid arthritis, inflammatory bowel diseases, and psoriasis. In 2020, its leading immunology product, Stelara generated sales of $7.70B, followed by Remicade, Simponi, and Tremfya with the revenue of $3.74B, $2.24B, and $1.34B respectively.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":63372,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/08/01-1024x143.jpg"" alt="""" class=""wp-image-63372""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Immunology Segment Revenue: $22.15B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2013</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $200.96B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 48,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: &nbsp;Illinois, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:group -->
<div class=""wp-block-group""><div class=""wp-block-group__inner-container""></div></div>
<!-- /wp:group -->

<!-- wp:paragraph -->
<p>Abbvie is an American Biopharmaceutical company focused on the development of products in immunology, oncology, virology and neuroscience, dermatology. In Dec’2020, Abbvie announced that CHMP recommended the approval of Rinvoq for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult ",,https://pharmashots.com/wp-content/uploads/2021/08/Top-20.jpg|https://pharmashots.com/wp-content/uploads/2021/08/20.jpg|https://pharmashots.com/wp-content/uploads/2021/08/19.jpg|https://pharmashots.com/wp-content/uploads/2021/08/01.jpg|https://pharmashots.com/wp-content/uploads/2021/08/02.jpg|https://pharmashots.com/wp-content/uploads/2021/08/03.jpg|https://pharmashots.com/wp-content/uploads/2021/08/04.jpg|https://pharmashots.com/wp-content/uploads/2021/08/05.jpg|https://pharmashots.com/wp-content/uploads/2021/08/06.jpg|https://pharmashots.com/wp-content/uploads/2021/08/07.jpg|https://pharmashots.com/wp-content/uploads/2021/08/08.jpg|https://pharmashots.com/wp-content/uploads/2021/08/09.jpg|https://pharmashots.com/wp-content/uploads/2021/08/10.jpg|https://pharmashots.com/wp-content/uploads/2021/08/11.jpg|https://pharmashots.com/wp-content/uploads/2021/08/13.jpg|https://pharmashots.com/wp-content/uploads/2021/08/14.jpg|https://pharmashots.com/wp-content/uploads/2021/08/15.jpg|https://pharmashots.com/wp-content/uploads/2021/08/16.jpg|https://pharmashots.com/wp-content/uploads/2021/08/17.jpg|https://pharmashots.com/wp-content/uploads/2021/08/18.jpg|https://pharmashots.com/wp-content/uploads/2021/08/12.jpg|https://pharmashots.com/wp-content/uploads/2021/08/12-1.jpg,Top 20,Top 20 Immunology Companies,,3S BIO|AbbVie|Amgen|Antares Pharma|Astellas|Biogen|BMS|Eli Lilly|GSK|Horizon|Immunology Companies|Immunology Segment|Incyte|J&amp;J|Merck|Mitsubishi Tanabe Pharma|Novartis|Pfizer|Revenue|Roche|Sanofi|Takeda|Top 20|UCB,publish,8/12/2021,17
41604,Top 20 Innovative Digital Therapeutics Companies of 2019,,"<!-- wp:list -->
<ul><li>The recent decades have shown an accelerated development and evolution in the technology world, leading to unexpected growth in digital health companies.</li><li>With the aid of health information technology, wearable devices, telehealth, telemedicine, and personalized medicine HCPs can make better insights for treatments and early diagnosis of life-threatening diseases</li><li>Our team at PharmaShots has categorized a list of 20 innovative digital therapeutics companies placed in alphabetical order</li></ul>
<!-- /wp:list -->

<!-- wp:image {""id"":41882,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/1-1-1024x173.png"" alt="""" class=""wp-image-41882"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2011&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>16</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>Washington, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Neurology<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>2Morrow is a digital health company developed by Brandon Masterson and Jo Masterson focusses on delivering wellness and behaviour change programs via smartphone apps for aiding healthcare issues including smoking, vaping, weight, stress/anxiety, and chronic pain. 2Morrow Health is a digital health platform allowing usage of ACT developed in collaboration with Fred Hutch Cancer Research Center targeting key chronic disease drivers and conditions. In Oct 2019, 2Morrow in collaboration with Washington State Department of Health developed and launched its first digital health app for quitting vaping in young and adults.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41876,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/2-1-1024x110.png"" alt="""" class=""wp-image-41876"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2011&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>33</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>Massachusetts, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Neurology&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Akili Interactive is a prescription digital medicine company delivering solutions through video game experiences targeting improvement in cognitive dysfunction and brain-related conditions. The company has also received multiple Series B and C funding from multiple companies including Amgen Ventures, Baillie Gifford, Jazz Ventures. In Mar 2019, Akili signed an agreement with Shionogi to develop and commercialize AKL-T01 &amp; AKL-T02 for ADHD and cognitive dysfunction related symptoms in children with ASD respectively in Japan and Taiwan. In Jun 2020, Akili’s EndeavorRx (AKL-T01) received the CE Mark approval as a digital treatment for children with ADHD. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41877,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/Band-1024x111.jpg"" alt="""" class=""wp-image-41877"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Employees: </strong>20&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>Massachusetts, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Neurology, Cardiology, Respiratory, Oncology</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Biofourmis is a global leading company founded by Kuldeep Singh Rajput and Wendou Niu addressing personalized predictive care by developing and delivering software-based cost-effective therapies. In Oct 2019, The US FDA approved Biofourmis’ Biovitals Analytics Engine an AI and ML-enabled monitoring device targeted to identify chronic conditions with heart failure, COPD, and atrial fibrillation. In Apr 2020, Biofourmis acquired Takeda's digital oncology tool, Gaido Health will combine remote monitoring, patient surveys, and analytics to monitor cancer patients at home and detecting signs of complications. In Jul 2020, Chugai and Biofourmis partnered to develop a digital solution utilizing Biofourmis' Biovitals platform for pain management in patients with endometriosis.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41878,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/4-1-1024x114.png"" alt="""" class=""wp-image-41878"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2011&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>33</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>Massachusetts, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Neurology<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Cara Care is a US-based company which offers mobile application enabling users to track their nutrition, symptoms, stress, mood, medication, and individual factors. In Jun 2019, the company raised Series A funding of 47M from Johnson &amp; Johnson Innovation and Asabys Partners for the expansion of mobile companion apps for people suffering from digestive health or GI issues. Cara Care is a free app with self-tests, diagnostics, and tracking tools to help individuals, couples, and families dealing with digestive health issues.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41879,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/5-1024x127.png"" alt="""" class=""wp-image-41879"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2012<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>70</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>NewYork, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Neurology<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Click Therapeutics is developed by David Benshoof Klein involved in developing, validation, and commercialization of software as prescription medical treatments for multiple therapeutic areas including insomnia, acute coronary syndrome, migraine, overactive bladder, and chronic low back pain. Sanofi Ventures granted $17M to Click Therapeutics and will be utilized in enhancing its platform and pipeline of prescription digital therapeutics to treat a wide range of diseases. Click’s CT-101 (clickotine) is a launched digitally held program for people to quit smoking.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41881,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/6-1-1024x176.png"" alt="""" class=""wp-image-41881"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year:</strong> 2011&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Total Employees:</strong> 33</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong> Tokyo,<strong> </strong>Japan</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong> Lifestyle Diseases<strong>&nbsp; </strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>CureApp is a Tokyo based digital health startup founded by Kohta Satake and a leader in the medical apps. In Feb 2018, the company received $14M funds for the reduction of lifestyle diseases globally from BNV and KII including Itochu Corporation plus Cyberdine. Additionally, CureApp is the first firm to launch DTx clinical studies in Japan also completed P-III trial for the first product of nicotine addiction, currently under regulatory review in Japan. In May 2020, Jichi Medical University and CureApp collaborated to initiate P-III trial of ""Digital Therapeutics"" for patients with hypertension in Japan.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41888,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/7-1024x115.png"" alt="""" class=""wp-image-41888"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2010&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>142</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>California, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Endocrine/Metabolic Diseases<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Glooko is a US-based firm founded by Yogen Dalal that focusses on transforming digital health for diabetic patients in connection with their health care professionals also enabling telehealth and clinical research. In early 2017, Glooko received Series C funding of $35M from Georgian Partners to accelerate growth, expand international footprints, and deepen expertise in data analytics. In Feb 2019, Glooko collaborated with Novo Nordisk for connected insulin pens the NovoPen 6 and NovoPen Echo Plus. In Jul 2020, Glooko collaborated with Sanofi to provide Free Remote Care solutions to upload and share their diabetic data with HCPs, viewed easily on the Glooko software platform.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41884,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/8-1024x221.png"" alt="""" class=""wp-image-41884"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2017<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>142</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>NewYork, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Musculoskeletal, Pulmonary</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Kaia Health is a US-based company founded by Konstantin Mehl which helps in chronic conditions including back pain and COPD with technology plus a human touch. Kaia has two digital health AI platforms i.e. Digital Biomarker and Motion Coach for improving quality of life. The Digital Biomarker assesses patients’ multiple activities including motion, balance, and stability with their smartphones. The Motion Coach is an AI-based real-time performer which analyze the movements and guide users through training. In Jun 2020, the company received Series B funding of $26M from Optum Ventures, Idinvest, and capital300 to expand and grow its core digital therapy platforms for MSK conditions including new therapy areas.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41885,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/9-1024x176.png"" alt="""" class=""wp-image-41885"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2011&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>92</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>California, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Chronic Diseases</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Lark Health is a digital care platform founded by Julia Hu and Jeff Zira. In May 2020, the company collaborated with HealthPartners for providing an AI-enabled diabetes management program at no cost. Lark Health also received Series C funding of $80M provided by Warburg Pincus, with participation from Accel, Partech, IQ Capital, Salesforce Ventures, and ABN AMRO Ventures. The company has multiple programs addressing chronic diseases including Behavioral Health, Hypertension Care, Diabetes Care program, and Diabetes Management Program.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41886,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/10-1024x118.png"" alt="""" class=""wp-image-41886"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2012<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>39</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>California, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Neurology</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Neuro Track is a mobile behavior company focusses on the combination of digital techniques with human behavior. In Apr 2019, the company received a $3.3M fast-track grant from the National Institute on Aging invested to study the effects of its Cognitive Health Digital Therapeutic program in patients at risk for Alzheimer’s and related dementias. Additionally, in Jun 2019, Neuro Track also received a Series C funding of $21M from Khosla Ventures and other contributors.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41890,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/11-1024x118.jpg"" alt="""" class=""wp-image-41890"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2008&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>1310</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>California, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Neurology</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Noom is a US-based company developed by Sean Duffy and Petakov. Noom is a leading brand in weight-loss designed by psychologists to create real and sustainable results. In May 2020, Noom hired 100+ health coaches for making lifestyle easy and healthier. Additionally, in May 2020, Noom with its partner LifeScan launched a Digital Diabetes and Weight Loss Management Pilot Program. The company also acquired Opus Growth to strengthen its digital performance marketing capabilities with added offline capabilities. In Jun 2020, the company highlighted its results of Noom Healthy Weight (HW) program which were also published in JMIR Diabetes.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41891,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/12-1024x118.jpg"" alt="""" class=""wp-image-41891"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2011<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>456</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>California, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Endocrine/Metabolic Diseases, Neurology, Musculoskeletal</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Omada Health is a leading digital care company developed by Sean Duffy and Adrian James offering patient-friendly and clinically effective digital health programs for diabetes prevention, type 2 diabetes management, hypertension, behavioural health, and musculoskeletal issues. In Oct 2019, Abbott collaborated with Omada Health to combine their solutions i.e. FreeStyle Libre system &amp; digital care program aiding to create a new paradigm for people withT2D. In May 2020, Omada acquired Physera for its musculoskeletal solution delivering interventions digitally and via telehealth. In 2020 the company also raised $57M as investment fund Perceptive Advisors.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41895,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/13-1024x176.png"" alt="""" class=""wp-image-41895"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2013&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Employees: </strong>188<strong>&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>California, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Neurology</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Pear Therapeutics is a US-based company and a leader in prescription digital therapeutics founded by Corey M. McCann developing product candidates across therapeutic areas including severe psychiatric and neurologic conditions. In Jan 2019, the company closed a $64M Series C financing led by Temasek and joined by other existing investors. In Jul 2020 it received a credit facility for up to $50M from Perceptive Advisors, a leading life sciences investment firm. Additionally, in Jan 2020 it entered into a collaboration agreement with Apricity Health to develop two therapies for patients’ precision management undergoing cancer treatment. Recently, in Aug 2020, the US FDA granted clearance for its lead product “reSET-O”, Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41896,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/14-1024x120.png"" alt="""" class=""wp-image-41896"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>NA&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>NA</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>California, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Neurology</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Pivot is created by Carrot, a digital health company with a mission to use mobile technology, behavioral science, and clinical expertise to help people quit smoking. In Jul 2020, AllegisNL Capital invested in financing for the commercialization of its Pivot tobacco cessation program. AllegisNL is supported by one of the largest life insurance companies worldwide. Also, Carrot entered a partnership with #FirstRespondersFirst to extend its Pivot digital tobacco cessation program to frontline healthcare workers for free during the COVID-19 crisis. Pivot will be launched initially in Boston with 1199SEIU United Healthcare Workers East, with the option for national expansion.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41897,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/15-1024x127.png"" alt="""" class=""wp-image-41897"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2001<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>191</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>Redwood City, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: NA</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Proteus Digital Health was founded by Andrew Thompson, George Savage, and Mark Zdeblick who invented Digital Medicine, a new category of pharmaceuticals that measures medication treatment effectiveness, helps physicians improve clinical outcomes and patients reach health goals. In Apr 2016, Proteus secured $50M in Series H financing which strengthened the company’s balance sheet. The company struggled to find a market for its digital pill and failed to close a $100M funding round in late 2019 and filed for Chapter 11 bankruptcy protection in Jun 2020. In the latest bid to exit bankruptcy, Otsuka Pharmaceutical is buying Proteus, while a group of companies including Novartis are opposing this bid.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41898,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/16-1024x188.png"" alt="""" class=""wp-image-41898"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>1989&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>7500</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>San Diego, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Neurology, Pulmonary</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>ResMed is the US-based cloud-connected medical device company founded by Peter Farrell for people with sleep apnea, COPD, and other chronic diseases. In Jul 2019, ResMed completed a $500M private placement debt offering. Additionally, it entered a collaboration agreement with Cerner Corporation along with the integration of its Cerner Millennium electronic health record (EHR) to help providers make more informed treatment decisions, control costs and more easily transition patients from acute settings to out-of-hospital care.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41899,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/17-1024x129.png"" alt="""" class=""wp-image-41899"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2015&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>106</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>Porto, Portugal</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Musculoskeletal</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sword Health is a digital health company founded by Virgilio Bento for the treatment of musculoskeletal disorders by combining physical therapy with digitally enabled behavioral coaching and continuous education. In Apr 2019, the company raised $8M in a Series A investment round led by Khosla Ventures and several other investors which allowed it to expand its footprints in the US market. Following the previous investment, in Feb 2020, Sword announced the addition of $9M to their Series A investment, bringing their total Series A investment to $17M.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41900,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/18-1024x124.png"" alt="""" class=""wp-image-41900"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year:</strong> 2014&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Employees: </strong>347</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>San Francisco, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Endocrine/Metabolic Diseases, Cardiovascular, Neurology</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Vida Health is founded by Stephanie Tilenius and targets conditions such as diabetes, depression, anxiety, and high blood pressure, and pairs them with a personal trainer, nutritionist, nurse, therapist, or other relevant support professional. The company’s platform also leverages machine learning to analyze data and personalize each user’s treatment plan. In Apr 2020, Vida Health raised $25M to treat chronic health conditions remotely- particularly around mental health.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41901,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/19-1024x127.png"" alt="""" class=""wp-image-41901"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2014<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>175</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>San Francisco, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Endocrine/Metabolic Diseases, Cardiovascular</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Virta Health is a US-based company founded by Sami Inkinen, Stephen Phinney, Jeff Volek is the first company with a treatment to sustainably reverse T2D without medications or surgery. In Oct 2019, Virta Health partnered with Accolade to expand access to Type 2 Diabetes Reversal Treatment. Additionally, in Jan 2020, the company raised $93M in Series C funding to combat the growing prevalence of T2D, bringing the total equity funding to $166M.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":41902,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""http://pharmashots.com/wp-content/uploads/2020/08/20-1024x127.png"" alt="""" class=""wp-image-41902"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2016&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: </strong>61</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>Houston, US</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Endocrine/Metabolic Diseases</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Vivante Health is a US-based company founded by Dr. Kimon Angelides focuses on digital health solutions to provide personalized, comprehensive care for people with digestive conditions. In Jan 2020, Vivante Health closed a $5.8M Series A1 funding to accelerate its efforts to provide relief to thousands of Americans with chronic GI symptoms, using a digital health solution called GIThrive. Additionally, in Aug 2020, Vivante Health partnered with Bucknell University to provide digestive disease health support to its employees and their families.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Sourc</strong>es: Companies Website &amp; Press releases </p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2020/08/Top-20.png|https://pharmashots.com/wp-content/uploads/2020/08/2-1.png|https://pharmashots.com/wp-content/uploads/2020/08/Band.jpg|https://pharmashots.com/wp-content/uploads/2020/08/4-1.png|https://pharmashots.com/wp-content/uploads/2020/08/5.png|https://pharmashots.com/wp-content/uploads/2020/08/6.png|https://pharmashots.com/wp-content/uploads/2020/08/6-1.png|https://pharmashots.com/wp-content/uploads/2020/08/1-1.png|https://pharmashots.com/wp-content/uploads/2020/08/8.png|https://pharmashots.com/wp-content/uploads/2020/08/9.png|https://pharmashots.com/wp-content/uploads/2020/08/10.png|https://pharmashots.com/wp-content/uploads/2020/08/7.png|https://pharmashots.com/wp-content/uploads/2020/08/11.jpg|https://pharmashots.com/wp-content/uploads/2020/08/12.jpg|https://pharmashots.com/wp-content/uploads/2020/08/13.png|https://pharmashots.com/wp-content/uploads/2020/08/14.png|https://pharmashots.com/wp-content/uploads/2020/08/15.png|https://pharmashots.com/wp-content/uploads/2020/08/16.png|https://pharmashots.com/wp-content/uploads/2020/08/17.png|https://pharmashots.com/wp-content/uploads/2020/08/18.png|https://pharmashots.com/wp-content/uploads/2020/08/19.png|https://pharmashots.com/wp-content/uploads/2020/08/20.png,Top 20,Top 20 Innovative Digital Therapeutics,,2morrow Inc.|Akili Interactive Labs|Biofourmis|Cara Care|Click Therapeutics|Cure app|Digital Therapeutics|Glooko|Kaia Health|Lark Health|Neuro Track|Noom|Omada Health|Pear Therapeutics|Pivot|Proteus Digital Health|ResMed|Sword Health|Vida Health|Virta Health,publish,8/14/2020,17
62073,Top 20 Innovative Digital Therapeutics Companies of 2020,,"<!-- wp:list -->
<ul><li>The digital therapeutics market has unsurprisingly exploded in last few years. Available virtually, digital therapies are developed by engineers, clinicians &amp; scientists and are rigorously tested, making it possible for people to access treatment for both physical &amp; psychological conditions at home</li><li>Demand for digital therapies has skyrocketed amid the COVID-19 pandemic. As a result, many digital therapeutics and telehealth offerings are added during the pandemic</li><li>Our team at PharmaShots, has listed 20 innovative digital therapeutics companies of 2020 in alphabetical orders</li></ul>
<!-- /wp:list -->

<!-- wp:image {""align"":""center"",""id"":62101,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/1-1024x116.png"" alt="""" class=""wp-image-62101""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2011</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong> Washington, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:</strong> ~25</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong> &nbsp;Neurology</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>2Morrow is a digital health company that delivers proven wellness and behavior change programs via smartphone apps. The company combines technology and behavioral science to address the largest healthcare issues including smoking, vaping, weight, stress/anxiety, and chronic pain. Programs are delivered via an easy-to-use smartphone application for participants and a real-time dashboard for program administrators offering both engagement data and population insights. In Feb 2020, 2Morrow collaborated with Walmart to distribute two DTx programs aimed at Smoking and Vaping Cessation on Walmart.com. In Sept 2020, research from Fred Hutch showed that 2Morrow’s app can help smokers to quit smoking while 2Morrow’s app-based, smoking-cessation therapy has demonstrated effectiveness in clinical trials and is 2-3 times more effective than unaided smoking cessation.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62102,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/2-1-1024x106.png"" alt="""" class=""wp-image-62102""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:</strong> 2011</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong> Massachusetts, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: </strong>~100</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong> Neurology</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games. It aims to develop a new type of electronic medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, with the potential to be developed at a fraction of the cost of traditional medical approaches. In 2020, Akili got the US FDA and EC approval for EndeavorRx for children with ADHD as the first prescription treatment delivered through a video game.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62099,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/3-1024x111.png"" alt="""" class=""wp-image-62099""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2015</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>Massachusetts, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: </strong>~350</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Neurology, Cardiology, Respiratory,&nbsp;&nbsp; Oncology</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Biofourmis is a biotechnology company that augments personalized care and therapies using digital therapeutics. The company's platform uses AI to integrate &amp; analyze continuous physiology data from clinical-grade wearables to detect personalized patterns and predict clinical exacerbation in advance of a critical event, enabling medical professionals to intervene days before a critical event and providing better outcomes for patients. In 2020, the company collaborated with Chugai to develop an objective assessment of pain using digital technology. Biofourmis’ Biovitals Sentinel platform has been deployed to remotely monitor COVID-19-positive patients to aid in early detection of deterioration and to enable clinicians and nurse teams to intervene early.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62097,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/4-1024x114.png"" alt="""" class=""wp-image-62097""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp;</strong>2016</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:&nbsp;</strong>Massachusetts, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:&nbsp;</strong>~45</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:&nbsp;</strong>Gastrointestinal</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Cara is a pharmaceutical company that empowers patients suffering from chronic digestive diseases. Cara Care develops companion digital therapeutics to enhance state-of-the-art therapies for GI diseases. In 2020, Cara Care collaborated with the Consumer Healthcare Business Unit of Sanofi Germany on a holistic approach to digestive health that bundled Sanofi’s with Cara Care’s digital companion app for digestive conditions. The company has apps to manage BS, IBD, GERD, and dyspepsia.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62096,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/5-1024x120.png"" alt="""" class=""wp-image-62096""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:</strong> 2012</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong> NewYork, NewYork, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:</strong> ~90</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong> Neurology</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics enable change within individuals and are designed to be used independently or in conjunction with biomedical treatments. In Dec 2020, Click Therapeutics secured $30M in growth capital from K2 Health Ventures to expand its operations. In Sep 2020, Boehringer Ingelheim and Click Therapeutics collaborated to develop and commercialize CT-155 as a novel prescription digital therapeutic to aid in the treatment of Schizophrenia.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62094,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/6-1024x112.png"" alt="""" class=""wp-image-62094""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:</strong>&nbsp;2014</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong> California, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:</strong>&nbsp;~70</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong>&nbsp;Neurology</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Cognoa is a pediatric behavioral health company developing digital diagnostics and therapeutics to enable the earlier diagnosis and treatment of behavioral health conditions, like autism. The company’s AI technology platform will enable Cognoa's product pipeline to address additional unmet needs including ADHD and anxiety. In 2021, Cognoa received the US FDA’s approval for first-of-its-kind autism diagnosis aid, designed to help physicians to diagnose autism in the primary care setting.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62118,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/Capturez-1024x112.png"" alt="""" class=""wp-image-62118""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:</strong>&nbsp;2014</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong>&nbsp;Tokyo, Japan</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:</strong>&nbsp;~35</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong>&nbsp;Lifestyle Diseases<strong>, </strong>Neurology</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>CureApp provides a digital platform for consumers to manage addiction and health vitals. The company offers a mobile app to aid users in smoking cessation and tracking their body vitals for better health management. The CureApp Smoking allows users to enter details about their smoking habits, which the built-in algorithm uses to make recommendations. In addition, users can log their activity which can be reviewed by a physician. The company develops NASH App for the treatment of liver cirrhosis for medical institutions. It also offers HERB-app for managing blood pressure, the Ascure app for smoking cessation programs for corporates, and ascureSPARX which offers mental health programs for cognitive training. In 2020, the company’s CureApp SC Nicotine addiction treatment app and CO checker got approval in Japan as Asia’s first therapeutics app.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62092,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/8-1024x113.png"" alt="""" class=""wp-image-62092""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp;</strong>2010</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:&nbsp;</strong>California, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:&nbsp;</strong>~160</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:&nbsp;</strong>Endocrine/Metabolic Diseases</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Glooko is the universal diabetes platform that provides insights to improve outcomes for people with diabetes (PWDs) and their care teams. Glooko connects to the world’s most popular diabetes devices, major fitness, and activity trackers and supplies personalized, timely patient information such as glucose level, food, insulin, medications, blood pressure, diet, and weight data. In Oct 2020, Glooko announced a new medical education program in collaboration with the diabetes technology network (DTN) / Association of British Clinical Diabetologists (ABCD). In July 2020, Glooko had provided free remote care solution and collaborated with Sanofi to share with medical clinics and people with diabetes. In Mar 2020, Glooko has enabled remote patient care at no charge to medical clinics and people with diabetes to minimize risk during pandemics.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62091,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/9-1024x110.png"" alt="""" class=""wp-image-62091""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:</strong> 2016</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong> NewYork, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:</strong> ~120</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong> Musculoskeletal, Pulmonary</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Kaia Health is a digital therapeutics company that creates evidence-based treatments for a range of medical disorders. Kaia offers digital programs to help people with chronic musculoskeletal pain—including back, hip, and knee pain and COPD. In 2020, Kaia Health collaborated with Chiesi Group to commercialize the Kaia Health COPD Pulmonary Rehabilitation app in Europe. The company reported that its pain management program is revolutionizing chronic pain therapy through digital coaching, offering value and reassurance to benefits managers concerned about costs from delayed, inadequate, or unnecessary care stemming from MSK conditions.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62104,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/10-1-1024x114.png"" alt="""" class=""wp-image-62104""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:</strong> 2011</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong> California, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:</strong> ~140</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong> Chronic Diseases</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Lark Health develops an AI-based chronic disease management platform for diabetes, hypertension, and behavioral health. It is a digital health startup that provides virtual care through AI coaching, smart devices, and telemonitoring. In 2020, Lark Health rolls out behavioral health coaching targeted at patients at risk for chronic conditions. The AI-enabled program focus on weight management, smoking cessation, stress management, and overall health.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62088,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/12-1024x116.png"" alt="""" class=""wp-image-62088""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2012</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>California, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: </strong>~50</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong> Neurology</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Neuro Track is a mobile behavior company that focuses on the combination of digital techniques with human behavior. Neurotrack is on a mission to transform the diagnosis and prevention of Alzheimer’s and related dementias through its app-based Cognitive Health Program. Its digital cognitive assessments, using groundbreaking eye-tracking technology, are coupled with a personalized intervention program to empower individuals at any age to strengthen their cognitive health through “brain checkups” and targeted lifestyle behaviors. In 2020, the company collaborated with Sompo Holdings to launch the Neurotrack Cognitive Health Program to policyholders in Japan.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62089,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/11-1024x113.png"" alt="""" class=""wp-image-62089""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2008</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>New York, NY, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: </strong>~1955</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Metabolic/Endocrine</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Noom is the world's leading behavior change company, disrupting the weight loss and healthcare industries. By combining the power of AI, mobile tech, and psychology with the empathy of 2,500+ personal coaches, Noom helps people live healthier lives by changing their long-term habits. The Noom platform is already being used by leading healthcare and pharmaceutical companies to improve treatment outcomes for patients worldwide. In Jan 2020, Eversana and Noom collaborated to improve therapy adherence and patient engagement for complex therapies. In Jun 2020, Noom reported the release of a new study revealing that age is a predictor of weight in a mobile health intervention. In Feb 2020, Noom reported two new studies on the impact of mobile coaching on binge eating disorders and obesity.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62087,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/13-1024x122.png"" alt="""" class=""wp-image-62087""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:</strong> 2011</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong> California, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:</strong> 456</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas</strong>: Endocrine/Metabolic Diseases, Neurology, Musculoskeletal</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Omada Health is a digital care company that offers innovative and clinically effective digital health programs to empower individuals to engage in their health and lead healthier lives. The program is personalized to meet each participant’s unique needs as they evolve, ranging from diabetes prevention, T2D management, hypertension, behavioral health, and musculoskeletal issues. Omada combines professional health coaching, connected health devices, real-time data, and personalized feedback to deliver clinically meaningful results. The company is the largest CDC-recognized provider of the National Diabetes Prevention Program. In 2020, Omada’s digital diabetes prevention program showed sustained HbA1c reduction and weight loss in a clinical study. The company acquired Physera that broadens its portfolio and extends its focus on depth of care and clinical rigor.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62086,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/14-1024x124.png"" alt="""" class=""wp-image-62086""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:</strong>&nbsp; 2015</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong>&nbsp; New York, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:</strong>&nbsp;142</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong>&nbsp; Metabolic/ Endocrine</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>One Drop is a diabetes management platform that helps people navigate diabetes together. The mobile app for diabetes management is available in 195 countries. The company harnesses the power of behavioral science, mobile computing, and data science to transform the lives of people with diabetes and other chronic conditions globally. In 2020, the company acquired all the assets and IP of Sano including its continuous glucose sensing platform. One Drop signed ~$98M agreement with Bayer to jointly develop digital health products for multiple therapeutic areas based on One Drop's predictive, preventative, personalized self-care platform. In April 2020, the company launched SugarRx, a digital subscription, offering consumers worldwide access to affordable on-demand support and educational content.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62085,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/15-1024x120.png"" alt="""" class=""wp-image-62085""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:</strong> 2013</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>California, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: </strong>188</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong> Neurology</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Pear Therapeutics is a privately held eHealth company that develops digital therapies addressing a broad range of conditions including addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and sleep. PEAR’s eFormulation platform combines pharmaceutical preparations with user-friendly, customizable, and scientifically validated software applications. PEAR’s patented approach provides better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payors. In Nov 2020, Pear launched Somryst for chronic insomnia via end to end virtual care experience. The company allied with HTA to provide access for reSET and reSET-O to self-insured employees.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62084,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/16-1024x123.png"" alt="""" class=""wp-image-62084""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:</strong> 1989</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong> San Diego, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:</strong> 7500</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong> Neurology, Pulmonary</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>ResMed is a developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Sleep-disordered breathing (SDB), includes obstructive sleep apnea (OSA), and other respiratory disorders that occur during sleep. It has developed several products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear, and other accessories. In 2020, ResMed ramps up ventilator output to meet global demand during the pandemic. The company launched AirTouch N20 CPAP nasal mask with a memory foam cushion. Additionally, last year the company launched a #WakeUpToGoodSleep Campaign, underscoring the Importance of good sleep.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62083,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/17-1024x118.png"" alt="""" class=""wp-image-62083""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2015</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>New York, New York, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>&nbsp;Total Employees: </strong>204</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Musculoskeletal</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sword Health is a digital health company that provides a digital musculoskeletal care solution. It offers AI-powered physical therapists enabling both patients to have sessions at home and get real-time biofeedback and therapists to monitor the progress of patients. Following the previous investment, in Feb 2020, Sword announced the addition of $9M to their Series A investment, bringing their total Series A investment to $17M. In Aug 2020, Sword health became the only digital musculoskeletal care provider with HITRUST, SOC 2, and FDA certifications.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62080,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/20-1024x121.png"" alt="""" class=""wp-image-62080""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year:</strong> 2002</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:</strong> New York, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:</strong> 2,000</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas:</strong> Neurology</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Teladoc Health is multinational telemedicine and virtual healthcare company based in the US. Primary services include telehealth, medical opinions, AI and analytics, telehealth devices, and licensable platform services. In Oct 2020, Teladoc and Livongo entered into a ~$18.5M merger agreement. The company also launched mental health telemedicine service. This service creates the first telemedicine solution to offer both general medical and mental health care from the same platform, enabling a more holistic and seamless approach to care.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62082,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/18-1024x124.png"" alt="""" class=""wp-image-62082""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Founded Year: </strong>2014</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: </strong>California, US</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees:</strong> 347</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Therapy Areas: </strong>Endocrine/Metabolic Diseases, Cardiovascular, Neurology</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Vida Health is a company developing a virtual care platform for chronic and behavioral health conditions. It integrates individual expert care with machine learning and remote monitoring to deliver personalized chronic condition management combined with health coaching and therapy through an online platform and a mobile app. The platform supports individuals in managing conditions such as diabetes, hypertension, obesity, depression, anxiety, etc. In Oct 2020, Vida Health became the first major chronic disease management platform to add a fully supported Spanish program to its services. Vida’s Spanish-language service allows Spanish speakers to fully engage with the Vida app and their coaches, therapists, registered dietitians, and care navigators completely in Spanish. In Nov 2020, Vida Health launched a virtual congestive heart failure management program. In Sep 2020, Vida Health had selected as the preferred virtual mental health provider for a new return to work solution called Working well launched by Castlight Health.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":62081,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/07/19-1024x124",,https://pharmashots.com/wp-content/uploads/2021/07/Website-Size.png|https://pharmashots.com/wp-content/uploads/2021/07/Website-Size-1.jpg|https://pharmashots.com/wp-content/uploads/2021/07/2-1.png|https://pharmashots.com/wp-content/uploads/2021/07/10-1.png|https://pharmashots.com/wp-content/uploads/2021/07/11-1.png|https://pharmashots.com/wp-content/uploads/2021/07/Website-Size-2.jpg|https://pharmashots.com/wp-content/uploads/2021/07/Capturez.png,Top 20,Top 20 Innovative Digital Therapeutics,,2MORROW|akili Interactive lab|Bifourmis|Cara Care|Click Therapeutics|Cognoa|CureApp|Glooko|Innovative Digital Therapeutics Companies|Kaia Health|Lark Health|NeuroTrack|Noom|Omada|One Drop|Pear Therapeutics|ResMed|Sword Health|TeleDoc|Top 20|Vida Health|Virta Health,publish,7/8/2021,17
19189,Top 20 Life Sciences Deals of 2018 Based on Total Deal Value,,"<!-- wp:paragraph {""align"":""left""} -->
<p style=""text-align:left"">Healthcare, pharmaceutical, and biotech companies are gearing up to tap new markets as they look to consolidate their positions after a spate of mergers &amp; acquisitions and licensing partnerships in 2018. The highest valued deal proved to be of Takeda’s acquisition of Shire for $57B with the focus on global R&amp;D, its robust and modality-diverse pipeline of oncology, GI, neuroscience, and rare diseases as well breakthrough innovations. The second-highest deal value was Sanofi’s acquisition of Bioverativ for $11B, strengthening Sanofi's rare blood disorder pipeline. Additionally, Novartis and Celgene also ranked high with the acquisitions of AveXis and Juno, respectively. In H2’18, Novartis spun off Alcon, its ophthalmology division, for $5B. Merck also initiated the acquisition of Antelliq, an animal health company, to strengthen its digital monitoring technology portfolio based on what Antelliq had developed for animal health. This article is based on the 2018 deals data as provided by Chris Dokomajilar of <a href=""https://dealforma.com/"">DealForma</a>. Our team at PharmaShots curated the top 20 deals in healthcare and life sciences.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19215} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h20-1024x138.png"" alt="""" class=""wp-image-19215"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Merrick Acquired AI Medical Systems</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -&nbsp;</strong>Oct 6, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value -&nbsp;</strong>$2.32B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Merrick acquired AI Medical Systems for $2.32B. The acquisition complements Merrick’s current portfolio and broadens its software platform with the addition of artificial intelligence and machine learning software coupled with robotic hardware.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19216} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h19-1024x136.png"" alt="""" class=""wp-image-19216"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Servier&nbsp;Purchased</strong>&nbsp;<strong>Shire's Global Oncology Business</strong>&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date - </strong>Apr 16, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value - </strong>$2.40B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Servier purchased Shire's global oncology business, including its marketed product ONCASPAR, ex-U.S. rights to ONIVYDE, certain early-stage pipeline drugs, and Calaspargase Pegol, which is currently under FDA review. Shire received a total deal value of $2.40B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19217} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h18-1024x139.png"" alt="""" class=""wp-image-19217"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Fortive Purchased Ethicon's Advanced Sterilization Products Business</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -&nbsp;</strong>Jun 6, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Value -&nbsp;</strong>$2.8B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Fortive acquired Ethicon's Advanced Sterilization Products
business for $2.8B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19218} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h17-1024x135.png"" alt="""" class=""wp-image-19218"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Colfax Acquired DJO Global</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Date -&nbsp;</strong>Nov 19, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Value -&nbsp;</strong>$3.15B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Colfax acquiredDJO Global from Blackstone, a
private equity firm managing DJO, for $3.15B. The acquisition was completed on
February 25, 2018 and strengthened Colfax's orthopedic solutions business.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19219} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h16-1024x140.png"" alt="""" class=""wp-image-19219"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Sangamo's Development and Commercialization Deal with Kite Pharma</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Date -&nbsp;</strong>Feb 22, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Value -&nbsp;</strong>$3.16B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sangamo granted Kite Pharma rights to develop and commercialize next-generation ex-vivo cell therapies by using Sangamo’s zinc finger nuclease (ZFN) technology platform for cancer treatment. Kite will be responsible for all development, manufacturing, and commercialization of products under the collaboration, and it will also be&nbsp;accountable for expenses incurred by Sangamo. Sangamo received $150M up front and eligible to receive up to $3.01B in development, regulatory, and sales milestones across 10 or more products utilizing Sangamo's technology, plus tiered royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19221} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h15-1024x139.png"" alt="""" class=""wp-image-19221"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Merck Acquired Animal Health Monitoring Company Antelliq</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -&nbsp;</strong>Dec 14, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value -&nbsp;</strong>$3.62B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Merck acquired Antelliq. The acquisition strengthened Merck's
digital monitoring technology portfolio with Antelliq’s animal health
monitoring technology. Antelliq shareholders received $2.3B up front and $1.3B
for Antelliq’s debt.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19222} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h14-1024x138.png"" alt="""" class=""wp-image-19222"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Nektar’s Development and Commercialization Deal with BMS for NKTR-214 with Opdivo and Yervoy</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Date -&nbsp;</strong>Feb 13, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Value -&nbsp;</strong>$3.63B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Nektar granted Bristol-Myers Squibb exclusive, worldwide rights
to co-develop and commercialize its NKTR-214 in combination with Opdivo and
Yervoy for the treatment of cancer. The companies will initially conduct a
joint clinical trial of NKTR-214 with Opdivo and Opdivo plus Yervoy for more
than 20 indications in 9 tumors. BMS would lead the commercialization of
NKTR-214 in combination with Opdivo/Yervoy. Nektar received $1.85B up front,
which includes $1B in cash and a purchas of 8,284,600 shares of Nektar common
stock at $102.60 per share for approximately $850M. Nektar is eligible for up
to $1.43B in development and regulatory milestones and up to $350M in sales
milestones. Nektar will book sales of NKTR-214 as monotherapy, or in
combination with a third-party&nbsp;medicine,
and will keep 65% of profits (35% to BMS). BMS retained 100% of product
revenues on its own medicines.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19223} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h13-1024x143.png"" alt="""" class=""wp-image-19223"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Dicerna’s Development and Commercialization Deal with Lilly for RNAi Based Drugs to be Discovered Using Dicerna's GalXC RNAi Technology</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -&nbsp;</strong>Nov 29, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value -&nbsp;</strong>$3.7B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Dicerna granted Lilly exclusive, worldwide right to develop and commercialize RNA interference (RNAi) based drugs for the treatment of cardio-metabolic, neurodegeneration, and pain targets using Dicerna's GalXC RNAi technology platform. Dicerna received $100M up front, $100M in upfront equity, and is eligible for up to $350M in milestones per program for more than 10 programs, plus royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19224} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h12-1024x139.png"" alt="""" class=""wp-image-19224"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>P&amp;G Acquired Merck KGaA's Consumer Health Business&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -&nbsp;</strong>Apr 19, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value -&nbsp;</strong>$3.71B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Procter &amp; Gamble purchased Merck KGaA's consumer health business. Merck KGaA received EUR 3.4B ($3.71B) up front.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19226} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h11-1-1024x139.png"" alt="""" class=""wp-image-19226"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Boston Scientific Acquired BTG</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Date -</strong>&nbsp;Nov 20, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Value -&nbsp;</strong>$4.20B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Boston Scientific acquired BTG. The acquisition strengthened Boston's peripheral intervention portfolio. BTG shareholders received $1.07 per share, or approximately $4.2B, which represented a 37% premium.&nbsp;The acquisition closed on August 19, 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19227} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h10-1024x138.png"" alt="""" class=""wp-image-19227"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Sanofi Acquired Ablynx</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Date -&nbsp;</strong>Jan 29, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Value -&nbsp;</strong>$4.66B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sanofi acquired Ablynx for EUR 3.9B ($4.8B) at EUR 45 per share in cash at a premium of 21%. Ablynx had a previous offer of EUR 2.6B from Novo Nordisk, which was rejected. Sanofi and Ablynx had partnered since July 2017 to find new treatments for inflammatory diseases. Ablynx's lead product is caplacizumab for thrombotic thrombocytopenic purpura.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19228} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h9-1024x143.png"" alt="""" class=""wp-image-19228"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Novartis Spun-off Alcon</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -&nbsp;</strong>June 29, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value -&nbsp;</strong>$5B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novartis spun-off Alcon and funded it with a $5B share buyback
through 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19229} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h8-1024x139.png"" alt="""" class=""wp-image-19229"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Affimed’s Development and Commercialization Deal with Genentech for NK Cell Engager-Based Immunotherapeutics&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -&nbsp;</strong>Aug 27, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value -</strong> $5.1B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Affimed granted Genentech rights to develop and commercialize NK cell engager-based immuno-therapeutics for the treatment of multiple cancers using Affimed's redirected optimized cell killing (ROCK) platform. Affimed received $96M up front and is eligible for up to $5B in milestones, plus royalties.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19247} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h7-2-1024x140.png"" alt="""" class=""wp-image-19247"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>GSK Acquired TESARO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -&nbsp;</strong>Dec 3, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value -&nbsp;</strong>$5.1B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>GlaxoSmithKline acquired TESARO for $75 per share in cash. The
acquisition strengthened GSK's oncology pipeline and commercial capabilities in
oncology. TESARO shareholders received an aggregate cash consideration of
roughly $5.1B (£4.0B). The acquisition price of $75/share represented a 110%
premium to TESARO’s 30-day Volume Weighted Average Price of $35.67. The
acquisition was completed on January 22, 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19231} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h6-1024x136.png"" alt="""" class=""wp-image-19231"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Eisai’s Development and Commercialization Deal with Merck for Lenvima Monotherapy and Combination with Keytruda/Everolimus</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -&nbsp;</strong>Mar 7, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value -&nbsp;</strong>$5.76B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Eisai granted Merck rights to co-develop and commercialize its oral, tyrosine kinase inhibitor Lenvima as a monotherapy and in combination with Keytruda/everolimus. Eisai is sponsoring the Phase III study of Lenvima with Keytruda or everolimus for renal cell carcinoma. Additionally, they are planning for 11 new indications and a basket trial targeting multiple cancers. Eisai will book sales worldwide and share costs and profits equally. Eisai received $300M up front, up to $650M for option rights through 2020, $450M as reimbursement for research and development expenses, and is eligible for up to $385M in clinical and regulatory milestones, and up to $3.97B in sales-based milestones.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19232} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h5-1024x139.png"" alt="""" class=""wp-image-19232"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Celgene Acquired Impact Biomedicines</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -&nbsp;</strong>Jan 7, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value -&nbsp;</strong>$7B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Celgene acquired Impact Biomedicines. Impact shareholders
received $1.1B upfront and are eligible to receive contingent payments of up to
$1.4M upon regulatory approval and an additional $4.5B based on sales
performance for cumulative sales between $1B and $5B.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19233} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h4-1024x140.png"" alt="""" class=""wp-image-19233"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Novartis Acquired AveXis</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -&nbsp;</strong>Apr 9, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value -</strong>&nbsp;$8.7B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Novartis acquired gene therapy company AveXis for $218 per share, or approximately $8.7B. AveXis' compounds are based on its AAV9 gene therapy technology with its lead compound, AVXS-101, being developed for SMA at the time and became Zolgensma, plus others in development for Rett Syndrome. Novartis completed the acquisition on May 15, 2018.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19241} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h3-1024x140.png"" alt="""" class=""wp-image-19241"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Celgene Acquired Juno</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -</strong><strong>&nbsp;</strong>Jan 22, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value -</strong><strong>&nbsp;</strong>$10.4B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Celgene acquired Juno Therapeutics for $9B. Previously, Celgene owned 9.7% of shares in Juno. The acquisition strengthened Celgene's cellular immunotherapy portfolio.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19238} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h2-1-1024x138.png"" alt="""" class=""wp-image-19238"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Sanofi Acquired Bioverativ for $11.6B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Date -</strong><strong>&nbsp;</strong>Jan 22, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal
Value -</strong><strong>&nbsp;</strong>$11.6B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sanofi acquired Bioverativ for $11.6B at a premium of 64% to its
January 19, 2018 closing price. The acquisition strengthened Sanofi's rare
blood disorders pipeline.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":19236} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/08/h1-1024x138.png"" alt="""" class=""wp-image-19236"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Takeda Acquired Shire</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date -&nbsp;</strong>May 8, 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value -&nbsp;</strong>$57.17B&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Takeda acquired Shire. Shire shareholders received $30.33 in
cash and either 0.839 new Takeda shares or 1.678 Takeda ADSs at a premium of
64.4%.</p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2019/08/FE3.png,Top 20,Top 20 Life Sciences Deals,,Alcon|Boston Scientific|Bristol-Myers Squibb|Celgene|Colfax|Eli Lilly|Fortive|Genentech|GlaxoSmithKline|Kite Pharma|Merck|Merrick|Novartis|Sanofi|Servier|Takeda,publish,8/23/2019,17
55338,Top 20 Life Sciences Deals of 2020 by Total Deal Value,,"<!-- wp:list -->
<ul><li>Life sciences companies are gearing up to enter new markets as they look to secure their positions after a spate of M&A, licensing, and research partnerships in 2020</li><li>Artios partnered with Merck with an option to license up to 8 oncology programs proving to be the highest valued deal of 2020 with a total deal value of $6.9B. The second-highest deal valued at $6B was Daiichi Sankyo’s development and commercialization deal with AstraZeneca for DS-1062</li><li>This article is based on the 2020 biotech and pharma deals data as provided by Chris Dokomajilar of <a href=""https://dealforma.com"">DealForma</a>. Our team at PharmaShots curated the top 20 deals in healthcare and life sciences by disclosed total deal value in R&amp;D partnerships</li></ul>
<!-- /wp:list -->

<!-- wp:image {""align"":""center"",""id"":55350,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/20-1-1024x141.jpg"" alt="""" class=""wp-image-55350""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>20. insitro’s Development and Commercialization Deal with Bristol Myers Squibb</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Oct 28, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.07B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>insitro granted Bristol Myers Squibb rights to develop and commercialize therapies for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). insitro will apply its platform, the insitro Human (ISH) platform, to generate induced pluripotent stem cell (iPSC) derived disease models for ALS and FTD to provide insights into disease progression after which BMS has the option to select a few targets for further clinical development and commercialization. Insitro received $50M up front and is eligible for up to $20M in operational and up to $2B in discovery, development, regulatory, and commercial milestones, plus royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55351,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/19-1-1024x141.jpg"" alt="""" class=""wp-image-55351""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>19. Silence Therapeutics’ Development and Commercialization Deal with AstraZeneca</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Mar 25, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.08B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Silence Therapeutics granted AstraZeneca rights to develop and commercialize 5 liver-based small interfering RNA (siRNA) therapies for cardiovascular, renal, metabolic, and respiratory diseases using Silence's established GalNAc-siRNA platform. AstraZeneca and Silence will conduct discovery research on the 5 targets during a 3-year research period. Silence is responsible for designing siRNA molecules against gene targets selected by AstraZeneca, and for manufacturing of material to support GLP toxicology studies and Phase I clinical studies. AstraZeneca will lead clinical development and commercialization. AstraZeneca has the option to extend the partnership for a further 5 targets. Silence has the option to co-develop 2 programs of their choice starting from Phase II. Silence received $60M up front, a $20M upfront equity investment, a potential $10M option fee for each selected target, and is eligible for up to $140M in development milestones and up to $250M in commercial milestones for each target, plus high single-digit to low double-digit tiered royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55352,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/18-1-1024x141.jpg"" alt="""" class=""wp-image-55352""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>18. UCB’s Research Partnership with Roche and Genentech with an Option to License for UCB0107</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: July 29, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.12B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>UCB granted Roche and Genentech an exclusive, worldwide option to license the development and commercialization of UCB0107 for the treatment of progressive supranuclear palsy (PSP) and Alzheimer's Disease. UCB will fund and conduct a proof-of-concept study in Alzheimer's Disease after which Genentech has the option to either progress with the development or return full rights to UCB. UCB received $120M up front. If Genentech exercises its option, UCB is eligible to receive up to $2B in cost reimbursement, development, and sales-based milestones, plus royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55353,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/17-1-1024x141.jpg"" alt="""" class=""wp-image-55353""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>17. Denali’s Development and Commercialization Deal with Biogen for DNL151</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Aug 6, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.15B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Denali granted Biogen rights to co-develop and co-commercialize Denali’s small molecule leucine-rich repeat kinase 2 (LRRK2) inhibitor program, DNL151, for the treatment of Parkinson’s disease. Additionally, Biogen has an exclusive option to license up to 2 preclinical programs including its Antibody Transport Vehicle (ATV), Abeta program (ATV enabled anti-amyloid beta program), and a second program utilizing its TV technology. Biogen also has the right of first negotiation on 2 additional TV-enabled therapeutics. Both companies will co-commercialize DNL151 in the US and China. Denali received $560M up front, $465M as an equity investment, and is eligible for up to $1.125B in development and commercial milestones for DNL151, plus royalties. Biogen and Denali will share responsibility and development costs on a 60:40 basis globally, share costs, profits, and losses 50:50 in the US, and 60:40 in China for the LRRK2 program.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55354,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/16-1-1024x141.jpg"" alt="""" class=""wp-image-55354""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>16. Skyhawk’s Research Partnership with Vertex with an Option to License Small Molecules</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: December 22, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.24B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Skyhawk signed a research partnership with Vertex to develop small molecule therapies that modulate RNA splicing using Skyhawk's SkySTAR platform for the treatment of neurodegenerative diseases and cancer. Vertex has a worldwide option to license intellectual property rights to compounds developed under the collaboration. Skyhawk will receive $40M up front and is eligible for up to $2.2B in milestones, plus royalties if Vertex exercises the option.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55355,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/15-1-1024x141.jpg"" alt="""" class=""wp-image-55355""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>15. Kymera Therapeutics’ Development and Commercialization Deal with Sanofi for Inflammatory Diseases</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: July 9, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.33B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Kymera granted Sanofi exclusive, worldwide rights to develop and commercialize 2 programs outside of oncology/immuno-oncology: a preclinical IRAK4 lead compound for immune-inflammatory diseases and an earlier stage program for an undisclosed use. Kymera is responsible for discovery and preclinical research and conducting a Phase 1 trial for at least 1 protein degrader directed against IRAK4, plus up to 3 backup degraders. Sanofi will be responsible for further clinical development and commercialization and will also be responsible for all clinical development activities for the second program. Kymera has the option to co-develop and co-commercialize both programs in the US and share all the costs and profits equally. Kymera will receive $150M up front and is eligible for up to $1.48B in the development milestones (more than $1B of the $1.48B relates to IRAK4 dev. and reg. events), up to $700M in sales milestones ($400M of the $700M relates to IRAK4), plus tiered royalties from the high single digits to high teens, subject to low-single digits upward adjustments in certain circumstances.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55356,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/14-1-1024x141.jpg"" alt="""" class=""wp-image-55356""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>14. Taiho and Astex’s Development and Commercialization Deal with Merck</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Jan 6, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.55B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Taiho and Astex granted Merck exclusive, worldwide rights to develop and commercialize Taiho and Astex's combined small molecule and data for the treatment of cancer. Taiho and Astex received $50M up front, undisclosed R&amp;D funding, and are eligible for up to $2.5B in milestones, plus royalties. Also, Taiho has co-commercialization rights in Japan and an option to promote in specific areas of South East Asia.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55357,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/13-1-1024x141.jpg"" alt="""" class=""wp-image-55357""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>13. Nurix’s Development and Commercialization Deal with Sanofi for Cancer</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Jan 9, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.58B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Nurix granted Sanofi exclusive, worldwide rights to develop and commercialize immuno-oncology therapeutics discovered by Nurix using its DELigase platform. Nurix's drug discovery platform integrates DNA-encoded libraries and a portfolio of E3 ligases to create small molecules designed to induce protein degradation of drug targets. Nurix granted Sanofi 3 specific targets and Sanofi has the option to expand to 5 targets. Sanofi is responsible for clinical development and commercialization. Nurix has the option to co-develop and co-promote up to 2 products in the US under certain conditions. The partnership excludes Nurix’s lead degradation programs for which Nurix retains all rights. Nurix received $55M up front, undisclosed option payments for additional targets, and is eligible for up to $2.5B in total payments including undisclosed research, preclinical, clinical, regulatory, and sales milestones. If Nurix exercises its option to co-develop and co-promote certain products, the partners will split US profits and losses for those products 50/50. Nurix to receive undisclosed royalties on ex-U.S. net sales on all optioned products. In January 2021, Nurix received $22M following Sanofi exercising its option for a total of five targets.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55358,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/12-1-1024x141.jpg"" alt="""" class=""wp-image-55358""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>12. Precision BioSciences’ Development and Commercialization Deal with Eli Lilly</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Nov 20, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.66B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Precision BioSciences granted Eli Lilly exclusive rights to develop and commercialize in vivo therapies for genetic disorders with the initial focus on Duchenne muscular dystrophy and 2 undisclosed gene targets by applying Precision's ARCUS genome editing platform. Eli Lilly will have an option to expand the partnership to 3 additional targets. Precision BioSciences received $100M up front, $35M in an upfront equity purchase of its common stock, and is eligible for up to $420M per product in development, regulatory, and sales milestones (up to $2.52B for 6 targets), plus tiered royalties ranging from the mid-single digits to low-teens.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55359,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/11-1-1024x141.jpg"" alt="""" class=""wp-image-55359""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>11. Sangamo’s Development and Commercialization Deal with Biogen</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Feb 27, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.72B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sangamo granted Biogen exclusive, worldwide rights to develop and commercialize gene regulation therapies, including ST-501, for the treatment of tauopathies, including Alzheimer's disease, ST-502 for the treatment of synucleinopathies, including Parkinson's disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets using Sangamo's zinc finger protein (ZFP) technology. Sangamo received $125M up front, $225M in upfront equity for approximately 24M shares at $9.21 per share, and is eligible for up to $2.37B in milestones, plus royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55360,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/10-1-1024x141.jpg"" alt="""" class=""wp-image-55360""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>10. Schrodinger’s Development and Commercialization Deal with BMS</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Nov 23, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $2.76B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Schrodinger granted BMS exclusive, worldwide rights to develop and commercialize small molecule therapeutics for the treatment of cancer, autoimmune, and neurologic diseases using Schrodinger’s physics-based computational platform. Schrodinger received $55M up front and is eligible for up to $2.7B in preclinical, development, regulatory, and sales milestones, plus royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55361,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/9-1-1024x141.jpg"" alt="""" class=""wp-image-55361""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>09. Repare’s Development and Commercialization Deal with BMS for Oncology</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: May 26, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $3.06B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Repare granted BMS exclusive, worldwide rights to develop and commercialize multiple oncology products using Repare’s SNIPRx synthetic lethal discovery platform for the treatment of cancer. Repare’s SNIPRx platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from therapies based on the genetic profile of their tumors. Repare received $65M up front comprised of $50M in cash and $15M in an upfront equity investment and is eligible for up to $3B in license fees and milestone payment, plus royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55363,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/8-1-1024x141.jpg"" alt="""" class=""wp-image-55363""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>08. Fate Therapeutics’ License Option Deal with Janssen Biotech for Cancer</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Apr 2, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $3.1B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Fate Therapeutics granted Janssen exclusive, worldwide option to develop and commercialize up to four iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell therapies using Fate's iPSC product platform for the treatment of hematologic malignancies and solid tumors. Janssen will reimburse development cost until IND after which Janssen has the right to exercise its option. Fate received $50M up front, a $50M upfront equity investment at $31.00 per share, and is eligible for up to $1.8B in development and regulatory milestones and up to $1.2B in commercial milestone, plus double-digit royalties. Additionally, Fate has the option to co-commercialize and share equally in profits and losses in the US in place of certain clinical development costs and adjustments in milestone and royalty payments.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55364,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/7-1024x141.jpg"" alt="""" class=""wp-image-55364""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>07. Sage Therapeutics’ Development and Commercialization Deal with Biogen</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Nov 27, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $3.12B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Sage Therapeutics granted Biogen exclusive rights to develop and commercialize zuranolone for the treatment of the major depressive disorder (MDD), postpartum depression (PPD), and other psychiatric disorders, and SAGE-324 for the treatment of tremor and other neurological disorders outside the US excluding rights to zuranolone in Japan, Taiwan, and South Korea. Sage received $875M in upfront cash and $650M in upfront equity in exchange for approximately 6.2M newly issued shares of Sage common stock at $104.14 per share and is eligible for up to $1.6B in development and commercial milestones. Both companies will equally share the responsibility and development costs and profits for commercialization in the US, whereas Biogen will be responsible for development and commercialization outside the US excluding Japan, Taiwan, and South Korea for which Sage will receive royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55373,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/6-2-1024x141.jpg"" alt="""" class=""wp-image-55373""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>06. Alteogen’s Development and Commercialization Deal with an Undisclosed Company</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: June 24, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $3.88B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Alteogen granted an undisclosed company non-exclusive, worldwide rights to ALT-B4, Alteogen's Hybrozyme technology, a hyaluronidase-derived technology used for subcutaneous administration of biologic products which are otherwise administered as an IV injection. The undisclosed company has the right to elect to develop additional products in combination with ALT-B4 upon achievement of a pre-specified milestone. Alteogen will be responsible for regulatory development and commercial supply of ALT-B4. Alteogen received $16M up front and is eligible for up to $3.865B in development, regulatory, and sales-based milestones.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55366,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/5-1-1024x141.jpg"" alt="""" class=""wp-image-55366""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>05. Genmab’s Development and Commercialization Deal with AbbVie for Cancer</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: June 10, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $3.9B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Genmab granted AbbVie worldwide rights to co-develop and co-commercialize three bispecific antibody programs: epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37, and DuoBody-CD3x5T4 using AbbVie's antibody-drug conjugate (ADC) platform for the treatment of hematological cancers. Additionally, AbbVie has the option to develop four additional antibody-based therapeutics using Genmab’s DuoBody technology and AbbVie’s ADC technology for solid tumors and hematological malignancies. Both companies will be responsible for the co-commercialization of epcoritamab in the US and Japan and will be responsible for the worldwide development and commercialization of DuoHexaBody-CD37, DuoBody-CD3x5T4, and any product candidates developed under the agreement in the US and Japan. Genmab has the right to co-commercialize these products outside of the US and Japan and AbbVie has the right to opt-in to program development. Genmab received $750M up front and is eligible for up to $1.15B in development and commercial milestones for epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37, and DuoBody-CD3x5T4 and up to $2B in success-based milestones for additional antibody product candidates developed under the collaboration, plus 26% royalties for epcoritamab outside the US and Japan. Both companies will share profits on a 50:50 basis.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55367,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/4-1-1024x141.jpg"" alt="""" class=""wp-image-55367""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>04. Seagen’s Development and Commercialization Deal with Merck</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Sep 14, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $4.2B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Seagen (formerly Seattle Genetics) granted Merck exclusive, worldwide rights to develop and commercialize ladiratuzumab vedotin, a Phase II antibody-drug conjugate targeting LIV-1 for the treatment of cancer. The partners will develop ladiratuzumab as a monotherapy and in combination with Merck's Keytruda (pembrolizumab) in triple-negative breast cancer (TNBC), hormone receptor-positive breast cancer, and other LIV-1-expressing solid tumors. Seagen will be responsible for the marketing applications in the US and Canada and will book sales in the US, Europe, and Canada. Merck will be responsible for the marketing applications in Europe and other territories and will book sales worldwide excluding the US, Europe, and Canada. The partners will share development costs and profit equally. Seagen received $600M in cash and Merck invested $1B in Seagen common stock by purchasing 5M shares at $200.00 per share. Also, Seagen is eligible to receive up to $850M in development milestones and up to $1.75B based on sales performance. The partners will share costs and profits equally.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55368,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/3-1-1024x141.jpg"" alt="""" class=""wp-image-55368""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>03. Myovant’s Development and Commercialization Deal with Pfizer for Orgovyx</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: December 28, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $4.25B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Myovant Sciences granted Pfizer rights to develop and commercialize Orgovyx (relugolix) for prostate cancer and relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for women's health in the US and Canada. Pfizer has an exclusive option to commercialize relugolix in oncology outside the US and Canada, excluding certain Asian countries. Both companies will equally share profits and expenses for Orgovyx and relugolix combination tablets. Myovant will receive $650M up front and is eligible for up to $200M in regulatory milestones for FDA approvals for the relugolix combination tablet in women’s health and up to $3.35B in sales-based milestones upon reaching certain thresholds up to $2.5B. If Pfizer exercises its option, Myovant will receive $50M and will be eligible for double-digit royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55369,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/2-1-1024x141.jpg"" alt="""" class=""wp-image-55369""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>02. Daiichi Sankyo’s Development and Commercialization Deal with AstraZeneca for DS-1062</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: July 27, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $6B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Daiichi Sankyo granted AstraZeneca worldwide rights to develop and commercialize DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) for the treatment of multiple tumors. Both companies will equally share development and commercialization costs and profits worldwide whereas Daiichi Sankyo will be responsible for all costs and will pay mid-single-digit royalties to AstraZeneca for Japan. Daiichi Sankyo received $1B up front and is eligible for up to $1B in regulatory milestones and up to $4B in sales-based milestones.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":55370,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/01/1-1-1024x141.jpg"" alt="""" class=""wp-image-55370""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>01. Artios’ Research Partnership with Merck with an Option to License up to 8 Oncology Targets</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Date: Dec 3, 2020</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Deal Value: $6.9B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Artios signed a research partnership with Merck to discover and develop therapies using Artios’ nuclease targeting discovery platform for the treatment of cancer. Merck has an exclusive, worldwide option to license the development and commercialization of up to 8 cancer targets. Additionally, Artios has opt-in rights for joint development and commercialization with Merck. Artios received $30M in upfront and near-term payments. If Merck chooses to exercise the option, Artios will receive undisclosed option fees and is eligible for up to $860M in milestones for each target, plus royalties.</p>
<!-- /wp:paragraph -->

<!-- wp:separator -->
<hr class=""wp-block-separator""/>
<!-- /wp:separator -->",,https://pharmashots.com/wp-content/uploads/2021/01/Picture2_752x440-1.png|https://pharmashots.com/wp-content/uploads/2021/01/20-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/19-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/18-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/17-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/16-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/15-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/14-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/13-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/12-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/11-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/10-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/9-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/8-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/7.jpg|https://pharmashots.com/wp-content/uploads/2021/01/6-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/5-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/4-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/3-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/2-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/1-1.jpg|https://pharmashots.com/wp-content/uploads/2021/01/6-2.jpg,Top 20,Top 20 Life Sciences Deals,,AbbVie|Alteogen|Artios|Astex|AstraZeneca|Biogen|BMS|Daiichi Sankyo|Denali|Eli Lilly|Fate|Genentech|Genmab|Insitro|Janssen|Kymera|Life Sciences Deals|Merck|Myovant|Nurix|Pfizer|Precision|Repare|Roche|Sage|Sangamo|Sanofi|Schrodinger|Seagen|Silence|Skyhawk|Taiho|Top 20|Total Deal Value|UCB|Vertex,publish,1/22/2021,17
15481,Top 20 Medical Device Companies Based on 2018 Revenue,,"<!-- wp:paragraph -->
<p>The Medical device market is growing with greater needs of patients and with their emerging diseases. 2018 has shown major advancement in medical device needs and upgrades with 55 novel drug approvals. The year 2018 has shown a slight change in the ledger of top 20 firms while Medtronic holds its first position with a generated revenue of $30.55B in the global market of the top 20 medical device firms. Our team at PharmaShots has compiled a list of top 20 medical devices companies based on their 2018 total revenue.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15483} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Terumo-1.png"" alt="""" class=""wp-image-15483"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $5.46B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~</strong> <strong>25,378 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1921&nbsp; </strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Stock Exchange: Tokyo Stock Exchange </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $21.4B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarters: Tokyo, Japan </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>&nbsp;</strong>Terumo Corporation is a Tokyo based firm divided into four segments: Interventional systems, Terumo Business System, Medical Products and Pharmaceutical Solutions. In Jul’18 Terumo acquired Essen Technology with its Drug-Eluting Stent (DES) to expand its footprints in markets of China. Additionally, Vascutek And Bolton Medical collaborated to form a firm Terumo Aortic focusing on the global aortic and vascular implants market. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15484} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Image20190606201853.png"" alt="""" class=""wp-image-15484"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $6.02B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~93,516</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1902&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: NA</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: NA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Headquarters: Minnesota, United States </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The 3M Company, formerly known as the Minnesota Mining and Manufacturing Company, is an American multinational company that focusses on Dental, Skin and wound care, Surgical solutions, personal care products. In Dec’18 3M acquired the technology business of M*Modal to expand its own Health Information system and is expected to close in H1’19.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15485} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/ALcon-1.png"" alt="""" class=""wp-image-15485"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $7.10B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~</strong> <strong>20,000 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1945&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: SWX </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$28.17B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarters: Geneva, Switzerland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Alcon is a global leader in eye care business and having a
complementary business in Surgical and Vision Care, to treat disorders related
to the eye. Alcon’s surgical portfolio includes technologies and devices for
cataract, retinal, refractive surgery, ATIOLs to treat cataracts and refractive
errors, like presbyopia and astigmatism. Additionally, the vision care
portfolio includes multiple daily disposable, reusable and color-enhancing
contact lenses and a comprehensive portfolio of ocular health products. In
H2’18 Alcon acquired Tear Film Innovations for its iLux Medical Device and
planned to develop SMART Suite Equipment for improving cataract surgery. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15486} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Olympus-1.png"" alt="""" class=""wp-image-15486"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $7.23B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~ 35,933</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1919&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: Tokyo</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$16.47B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarters: Tokyo,
Japan&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Olympus Corporation is a Japanese manufacturer of optics and
reprography products. Olympus also has a portfolio of multiple technologies
like Optical, Opto-Digital, Precision including Bio-science and Digital
Imaging. In Oct’18 the company acquired LPixel aiming to focus on
AI-technologies to support endoscopic and microscopic diagnostic imaging. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15487} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Braun-1.png"" alt="""" class=""wp-image-15487"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $7.73B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~</strong> <strong>63,751 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1839&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: Nil&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: NA &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarters: Melsungen, Germany </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>B. Braun Melsungen AG is a German medical and pharmaceutical
device company offering a portfolio of anesthesia, intensive care, cardiology,
extracorporeal blood treatment, and surgery. In Jan’18 B. Braun received FDA’s
approval for 0.9% Sodium Chloride Injection, USP in the Ecoflac Plus 500 mL
container. Additionally, B. Braun acquired the bloodlines business of Medisystems
name by NxStage Medical Inc. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15488} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Image20190606201903-1024x159.png"" alt="""" class=""wp-image-15488"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $7.93B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~19,000&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1927&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$22.97B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarters: Indiana, United States </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Zimmer Biomet, a subsidiary of Zimmer Inc., is a global leader in musculoskeletal healthcare that design, manufacture, and markets orthopedic reconstructive products, sports medicine and trauma products, spine, craniomaxillofacial and thoracic products, dental implants and related surgical products. The net sales of 2018 increased by 1.7% in comparison to 2017. In Oct’18 Zimmer Biomet collaborated with Apple to launch a clinical study detailing patient experience and improving joint replacement journey. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15490} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Image20190606201857-1024x159.png"" alt="""" class=""wp-image-15490"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $8.80B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~71,000&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1969&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$93.</strong><strong>16B&nbsp;
</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Headquarters:
Washington, D.C, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Danaher is focused on the design, manufacturing, and marketing of
industrial and consumer products. It operates in five segments: Test &amp;
Measurement, Dental, Industrial Technologies, Environmental, and Life Science
&amp; Diagnostics. Additionally, in Jul’18 the company decided to spin-off its
dental portfolio consisting of services and products used to diagnose, treat, prevent
disease and ailments of the teeth and gums into an independent business unit
which its expected closure in H2’19. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15491} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Image20190606201900-1-1024x159.png"" alt="""" class=""wp-image-15491"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong> Medical Device Revenue: $9.43B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~103,000&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1900&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$133.57B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarters:
Illinois, United States </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Abbott is a public healthcare company focused on the development, manufacturing, and commercialization of diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. In 2018, Abbott received FDA’s approval for the Advisor HD grid mapping catheter, sensor enabled MitraClip, a heart valve repair device, HeartMate 3 left ventricular assist device (LVAD), XIENCE Sierra drug-eluting stent system.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15537} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Boston-1-1024x163.png"" alt="""" class=""wp-image-15537"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $9.82B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~32,000&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1979&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$53.47B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarters: Massachusetts, United States </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Boston Scientific Corporation is a global developer,
manufacturer, and marketer of medical devices used for interventional medical
specialties. In early, 2018 Boston acquired NxThera, for the expansion of its Urology
and Pelvic Health business with the addition of Rezum system, used to treat
patients with symptomatic benign prostatic hyperplasia (BPH). Additionally, the
company has received CE mark approval for its GUIDE XT System used for
visualizing of Deep Brain Stimulation (DBS). In Q3’18 Boston acquired BTG to
strengthen its peripheral interventions portfolio with minimally-invasive
treatments for cancers and vascular conditions. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15493} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Baxter-1-1024x154.png"" alt="""" class=""wp-image-15493"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $11.12B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Total Employees: ~50,000&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1931&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$37.84B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarters: Illinois, United States </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Baxter is an American health care company focuses on products to
treat hemophilia, kidney disease, immune disorders, and other chronic and acute
medical conditions. The companies’ medical products unit portfolio contains intravenous
products used in the delivery of fluids and drugs to patients, inhalational
anesthetics, contract manufacturing services, including products to treat
end-stage renal disease and hemodialysis. In Mar’18 Baxter acquired a
hemostat and a sealant product from Mallinckrodt, Recothrom Thrombin topical
(Recombinant), &amp; Preveleak Surgical Sealant respectively.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15494} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Essilor-2-1024x153.png"" alt="""" class=""wp-image-15494"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $12.05B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; Total Employees: ~1,50,000&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1849 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Exchange: Euronext Paris</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$50.1B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarters: Charenton-le-Pont, France </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Essilor is a leading firm that designs, manufactures and markets lenses to correct or protect eyesight. In Dec’18 Essilor partnered with Royal Government of Bhutan with the focus to treat patients with unprotected and uncorrected poor vision. Essilor generated an exceeded revenue of 4.6% in comparison to its 2017 revenue.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15495} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Siemens-2-1024x153.png"" alt="""" class=""wp-image-15495"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $13.4B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~50,000&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1971&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: Frankfurt, Xetra&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$39.74B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarters: Erlangen, Germany </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Siemens Healthineers is a subsidiary of Siemens AG, a
diagnostic company focused on the development of diagnostic, therapeutic
imaging, laboratory diagnostics, molecular medicine, digital health services,
and enterprise services. In Aug’18 Siemens Healthineers collaborated with NuVasive
to develop and advance technology designed for minimally invasive spinal
surgery.&nbsp; </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15496} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Stryker-3-1024x153.png"" alt="""" class=""wp-image-15496"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $13.6B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~36,000  </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp;1941&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$67.90B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarters: Michigan, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Stryker is one of the world’s leading medical technology company which offers innovative products and services in Orthopaedics &amp; Spine, Neurotechnology, Medical, and Surgical. In Aug’18 Stryker acquired K2M to strengthen its Spine portfolio offering products in core spinal segment, including an attractive minimally invasive spine portfolio.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15497} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/Cardinal-1-1024x152.png"" alt="""" class=""wp-image-15497"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $15.58B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~50,000&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp;1971&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$13.56B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarters:
Ohio, United States</strong><strong></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Cardinal Health is an American multinational health care services company offering customized solutions for hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The portfolio focuses on Cardiovascular Products, Enteral Feeding, Patient Monitoring, Infection Control, Women and Baby Care products. In Jun’18 Carinal also received FDA’s approval for its INCRAFT AAA Stent Graft System to Treat Infrarenal Abdominal Aortic Aneurysms. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15498} -->
<figure class=""wp-block-image""><img src=""https://pharmashots.com/wp-content/uploads/2019/06/BD-2-1024x150.png"" alt="""" class=""wp-image-15498"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue</strong> <strong>: $15.98B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~76,032  </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year:&nbsp;1895&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$63B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarters: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Becton, Dickinson, and Company (BD) is a global American medical technology company that manufactures and sells medical devices instrument systems, and reagents. The company is divided into three worldwide segments BD Medical, BD Interventional and BD life sciences offering solutions in Diabetes, Surgeries, Medical Management solutions, and Urology and Critical Care.&nbsp; </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":15499",,https://pharmashots.com/wp-content/uploads/2019/06/Mg257OVy68X2RKwq9EdXn1559828799.png,Top 20,Top 20 Medical Device Companies,,3M Company|Abbott|Alcon|Baxter|Bbraun|BD|Boston Scientific|Cardinal Health|Danaher|Essilor|Fresenius|J&J|Medtronic|Olympus|Royal Philips|Seimen Healthineers|Smith+Nephew|Stryker|Terumo Corporation|Zimmer Biomet,publish,6/6/2019,17
33540,Top 20 Medical Device Companies Based on 2019 Revenue,,"<!-- wp:paragraph -->
<p>The Medical device market is growing with evolving needs of patients and with their emerging diseases encouraging them to develop novel and innovative therapies or devices for maintaining quality of life. The ledger for 2019 of medical devices has shown changes for multiple companies but the position for Medtronic remains same to be one top with generated revenue of $30.55B. PharmaShots has compiled a list of top 20 medical device companies based on their 2019 medical device revenue. </p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[33541]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/20-1-1024x154.png"" alt="""" data-id=""33541"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/05/20-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=33541"" class=""wp-image-33541""/></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $5.13B&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~17,500</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1856&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock Exchange: LON</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$17.72B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Headquarters: London, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Smith+Nephew is a UK based medical technology company which is divided into three global franchises of Orthopedics, Advanced Wound Management, Sports Medicine &amp; ENT. In Mar 2019, Smith &amp; Nephew acquired Osiris Therapeutics for $0.6B with the focus to strengthen and expand its footprints in regenerative medicine market. In Nov 2019, the company launched its OR3O Dual Mobility System for use in primary and revision hip arthroplasty.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[33542]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/19-1-1024x153.png"" alt="""" data-id=""33542"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/05/19-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=33542"" class=""wp-image-33542""/></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $5.24B&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~80,495</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1891&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;       Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$38.45B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;      Headquarters: Amsterdam, Netherlands</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Royal Philips is a diversified company focusing on improving public health with meaningful innovation offering treatments at a lower cost. Philips Healthcare has focused their research and development efforts to develop new approaches in the areas of radiology, cardiology, oncology, decision support, home health, respiratory and other critical areas. In Oct 2019, Philips signed an agreement with Air Ambulance Kent Surrey Sussex for providing emergency services in the UK. In Dec 2019, Philips collaborated with Humana to advance or improve healthcare outcomes in selected high-risk Medicare Advantage members with congestive heart failure.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[33543]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/18-1-1024x153.png"" alt="""" data-id=""33543"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/05/18-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=33543"" class=""wp-image-33543""/></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $5.29B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;     Total Employees: ~205,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1891&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;    Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$56.68B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;      Headquarters: Illinois, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>GE Healthcare is a leading global wholly owned subsidiary of General Electric Company focused on the development, manufacturing, and commercialization of healthcare technologies. The portfolio provides solutions and products in diagnosis, treatment, and monitoring of patients. The company has more than 4M imaging, mobile diagnostics and monitoring units installed globally in 43 global centers. GE Healthcare also have an AIR Technology, AI-based technology for intelligent MR slice presentation using artificial neural networks delivering consistent and accurate scans. In Sep 2019, GE Healthcare launched its super-resolution microscope, the DeltaVision OMX Flex for highly stable, multichannel imaging platform optimized for structured illumination microscopy (SIM), also including EDGE confocal technology allows deeper imaging into samples, tissues, or organisms. Additionally, in Sep 2019, the company received the US FDA’s 510(k) approval for its novel Critical Care Suite including collection of artificial intelligence (AI) algorithms embedded on a mobile X-ray device for detection of suspected pneumothorax, a type of collapsed lung. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""left"",""id"":33545,""width"":569,""height"":86,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""alignleft size-large is-resized""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/17-1-1024x152.png"" alt="""" class=""wp-image-33545"" width=""569"" height=""86""/></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $5.40B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Total Employees: ~25,378</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1921&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;       Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$133.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;      Headquarters: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Terumo Corporation is a Tokyo based firm divided into four segments: Interventional systems, Terumo Business System, Medical Products and Pharmaceutical Solutions. In Sep 2019, Terumo launched its Fentanyl injection, a Prescription-only analgesic for pain management in Japan. In Oct 2019, Terumo with its partner Mallinckrodt received TGA’s approval for Uvadex (methoxsalen) for its usage with the THERAKOS CELLEX Photopheresis System to treat Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in adults. In Sep 2019, Terumo launched its Fentanyl injection, a Prescription-only analgesic for pain management in Japan. In late 2019, Terumo acquired Aortica Corporation with the focus to grow its Vascular Graft Business while contributing to Personalized Aortic Therapy.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[33546]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/16-1-1024x152.png"" alt="""" data-id=""33546"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/05/16-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=33546"" class=""wp-image-33546""/></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $5.72B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;     Total Employees: ~35,124</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1919&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;         Stock Exchange: TKO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$21.59B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;        Headquarters: Tokyo, Japan&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Olympus Corporation is a Japanese manufacturer of optics and reprography products. Olympus also has a portfolio of multiple technologies like Optical, Opto-Digital, Precision including Bioscience and Digital Imaging. In Mar 2019, Olympus developed an open platform AI-assisted for the detection and diagnosis of diseases during endoscopic examinations.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[33547]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/15-2-1024x151.png"" alt="""" data-id=""33547"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/05/15-2.png"" data-link=""https://www.pharmashots.com/?attachment_id=33547"" class=""wp-image-33547""/></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $6.95B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;  Total Employees: ~60,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1969&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;      Stock Exchange: NYSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$111.61B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;       Headquarters: Washington, D.C, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Danaher is focused on the design, manufacturing, and marketing of industrial and consumer products. It operates in five segments: Test &amp; Measurement, Dental, Industrial Technologies, Environmental, and Life Science &amp; Diagnostics. In Feb 2019, Danaher acquired biopharma unit of GE LifeScience for $21.4B, with the focus to strengthen and advance its life science portfolio with the addition of GE’s bioprocessing technologies for developing therapies. In Oct 2019, Danaher sold its Life Science Portfolio to Sartorius for $750M which included label-free biomolecular characterization (FortéBio), chromatography hardware and resins, and microcarriers (SoloHill) businesses with the focus to strengthen Sartorius’ presence in bio-analytics and bioprocessing segments.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[33548]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/14-1-1024x150.png"" alt="""" data-id=""33548"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/05/14-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=33548"" class=""wp-image-33548""/></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $7.36B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;Total Employees: ~20,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1945&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    Stock Exchange: SIX</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$30.37B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;   Headquarters: Hunenberg, Switzerland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Alcon is a global leader in eye care business and having a complementary business in Surgical and Vision Care, to treat disorders related to the eye. Alcon’s surgical portfolio includes technologies and devices for cataract, retinal, refractive surgery, ATIOLs to treat cataracts and refractive errors, like presbyopia and astigmatism. In Mar 2019, Alcon acquired PowerVision for $0.2B for the expansion of its ophthalmology portfolio utilizing PowerVision’sadvanced technology intraocular lenses (AT-IOLS) to deliver therapies to cataract surgery patients desiring spectacle independence. In Aug 2019, Alcon Launched PRECISION1 Daily Disposable Contact Lenses based on its SMARTSURFACE technology enhancing its DAILIES TOTAL1 and DAILIES AquaComfort PLUS contact lenses in the US.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[33550]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/13-1-1024x150.png"" alt="""" data-id=""33550"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/05/13-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=33550"" class=""wp-image-33550""/></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $7.43B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;  Total Employees: ~96,163</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1902&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;    Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$83.87B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headquarters: Minnesota, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The 3M Company, formerly known as the Minnesota Mining and Manufacturing Company, is an American multinational company that focusses on Dental, Skin, and wound care, Surgical solutions, personal care products. In Dec 2019, 3M company completed the acquisition of M*Modal’s Technology Business for $1B focusing on the improvements in the patient experience, while enhancing documentation accuracy and operational efficiency. Additionally, in late 2019, the company agree to divest its Drug Delivery Business to Altaris Capital Partners for $0.65B with its expected closure in H1’20.&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[33551]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/12-1-1024x149.png"" alt="""" data-id=""33551"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/05/12-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=33551"" class=""wp-image-33551""/></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $7.98B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; Total Employees: ~19,900</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1927&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$25.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;      Headquarters: Indiana, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Zimmer Biomet, is a global leader in musculoskeletal healthcare that design, manufacture, and markets orthopedic reconstructive products, sports medicine and trauma products, spine, craniomaxillofacial and thoracic products, dental implants, and related surgical products. In Jan 2019, Zimmer received the US FDA’s 510 (k) Clearance for its ROSA Knee System for robotically assisted surgeries. In Aug 2019, the company received the US FDA’s approval for its Tether to treat scoliosis, providing a fusion-less alternative for young patients requiring surgery. </p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[33553]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/11-1-1024x149.png"" alt="""" data-id=""33553"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/05/11-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=33553"" class=""wp-image-33553""/></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $8.38B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Total Employees: ~ 64,585</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1839&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;    Stock Exchange: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: NA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;      Headquarters: Melsungen, Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>B. Braun Melsungen AG is a German medical and pharmaceutical device company offering a portfolio of anesthesia, intensive care, cardiology, extracorporeal blood treatment, and surgery. In Apr 2019, B. Braun launched its heparin sodium prefilled syringe in the US. In Sep 2019, the company with its partner Philips launched Onvision for real-time needle tip tracking in regional anesthesia.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[33554]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/10-1-1024x148.png"" alt="""" data-id=""33554"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/05/10-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=33554"" class=""wp-image-33554""/></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $10.65B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;Total Employees: ~36,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1979&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;    Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$48.68&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;       Headquarters: Massachusetts, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used for interventional medical specialties. In May 2019, the company planned to initiate OPTION Study for its Watchman FLX device for the reduction of stroke risk in post-AF ablation. Additionally, in May 2019, the company acquired Vertiflex for its Superion Indirect Decompression System. In Nov 2019, Boston Scientific acquired BTG with its Interventional Medicine Portfolio to strengthen its minimally invasive treatments including TheraSphere Y-90 radiotherapy, GALI cryoablation and EKOS Endovascular System for treatment of cancer and vascular diseases. </p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[33556]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/9-1-1024x148.png"" alt="""" data-id=""33556"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/05/9-1.png"" data-link=""https://www.pharmashots.com/?attachment_id=33556"" class=""wp-image-33556""/></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $11.36B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; Total Employees: ~50,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1931&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;     Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$44.04B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    Headquarters: Illinois, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Baxter is an American health care company focuses on products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions. The companies’ medical products unit portfolio contains intravenous products used in the delivery of fluids and drugs to patients, inhalational anesthetics, contract manufacturing services, including products to treat end-stage renal disease and hemodialysis. In Mar 2019, Baxter collaborated with BioMerieux to develop Biomarkers for Acute Kidney Injury (AKI). In Aug 2019, the company’s PrisMax System received the Health Canada approval to maximize the treatment in intensive care unit. In Sep 2019, Baxter acquired Seprafilm Adhesion Barriers from Sanofi for $0.35B and in Dec 2019, Baxter acquired Cheetah Medical for $0.23B.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[33557]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://www.pharmashots.com/wp-content/uploads/2020/05/8-2-1024x147.png"" alt="""" data-id=""33557"" data-full-url=""https://www.pharmashots.com/wp-content/uploads/2020/05/8-2.png"" data-link=""https://www.pharmashots.com/?attachment_id=33557"" class=""wp-image-33557""/></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $12.23B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Total Employees: ~107,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1900&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",,https://pharmashots.com/wp-content/uploads/2020/05/Top-20-1.png,Top 20,Top 20 Medical Device Companies,,3M Company|Abbott|Alcon|B. Braun|Baxter|Becton Dickinson|Boston Scientific|Cardinal Health|Danaher Corporation|Essilor|Fresenius Medical Care|GE Healthcare|Medtronic|Olympus Corporation|Royal Philips|Smith &amp; Nephew|Stryker|Terumo|Zimmer Biomet,publish,5/22/2020,17
60253,Top 20 Medical Device Companies Based on 2020 Revenue,,"<!-- wp:list -->
<ul><li>The medical devices industry is a fast-growing market driven by the complex needs of patients encouraging life science companies to develop innovative therapies to improve health and QoL</li><li>In 2020, the companies have shown growth resulted from a rise in the number of healthcare facilities, healthcare expenditure, technological advancements. Medtronic remains at the top of the ledger with total revenue of $28.91B, followed by J&amp;J with $22.95B</li><li>PharmaShots has compiled a list of the top 20 medical device companies based on their 2020 medical device revenue</li></ul>
<!-- /wp:list -->

<!-- wp:image {""align"":""center"",""id"":60260,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/20-1024x202.png"" alt="""" class=""wp-image-60260""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $1.99B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1971</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$64.13B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~54,300</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: ETR</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Erlangen, Germany</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Siemens Healthineers is a global provider of healthcare solutions and services, with activities in numerous countries around the world. The business operations are divided into three segments: Imaging, Diagnostics and Advanced Therapies. With the acquisition of Corindus Vascular Robotics in early 2020, the company strengthens its business across the robotic-assisted platform for endovascular coronary and peripheral vascular interventions.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60261,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/19-1024x185.png"" alt="""" class=""wp-image-60261""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $4.56B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1856</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$19.28B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~</strong> <strong>18,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: LON</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: London, United Kingdom</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Smith+Nephew is a global medical technology company that is divided into three global franchises of Orthopedics, Advanced Wound Management, Sports Medicine &amp; ENT. In 2020, the company launches Intellio Connected Tower Solution, the CORI surgical platform, HEALICOIL KNOTLESS Suture Anchor and many other devices. The company has done major acquisitions including the acquisition of Tusker Medical and the acquisition of Extremity Orthopedics business of Integra LifeSciences for $240M.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60262,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/18-1024x163.png"" alt="""" class=""wp-image-60262""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: &nbsp;$5.68B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1921</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$28.08B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~25,319</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Tokyo, Japan</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Terumo Corporation is a Tokyo based firm divided into four segments: Interventional systems, Terumo Business System, Medical Products and Pharmaceutical Solutions. In July’2020, the company acquires Quirem Medical to enhance its interventional oncology field. Terumo in collaboration with Marker Therapeutics received the first device FDA’s EUA to treat acute respiratory failure in COVID-19 patients.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60263,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/17-1024x167.png"" alt="""" class=""wp-image-60263""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $5.86B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1919</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$27.62B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~35,174</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TKO</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Tokyo, Japan</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Olympus Corporation is a Japanese manufacturer of optics and reprography products. Olympus also has a portfolio of multiple technologies like Optical, Opto-Digital, Precision including Bioscience and Digital Imaging. Its medical device segment consists of the Endoscopic Solutions Division and the Therapeutic Solutions Division and accounts for 80% of Olympus’ revenue.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60264,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/16-1024x172.png"" alt="""" class=""wp-image-60264""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $6.76B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1945</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$34.33B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~</strong> <strong>23,655</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: SIX</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Hunenberg, Switzerland</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Alcon is a global leader in the eye care business and having a complementary business in Surgical and Vision Care, to treat disorders related to the eye. Its surgical portfolio includes Implantables, Consumables, Equipment / Other while Vision Care comprises contact lenses and Ocular health. In 2020, the company received CE marking for Systane Ultra MDPF and Systane Hydration MDPF.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60265,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/15-1024x165.png"" alt="""" class=""wp-image-60265""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $6.80B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1891</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$51.10B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~81,592</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: AMS</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Amsterdam, Netherlands</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>With over a hundred years in business, Philips is a diversified technology company. Philips’ health care focuses on three key areas; Diagnosis &amp; Treatment, Connected Care and Personal Health. In Dec 2020, Philips acquired BioTelemetry with its wearable connected heart monitors, AI-based data analytics and a services platform while in 2021, Philips signed an agreement to acquire Capsule Technologies.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60266,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/14-1024x172.png"" alt="""" class=""wp-image-60266""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $7.02B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1927</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$34.56B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~</strong> <strong>20,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Indiana, United States</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Zimmer Biomet is a global leader in musculoskeletal healthcare that design, manufacture, and markets orthopedic reconstructive products, sports medicine and trauma products, spine, craniomaxillofacial and thoracic products, dental implants, and related surgical products<strong>. </strong>&nbsp;The company experienced a decrease by 12% in net sales compared to 2019 due to the deferral of elective surgical procedures from the COVID-19 pandemic. Currently, the company plan to spin off Spine and Dental businesses to form NewCo. The plan is expected to be executed in 2021.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60267,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/13-1024x163.png"" alt="""" class=""wp-image-60267""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $8.34B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1902</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~ $117.44B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~</strong> <strong>94,987</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Minnesota, United States</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>3M is a diversified technology company with a global presence in the following businesses: Safety and Industrial, Transportation and Electronics, Health Care and Consumer. The company experienced&nbsp; an increase in healthcare volumes that benefited both medical solutions and oral care after significant disruptions in Q2’20, with strong pandemic-related demand for disposable respirators resulting in increased sales for medical solutions, while oral care sales decreased year-on-year.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60268,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/12-1024x160.png"" alt="""" class=""wp-image-60268""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $9.08B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1839</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: Nil</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~ 64,317</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: Nil</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Melsungen, Germany</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>B. Braun Melsungen AG is a German medical and pharmaceutical device company offering a portfolio of anesthesia, intensive care, cardiology, extracorporeal blood treatment, and surgery. In 2020, B. Braun receives the US FDA’s approval for SpaceStation MRI. The global pandemic has impacted the sales of products such as implants from the Aesculap division and basic medical care products including infusion solutions fell considerably due to the postponement of non-essential surgeries in hospitals globally.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60269,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/11-1024x169.png"" alt="""" class=""wp-image-60269""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $</strong> <strong>9.69B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1979</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$58.87B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~38,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Massachusetts, United States</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used for interventional medical specialties. The business of the company is reportable in three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. In 2020, the company received the US FDA’s approval for WATCHMAN FLX which is designed to offer increased ease-of-use for physicians and improved procedural outcomes for patients, including reduced complication risk and healing time. The new device also received PMDA approval and Japanese National Health Insurance reimbursement approval.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60270,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/10-1024x158.png"" alt="""" class=""wp-image-60270""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $10.57B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1969</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$177.84B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~69,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Washington, D.C, United States</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:group -->
<div class=""wp-block-group""><div class=""wp-block-group__inner-container""></div></div>
<!-- /wp:group -->

<!-- wp:paragraph -->
<p>Danaher is a global science and technology group, comprising 20+ operating companies with three segments (Life Sciences, Diagnostics, and Environmental &amp; Applied Solutions). On Mar 31, 2020, the Company acquired the Biopharma business of GE Life Sciences division, now known as Cytiva, for a ~$20.7B in cash<strong>.</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60271,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/9-1024x154.png"" alt="""" class=""wp-image-60271""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $11.67B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1931</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$41.48B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~</strong> <strong>50,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Illinois, United States</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Baxter through its subsidiaries provides a broad portfolio of essential healthcare products, including acute &amp; chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, and surgical hemostat and sealant products. In 2020, the company completed the acquisition of the product rights to Seprafilm from Sanofi for ~$342M in cash and acquire the rights to Caelyx and Doxil from a subsidiary of Johnson &amp; Johnson for specified territories outside the US for $325M.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60272,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/8-1024x159.png"" alt="""" class=""wp-image-60272""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $11.78B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1900</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$206.79B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~ 109,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Illinois, United States</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Abbott is a public healthcare company focused on the development, manufacturing, and commercialization of diagnostics, medical devices, nutritional and branded generic pharmaceuticals. In 2020, the US FDA has granted EUA for the company’s several COVID-19 related products including its diagnostic tests. The company has received a CE mark for the TriClip heart valve repair system, Tendyne Transcatheter Mitral Valve Implantation and FreeStyle Libre 3 system and many more in the medical device segment. Though the operating earnings for the Medical Devices segment were decreased by 19.4%.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60273,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/7-1024x154.png"" alt="""" class=""wp-image-60273""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $12.50B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1895</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$70.56B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~ 70,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: New Jersey, United States</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Becton, Dickinson, and Company (BD) is a global American medical technology company that manufactures and sells medical device instrument systems and reagents. The company has three worldwide business segments: BD Medical, BD Life Science and BD Interventional. BD has launched multiple products in the year 2020 which include BD Veritor Assay for rapid detection of SARS-CoV-2, the Caterpillar and Caterpillar Micro Arterial Embolization Devices and many other devices.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60274,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/6-1024x157.png"" alt="""" class=""wp-image-60274""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $14.35B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1941</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$95.03B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~43,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Michigan, United States</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Stryker Corporation is one of the world's leading medical technology companies, offering innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. In Nov’2020, the company completed the acquisition of Wright Medical for $30.75/ share while in Dec’2020, it completed the acquisition of OrthoSensor.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60275,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/5-1024x160.png"" alt="""" class=""wp-image-60275""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $15.44B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1971&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$16.23B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~48,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Ohio, United States</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Cardinal Health is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. Medical segment revenue decreased due to the adverse impact of the COVID-19 pandemic, partially offset by sales growth from Cardinal Health at-Home Solutions.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60276,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/4-1024x151.png"" alt="""" class=""wp-image-60276""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $17.60B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1849</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$74.94B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~ 140,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: Euronext Paris</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Charenton-le-Pont, France</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames, and sunglasses. In 2020, the company collaborated with Facebook on smart glasses and launches EssilorLuxottica 360 in the US as the first joint commercial program.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60283,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/Image20210520201144-1024x161.png"" alt="""" class=""wp-image-60283""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $21.83B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1996</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$23.99B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~125,364</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE, ETR</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Bad Homburg, Germany</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Fresenius Medical Care is a global healthcare firm offering solutions in lifesaving medicines, biosimilars and technologies for infusion, transfusion, and clinical nutrition. The company develops, manufactures and distributes a wide variety of health care products, which includes dialysis and non-dialysis products. In 2020, Xenios's Novalung which is a heart and lung support system received the US FDA’s approval for acute respiratory or cardiopulmonary failure and get FDA approval for Biofine PD solution bags.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60258,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/2-1024x171.png"" alt="""" class=""wp-image-60258""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $22.95B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1886</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$447.89B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~134, 500</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: New Jersey, United States</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>J&amp;J is an American multinational medical device, pharmaceutical, and consumer packaged goods manufacturing company. Its Medical Devices segment includes a broad range of products used in the Interventional Solutions, Orthopaedics, Surgery, and Vision fields. The company experienced a decrease of 11.6% in the sale from 2019 in this segment. In 2020, J&amp;J collaborated with Health First Europe to highlight the unmet needs in the prevention of surgical site infections.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":60259,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/05/1-1024x173.png"" alt="""" class=""wp-image-60259""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Medical Device Revenue: $28.91B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1949</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$169.41B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~104,950</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarters: Dublin, Ireland</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Medtronic is the world’s largest medical device compan",,https://pharmashots.com/wp-content/uploads/2021/05/Top-20-Medical-Device.png|https://pharmashots.com/wp-content/uploads/2021/05/Image20210520201144.png,Top 20,Top 20 Medical Device Companies,,3M Company|Abbott|Alcon|Baxter|Bbraun|BD|Boston Scientific|Cardinal Health|Danaher|Essilor|Fresenius|J&amp;J|Medtronic|Olympus Corporation|Royal Philips|Seimen Healthineers|Smith+Nephew|Stryker|Terumo Corporation|Zimmer Biomet,publish,5/20/2021,17
64301,Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue,,"<!-- wp:list -->
<ul><li>Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020, the world witnessed a major acquisition of Immunomedic by Gilead of $21B for Trodelvy</li><li>Our team at PharmaShots has compiled a list of top 20 oncology companies based on their 2020 oncology revenue</li><li>In in the list of top 20 companies, BMS secured the top position with total revenue of $28B from oncology segment in 2020, followed by Roche and Merck with $26B &amp; $15B</li></ul>
<!-- /wp:list -->

<!-- wp:image {""align"":""center"",""id"":64316,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/20-1024x165.png"" alt="""" class=""wp-image-64316""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $0.23B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1984</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $11.03B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 22,739</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Hyderabad, India</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Dr.Reddy is an Indian Pharmaceutical company that is mainly involved in developing a wide range of generic formulations and proprietary products. The company focuses on multiple therapeutic areas including oncology, cardiovascular, dermatology, gastrointestinal, diabetology, pain management, and nephrology. In September 2020, Dr. Reddy’s Laboratories launched Faslodex (fulvestrant) injection which is used to treat metastatic breast cancer. The company generated a sale of $0.23B from its oncology segment in 2020.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64319,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/19-1024x164.png"" alt="""" class=""wp-image-64319""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $0.30B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 2010</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$32.58B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 5,100</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter:&nbsp; Beijing, China</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: HKG</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>BeiGene is a global biotechnology company that focuses mainly on developing medicines for cancer treatment. In June 2020, BeiGene reported EMA’s acceptance of its marketing authorization application for Brukinsa (zanubrutinib) for the treatment of patients with Waldenstrom’s Macroglobulinemia. In 2020, BeiGene's key drug, Brukinsa generated total sales of $0.04B and the company generated total revenue of $0.30B from the oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64320,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/18-1024x163.png"" alt="""" class=""wp-image-64320""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $0.39B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 2005</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$49.86B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 16,033</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Daiichi Sankyo is a global pharmaceutical company that focuses on developing novel therapies in therapeutic areas including oncology and rare diseases. In May 2020, Daiichi Sankyo launched Enhertu in Japan for patients with metastatic breast cancer. In 2020, the company’s key drug, Trastuzumab deruxtecan <strong>(</strong>Enhertu) generated total sales of $0.39B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64321,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/17-1024x161.png"" alt="""" class=""wp-image-64321""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $0.51B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 2000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$100.88B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total employees: 94,066</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Brentford, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: LON</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>GlaxoSmithKline (GSK) is a British multinational pharmaceutical company that focuses on developing therapies in areas including oncology, respiratory, and immuno-inflammation. In August 2020, FDA approved GSK's Blenrep for the treatment of patients with relapsed or refractory multiple myeloma. With its two approved drugs, Zezula and Blenrep, GSK generated total revenue of $0.51B from its oncology segment in 2020.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64322,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/16-1024x160.png"" alt="""" class=""wp-image-64322""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $0.67B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1987</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$89.26B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 13,600</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Gilead Sciences is an American biopharmaceutical company that focuses on researching and developing medicines in areas including HIV/AIDS, oncology, liver diseases, and hematology, inflammatory and respiratory. In October 2020, Gilead Sciences acquired Immunomedics. Gilead’s oncology drug, Yescarta recorded total sales of $0.56B in 2020. The company generated total revenue of $0.67B from its oncology segment in 2020.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64323,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/15-1024x159.png"" alt="""" class=""wp-image-64323""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $0.97B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1973</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$126.55B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 99,412</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Paris, France</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: EPA</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sanofi is a French multinational pharmaceutical company that focuses on developing novel therapies for oncology, cardiovascular, neurology, immunology, and inflammation. In June 2020, European Commission approved Sarclisa (isatuximab) for adults with relapsed and refractory multiple myeloma. Sanofi's leading oncology drug, Jevtana recorded sales of $0.65B last year. In 2020, Sanofi generated total revenue of $0.97B from its oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64324,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/14-1024x157.png"" alt="""" class=""wp-image-64324""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $1.68B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1863</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market cap:</strong> <strong>$55.01B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 99,538</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Leverkusen, Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: ETR</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Bayer is a German multinational pharmaceutical company with a focus on cancer, cardiovascular, and kidney diseases. In March 2020, Nubeqa received EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer. Bayer's leading drug, Nexavar recorded total sales of $0.78B last year. In 2020, Bayer generated total revenue of $1.68B from its oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64325,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/13-1024x156.png"" alt="""" class=""wp-image-64325""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $2.06B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1991</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$16.50B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 1,773</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Delaware, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Incyte is an American multinational pharmaceutical company that focuses on multiple therapeutic areas including oncology, inflammation and autoimmunity. In May 2020, the US FDA approved Tabrecta (capmatinib) for the treatment of patients with metastatic NSCLC with METex14. The leading oncology drug of the company, Jakafi recorded total sales of $1.93B while the total revenue of the company is $2.06B from its oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64326,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/12-1024x155.png"" alt="""" class=""wp-image-64326""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $3.76B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1781</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;$54.41B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 47,099</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Takeda is a Japanese multinational pharmaceutical company that develops innovative therapies in areas including oncology, rare diseases, and gastroenterology. In May 2020, the US FDA approved Takeda’ Alunbrig as a 1L treatment for patients diagnosed with a rare and serious form of lung cancer. Last year, the company generated total revenue of $3.76B from its oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64327,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/11-1024x153.png"" alt="""" class=""wp-image-64327""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $4.47B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2005</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market cap:</strong> <strong>$32.57B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 15,455</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Astellas Pharma is a Japanese multinational pharmaceutical company that focuses on developing novel therapies for therapeutic areas including oncology, nephrology, urology, and transplantation. In 2020, Astellas acquired Audentes Therapeutics, and its product, Xtandi received Xtandi’s approval in NMPA for the treatment of non-mCRPC. Xtandi (lead drug) contributes 90% of the total oncology segment i.e $4.14B whereas Astellas generated total revenue of $4.47B from the oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64329,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/10-1024x152.png"" alt="""" class=""wp-image-64329""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $5.31B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1876</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$243.78B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 34,960</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Indiana, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Eli Lilly is an American pharmaceutical company that deals in oncology, endocrinology, neurodegenerative diseases, immunology, pain, and migraine. In 2020, Selpercatinib (Retevmo) was granted accelerated approval by the FDA for thyroid and lung cancer. Alimta, the leading candidate of the company recorded total sales of $2.33B whereas the total revenue oncology segment is $5.31B in 2020</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64333,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/09-1024x151.png"" alt="""" class=""wp-image-64333""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $6.65B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 2013</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$195.03B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 47,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Illinois, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Abbvie is an American pharmaceutical company that focuses on developing novel products for therapeutic areas including oncology, immunology, dermatology, and virology. In 2020, Venclexta received FDA approval for AML and Imbruvica recorded total sales of $5.31B. Last year, Abbvie generated total revenue of $6.65B from its oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64334,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/08-1024x150.png"" alt="""" class=""wp-image-64334""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $8.32B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1980</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $125.42B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 24,300</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Amgen is an American biopharmaceutical company that is working on multiple therapeutic areas including oncology, neurology, immunology, nephrology, and inflammation. In December 2020, FDA approved Riabni, a biosimilar to Rituxan, for the treatment of adult patients with NHL &amp; CLL. Amgen’s key drug, Xgeva recorded total sales of $1.89B while the company generated total revenue of $8.32B from its oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64335,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/07-1024x149.png"" alt="""" class=""wp-image-64335""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $10.85B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1999</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$181.52B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 76,100</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Cambridge, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>AstraZeneca is a multinational pharmaceutical and biotechnology company that focuses on a portfolio of products in areas including oncology, cardiovascular, gastrointestinal, infection, respiratory, and inflammation. In September 2020, AZ’sImfinzi was approved in the EU for 1L treatment of adults with ES-SCLC. Last year, Tagrisso recorded total sales of $4.32B while the company’s total revenue is $10.85B from its oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64336,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/06-1024x147.png"" alt="""" class=""wp-image-64336""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $10.86B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1849</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;$262.11B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 78,500</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Pfizer is an American multinational pharmaceutical and biotechnology company that develops novel medicines and vaccines for therapeutic areas including oncology, immunology, cardiology, endocrinology and neurology. In June 2020, the EU approved Bavencio as a treatment for patients with LA or metastatic urothelial carcinoma. Pfizer’s leading drug, Ibrance recorded 50% of the total sales of the company in the oncology segment i.e. $5.39B.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64337,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/05-1024x146.png"" alt="""" class=""wp-image-64337""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $12.36B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1887</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$452.52B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 134,500</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Johnson and Johnson is an American multinational pharmaceutical company that has a product portfolio of multiple therapeutic areas including CV, oncology, immunology, and endocrinology. In its oncology segment, J&amp;J focuses on core diseases including prostate cancer and multiple myeloma. The company’s leading drug, Darzalex recorded total sales of $4.19B whereas the total revenue is $12.36B in the oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64338,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/04-1024x146.png"" alt="""" class=""wp-image-64338""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $14.71B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1996</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:</strong> <strong>$222.98B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 105,794</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Basel, Switzerland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: SWX</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Novartis is a Swiss multinational pharmaceutical company that works in multiple disease areas including oncology, hepatology, immunology, dermatology, musculoskeletal diseases, neuroscience, and ophthalmology. In 2020, Novartis generated total revenue of $14.71B from its oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64339,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/03-1024x145.png"" alt="""" class=""wp-image-64339""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $15.83B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1891</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $190.76B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 74,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Merck is an American multinational pharmaceutical company focused on developing innovative medicines in areas including oncology, infectious diseases, respiratory and immunology. In 2020, FDA approved Merck’ Keytruda in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer. Keytruda recorded total sales of $14.38B whereas the total revenue of the company is $15.83B in its oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64340,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/02-1024x144.png"" alt="""" class=""wp-image-64340""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $26.37B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1896</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;$380.16B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 101,465</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Basel, Switzerland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: SWX</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Roche is a Swiss multinational pharmaceutical company focused on developing products in areas including oncology, immunology, and ophthalmology, cardiovascular and respiratory. In December 2020, EC approved Roche’ Phesgo for people with HER2- breast cancer. Roche’s Avastin recorded total sales of $5.64B whereas the company generated total revenue of $26.37B from its oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":64341,""sizeSlug"":""large"",""linkDestination"":""none""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2021/09/01-1024x143.png"" alt="""" class=""wp-image-64341""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Oncology Segment Revenue: $28.14B</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founding Year: 1887</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;$144.86B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: 30,250</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>BMS is a global biopharmaceutical company focused on developing innovative products in oncology, immunology, and hematology, cardiovascular. In November 2020, BMS received EC’s approval for Opdivo + Yervoy with two cycles of CT for 1L treatment of mNSCLC. BMS’ Revlimid recorded total sales of $12.10B while the company generated total revenue of $28.14B from its oncology segment.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Source: Company annual reports, SEC filings, press releases, and company websites</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap source: Google finance (as of 09<sup>th</sup> September 2021)</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>All revenues are reported in USD.</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Related Post: <a href=""https://pharmashots.com/48325/top-20-oncology-comp",,https://pharmashots.com/wp-content/uploads/2021/09/Top-20.jpg|https://pharmashots.com/wp-content/uploads/2021/09/20.png|https://pharmashots.com/wp-content/uploads/2021/09/19.png|https://pharmashots.com/wp-content/uploads/2021/09/18.png|https://pharmashots.com/wp-content/uploads/2021/09/17.png|https://pharmashots.com/wp-content/uploads/2021/09/16.png|https://pharmashots.com/wp-content/uploads/2021/09/15.png|https://pharmashots.com/wp-content/uploads/2021/09/14.png|https://pharmashots.com/wp-content/uploads/2021/09/13.png|https://pharmashots.com/wp-content/uploads/2021/09/12.png|https://pharmashots.com/wp-content/uploads/2021/09/11.png|https://pharmashots.com/wp-content/uploads/2021/09/10.png|https://pharmashots.com/wp-content/uploads/2021/09/09.png|https://pharmashots.com/wp-content/uploads/2021/09/08.png|https://pharmashots.com/wp-content/uploads/2021/09/07.png|https://pharmashots.com/wp-content/uploads/2021/09/06.png|https://pharmashots.com/wp-content/uploads/2021/09/05.png|https://pharmashots.com/wp-content/uploads/2021/09/04.png|https://pharmashots.com/wp-content/uploads/2021/09/03.png|https://pharmashots.com/wp-content/uploads/2021/09/02.png|https://pharmashots.com/wp-content/uploads/2021/09/01.png,Top 20,Top 20 Oncology Companies,,AbbVie|Amgen|Astellas|AstraZeneca|Bayer|BeiGene|BMS|Daiichi Sankyo|Dr. Reddy|Eli Lilly|Gilead|GSK|Incyte|J&amp;J|Janssen|Merck|Novartis|Oncology Companies|Pfizer|Roche|Sanofi|Takeda|Top 20,publish,9/9/2021,17
48325,Top 20 Oncology Companies by Total Products of 2019,,"<!-- wp:paragraph -->
<p>To remain successful in the oncology market, change is now a key to adapt to this altering market dynamics. A recent development in science and technology platforms are likely to grow faster for cancer treatment in comparison to other therapy areas. However, despite robust levels of pipeline activity, oncology remains a challenging area for research and development. The top oncology companies are now developing more advanced, effective, and tolerable drugs to improve treatment outcomes and patient experience. Our team at PharmaShots has compiled lists of the top 20 oncology companies based on their total product including pipeline and approved products.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49040,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/20-1024x165.png"" alt="""" class=""wp-image-49040""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 11</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2005</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$28.08B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~15,883</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Astellas Pharma is a Japanese multinational pharmaceutical company focused on the therapeutic fields of urology, immunology including transplantation and infectious diseases, oncology, neuroscience and DM complications, and metabolic diseases. Astellas has three approved drugs in its oncology portfolio which include Xtandi, PADCEV &amp; Xospata. It has successfully generated revenue of $3.72B in 2019 from Xtandi for the treatment of prostate cancer. In Dec’2019, the US FDA approved Xtandi for patients with metastatic castration-sensitive prostate cancer (mCSPC).</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49042,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/19-1024x164.png"" alt="""" class=""wp-image-49042""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 11</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1899</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$62.85B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~15,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Tokyo, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Daiichi Sankyo is a Japanese pharmaceutical company that focuses on research and development for developing novel therapies in oncology, including immune-oncology, with further focus on new areas, such as pain management, neurodegenerative diseases, heart, and kidney diseases. The company has 2 approved drugs including Vanflyta and Enhertu. Vanflyta (quizartinib) was launched in Oct’2019 in Japan for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). In Dec’2019, Enhertu was approved in the US for HER2 positive unresectable or metastatic breast cancer.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49043,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/18-1024x163.png"" alt="""" class=""wp-image-49043""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 12</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1891</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$214.68B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~71,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph {""align"":""left""} -->
<p class=""has-text-align-left""><strong>Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Merck &amp; Co. is a global health care company delivering innovative health care products with its Prescription medicines, Oncology drugs, Vaccines, Biologic therapies, and Animal Health care products. With 3 approved drugs including Keytruda, Lynparza, and Lenvima, Merck has 12 products in its oncology portfolio. Merck’s blockbuster drug, Keytruda used to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer has generated revenue of $11.08B in 2019. In Jan’20, FDA approved Merck &amp; Co’s Keytruda (pembrolizumab) for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49044,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/17-1024x161.png"" alt="""" class=""wp-image-49044""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 13</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1993</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$2.78B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~5,047</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Shenyang, China</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: HKD</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>3SBio is a fully integrated Chinese biotechnology company with market-leading biopharmaceutical franchises in oncology, auto-immune diseases, nephrology, metabolic diseases, and dermatology. There are 3 approved drugs in its oncology portfolio including Cipterbin, Ruisiyi, and Inleusin. In Jun’1995, NMPA production approval documents were obtained for Inleusin, and it was launched in Mar’1996. Cipterbin was formally approved in Jun’2020 as the 1<sup>st</sup> innovative anti-HER2 monoclonal antibody in China with the engineered Fc region, optimized production process, and a stronger ADCC effect.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49089,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/GSK16-1024x160.png"" alt="""" class=""wp-image-49089""/></figure></div>
<!-- /wp:image -->

<!-- wp:group -->
<div class=""wp-block-group""><div class=""wp-block-group__inner-container""><!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 14</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2000&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;~$99.90B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~100,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Brentford, United Kingdom</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: LON</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns --></div></div>
<!-- /wp:group -->

<!-- wp:paragraph -->
<p>GlaxoSmithKline (GSK) is a global healthcare company serving the world with drugs, vaccines &amp; consumer healthcare products. With 12 pipeline products and 2 approved products, GSK has 14 cancer drugs in its oncology portfolio including Zejula indicated for the ovarian, fallopian tube, or primary peritoneal cancer and BLENREP used to treat relapsed or refractory multiple myeloma. In Apr’20, FDA approved GSK’s Zejula (niraparib) as 1L monotherapy maintenance treatment for women with advanced ovarian cancer regardless of biomarker status.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49052,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/15-1024x155.png"" alt="""" class=""wp-image-49052""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 14</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1887</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$394.13B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~132,100</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New Jersey, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Johnson &amp; Johnson (J&amp;J) is an American multinational healthcare company focused on the development and commercialization of pharmaceutical, medical devices, and consumer packaged products. The pharmaceutical portfolio offers products for Cardiovascular, Endocrinology, Immunology, Neuroscience, and Oncology. J&amp;J has 14 drugs in its oncology portfolio with 6 approved products including Darzalex, Imbruvica, Velcade, Zytiga, Balversa, and Niraparib. Imbruvica, an approved small molecule drug used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukaemia, and Waldenstrom's macroglobulinemia and jointly marketed by Janssen Biotech and Pharmacyclics (AbbVie) has generated the revenue $3.41B in 2019. In Apr’19, FDA approved Johnson &amp; Johnson’s Balversa (erdafitinib) for advanced or metastatic urothelial carcinoma.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49053,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/14-1024x157.png"" alt="""" class=""wp-image-49053""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 15</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2010</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$21.91B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~4,200</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Changping District, China</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: HKG</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>BeiGene is a global commercial-stage research-based biotechnology company focused on developing small molecules, monoclonal antibodies, molecularly targeted, and immuno-oncology drugs. BeiGene has a portfolio of 15 oncology drugs with 13 pipeline drugs and 2 approved drugs including Brukinsa to treat mantle cell lymphoma and Tislelizumab to treat solid tumours. In Nov’19, FDA granted Accelerated Approval to BeiGene’s Brukinsa (zanubrutinib) for patients with mantle cell lymphoma who received at least one prior therapy.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49054,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/13-1024x156.png"" alt="""" class=""wp-image-49054""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 15</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1901</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$145.35B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~33,625</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Indiana, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Eli Lilly and Company is a global pharmaceutical firm focused on delivering therapies in two divisions Human Pharmaceutical Products and Animal Health products. The pharmaceutical portfolio offers products for Cardiovascular, Endocrinology, Immunology, Neuroscience, and Oncology. Eli Lilly has 7 approved drugs in its oncology portfolio including Cyramza, Verzenio, Erbitux, Portrazza, Gemzar, and Retevmo. Lilly’s Alimta, an approved drug for pleural mesothelioma and non-small cell lung cancer has generated a revenue of $2.11B in 2019. In May’20, Eli Lilly’s Retevmo (selpercatinib) received the US FDA’s approval to treat advanced RET-driven lung and thyroid cancers.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49055,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/12-1024x155.png"" alt="""" class=""wp-image-49055""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 17</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1863&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~64.27B&nbsp;</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~103,824</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Leverkusen, Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: ETR</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Bayer is a leading life science firm with three divisions pharmaceuticals, consumer health, and crop science. Bayer has 11 pipeline drugs and 6 approved drugs in its oncology portfolio including Darolutamide, Copanlisib, Regorafenib, Radium-223 Dichloride, Larotrectinib and Nexavar. With the revenue of $0.79B in 2019, Nexavar used to treat liver cancer, thyroid cancer, or kidney cancer is the highest cancer selling drug for Bayer. In Sep’19, EMA approved Bayer’s Vitrakvi (larotrectinib) for NTRK fusion-positive cancers in Europe.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49056,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/11-1024x153.png"" alt="""" class=""wp-image-49056""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 18</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1991</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$20.01B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~1300</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Delaware, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Incyte Corp is a global biopharmaceutical firm focused on developing therapies in two categories Oncology and Inflammation &amp; Autoimmune. Incyte has 6 approved drugs in its oncology portfolio including Pemazyre, Jakafi, Monjuvi, Iclusig, Olumiant and Capmatinib indicated for multiple tumour types. In Apr’20, FDA approved Incyte’s Pemazyre (pemigatinib) as the novel treatment for adults with previously treated, unresectable LA or metastatic cholangiocarcinoma.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49057,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/10-1024x152.png"" alt="""" class=""wp-image-49057""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 19</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1987</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$80.88B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~11,800</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Gilead Sciences is a research-based biopharmaceutical company with a broad portfolio of drugs. Gilead has 16 pipeline drugs and 3 approved drugs in its oncology segment including Tecartus, Yescarta, and Zydelig. With the revenue of $0.45B in 2019, Yescarta used to treat B-cell non-Hodgkin lymphoma is the highest revenue generated cancer drug for Gilead. In Jul’2020, FDA has granted accelerated approval to Kite’s Tecartus used to treat Mantle cell lymphoma (MCL).</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49059,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/09-1024x152.png"" alt="""" class=""wp-image-49059""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 22</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1925</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$57.12B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~49,578</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Osaka, Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: TYO</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Takeda is a global biopharma company focused on Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases, and Immunology. Takeda has a total of 22 products in its oncology segment with 10 approved drugs including Velcade, Leuprogel, Ninlaro, Adcetris, Iclusig, Alunbrig, Vectibix, Relumina, Cometriq, and Zejula. Takeda has generated revenue of $1.10B from its approved drug, Velcade used to treat multiple myeloma and mantle cell lymphoma.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49060,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/08-1024x150.png"" alt="""" class=""wp-image-49060""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 23</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2012</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~161.71B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~30,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Illinois, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>AbbVie is a global, research and development-based biopharmaceutical company focused on developing innovative advanced therapies. The company is focused on developing products in immunology, oncology, virology, and neuroscience, dermatology. AbbVie has 23 products in its oncology segment with 3 approved drugs including Empliciti, Imbruvica, and Venclexta. Imbruvica indicated for B cell cancers like mantle cell lymphoma, chronic lymphocytic leukaemia, and Waldenstrom's macroglobulinemia has reported a revenue of $4.67B in 2019. In May’2019, FDA granted Breakthrough Therapy designation to AbbVie’s Venclexta + obinutuzumab (Gazyva) to treat chronic lymphocytic leukaemia or small lymphocytic lymphoma.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49061,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/7-1024x149.png"" alt="""" class=""wp-image-49061""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 24</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1973</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;~$131.10B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~100,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Paris, France</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: EPA</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Sanofi is a global healthcare leader in vaccines providing healthcare solutions in 170+ countries around the world. Sanofi is ranked third in the global market and first in EU and Latin America. Sanofi has 7 approved products in its oncology segment including Jevtana, Eloxatin, Taxotere, Zaltrap, Sarclisa, Libtayo, and Clolar. Sanofi has generated revenue of $0.57B in 2019 from its approved drug Jevtana used to treat castration-resistant prostate cancer. In Mar’2020, Sanofi received FDA approval for Sarclisa (isatuximab-irfc) used to treat relapsed refractory multiple myeloma.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49062,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/6-1024x147.png"" alt="""" class=""wp-image-49062""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 24</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1849</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$201.05B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~83,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: New York, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NYSE</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Pfizer is a research-based, global biopharmaceutical company having a vast portfolio including Oncology, Vaccine, and other health care products for the prevention &amp; treatment of untreated diseases. With 11 approved drugs including Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Bosulif, Mektovi+Braftovi, Lorbrena, Talzenna, Bavencio, and Daurismo, Pfizer has 24 products in its oncology portfolio indicated for breast, renal cell carcinoma, gastrointestinal stromal tumour, prostate cancer, and several other tumour types. Ibrance, an approved drug for breast cancer has generated revenue of $4.96B in 2019. In Jun’2019, FDA approved Pfizer’s Zirabev (bevacizumab, biosimilar) to treat metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and metastatic cervical cancer.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49064,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/5-1024x146.png"" alt="""" class=""wp-image-49064""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 28</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1980</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$143.83B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~23,400</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: California, United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Amgen is one of the leading biotechnology companies developing novel therapies focused on cardiology, oncology, neurology, nephrology, and inflammatory diseases. Amgen has a total of 28 drugs with 21 pipeline drugs and 7 approved drugs including Blincyto, Vectibix, Kanjint, Kyprolis, Mvasi, Xgeva, and Imlygic. Amgen’s Xgeva used to prevent bone problems in patients with multiple myeloma or from solid tumours has generated sales of $1.93B in 2019.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49065,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/04-1024x173.png"" alt="""" class=""wp-image-49065""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 39</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1896</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap:&nbsp;~</strong> <strong>$315.6B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~98,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Basel, Switzerland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: SWX</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Roche Holding AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche’s oncology portfolio is currently focusing on breast, bladder, cervical, ovarian, liver cancer with 26 pipeline drugs, and 13 approved drugs including Herceptin, Perjeta, Tecentriq, Kadcyla, Alecensa, etc. Roche’s Avastin used to treat several cancers and a specific eye disease has generated revenue of $7.30B in 2019. In Aug’2019, FDA approved Roche’s Rozlytrek (entrectinib) for ROS1+ NSCLC and granted accelerated approval for solid tumours having NTRK gene fusion.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49066,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/03-1024x274.png"" alt="""" class=""wp-image-49066""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 62</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1996</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$219.56B</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Employees: ~109,000</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Headquarter: Basel, Switzerland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Stock Exchange: SWX</strong></p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Novartis is a multinational group of companies specializing in the research, development, manufacture, and marketing of drugs. Novartis has the highest number of approved drugs in the oncology segment including Tasigna, Sandostatin, Afinitor/Votubia, Promacta/Revolade, Tafinlar + Mekinist, Gleevec/Glivec, Jakavi, Afinitor Disperz/Votubia, Votrient, Kisqali, Lutathera, Kymriah, Piqray, Arzerra, Farydak, Femara, Mekinist, Proleukin, Rydapt, Tabrecta, Tafinlar, Tyverb, Zometa, Zykadia. With a revenue of $1.88B in 2019, Tasigna is the blockbuster drug for Novartis used to treat Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML). In May’19, Novartis has received FDA approval for Piqray (alpelisib) + Fulvestrant to treat breast cancer.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":49067,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/09/02-1024x215.png"" alt="""" class=""wp-image-49067""/></figure></div>
<!-- /wp:image -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Total Oncology Products: 63</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1887</strong></p>
<!-- /wp:paragrap",,https://pharmashots.com/wp-content/uploads/2020/09/TOP-20.png|https://pharmashots.com/wp-content/uploads/2020/09/20.png|https://pharmashots.com/wp-content/uploads/2020/09/19.png|https://pharmashots.com/wp-content/uploads/2020/09/18.png|https://pharmashots.com/wp-content/uploads/2020/09/17.png|https://pharmashots.com/wp-content/uploads/2020/09/15.png|https://pharmashots.com/wp-content/uploads/2020/09/14.png|https://pharmashots.com/wp-content/uploads/2020/09/13.png|https://pharmashots.com/wp-content/uploads/2020/09/12.png|https://pharmashots.com/wp-content/uploads/2020/09/11.png|https://pharmashots.com/wp-content/uploads/2020/09/10.png|https://pharmashots.com/wp-content/uploads/2020/09/09.png|https://pharmashots.com/wp-content/uploads/2020/09/08.png|https://pharmashots.com/wp-content/uploads/2020/09/7.png|https://pharmashots.com/wp-content/uploads/2020/09/6.png|https://pharmashots.com/wp-content/uploads/2020/09/5.png|https://pharmashots.com/wp-content/uploads/2020/09/04.png|https://pharmashots.com/wp-content/uploads/2020/09/03.png|https://pharmashots.com/wp-content/uploads/2020/09/02.png|https://pharmashots.com/wp-content/uploads/2020/09/01.png|https://pharmashots.com/wp-content/uploads/2020/09/GSK16.png,Top 20,Top 20 Oncology Companies,,3SBio|AbbVie|Amgen|Astellas|AstraZeneca|Bayer|BeiGene|BMS|Daichii Sankyo|Eli Lilly|GSK|Merck|Novartis|Pfizer|Products|Roche|Sanofi|Takeda,publish,9/24/2020,17
36441,Top 20 Prescription Drugs Based on 2019 Revenue,,"<!-- wp:paragraph -->
<p>The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology, cardiology, and neurology but are they not limited to only these indications and are rapidly increasing with the increasing medical needs. The drugs are developed targeting with the motive to&nbsp;cure,&nbsp;vaccinate,&nbsp;and alleviate the&nbsp;symptoms. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>We have compiled a list of global top 20 drugs blockbuster prescription drugs based on their sales for last year i.e. 2019. The top position was maintained by AbbVie's blockbuster drug Humira with $19.16B another drug grasped the second position headed by Merck's Keytruda with $11.08B following the third was occupied by BMS's Revlimid with $9.37B while ended at the low end by Gilead’s Truvada.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>If you have any questions or see something we might have missed? Please reach out to Senior Editor, Shiwani  Sharma by email.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[36866]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://pharmashots.com/wp-content/uploads/2020/07/truvada-4-1024x164.png"" alt="""" data-id=""36866"" data-full-url=""https://pharmashots.com/wp-content/uploads/2020/07/truvada-4.png"" data-link=""https://pharmashots.com/?attachment_id=36866"" class=""wp-image-36866"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column {""verticalAlignment"":""top""} -->
<div class=""wp-block-column is-vertically-aligned-top""><!-- wp:paragraph -->
<p><strong>Product -</strong> Truvada</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved -</strong> US (Aug 02, 2004), EU (Feb 20, 2005)</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved -</strong> HIV-1</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Company -</strong> Gilead Sciences</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Revenue -</strong> $2.81B</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Truvada is a combination of tenofovir disiproxil fumarate (tenofovir DF) and emtricitabine used for HIV treatment and pre-exposure prophylaxis for PrEP (pre-exposure prophylaxis) that can help reduce the risk of getting HIV-1 through sex. On July 23, 2019, Gilead presented new findings on the profile of Descoy for potential use as HIV Pre-exposure Prophylaxis compared with Truvada. Descovy and Truvada are only 2 FDA-approved pills for PrEP.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[36867]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://pharmashots.com/wp-content/uploads/2020/07/nuelasta-1024x164.png"" alt="""" data-id=""36867"" data-full-url=""https://pharmashots.com/wp-content/uploads/2020/07/nuelasta.png"" data-link=""https://pharmashots.com/?attachment_id=36867"" class=""wp-image-36867"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:columns -->
<div class=""wp-block-columns""><!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Product</strong> <strong>–</strong> Neulasta&nbsp;&nbsp;&nbsp;&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved</strong> <strong>-</strong> US (Jan 31, 2002), EU (Aug 22, 2002)</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><strong>Indications Approved - </strong></strong>Febrile Neutropenia</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column -->

<!-- wp:column -->
<div class=""wp-block-column""><!-- wp:paragraph -->
<p><strong>Company</strong> <strong>-</strong> Amgen</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong><strong>Total Revenue</strong> <strong>-</strong> </strong>$3.22B</p>
<!-- /wp:paragraph --></div>
<!-- /wp:column --></div>
<!-- /wp:columns -->

<!-- wp:paragraph -->
<p>Neulasta is a PEGylated form of the recombinant human granulocyte colony-stimulating factor analogue filgrastim.  Neulasta has been steadily losing market share due to the launch of multiple biosimilars and the utilization of Neulasta’s OnPro on-body injector (the dominant player at &gt; 55%) has been relatively steady. </p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[36868]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://pharmashots.com/wp-content/uploads/2020/07/victoza-2-1024x160.png"" alt="""" data-id=""36868"" data-full-url=""https://pharmashots.com/wp-content/uploads/2020/07/victoza-2.png"" data-link=""https://pharmashots.com/?attachment_id=36868"" class=""wp-image-36868"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Product</strong> <strong>–</strong> Victoza&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;       <strong>Company</strong> <strong>-</strong> Novo Nordisk</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved</strong> <strong>-</strong> US (Jan 25, 2010), EU (Jun 30, 2009) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    <strong>Total Revenue</strong> <strong>-</strong> $3.29B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved - </strong>Glycemic control in type 2 diabetes mellitus patients, Reduce adverse cardiovascular events in adults with type 2 diabetes mellitus</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Victoza or liraglutide belongs to a class of drugs called glucagon-like peptide-1 agonists (GLP-1).  Recently Novo Nordisk’s patent on Victoza is been reviewed as Mylan has claimed that its invalid because it covers an obvious invention. Mylan has challenged the Victoza patent with an aim to launch the low-cost copy of the drug.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[36869]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://pharmashots.com/wp-content/uploads/2020/07/lyrica-1-1024x200.png"" alt="""" data-id=""36869"" data-full-url=""https://pharmashots.com/wp-content/uploads/2020/07/lyrica-1.png"" data-link=""https://pharmashots.com/?attachment_id=36869"" class=""wp-image-36869"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Product</strong> <strong>– </strong>Lyrica&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;     <strong>Company</strong> <strong>-</strong> Pfizer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved</strong> <strong>-</strong> US (Dec 30, 2004), EU (Jul 05, 2004) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    <strong>Total Revenue</strong> <strong>-</strong> $3.32 B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved - </strong>Neuropathic pain associated with diabetic peripheral neuropathy, Postherpetic neuralgia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Lyrica is an anticonvulsant or an anti-seizure drug that can treat a range of conditions, including epilepsy, fibromyalgia, and nerve pain. The recent update on May 28, 2019, Pfizer announced that its epilepsy drug Lyrica (pregabalin), failed to meet the primary endpoint in P-III study, assessing it as adjunctive therapy in epilepsy patients (aged 5 to 65 years) with primary generalized tonic-clonic (“PGTC”) seizures.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[36870]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://pharmashots.com/wp-content/uploads/2020/07/imbruvica-2-1024x160.png"" alt="""" data-id=""36870"" data-full-url=""https://pharmashots.com/wp-content/uploads/2020/07/imbruvica-2.png"" data-link=""https://pharmashots.com/?attachment_id=36870"" class=""wp-image-36870"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:group -->
<div class=""wp-block-group""><div class=""wp-block-group__inner-container""></div></div>
<!-- /wp:group -->

<!-- wp:paragraph -->
<p><strong>Product</strong> <strong>–</strong> Imbruvica&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Company</strong> <strong>-</strong> Johnson &amp; Johnson</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved</strong> <strong>-</strong> US (Nov 13, 2013), EU (Nov 21, 2014) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Total Revenue</strong> <strong>-</strong> $3.41B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved - </strong>Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Imbruvica&nbsp;is an oral therapy which inhibits Bruton's tyrosine kinase (BTK)&nbsp;and has received its 10 FDA approval.&nbsp;In Apr 2020, US FDA approved&nbsp;Imbruvica&nbsp;(ibrutinib) plus Rituximab for the treatment of patients with Chronic Lymphocytic Leukemia (CLL)&nbsp;</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[36871]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://pharmashots.com/wp-content/uploads/2020/07/genvoya-2-1024x156.png"" alt="""" data-id=""36871"" data-full-url=""https://pharmashots.com/wp-content/uploads/2020/07/genvoya-2.png"" data-link=""https://pharmashots.com/?attachment_id=36871"" class=""wp-image-36871"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Product</strong> <strong>– </strong>Genvoya&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Company -</strong> Gilead Sciences</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved</strong> - US (Nov 05, 2015), EU (Nov 19, 2015) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Total Revenue</strong> <strong>-</strong> $3.93 B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved </strong>- HIV-1</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Genvoya is a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide targeting HIV. In Aug 2018, The CNDA approved Gilead’s Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for treating HIV Infection.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[36872]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://pharmashots.com/wp-content/uploads/2020/07/remicade-1-1024x158.png"" alt="""" data-id=""36872"" data-full-url=""https://pharmashots.com/wp-content/uploads/2020/07/remicade-1.png"" data-link=""https://pharmashots.com/?attachment_id=36872"" class=""wp-image-36872"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Product </strong>– Remicade&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Company -</strong> Johnson &amp; Johnson</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved</strong> <strong>-</strong> US (Aug 24, 1998), EU (Aug 13, 1999) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong>Total Revenue</strong> <strong>-</strong> $4.38B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved - </strong>Crohn’s Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Psoriatic Arthritis, Pediatric Ulcerative Colitis, Pediatric Crohn's Disease</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Remicade or infliximab is a tumour necrosis factor (TNF-alpha or TNF-a) blocker and a chimeric monoclonal IgG1 antibody. In June 2019, Janssen’s Remicade was issued a Civil Investigative Demand to Johnson &amp; Johnson by FTC for investigating whether its contracting practices violate federal antitrust.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[36873],""align"":""center""} -->
<figure class=""wp-block-gallery aligncenter columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://pharmashots.com/wp-content/uploads/2020/07/ibrance-2-1024x156.png"" alt="""" data-id=""36873"" data-full-url=""https://pharmashots.com/wp-content/uploads/2020/07/ibrance-2.png"" data-link=""https://pharmashots.com/?attachment_id=36873"" class=""wp-image-36873"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Product – </strong>Ibrance&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Company -</strong> Pfizer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved</strong> <strong>-</strong> US (Feb 03, 2015), EU (Nov 09, 2016) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Total Revenue</strong> <strong>-</strong> $4.96B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved - </strong>HER2 Negative Advanced Breast Cancer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Ibrance PO is CDKs 4 and 6 inhibitors indicated for HR+, HER2- advance or mBC and has been prescribed up xto 160,000 patients with approval in 85 countries worldwide. On May 29, 2020, the Data Monitoring Committee (DMC) of the collaborative P-III early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined that the trial failed in the primary endpoint of invasive disease-free survival (iDFS). Eli Lilly’s Verzenio has been chasing Ibrance in the metastatic setting since it hit the market and it now its ahead of Ibrance which recently took a big blow. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""align"":""center"",""id"":36874,""width"":580,""height"":86,""sizeSlug"":""large""} -->
<div class=""wp-block-image""><figure class=""aligncenter size-large is-resized""><img src=""https://pharmashots.com/wp-content/uploads/2020/07/enbrel-1-1024x152.png"" alt="""" class=""wp-image-36874"" width=""580"" height=""86"" /></figure></div>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Product –</strong> Enbrel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Company -</strong> Amgen</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved</strong> <strong>-</strong> US (Nov 02, 1998), EU (Feb 02, 2000)&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Total Revenue</strong> <strong>-</strong> $5.22B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved - </strong>Rheumatoid Arthritis, Polyarticular-Course Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Enbrel is a TNF inhibitor drug that treats autoimmune diseases by interfering with tumour necrosis factor by acting as a TNF inhibitor. Enbrel was the drug of choice for multiple autoimmune indications. On Jul 01, 2020, the US Court of Appeals for the Federal Circuit held in Amgen’s favour on the validity of 2 patents that describe and claim Enbrel's methods.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[36875]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://pharmashots.com/wp-content/uploads/2020/07/prevnar-2-1024x152.png"" alt="""" data-id=""36875"" data-full-url=""https://pharmashots.com/wp-content/uploads/2020/07/prevnar-2.png"" data-link=""https://pharmashots.com/?attachment_id=36875"" class=""wp-image-36875"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Product -</strong> Prevnar 13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Company - </strong>Pfizer</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved</strong> <strong>- </strong>US (Feb 24, 2010), EU (Dec 12, 2009) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Total Revenue</strong> <strong>-</strong> $5.84B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved - </strong>S. Pneumoniae Infection</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Prevnar 13 or Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein is a vaccine approved for adults 18 years of age and older for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumonia strains. In June 2020, Pfizer started four P-III clinical trials for investigational vaccines including Prevnar 13.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":36876,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/07/her-1024x152.png"" alt="""" class=""wp-image-36876"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Product –</strong> Herceptin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   <strong>Company - </strong>Roche</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved - </strong>US (Sep 25, 1998), EU (Aug 28, 2000)<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Revenue - </strong>$6.23 B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved - </strong>Metastatic Breast Cancer, Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma<strong>&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Herceptin or trastuzumab is a mAb that binds to HER2 receptors on the surface of HER2-positive tumor cells, blocking them from receiving growth signals and flagging them for destruction by the immune system. It is on the WHO's List of Essential Medicines, the safest and most effective medicines needed in a health system. On 29 June 2020, Roche got the approval of Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin with hyaluronidase, administered by SC injection in combination with IV chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two mAbs that can be administered by a single SC injection.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[36877]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://pharmashots.com/wp-content/uploads/2020/07/stelera-1-1024x149.png"" alt="""" data-id=""36877"" data-full-url=""https://pharmashots.com/wp-content/uploads/2020/07/stelera-1.png"" data-link=""https://pharmashots.com/?attachment_id=36877"" class=""wp-image-36877"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Product – </strong>Stelara&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Company - </strong>Johnson &amp; Johnson</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved - </strong>US (Sep 25, 2009), EU (Jan 15, 2009)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Total Revenue - </strong>$6.36B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved -</strong> Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Stelara or ustekinumab is a mAb with a novel mechanism of action that targets the p40 subunit of cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23). In Apr 2020, Johnson &amp; Johnson received NICE's positive Final Appraisal Document (FAD) recommending Stelara (ustekinumab) for the treatment of ulcerative colitis.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":36878,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/07/rituxan-1-1024x158.png"" alt="""" class=""wp-image-36878"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Product – </strong>Rituxan&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Company - </strong>Roche</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved - </strong>US (Nov 26, 1997), EU (Jun 02, 1998)<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total Revenue - </strong>$6.69B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved - </strong>Non-Hodgkin’s lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Granulomatosis with Polyangiitis, Microscopic Polyangiitis, Pemphigus Vulgaris</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Rituxan or rituximab is a mAb used to target cancer cells with CD20 markers in patients. In Sep 2019, The US FDA approved Roche's Rituxan (rituximab) in combination with glucocorticoids for treating granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) disorders.</p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[36879]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://pharmashots.com/wp-content/uploads/2020/07/opdivo-1-1024x149.png"" alt="""" data-id=""36879"" data-full-url=""https://pharmashots.com/wp-content/uploads/2020/07/opdivo-1.png"" data-link=""https://pharmashots.com/?attachment_id=36879"" class=""wp-image-36879"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Product – </strong>Opdivo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Company -</strong> Bristol-Myers Squibb</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved - </strong>US (Dec 22, 2014), EU (Jun 19, 2015)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Total Revenue - </strong>$7.20B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved - </strong>Metastatic Melanoma, Non-Small Cell Lung Cancer,Melanoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Hodgkin Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, Mismatch Repair Deficient Metastatic Colorectal Cancer, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Opdivo or nivolumab is a PD-1 immune checkpoint inhibitor targeted for cancer cells and is approved in 65 countries including the US, EU, Japan &amp; China. In Jun 2020, the US FDA granted approval for Opdivo (nivolumab) following the P-III ATTRACTION-3 study results evaluate it in comparison with taxane CT (docetaxel/paclitaxel) to treat patients with unresectable advanced, recurrent or ESCC, refractory/ intolerant to at least one prior fluoropyrimidine &amp; platinum-based CT.</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":36880,""sizeSlug"":""large""} -->
<figure class=""wp-block-image size-large""><img src=""https://pharmashots.com/wp-content/uploads/2020/07/avastin-2-1024x147.png"" alt="""" class=""wp-image-36880"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Product – </strong>Avastin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Company - </strong>Roche</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>First Approved - </strong>US (Feb 26, 2004), EU (Jan 12, 2005)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Total Revenue - </strong>$7.30B</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Indications Approved </strong><strong>- </strong>Metastatic Carcinoma, Metastatic Colorectal Cancer, Non–Small Cell Lung Cancer, Glioblastoma, Metastatic Renal Cell Carcinoma, Metastatic Cervical Cancer, Primary Peritoneal Cancer, Hepatocellular Carcinoma</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Avastin or bevacizumab is a tumour-starving (anti-angiogenic) therapy targeted for preventing tumour growth. In Jun 2020, Roche received the US FDA’s approval for a combination of Avastin (bevacizumab) + Tecentriq (atezolizumab) to treat patients with Unresectable Or Metastatic Hepatocellular Carcinoma (HCC) who have not received prior systemic therapy, which lead to a novel immunotherapy approval for the indication. The approval followed the P-III IMbrave150 study results assessing the combination. </p>
<!-- /wp:paragraph -->

<!-- wp:gallery {""ids"":[36881]} -->
<figure class=""wp-block-gallery columns-1 is-cropped""><ul class=""blocks-gallery-grid""><li class=""blocks-gallery-item""><figure><img src=""https://pharmashots.com/wp-content/uploads/2020/07/eylea-2-1024x146.png"" alt="""" data-id=""36881"" data-full-url=""https://pharmashots.com/wp-content/uploads/2020/07/eylea-2.png"" data-link=""https://pharmashots.com/?attachment_id=36881"" class=""wp-image-36881"" /></figure></li></ul></figure>
<!-- /wp:gallery -->

<!-- wp:paragraph -->
<p><strong>Product – </strong>Eylea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n",,https://pharmashots.com/wp-content/uploads/2020/07/Prescription-drugs.png,Top 20,Top 20 BioPharma Companies,,AbbVie|Amgen|Avastin|BMS|Celgene|Eliquis|Enbrel|EYLEA|Genvoya|Gilead Sciences|Herceptin|Humira|Ibrance|Imbruvica|Johnson &amp; Johnson|KEYTRUDA|Lyrica|MSD|Neulasta|Novo Nordisk|Opdivo|Pfizer|Prevnar 13|Regeneron Pharmaceuticals|Remicade|Revlimid|Rituxan|Stelara|Truvada|Victoza,publish,7/17/2020,17
25104,Top Biopharma Deal Terminations of 2018-2019 by Total Value Received,,"<!-- wp:paragraph -->
<p>The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. We used the <a href=""https://dealforma.com/"">DealForma</a> database to track partnership terminations announced in 2018 and 2019. We compiled a list of the top 20 terminations of 2018 and 2019 based on the total value received during the partnership, including upfront, milestone payments, and termination fees the company received.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In 2019, Reata / Abbott positioned first with Reata reacquiring baradoxolone and two additional NrF2 activators for $330M plus royalties. Second goes to Celgene’s agreement with BeiGene and Jounce Therapeutics for limitations and priorities related to the BMS acquisition. Sanofi secured third place when it terminated its $1.8B agreement with Lexicon Pharmaceuticals for mixed clinical results. In 2018, Eli Lilly came in first with its discontinuation of Phase III development of Lanabecestat. Additionally, Biogen terminated a $1B partnership with AGTC following the failure of a gene therapy trial. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>2019 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>1. <strong>Reata Terminated its Bardoxolone Agreement with Abbott </strong> <strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25107} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T1.png"" alt="""" class=""wp-image-25107"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p> In Sep. 2010, Reata granted Abbott exclusive rights to develop and commercialize bardoxolone and other molecules for the treatment of renal, metabolic, and cardiovascular diseases, including CKD and PH, worldwide excluding the U.S. and the territories previously granted to Kyowa Hakko Kirin (KHK). In 2009, Reata granted KHK exclusive rights to commercialize bardoxolone in Japan, China, South Korea, Taiwan, Thailand, Singapore, Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia. Reata would receive $450M in upfront and near time milestone payments and to up to $350M in milestones per product, plus royalties. Further in 2011, Abbott expanded the partnership by adding 2<sup>nd</sup> and 3<sup>rd</sup> generation NrF2 activators globally for all indications excluding renal, CVS, and metabolic disease for an additional $400M up front and a 50% share of profits for the therapies excluding rheumatoid arthritis and autoimmune disease for which Abbott retains 70% of profits. As of Dec. 2018, Abbott had not opted for any program and Reata received $300M in upfront cash and equity. In Oct. 2019, Reata reacquired baradoxolone and additional NrF2 activators in exchange for $330M.&nbsp;  </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>2. <strong>Celgene Terminated its 2017 Agreement with BeiGene </strong> <strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25191} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/2.png"" alt="""" class=""wp-image-25191"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Jul. 2017, BeiGene granted Celgene worldwide rights, excluding Asia, to develop and commercialize PD-1 inhibitor tislelizumab for solid tumors. BeiGene received $413M up front, including the purchase of 32.7M shares in BeiGene for approximately 5.9%, with a potential for up to $980M in milestones plus royalties. In Jan. 2019, BMS’s acquisition of Celgene mandated that BMS not hold two PD-1 assets. Further, Celgene decided to terminate its agreement with BeiGene and paid $150M as an exit fee.    </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>3. <strong>Sanofi Terminated its $1.7B Diabetes Agreement with Lexicon&nbsp; </strong> </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25109} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T3.png"" alt="""" class=""wp-image-25109"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Nov. 2015, Lexicon signed an exclusive, worldwide license agreement with Sanofi for its dual SGLT 1/2 inhibitor, Zynquista, for diabetes. Lexicon received $300M upfront and was eligible for up to $1.42B in milestones, including accelerated royalties of up to 40%. Lexicon had an option to co-promote in the U.S. for up to 40% in addition to a $100M contribution in Phase II development. In Jul. 2019, Lexicon published Phase III results for Zynquista. Sanofi decided to terminate the agreement and cited that the Zynquista study generated mixed clinical data. Lexicon denied accepting Sanofi’s statement and concluded that Sanofi breached the agreement. Further, Sanofi decided to pay a $260M exit fee. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>4. <strong>Celgene Terminated its $2.6B mAb Partnership with Jounce </strong> </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25192} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/4.png"" alt="""" class=""wp-image-25192"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p> In Jul. 2016, Jounce Therapeutics granted Celgene exclusive, worldwide rights to develop and commercialize mAb JTX211 and 4 early-stage programs. Jounce and Celgene will conduct research over 4 years and can expand to 3 additional 1-year periods. In addition, Celgene has an exclusive option to license JTX4041. Jounce will receive $224M in cash, $36M in its B1 preferred stock in the form of 10.4M shares, and up to $2.3B in milestones, plus option exercise fees. Celgene will lead the commercialization for all programs exercised, excluding JTX4014. Jounce is eligible for 60% of US profits for JTX211, 25% for the first early-stage program, and 50% of the other three. In addition, Jounce is eligible for mid-teens royalties outside the US. If Celgene exercises JTX4014, the companies would sign a separate license agreement to develop a combination therapy under equal rights to develop their respective pipelines and a 50% profit and loss share; otherwise, Celgene would be fully responsible for that development. In January 2019, BMS proposed to acquire Celgene and Celgene terminated this agreement with Jounce after a pipeline review with BMS. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>5. <strong>MyoKardia Terminated its Development and Commercialization Deal with Sanofi</strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25111} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T5.png"" alt="""" class=""wp-image-25111"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Sep. 2014, MyoKardia granted Sanofi exclusive, worldwide rights to develop and commercialize 3 programs for genetic heart disease. Two programs focused on hypertrophic cardiomyopathy (HCM) and the other for dilated cardiomyopathy. In Jan. 2019, MyoKardia regained worldwide rights to mavacamten and MYK-491. Sanofi paid $230M to MyoKardia over the course of the agreement.  </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>6. <strong>Novartis Discontinued the Development of </strong> <strong>MorphoSys ’ MOR106 Candidate </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25566} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2020/01/morphosys.png"" alt="""" class=""wp-image-25566"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Jul. 2018, MorphoSys and Galapagos granted Novartis exclusive, worldwide rights to develop and commercialize mAb candidate MOR106 for atopic dermatitis and additional skin disorders. MorphoSys and Galapagos received $111M up front and were eligible for up to $1B in milestones, plus royalties of up to the low twenty percent range. MOR106 is a mAb developed by MorphoSys and Galapagos in 2008 where the companies share profit equally. In Oct. 2019, the companies terminated their P-II IGUANA trial following an interim analysis, which showed a lack of efficacy and a low possibility to achieve its primary endpoint.  </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>7. <strong>Hanmi Terminated its Metabolic Disorder Agreement with Janssen </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25113} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T7.png"" alt="""" class=""wp-image-25113"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Nov. 2015, Hanmi granted Janssen exclusive, worldwide rights to develop and commercialize oxyntomodulin-based therapies, including HM12525A, for the treatment of diabetes and obesity. Hanmi received $105M up front and was eligible for up to $810M in milestones, plus royalties. Janssen terminated the agreement in Jun. 2019 after reviewing data from the Phase II obesity trial. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>8.  <strong>Sanofi Terminated its Option Agreement with Voyager for VY-AADC01, VY-FXN01, and VY-HTT01 </strong> </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25114} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T8.png"" alt="""" class=""wp-image-25114"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Feb. 2015, Voyager granted Sanofi Genzyme an exclusive option to license worldwide ex-US rights to develop and commercialize its gene-therapies VY-ADC01, VY-FXN01, and VY-HTT01 for neurological indications. Voyager received $65M in cash, $30M in equity, an additional $5M in fair value, and was eligible for up to $745M in milestones. In 2017, Sanofi suspended the development of VYADC following Voyager turning down efforts to co-commercialize in the US, and in Jun. 2019, Sanofi terminated the agreement.  </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>9. <strong>Novartis Terminated its Agreement with Conatus </strong> <strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25116} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T9.png"" alt="""" class=""wp-image-25116"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Dec. 2016, Conatus granted Novartis exclusive, worldwide option rights to develop and commercialize orally active pancaspase inhibitors as monotherapy or in combination with Novartis products. Conatus received $50M up front, a $7M option exercise fee, $15M in the form of convertible permission notes, and is eligible for up to $650M in milestones, plus royalties. Conatus had the option to co-promote in the US and share profit equally in exchange for US royalties with the reduction in ROW royalties. Novartis would contribute 50% of the Phase IIb emricascan development costs which cover the ENCORE-PH trial for NASH fibrosis, POLIHCVSVR trial for post-transplant HCV fibrosis and cirrhosis, and ENCORE-NF trial for NASH fibrosis. In May 2017, Novartis exercised its option and Conatus received a $7M option exercise fee plus $15M convertible note. On Sep. 30, 2019, the Phase II trial of emricascan in NASH therapy failed to achieve its primary endpoint and Novartis terminated the agreement with Conatus. Novartis agreed to pay up to $150,000 in clinical trial expenses in 2020.  </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>10. <strong>Hanmi Pharmaceutical Terminated its Development and Commercialization Deal with Eli Lilly </strong> </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25117} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T10.png"" alt="""" class=""wp-image-25117"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Mar. 2015, Hanmi Pharmaceutical granted Eli Lilly rights outside of China, Hong Kong, Taiwan, and Korea to develop and commercialize its BTK inhibitor, HM71224, for the treatment of autoimmune and other immunological diseases. Hanmi received $50M up front and was eligible for up to $640M in development, regulatory, and sales milestones, plus double-digit royalties. In Feb. 2018, Eli Lilly discontinued the Phase II development of LY3337641 after an interim analysis. On Jan. 23, 2019, Eli Lilly returned the rights to Hanmi Pharmaceutical after the review of all clinical data and the BTK inhibitor market. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>2018 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>1. <strong>Eli Lilly Discontinued the Development of Lanabecestat with AstraZeneca </strong> </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25118} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T11.png"" alt="""" class=""wp-image-25118"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Sep. 2014, AstraZeneca granted Lilly rights to co-develop and commercialize its small molecule, AZD3293, for Alzheimer’s Disease. Lilly would lead clinical development and AstraZeneca would be responsible for manufacturing AZD3293. AstraZeneca was eligible for up to $500M in milestones. The partners shared costs and profits 50/50. The partners formed a second deal in 2016 for the antibody, MEDI1814, for Alzheimer's. On Jun. 12, 2018, AstraZeneca and Eli Lilly discontinued Phase III development of lanabecestat, which effectively terminated this deal.   </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>2. <strong>Biogen Terminated its $1B Partnership with AGTC </strong> <strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25119} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T12.png"" alt="""" class=""wp-image-25119"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Jul. 2015, Applied Genetic Technologies granted Biogen exclusive, worldwide rights to its preclinical and clinical gene therapy candidates for the treatment of ophthalmic disease. In addition, Biogen had the option to license 2 early-stage discovery programs for ophthalmic disease and 1 program for non-ophthalmic disease. AGTC received $94M and Biogen invested $30M in equity at 20.63/per share. Additionally, AGTC was eligible to receive up to $472.5M in milestones for 2 lead programs and up to $592.5M for discovery programs, plus royalties. In Dec. 2018, Biogen terminated the agreement following the failure of the gene therapy trial.  </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>3. <strong>Amgen Terminated its Agreement with Advaxis </strong> </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25120} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T13.png"" alt="""" class=""wp-image-25120"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Aug. 2016, Advaxis granted Amgen exclusive, worldwide rights to develop and commercialize its preclinical Immunotherapy, ADXS-NEO, for cancer. Advaxis will receive $65M up front, including $25M in its common stock, and is eligible for up to $475M in milestones, plus single digit to mid-double digit royalties. In December 2018, Amgen terminated the agreement with Advaxis&nbsp; following their internal portfolio review. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>4. <strong>Servier Terminated its Agreement for E-3810 with Ethical Oncology Science </strong> </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25121} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T14.png"" alt="""" class=""wp-image-25121"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Oct. 2012, Ethical Oncology Science (EOS) granted Servier exclusive, worldwide rights excluding China to develop and commercialize VEGFR-1-3 inhibitor E-3810 for the treatment of cancer. E-3810 is currently in a Phase II/III study. EOS is eligible to receive up to €45 (approx.$58M) in total undisclosed upfront and milestone payments, plus royalties. In October 2018, Servier notified Clovis Oncology, the holding entity of Ethical Oncology Science, of its intention to terminate the agreement.  </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> 5. <strong>Janssen Terminated its Agreement with Aduro Biotech </strong> <strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25122} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T15.png"" alt="""" class=""wp-image-25122"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Oct. 2014, Aduro granted Janssen exclusive, worldwide rights to
develop its AD741 gene therapy for the treatment of prostate cancer. Aduro was
eligible to receive up to $365M in milestones. Additionally, in 2014, Aduro
licensed its GVAX prostate cancer vaccine and to generate revenue of up to $2M.
In Nov. 2014, Aduro expanded the agreement with Janssen for the development of
LADD product ADU214 for an additional $847M in potential payments. Aduro
received $12M up front for ADU714, $30M for ADU214, and $0.5M for the GVAX prostate
cancer vaccine. In 2015, Aduro received a $22.4M milestone payment. In Sep.
2018, Janssen terminated the agreement. </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>6. <strong>Servier Terminated its GeNeuro Agreement for Multiple Sclerosis </strong> </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25123} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T16.png"" alt="""" class=""wp-image-25123"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Dec. 2014, GeNeuro granted Servier an exclusive option to license GNbAC1 worldwide ex-US and Japan rights to its treatment of multiple sclerosis. GeNeuro holds responsibility for the development until Phase II, Servier had an option of further development and commercialization. GeNeuro received $47M up front and was eligible for up to $408M in milestones, plus royalties. Servier acquired a minority stake in GeNeuro. In addition, GeNeuro received up to $40M in milestones from Servier on completion of the Phase II study. In Mar. 2018, GeNeuro regained worldwide rights to GNbAC1 following Servier’s strategic decision to terminate.  </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>7.  <strong>Teva Terminated its Agreement with Xenon for Pain Medication </strong> </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25124} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T17.png"" alt="""" class=""wp-image-25124"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Dec. 2012, Xenon granted Teva exclusive, worldwide rights to develop and commercialize XEN402 for the treatment of various pain disorders. Xenon received $41M up front and was eligible for up to $335M in development, regulatory, and sales milestones. In Mar. 2018, Teva terminated the agreement after XEN402 failed to meet its primary endpoint in a Phase II study. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25125} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T18.png"" alt="""" class=""wp-image-25125"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>8. <strong>Teijin Terminated its Agreement with Versartis  </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p> </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>In Aug. 2016, Versartis granted Teijin exclusive rights to develop and commercialize its recombinant fusion protein, somavaratan, for somatotropin deficiencies. Versartis received $40M up front and was eligible for up to $125M in milestones, plus royalties. In Jan. 2018, Teijin Pharma terminated the agreement after the Phase III clinical study of somavaratan failed to meet its primary endpoint.  </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>9. <strong>Janssen Biotech Terminated its Agreement with Geron </strong> </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25126} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T19.png"" alt="""" class=""wp-image-25126"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Nov. 2014, Geron granted Janssen exclusive, worldwide rights to develop and commercialize its telomerase inhibitor, Imetelstat, for the treatment of cancer. Imetelstat is a modified oligonucleotide once viewed as a potential blockbuster. Geron received $35M up front was eligible for up to $900M in milestones, plus royalties. In Sep 2018, Janssen Biotech announced its decision to terminate the agreement following a strategic portfolio evaluation and prioritization.  </p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>10. <strong>BMS Terminated its Agreement with Rigel for TGF beta </strong> <strong> </strong></p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":25127} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/12/T20.png"" alt="""" class=""wp-image-25127"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p>In Feb. 2015, Rigel Pharmaceuticals granted BMS exclusive, worldwide rights to develop and commercialize its small molecule TGF beta receptor kinase inhibitor, including its library for immuno-oncology indications. Rigel received $30M up front and was eligible for up to $309M in milestones, plus royalties. In Jul. 2018, BMS discontinued preclinical development of the small molecule. </p>
<!-- /wp:paragraph -->",,https://pharmashots.com/wp-content/uploads/2020/01/1.png,Top 20,Top 20 Biopharma Deal Terminations,,2018-2019|Abbott|Aduro Biotech|Advaxis|AGTC|Amgen|BeiGene|Biogen|BioPharma|BMS|Bristol-Myers Squibb|Celgene|Conatus|Deals|Eli Lilly|Ethical Oncology Science|GeneNeuro|Geron|Hanmi|Janssen|Janssen Biotech|Jounce|Lexicon|MorphoSys|MyoKardia|Novartis|Reata|Sanofi|Servier|Teijin|Termination|Teva|TGF beta|Top 20|Total Value|Versartis|Voyager|Xenon,publish,1/3/2020,17
24011,Top Biosimilar Companies with Approved and Pipeline Products in the US and EU,,"<!-- wp:paragraph -->
<p>Biosimilars are the key
alternatives for expensive Biologics therapies and saving millions of dollars
of patients spent in the treatment of multiple diseases. Hence physicians are
likely to adopt biosimilars “a reference product to biologics” possessing
similar therapeutic properties in terms of potency, safety, and efficacy to
original biologic products. The companies are focusing on the expansion of their
pipeline and portfolio in Biosimilars. In 2018, Amgen collaborated with Orion
for the commercialization of Amgevita (biosimilar, adalimumab) in Finland in
addition to STADA’s joint development agreement with Xbrane Biopharma for Xlucane
(biosimilar, ranibizumab). Biocon also came up with CHMP recommendations for
its biosimilars Fulphila (biosimilar, pegfilgrastim) and Ogivri (biosimilar, trastuzumab)
targeted to treat Neutropenia and HER-2 Breast Cancer respectively. Our team at
PharmaShots has compiled a list of top biosimilar companies developing and
marketing biosimilars in the EU and the US arranged in alphabetical orders. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24024} -->
<figure class=""wp-block-image""><img src=""http://www.pharmashots.com/wp-content/uploads/2019/11/AG.png"" alt="""" class=""wp-image-24024"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Amgen </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilar Pipeline Products: 4</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1980&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Headquarter: United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $139.36B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Exchange: NASDAQ </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Amgen is one of the leading biotechnology company developing
novel therapies focused on Cardiology, Oncology, Immunology, Neurology,
Nephrology, and Inflammatory diseases. In Oct 2018 Amgen signed an agreement
with Orion for the commercialization of Amgevita (adalimumab, biosimilar) in
Finland. Additionally, in H2’18 Amgen also launched its first inflammation
biosimilar Amgevita (biosimilar, adalimumab) in Europe for the treatment of inflammatory
diseases including all possible indications for Humira (adalimumab). Amgen’s ABP
710 (biosimilar infliximab) reported results of P-III study in comparison with Remicade
(infliximab) for patients with moderate-to-severe rheumatoid arthritis with its
BLA submitted to the FDA. Amgen’s ABP 798 (biosimilar, rituximab) has completed
its P-III studies for moderate to severe RA &amp; NHL and the trial evaluating
ABP 959 (biosimilar, eculizumab) is recruiting patients for P-III for Paroxysmal
nocturnal hemoglobinuria (PNH). </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24025} -->
<figure class=""wp-block-image""><img src=""http://www.pharmashots.com/wp-content/uploads/2019/11/AP.png"" alt="""" class=""wp-image-24025"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Apotex/Apobiologix</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilar Pipeline Products: 5</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1974 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: Canada</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: NA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Stock Exchange: NA </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Apotex is a generics drugs company, headquartered in Canada. &nbsp;Apobiologix is a member of the Apotex Group of Companies, focused on the development of biosimilars. Apobiologix has launched its pegfilgrastim biosimilar, Lapelga, in Canada in Q1’19. Apobiologix has been developing 5 products for the US market, including Epoetin alfa, Darbepoetin alfa, Bevacizumab, Rituximab, and Trastuzumab. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24026} -->
<figure class=""wp-block-image""><img src=""http://www.pharmashots.com/wp-content/uploads/2019/11/bi.png"" alt="""" class=""wp-image-24026"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Biocon</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilar Pipeline Products: 4</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1978&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: India </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$4.29B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Stock Exchange: NSE &nbsp;&nbsp;&nbsp;</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Biocon is a global pharmaceutical company involved in
discovering, developing and producing therapies in chronic therapies such as
Diabetes, Oncology, and Immunology. The vast portfolio of Biocon can be further
divided into APIs and Generic formulations, Biologics &amp; Biosimilars and
Branded Formulations. In Sept 2018, Biocon and Mylan’s Fulphila (biosimilar, pegfilgrastim)
received CHMP recommendation for neutropenia. Biocon’s Insulin Aspart and Krabeva
(biosimilar, bevacizumab) are targeted for diabetes and multiple indications in
cancer respectively while they are currently being evaluated in P-III
study.&nbsp; </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24027} -->
<figure class=""wp-block-image""><img src=""http://www.pharmashots.com/wp-content/uploads/2019/11/BO.png"" alt="""" class=""wp-image-24027"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Biogen </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilar Pipeline Products: 2</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1978 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter:
United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$54.74B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NASDAQ</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Biogen is a US-based biotech company focused on the
development of therapies in neuroscience particularly in multiple sclerosis and
neuroimmunology, neuromuscular disorders, movement disorders, ophthalmology,
immunology, neurocognitive disorders, acute neurology, and pain. In 2018, the
company also reported pooled results of P-III studies for Benepali (biosimilar,
etanercept), Flixabi (biosimilar, infliximab), and Imraldi (biosimilar,
adalimumab) in patients with moderate to severe rheumatoid arthritis. In 2019,
Biogen signed an agreement with Samsung Bioepis to acquire exclusive
commercialization rights for SB11 (biosimilar, ranibizumab) in the US, EU,
Japan, Australia and Canada including Benepali, Flixabitm, and Imraldi in China.
</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24031} -->
<figure class=""wp-block-image""><img src=""http://www.pharmashots.com/wp-content/uploads/2019/11/DW.png"" alt="""" class=""wp-image-24031"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Boehringer Ingelheim </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilar Pipeline Products: 12 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1885&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter: Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: N/A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    Stock Exchange: N/A</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Boehringer Ingelheim is a Germany based global
pharmaceutical company focused on developing therapies for multiple therapy
areas including Cardiovascular, Oncology, CNS, Respiratory, Immunology,
Metabolic diseases, and Retinal Health. In 2018, BI reported P-III results of Cyltezo
(biosimilar, adalimumab) in patients with moderate-to-severe plaque psoriasis.
Additionally, BI has BI 695502 (biosimilar, bevacizumab) in P-III targeted for the
treatment of patients with advanced non-squamous NSCLC. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24028} -->
<figure class=""wp-block-image""><img src=""http://www.pharmashots.com/wp-content/uploads/2019/11/CE.png"" alt="""" class=""wp-image-24028"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Celltrion </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Biosimilar Pipeline Products: 1</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2002 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter:
South Korea</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: $20.189B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: KRX&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Celltrion is a Korea based healthcare company offering
development and sales of the biosimilar in fields of Autoimmune Disorders and
Oncology. In Dec 2018 Celltrion’s CT-P10 (biosimilar, rituximab) showed
well-tolerated and safe results in P-III in patients with advanced follicular
lymphoma (AFL). In 2018, Celltrion and Teva’s Herzuma (CT-P6, biosimilar, trastuzumab)
and Truxima (rituximab-abbs) also received the FDA’s approval for
HER2-overexpressing breast cancer and three NHL indications respectively.
Additionally, Celltrion’s CT-P16 (biosimilar, bevacizumab) is also evaluated in
P-III trial for treating Colorectal Cancer.&nbsp;
</p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24032} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/11/CO.png"" alt="""" class=""wp-image-24032"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Coherus Biosciences </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilar Pipeline Products: 3</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2010&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Headquarter: United States</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$1.35B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Stock Exchange: NASDAQ </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Coherus is a leading biosimilar company focused on
developing candidates in multiple therapeutic areas including oncology,
immunology, and ophthalmology. In 2018, Coherus’ Udenyca (biosimilar, pegfilgrastim)
received the EU’s MAA and the US FDA’s approval for febrile neutropenia and patients
receiving myelosuppressive chemotherapy respectively. Coherus’ two biosimilars CHS-1420
(biosimilar, adalimumab) and CHS-0214 (biosimilar, etanercept) have also
completed their P-III studies for psoriasis and RA respectively. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24053} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/11/Image20191129181658-1024x110.png"" alt="""" class=""wp-image-24053"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Fresenius Kabi</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Biosimilar Pipeline Products: 4 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1999&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Headquarter: Germany</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: N/A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;        Stock Exchange: N/A</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Fresenius Kabi is a global
healthcare company with a portfolio of IV generic drugs, infusion therapies,
and clinical nutrition products including devices for administration of these
drugs and biosimilars focusing on Oncology and autoimmune disorders. In 2018,
the company signed a settlement and license agreement with AbbVie for its all
pending patent litigations regarding the commercialization of Fresenius’ MSB11022
(biosimilar, adalimumab) in the US. In late 2018, Fresenius also released the
results of its MSB11455 (biosimilar, pegfilgrastim) meeting all 1EPs. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24058} -->
<figure class=""wp-block-image""><img src=""http://www.pharmashots.com/wp-content/uploads/2019/11/Image20191129183522.png"" alt="""" class=""wp-image-24058"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Fujifilm Kyowa Kirin Biologics</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Biosimilar Pipeline Products: 2 </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1934&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Headquarter: Japan</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$24.4B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Exchange: TYO </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Fujifilm Kyowa Kirin Biologics is a Japan-based biopharmaceutical company focused on developing biosimilars targeting Immunology &amp; Oncology. The company leverages Kyowa Kirin’s R&amp;D and production expertise, manufacturing, quality management, and analytical skills along with Fujifilm wide-ranging business to create an innovative production process leading to a reduction in production cost., In 2018, Kyowa Kirin and Mylan collaborated to commercialize Hulio (FKB327) (biosimilar, adalimumab) and has also received EMA’s marketing authorization for Rheumatoid Arthritis, Psoriasis, Crohn's Disease. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24035} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/11/GR.png"" alt="""" class=""wp-image-24035"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Gedeon Richter</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilar Pipeline Products: 2</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1901 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter:
Hungary</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: 3.174B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Exchange</strong>: <strong>Budapest Stock Exchange</strong><strong></strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Gedeon
Richter is a Budapest based company, focused on developing therapies for
multiple therapeutic areas including Women's Healthcare, Central Nervous
System, and Cardiovascular areas. In early 2018, EMA initiated the evaluation
of Richter’s resubmitted marketing authorization application for proposed biosimilar
pegfilgrastim. In 2018, Richter acquired IPR for Bemfola for use in the US. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24036} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/11/IN.png"" alt="""" class=""wp-image-24036"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Intas/Accord Healthcare</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilar Pipeline Products: 6</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1968 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headquarter:
Ahmedabad, India </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: NA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Stock Exchange</strong>: <strong>NA</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Intas is a pharmaceutical company focused on developing therapies
for CNS, CVS, Oncology, Diabetes, Gastroenterology, Pain Management, Urology,
Nephrology, Gynecology, Infertility, and Respiratory Care. Intas biosimilars
are developed at the company’s European Union-Good Manufacturing Practices
(EU-GMP) certified biotechnology plant situated near Ahmedabad.&nbsp; </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24037} -->
<figure class=""wp-block-image""><img src=""https://www.pharmashots.com/wp-content/uploads/2019/11/MB.png"" alt="""" class=""wp-image-24037"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Mabion &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilar Pipeline Products: 3</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 2007&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Headquarter: Poland</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$1.34B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: WSE</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Mabion is a Poland based leading biopharmaceutical
company developing and commercializing biosimilar and drugs based on its monoclonal
antibody technology. In 2018, Mabion filed marketing authorization for its Mabion
CD20 (biosimilar, rituximab) candidate, targeted to treat RA patients and patients
with non-Hodgkin's lymphoma. </p>
<!-- /wp:paragraph -->

<!-- wp:image {""id"":24038} -->
<figure class=""wp-block-image""><img src=""http://www.pharmashots.com/wp-content/uploads/2019/11/MK.png"" alt="""" class=""wp-image-24038"" /></figure>
<!-- /wp:image -->

<!-- wp:paragraph -->
<p><strong>Merck &amp; Co.</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Total Biosimilar Products: 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilar Pipeline Products: 0</strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Founded Year: 1894&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Headquarter: United States </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Market Cap: ~$222.37B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stock Exchange: NYSE </strong></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Merck is a global healthcare leader focused on developing, discovering and providing prescription medicines, vaccines, biologic therapies, and animal health products. In 2018, Merck Renflexis (biosimilar, infliximab) determined to be of the lowest-priced infliximab option available and was also awarded a national contract by the VA. With the approval, in 2018 Merck also terminated its deal with Samsung Bioepis for Lusduna (biosimilar, insulin glargine) and paid $155M as a termination fee. </p>
<!-- /wp:para",,https://pharmashots.com/wp-content/uploads/2019/11/Image20191129183642.png,Top 20,Top 20 BioPharma Companies,,Amgen|Apotex|Biocon|Biogen|Boehringer Ingelheim|Celltrion|Coherus Biosciences|Fresenius Kabi|Fujifilm Kyowa Kirin Biologics|Gedeon Richter|Intas/Accord Healthcare|Mabion|Merck &amp; Co|Mundipharma|Mylan|Pfizer|Samsung Bioepis|Sandoz|STADA Arzneimittel|Teva,publish,11/29/2019,17
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
,,,,,,,,,,,,
